XOMA,XOMA,2017-03-23,XOMA Announces Four Presentations At The 2017 ENDO Meeting
XOMA,XOMA,2017-03-22,XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation
XOMA,XOMA,2017-03-16,XOMA Reports Fourth Quarter And Full Year 2016 Financial Results
XOMA,XOMA,2017-03-14,XOMA To Announce Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call Focused On Its New Strategic Direction On March 16, 2017
XOMA,XOMA,2017-02-28,XOMA To Present New Strategic Initiatives At The Cowen And Company 37th Annual Health Care Conference
XOMA,XOMA,2017-02-16,XOMA Appoints Matthew Perry To Its Board Of Directors
XOMA,XOMA,2017-02-13,XOMA Announces Pricing Of $25 Million Registered Offering Of Common Stock And Convertible Preferred Stock
XOMA,XOMA,2017-01-31,XOMA Establishes Proof-of-Concept For 358 In Congenital Hyperinsulinism And Hypoglycemia Post-Bariatric Surgery
XOMA,XOMA,2016-12-21,XOMA Announces Up To $22 Million Generated From Sale Of Royalty Streams From Two License Agreements To HealthCare Royalty Partners And Provides Corporate Update
XOMA,XOMA,2016-11-09,XOMA Reports Third Quarter 2016 Achievements And Financial Results
XOMA,XOMA,2016-11-08,New XOMA Antibodies Unveiled At The Society For Immunotherapy Of Cancer 31st Annual Meeting
XOMA,XOMA,2016-10-19,XOMA Reaches Analyst Target Price
XOMA,XOMA,2016-10-19,XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study For XOMA 358 In Children With Congenital Hyperinsulinism
XOMA,XOMA,2016-10-14,XOMA Announces Reverse Stock Split
XOMA,XOMA,2016-09-15,XOMA Provides Update From Ongoing Phase 2 XOMA 358 Clinical Studies
XOMA,XOMA,2016-09-06,XOMA To Host XOMA 358 Clinical Update Webcast And Conference Call On September 15, 2016
XOMA,XOMA,2016-08-11,XOMA To Present At The 2016 Wedbush PacGrow Healthcare Conference
XOMA,XOMA,2016-08-03,XOMA Reports Second Quarter 2016 Achievements And Financial Results
XOMA,XOMA,2016-07-20,XOMA Receives Orphan Drug Designation In The European Union For XOMA 358 For Treatment Of Congenital Hyperinsulinism
XOMA,XOMA,2016-07-05,XOMA To Present At The Cantor Fitzgerald Healthcare Conference
XOMA,XOMA,2016-06-28,XOMA Initiates Phase 2 Proof-of-Concept Study Of XOMA 213
XOMA,XOMA,2016-06-02,XOMA To Present At The Jefferies Global Healthcare Conference
XOMA,XOMA,2016-05-04,XOMA Reports First Quarter 2016 Operational Achievements And Financial Results
XOMA,XOMA,2016-04-27,XOMA Initiates XOMA 358 Proof-of-Concept Study In Patients With Hypoglycemia Post Gastric Bypass Surgery
XOMA,XOMA,2016-04-04,XOMA Presented First Data From Novel Antibody Fragment To Address Severe Acute Hypoglycemia At The ENDO Meeting
XOMA,XOMA,2016-03-11,XOMA (XOMA) Weak On High Volume
XOMA,XOMA,2016-03-10,Xoma Stock Soaring on Q4 Earnings Beat
XOMA,XOMA,2016-03-09,Xoma Stock Surges in After-Hours Trading on Q4 Results
XOMA,XOMA,2016-03-09,XOMA Reports Fourth Quarter And Full-Year 2015 Financial Results
XOMA,XOMA,2016-03-02,XOMA To Present At The Cowen & Company Health Care Conference
XOMA,XOMA,2016-02-24,XOMA To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Webcast On March 9
XOMA,XOMA,2015-12-11,Friday Small-Cap Focus: Xoma
XOMA,XOMA,2015-12-01,Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million
XOMA,XOMA,2015-12-01,XOMA Announces License Agreement With Novo Nordisk For XMetA Program In Diabetes
XOMA,XOMA,2015-11-12,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2015-11-09,Strong On High Volume: XOMA (XOMA)
XOMA,XOMA,2015-11-05,XOMA Announces The Sale Of Its Manufacturing Facilities To Agenus
XOMA,XOMA,2015-11-05,XOMA Provides Corporate Update And Reports Financial Results For Third Quarter 2015
XOMA,XOMA,2015-10-29,XOMA To Announce Third Quarter 2015 Financial Results And Host Webcast On November 5
XOMA,XOMA,2015-10-26,XOMA Initiates Proof-of-Concept Study For XOMA 358 In Patients With Congenital Hyperinsulinism
XOMA,XOMA,2015-10-01,XOMA Announces Development And Commercialization Agreement For First-in-Class Anti-TGF-beta Antibody Program In Immuno-Oncology
XOMA,XOMA,2015-09-08,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against XOMA Corporation And Lead Plaintiff Deadline September 22, 2015
XOMA,XOMA,2015-08-18,TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors Of Important Deadline In Class Action - XOMA
XOMA,XOMA,2015-08-07,XOMA To Present At The 2015 Wedbush PacGrow Healthcare Conference
XOMA,XOMA,2015-08-06,XOMA Reports Financial Results For Second Quarter 2015
XOMA,XOMA,2015-08-03,Robbins Arroyo LLP: XOMA Corporation (XOMA) Misled Shareholders According To A Recently Filed Class Action
XOMA,XOMA,2015-07-30,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against XOMA Corporation
XOMA,XOMA,2015-07-30,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against Xoma Corporation
XOMA,XOMA,2015-07-23,XOMA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Xoma Corporation
XOMA,XOMA,2015-07-22,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of XOMA Corporation.
XOMA,XOMA,2015-07-22,Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
XOMA,XOMA,2015-07-22,XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study
XOMA,XOMA,2015-07-17,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
XOMA,XOMA,2015-07-16,XOMA To Announce Second Quarter 2015 Financial Results And Host Webcast On August 6
XOMA,XOMA,2015-07-10,XOMA Stock Closed in the Green Following Upbeat Piper Note
XOMA,XOMA,2015-07-10,Stock To Watch: XOMA (XOMA) In Perilous Reversal
XOMA,XOMA,2015-07-09,Trade-Ideas: XOMA (XOMA) Is Today's "Dead Cat Bounce" Stock
XOMA,XOMA,2015-07-01,Trade-Ideas: XOMA (XOMA) Is Today's Weak On High Relative Volume Stock
XOMA,XOMA,2015-06-30,XOMA (XOMA) Showing Signs Of A Dead Cat Bounce Today
XOMA,XOMA,2015-06-23,Interesting XOMA Put And Call Options For August 21st
XOMA,XOMA,2015-06-23,XOMA (XOMA) Is Weak On High Volume Today
XOMA,XOMA,2015-06-22,XOMA (XOMA) Is Strong On High Volume Today
XOMA,XOMA,2015-06-16,XOMA Receives Orphan Drug Designation For XOMA 358 From U.S. FDA For Treatment Of Congenital Hyperinsulinism (HI)
XOMA,XOMA,2015-06-11,XOMA (XOMA) Is Today's Strong On High Volume Stock
XOMA,XOMA,2015-05-28,XOMA Stock Gains After Reaching Necessary Number of Events to Analyze Behcets Disease Drug Study
XOMA,XOMA,2015-05-28,XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event
XOMA,XOMA,2015-05-19,First Week Of July 17th Options Trading For XOMA
XOMA,XOMA,2015-05-07,XOMA Reports First Quarter 2015 Achievements And Financial Results
XOMA,XOMA,2015-05-04,XOMA To Present At Credit Suisse Antibody Day 2015
XOMA,XOMA,2015-04-30,XOMA To Announce First Quarter 2015 Financial Results And Host Conference Call On May 7
XOMA,XOMA,2015-04-21,First Week Of XOMA December 18th Options Trading
XOMA,XOMA,2015-03-25,First Week Of May 15th Options Trading For XOMA
XOMA,XOMA,2015-03-23,XOMA (XOMA): Today's Weak On High Volume Stock
XOMA,XOMA,2015-03-11,XOMA Highlights Recent Achievements And Reports Fourth Quarter And Full-Year 2014 Financial Results
XOMA,XOMA,2015-03-07,XOMA Presents Positive Phase 1 XOMA 358 Data At The ENDO Meeting
XOMA,XOMA,2015-03-05,XOMA Will Present XOMA 358 Phase 1 Data At ENDO 2015
XOMA,XOMA,2015-03-03,XOMA Announces Retirement Of Fred Kurland And Appointment Of Thomas Burns As Chief Financial Officer
XOMA,XOMA,2015-02-26,XOMA To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Webcast On March 11
XOMA,XOMA,2015-02-24,First Week Of April 17th Options Trading For XOMA
XOMA,XOMA,2015-02-18,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2015-01-23,First Week Of September 18th Options Trading For XOMA
XOMA,XOMA,2015-01-23,XOMA (XOMA) Weak On High Volume
XOMA,XOMA,2015-01-06,Stock To Watch: XOMA (XOMA) In Perilous Reversal
XOMA,XOMA,2014-12-24,XOMA (XOMA) Is Today's Dead Cat Bounce Stock
XOMA,XOMA,2014-12-09,Today's Perilous Reversal Stock: XOMA (XOMA)
XOMA,XOMA,2014-12-09,XOMA Announces Pricing Of $40.0 Million Registered Offering Of Common Stock And Warrants
XOMA,XOMA,2014-12-05,Strong On High Relative Volume: XOMA (XOMA)
XOMA,XOMA,2014-12-03,XOMA (XOMA) Stock: Weak On High Volume Today
XOMA,XOMA,2014-11-24,XOMA To Present At The Piper Jaffray Healthcare Conference
XOMA,XOMA,2014-11-20,Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock
XOMA,XOMA,2014-11-17,Interesting XOMA Call Options For January 2017
XOMA,XOMA,2014-11-10,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2014-11-07,XOMA (XOMA) Stock: Weak On High Volume Today
XOMA,XOMA,2014-11-06,XOMA Highlights Recent Achievements And Reports Financial Results For The Third Quarter Of 2014
XOMA,XOMA,2014-11-04,XOMA Initiates Pivotal Phase 3 Gevokizumab Study In Patients With Pyoderma Gangrenosum
XOMA,XOMA,2014-10-27,XOMA To Announce Third Quarter 2014 Financial Results And Host Webcast On November 6
XOMA,XOMA,2014-10-09,XOMA Launches XOMA 358 Clinical Development
XOMA,XOMA,2014-10-06,The Texas A&M University System And XOMA License Innovative Manufacturing Technology
XOMA,XOMA,2014-09-30,XOMA Initiates U.S. Clinical Trial Of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD(TM)-US
XOMA,XOMA,2014-08-19,First Week of October 18th Options Trading For XOMA
XOMA,XOMA,2014-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2014
XOMA,XOMA,2014-08-06,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2014-07-30,XOMA To Announce Second Quarter 2014 Financial Results And Host Webcast On August 7
XOMA,XOMA,2014-07-22,First Week of March 2015 Options Trading For XOMA
XOMA,XOMA,2014-07-11,XOMA Corp Stock Sees Short Interest Drop 27.6%
XOMA,XOMA,2014-06-30,XOMA Call Today At 4:30pm ET/1:30pm PT To Confirm Communication Plan For EYEGUARD(TM)-B Clinical Program
XOMA,XOMA,2014-06-24,Interesting XOMA Put And Call Options For August 16th
XOMA,XOMA,2014-05-28,XOMA To Present At The Jefferies Global Healthcare Conference
XOMA,XOMA,2014-05-16,Insider Trading Alert - ITMN, WAC And XOMA Traded By Insiders
XOMA,XOMA,2014-05-12,XOMA To Present At The Bank Of America Merrill Lynch Health Care Conference
XOMA,XOMA,2014-05-07,XOMA Reports First Quarter 2014 Operational Highlights And Financial Results
XOMA,XOMA,2014-04-30,XOMA To Announce First Quarter 2014 Financial Results And Host Webcast On May 7
XOMA,XOMA,2014-04-29,Why XOMA (XOMA) Stock Is Surging Today
XOMA,XOMA,2014-04-28,XOMA Finalizes Plans For Gevokizumab Phase 3 Clinical Program In Pyoderma Gangrenosum
XOMA,XOMA,2014-04-22,First Week of December 20th Options Trading For XOMA
XOMA,XOMA,2014-03-21,Insider Trading Alert - SFY, XOMA And SNI Traded By Insiders
XOMA,XOMA,2014-03-07,XOMA Corp Stock Downgraded (XOMA)
XOMA,XOMA,2014-03-06,July 19th Options Now Available For XOMA
XOMA,XOMA,2014-03-06,XOMA (XOMA) Marked As A Dead Cat Bounce Stock
XOMA,XOMA,2014-03-05,Why XOMA Corporation (XOMA) Is Plunging Today
XOMA,XOMA,2014-03-05,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
XOMA,XOMA,2014-03-04,XOMA Reports 2013 Operational Highlights And Fourth Quarter And Full-Year 2013 Financial Results
XOMA,XOMA,2014-03-04,XOMA Provides Update On Gevokizumab Proof-of-Concept Program
XOMA,XOMA,2014-02-25,First Week of XOMA April 19th Options Trading
XOMA,XOMA,2014-02-24,XOMA Receives Orphan Drug Designation From U.S. FDA For Pyoderma Gangrenosum
XOMA,XOMA,2014-02-20,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2014-01-22,Interesting XOMA Put And Call Options For September 20th
XOMA,XOMA,2013-12-26,Short Interest In XOMA Drops 19.7%
XOMA,XOMA,2013-12-18,XOMA Announces Closing Of The Offering And Exercise Of Option
XOMA,XOMA,2013-12-16,Today's Dead Cat Bounce Stock Is XOMA (XOMA)
XOMA,XOMA,2013-12-13,XOMA Announces Pricing Of Approximately $50.0 Million Offering Of Common Stock
XOMA,XOMA,2013-12-12,XOMA Announces Proposed Public Offering Of Common Stock
XOMA,XOMA,2013-11-26,XOMA To Present At The Piper Jaffray Healthcare Conference
XOMA,XOMA,2013-11-20,XOMA Awarded Key Flexible Manufacturing Patent
XOMA,XOMA,2013-11-19,First Week Of January 2014 Options Trading For XOMA
XOMA,XOMA,2013-11-11,XOMA January 2016 Options Begin Trading
XOMA,XOMA,2013-11-08,Interesting XOMA Put And Call Options For January 2015
XOMA,XOMA,2013-11-07,XOMA Highlights Recent Achievements And Reports Financial Results For Third Quarter 2013
XOMA,XOMA,2013-11-06,XOMA To Present At The Credit Suisse Healthcare Conference
XOMA,XOMA,2013-10-31,XOMA To Announce Third Quarter 2013 Financial Results And Host Webcast On November 7
XOMA,XOMA,2013-10-30,Results From Two Phase 2 Studies In XOMA's Gevokizumab Proof-of-Concept Program Are Very Encouraging And Compelling
XOMA,XOMA,2013-10-25,Short Interest In XOMA Falls 31.6%
XOMA,XOMA,2013-10-01,Interesting XOMA Call For November 16th
XOMA,XOMA,2013-09-05,XOMA To Present At The Morgan Stanley Healthcare Conference
XOMA,XOMA,2013-08-23,XOMA Announces Closing Of The Offering And Exercise Of Over-Allotment Option
XOMA,XOMA,2013-08-20,XOMA Announces Pricing Of $27.5 Million Offering Of Common Stock
XOMA,XOMA,2013-08-08,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2013-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2013
XOMA,XOMA,2013-07-25,XOMA To Announce Second Quarter 2013 Financial Results And Host Webcast On August 7
XOMA,XOMA,2013-07-22,XOMA Completes Enrollment In Phase 2 Proof-of-Concept Gevokizumab Trial In Patients With Erosive Osteoarthritis Of The Hand
XOMA,XOMA,2013-07-12,Short Interest Moves 10.7% Lower For XOMA
XOMA,XOMA,2013-07-03,XOMA Transfers Perindopril Franchise Rights To Symplmed
XOMA,XOMA,2013-07-02,XOMA To Present At The JMP Securities Healthcare Conference
XOMA,XOMA,2013-06-25,XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program For Gevokizumab
XOMA,XOMA,2017-03-23,XOMA Announces Four Presentations At The 2017 ENDO Meeting
XOMA,XOMA,2017-03-22,XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation
XOMA,XOMA,2017-03-16,XOMA Reports Fourth Quarter And Full Year 2016 Financial Results
XOMA,XOMA,2017-03-14,XOMA To Announce Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call Focused On Its New Strategic Direction On March 16, 2017
XOMA,XOMA,2017-02-28,XOMA To Present New Strategic Initiatives At The Cowen And Company 37th Annual Health Care Conference
XOMA,XOMA,2017-02-16,XOMA Appoints Matthew Perry To Its Board Of Directors
XOMA,XOMA,2017-02-13,XOMA Announces Pricing Of $25 Million Registered Offering Of Common Stock And Convertible Preferred Stock
XOMA,XOMA,2017-01-31,XOMA Establishes Proof-of-Concept For 358 In Congenital Hyperinsulinism And Hypoglycemia Post-Bariatric Surgery
XOMA,XOMA,2016-12-21,XOMA Announces Up To $22 Million Generated From Sale Of Royalty Streams From Two License Agreements To HealthCare Royalty Partners And Provides Corporate Update
XOMA,XOMA,2016-11-09,XOMA Reports Third Quarter 2016 Achievements And Financial Results
XOMA,XOMA,2016-11-08,New XOMA Antibodies Unveiled At The Society For Immunotherapy Of Cancer 31st Annual Meeting
XOMA,XOMA,2016-10-19,XOMA Reaches Analyst Target Price
XOMA,XOMA,2016-10-19,XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study For XOMA 358 In Children With Congenital Hyperinsulinism
XOMA,XOMA,2016-10-14,XOMA Announces Reverse Stock Split
XOMA,XOMA,2016-09-15,XOMA Provides Update From Ongoing Phase 2 XOMA 358 Clinical Studies
XOMA,XOMA,2016-09-06,XOMA To Host XOMA 358 Clinical Update Webcast And Conference Call On September 15, 2016
XOMA,XOMA,2016-08-11,XOMA To Present At The 2016 Wedbush PacGrow Healthcare Conference
XOMA,XOMA,2016-08-03,XOMA Reports Second Quarter 2016 Achievements And Financial Results
XOMA,XOMA,2016-07-20,XOMA Receives Orphan Drug Designation In The European Union For XOMA 358 For Treatment Of Congenital Hyperinsulinism
XOMA,XOMA,2016-07-05,XOMA To Present At The Cantor Fitzgerald Healthcare Conference
XOMA,XOMA,2016-06-28,XOMA Initiates Phase 2 Proof-of-Concept Study Of XOMA 213
XOMA,XOMA,2016-06-02,XOMA To Present At The Jefferies Global Healthcare Conference
XOMA,XOMA,2016-05-04,XOMA Reports First Quarter 2016 Operational Achievements And Financial Results
XOMA,XOMA,2016-04-27,XOMA Initiates XOMA 358 Proof-of-Concept Study In Patients With Hypoglycemia Post Gastric Bypass Surgery
XOMA,XOMA,2016-04-04,XOMA Presented First Data From Novel Antibody Fragment To Address Severe Acute Hypoglycemia At The ENDO Meeting
XOMA,XOMA,2016-03-11,XOMA (XOMA) Weak On High Volume
XOMA,XOMA,2016-03-10,Xoma Stock Soaring on Q4 Earnings Beat
XOMA,XOMA,2016-03-09,Xoma Stock Surges in After-Hours Trading on Q4 Results
XOMA,XOMA,2016-03-09,XOMA Reports Fourth Quarter And Full-Year 2015 Financial Results
XOMA,XOMA,2016-03-02,XOMA To Present At The Cowen & Company Health Care Conference
XOMA,XOMA,2016-02-24,XOMA To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Webcast On March 9
XOMA,XOMA,2015-12-11,Friday Small-Cap Focus: Xoma
XOMA,XOMA,2015-12-01,Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million
XOMA,XOMA,2015-12-01,XOMA Announces License Agreement With Novo Nordisk For XMetA Program In Diabetes
XOMA,XOMA,2015-11-12,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2015-11-09,Strong On High Volume: XOMA (XOMA)
XOMA,XOMA,2015-11-05,XOMA Announces The Sale Of Its Manufacturing Facilities To Agenus
XOMA,XOMA,2015-11-05,XOMA Provides Corporate Update And Reports Financial Results For Third Quarter 2015
XOMA,XOMA,2015-10-29,XOMA To Announce Third Quarter 2015 Financial Results And Host Webcast On November 5
XOMA,XOMA,2015-10-26,XOMA Initiates Proof-of-Concept Study For XOMA 358 In Patients With Congenital Hyperinsulinism
XOMA,XOMA,2015-10-01,XOMA Announces Development And Commercialization Agreement For First-in-Class Anti-TGF-beta Antibody Program In Immuno-Oncology
XOMA,XOMA,2015-09-08,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against XOMA Corporation And Lead Plaintiff Deadline September 22, 2015
XOMA,XOMA,2015-08-18,TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors Of Important Deadline In Class Action - XOMA
XOMA,XOMA,2015-08-07,XOMA To Present At The 2015 Wedbush PacGrow Healthcare Conference
XOMA,XOMA,2015-08-06,XOMA Reports Financial Results For Second Quarter 2015
XOMA,XOMA,2015-08-03,Robbins Arroyo LLP: XOMA Corporation (XOMA) Misled Shareholders According To A Recently Filed Class Action
XOMA,XOMA,2015-07-30,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against XOMA Corporation
XOMA,XOMA,2015-07-30,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against Xoma Corporation
XOMA,XOMA,2015-07-23,XOMA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Xoma Corporation
XOMA,XOMA,2015-07-22,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of XOMA Corporation.
XOMA,XOMA,2015-07-22,Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
XOMA,XOMA,2015-07-22,XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study
XOMA,XOMA,2015-07-17,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
XOMA,XOMA,2015-07-16,XOMA To Announce Second Quarter 2015 Financial Results And Host Webcast On August 6
XOMA,XOMA,2015-07-10,XOMA Stock Closed in the Green Following Upbeat Piper Note
XOMA,XOMA,2015-07-10,Stock To Watch: XOMA (XOMA) In Perilous Reversal
XOMA,XOMA,2015-07-09,Trade-Ideas: XOMA (XOMA) Is Today's "Dead Cat Bounce" Stock
XOMA,XOMA,2015-07-01,Trade-Ideas: XOMA (XOMA) Is Today's Weak On High Relative Volume Stock
XOMA,XOMA,2015-06-30,XOMA (XOMA) Showing Signs Of A Dead Cat Bounce Today
XOMA,XOMA,2015-06-23,Interesting XOMA Put And Call Options For August 21st
XOMA,XOMA,2015-06-23,XOMA (XOMA) Is Weak On High Volume Today
XOMA,XOMA,2015-06-22,XOMA (XOMA) Is Strong On High Volume Today
XOMA,XOMA,2015-06-16,XOMA Receives Orphan Drug Designation For XOMA 358 From U.S. FDA For Treatment Of Congenital Hyperinsulinism (HI)
XOMA,XOMA,2015-06-11,XOMA (XOMA) Is Today's Strong On High Volume Stock
XOMA,XOMA,2015-05-28,XOMA Stock Gains After Reaching Necessary Number of Events to Analyze Behcets Disease Drug Study
XOMA,XOMA,2015-05-28,XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event
XOMA,XOMA,2015-05-19,First Week Of July 17th Options Trading For XOMA
XOMA,XOMA,2015-05-07,XOMA Reports First Quarter 2015 Achievements And Financial Results
XOMA,XOMA,2015-05-04,XOMA To Present At Credit Suisse Antibody Day 2015
XOMA,XOMA,2015-04-30,XOMA To Announce First Quarter 2015 Financial Results And Host Conference Call On May 7
XOMA,XOMA,2015-04-21,First Week Of XOMA December 18th Options Trading
XOMA,XOMA,2015-03-25,First Week Of May 15th Options Trading For XOMA
XOMA,XOMA,2015-03-23,XOMA (XOMA): Today's Weak On High Volume Stock
XOMA,XOMA,2015-03-11,XOMA Highlights Recent Achievements And Reports Fourth Quarter And Full-Year 2014 Financial Results
XOMA,XOMA,2015-03-07,XOMA Presents Positive Phase 1 XOMA 358 Data At The ENDO Meeting
XOMA,XOMA,2015-03-05,XOMA Will Present XOMA 358 Phase 1 Data At ENDO 2015
XOMA,XOMA,2015-03-03,XOMA Announces Retirement Of Fred Kurland And Appointment Of Thomas Burns As Chief Financial Officer
XOMA,XOMA,2015-02-26,XOMA To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Webcast On March 11
XOMA,XOMA,2015-02-24,First Week Of April 17th Options Trading For XOMA
XOMA,XOMA,2015-02-18,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2015-01-23,First Week Of September 18th Options Trading For XOMA
XOMA,XOMA,2015-01-23,XOMA (XOMA) Weak On High Volume
XOMA,XOMA,2015-01-06,Stock To Watch: XOMA (XOMA) In Perilous Reversal
XOMA,XOMA,2014-12-24,XOMA (XOMA) Is Today's Dead Cat Bounce Stock
XOMA,XOMA,2014-12-09,Today's Perilous Reversal Stock: XOMA (XOMA)
XOMA,XOMA,2014-12-09,XOMA Announces Pricing Of $40.0 Million Registered Offering Of Common Stock And Warrants
XOMA,XOMA,2014-12-05,Strong On High Relative Volume: XOMA (XOMA)
XOMA,XOMA,2014-12-03,XOMA (XOMA) Stock: Weak On High Volume Today
XOMA,XOMA,2014-11-24,XOMA To Present At The Piper Jaffray Healthcare Conference
XOMA,XOMA,2014-11-20,Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock
XOMA,XOMA,2014-11-17,Interesting XOMA Call Options For January 2017
XOMA,XOMA,2014-11-10,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2014-11-07,XOMA (XOMA) Stock: Weak On High Volume Today
XOMA,XOMA,2014-11-06,XOMA Highlights Recent Achievements And Reports Financial Results For The Third Quarter Of 2014
XOMA,XOMA,2014-11-04,XOMA Initiates Pivotal Phase 3 Gevokizumab Study In Patients With Pyoderma Gangrenosum
XOMA,XOMA,2014-10-27,XOMA To Announce Third Quarter 2014 Financial Results And Host Webcast On November 6
XOMA,XOMA,2014-10-09,XOMA Launches XOMA 358 Clinical Development
XOMA,XOMA,2014-10-06,The Texas A&M University System And XOMA License Innovative Manufacturing Technology
XOMA,XOMA,2014-09-30,XOMA Initiates U.S. Clinical Trial Of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD(TM)-US
XOMA,XOMA,2014-08-19,First Week of October 18th Options Trading For XOMA
XOMA,XOMA,2014-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2014
XOMA,XOMA,2014-08-06,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2014-07-30,XOMA To Announce Second Quarter 2014 Financial Results And Host Webcast On August 7
XOMA,XOMA,2014-07-22,First Week of March 2015 Options Trading For XOMA
XOMA,XOMA,2014-07-11,XOMA Corp Stock Sees Short Interest Drop 27.6%
XOMA,XOMA,2014-06-30,XOMA Call Today At 4:30pm ET/1:30pm PT To Confirm Communication Plan For EYEGUARD(TM)-B Clinical Program
XOMA,XOMA,2014-06-24,Interesting XOMA Put And Call Options For August 16th
XOMA,XOMA,2014-05-28,XOMA To Present At The Jefferies Global Healthcare Conference
XOMA,XOMA,2014-05-16,Insider Trading Alert - ITMN, WAC And XOMA Traded By Insiders
XOMA,XOMA,2014-05-12,XOMA To Present At The Bank Of America Merrill Lynch Health Care Conference
XOMA,XOMA,2014-05-07,XOMA Reports First Quarter 2014 Operational Highlights And Financial Results
XOMA,XOMA,2014-04-30,XOMA To Announce First Quarter 2014 Financial Results And Host Webcast On May 7
XOMA,XOMA,2014-04-29,Why XOMA (XOMA) Stock Is Surging Today
XOMA,XOMA,2014-04-28,XOMA Finalizes Plans For Gevokizumab Phase 3 Clinical Program In Pyoderma Gangrenosum
XOMA,XOMA,2014-04-22,First Week of December 20th Options Trading For XOMA
XOMA,XOMA,2014-03-21,Insider Trading Alert - SFY, XOMA And SNI Traded By Insiders
XOMA,XOMA,2014-03-07,XOMA Corp Stock Downgraded (XOMA)
XOMA,XOMA,2014-03-06,July 19th Options Now Available For XOMA
XOMA,XOMA,2014-03-06,XOMA (XOMA) Marked As A Dead Cat Bounce Stock
XOMA,XOMA,2014-03-05,Why XOMA Corporation (XOMA) Is Plunging Today
XOMA,XOMA,2014-03-05,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
XOMA,XOMA,2014-03-04,XOMA Reports 2013 Operational Highlights And Fourth Quarter And Full-Year 2013 Financial Results
XOMA,XOMA,2014-03-04,XOMA Provides Update On Gevokizumab Proof-of-Concept Program
XOMA,XOMA,2014-02-25,First Week of XOMA April 19th Options Trading
XOMA,XOMA,2014-02-24,XOMA Receives Orphan Drug Designation From U.S. FDA For Pyoderma Gangrenosum
XOMA,XOMA,2014-02-20,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2014-01-22,Interesting XOMA Put And Call Options For September 20th
XOMA,XOMA,2013-12-26,Short Interest In XOMA Drops 19.7%
XOMA,XOMA,2013-12-18,XOMA Announces Closing Of The Offering And Exercise Of Option
XOMA,XOMA,2013-12-16,Today's Dead Cat Bounce Stock Is XOMA (XOMA)
XOMA,XOMA,2013-12-13,XOMA Announces Pricing Of Approximately $50.0 Million Offering Of Common Stock
XOMA,XOMA,2013-12-12,XOMA Announces Proposed Public Offering Of Common Stock
XOMA,XOMA,2013-11-26,XOMA To Present At The Piper Jaffray Healthcare Conference
XOMA,XOMA,2013-11-20,XOMA Awarded Key Flexible Manufacturing Patent
XOMA,XOMA,2013-11-19,First Week Of January 2014 Options Trading For XOMA
XOMA,XOMA,2013-11-11,XOMA January 2016 Options Begin Trading
XOMA,XOMA,2013-11-08,Interesting XOMA Put And Call Options For January 2015
XOMA,XOMA,2013-11-07,XOMA Highlights Recent Achievements And Reports Financial Results For Third Quarter 2013
XOMA,XOMA,2013-11-06,XOMA To Present At The Credit Suisse Healthcare Conference
XOMA,XOMA,2013-10-31,XOMA To Announce Third Quarter 2013 Financial Results And Host Webcast On November 7
XOMA,XOMA,2013-10-30,Results From Two Phase 2 Studies In XOMA's Gevokizumab Proof-of-Concept Program Are Very Encouraging And Compelling
XOMA,XOMA,2013-10-25,Short Interest In XOMA Falls 31.6%
XOMA,XOMA,2013-10-01,Interesting XOMA Call For November 16th
XOMA,XOMA,2013-09-05,XOMA To Present At The Morgan Stanley Healthcare Conference
XOMA,XOMA,2013-08-23,XOMA Announces Closing Of The Offering And Exercise Of Over-Allotment Option
XOMA,XOMA,2013-08-20,XOMA Announces Pricing Of $27.5 Million Offering Of Common Stock
XOMA,XOMA,2013-08-08,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2013-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2013
XOMA,XOMA,2013-07-25,XOMA To Announce Second Quarter 2013 Financial Results And Host Webcast On August 7
XOMA,XOMA,2013-07-22,XOMA Completes Enrollment In Phase 2 Proof-of-Concept Gevokizumab Trial In Patients With Erosive Osteoarthritis Of The Hand
XOMA,XOMA,2013-07-12,Short Interest Moves 10.7% Lower For XOMA
XOMA,XOMA,2013-07-03,XOMA Transfers Perindopril Franchise Rights To Symplmed
XOMA,XOMA,2013-07-02,XOMA To Present At The JMP Securities Healthcare Conference
XOMA,XOMA,2013-06-25,XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program For Gevokizumab
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
BLRX,BL-8040,2017-03-20,BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2017-01-17,BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
BLRX,BL-8040,2016-12-05,BioLineRx Presents Positive Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
BLRX,BL-8040,2016-11-03,BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
BLRX,BL-8040,2016-10-05,BioLineRx Announces Acceptance Of BL-8040 Abstracts For Oral And Poster Presentations At 58th American Society Of Hematology (ASH) Annual Meeting
BLRX,BL-8040,2016-09-20,BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
BLRX,BL-8040,2016-09-07,BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications
BLRX,BL-8040,2016-08-08,BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
BLRX,BL-8040,2016-06-28,BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
BLRX,BL-8040,2016-05-19,BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences
BLRX,BL-8040,2016-03-23,BioLineRx Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2016-01-12,BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer
BLRX,BL-8040,2015-12-14,BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2014-12-12,BioLineRx Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform
BLRX,BL-8040,2014-09-03,BioLineRx Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2014-03-14,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 In Immunotherapy
BLRX,BL-8040,2013-09-09,BioLineRx's BL-8040 Receives Orphan Drug Designation For Treatment Of AML
BLRX,BL-8040,2013-09-03,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 For Obtaining Stem Cells
BLRX,BL-8040,2013-08-05,BioLineRx Announces Publication Of Positive Pre-Clinical Results For BL-8040 In Treatment Of Thrombocytopenia
BLRX,BL-8040,2012-11-07,BioLineRx Announces BL-8040, For The Treatment Of Leukemia And Other Types Of Hematological Cancer, To Be Presented At 2012 ASH Annual Meeting
BLRX,BL-8040,2017-03-20,BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2017-01-17,BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
BLRX,BL-8040,2016-12-05,BioLineRx Presents Positive Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
BLRX,BL-8040,2016-11-03,BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
BLRX,BL-8040,2016-10-05,BioLineRx Announces Acceptance Of BL-8040 Abstracts For Oral And Poster Presentations At 58th American Society Of Hematology (ASH) Annual Meeting
BLRX,BL-8040,2016-09-20,BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
BLRX,BL-8040,2016-09-07,BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications
BLRX,BL-8040,2016-08-08,BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
BLRX,BL-8040,2016-06-28,BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
BLRX,BL-8040,2016-05-19,BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences
BLRX,BL-8040,2016-03-23,BioLineRx Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2016-01-12,BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer
BLRX,BL-8040,2015-12-14,BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2014-12-12,BioLineRx Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform
BLRX,BL-8040,2014-09-03,BioLineRx Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2014-03-14,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 In Immunotherapy
BLRX,BL-8040,2013-09-09,BioLineRx's BL-8040 Receives Orphan Drug Designation For Treatment Of AML
BLRX,BL-8040,2013-09-03,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 For Obtaining Stem Cells
BLRX,BL-8040,2013-08-05,BioLineRx Announces Publication Of Positive Pre-Clinical Results For BL-8040 In Treatment Of Thrombocytopenia
BLRX,BL-8040,2012-11-07,BioLineRx Announces BL-8040, For The Treatment Of Leukemia And Other Types Of Hematological Cancer, To Be Presented At 2012 ASH Annual Meeting
CLCD,Lasmiditan,2016-10-05,CoLucid Pharmaceuticals Announces Additional Analyses Of Lasmiditan's Onset Of Action Data From SAMURAI And Supporting Non-Clinical Data
CLCD,Lasmiditan,2016-09-06,CoLucid Pharmaceuticals Announces Achievement Of Both Primary And Key Secondary Endpoints In The SAMURAI Phase 3 Pivotal Trial Of Lasmiditan In Migraine
CLCD,Lasmiditan,2016-06-07,CoLucid Pharmaceuticals Announces Last Patient Randomized In SAMURAI Phase 3 Pivotal Trial Of Lasmiditan In Migraine
CLCD,Lasmiditan,2016-05-19,CoLucid Pharmaceuticals Announces Initiation Of Second Phase 3 Pivotal Trial Of Lasmiditan In Migraine
CLCD,Lasmiditan,2016-02-23,CoLucid Pharmaceuticals Announces Confirmatory Support For Non-vasoconstrictive Mechanism Of Action For Lasmiditan
CLCD,Lasmiditan,2015-10-08,CoLucid Pharmaceuticals Announces Initiation Of Phase 3 Long-Term, Open-Label Trial Of Lasmiditan In Migraine
ARLZ,YOSPRALA,2017-01-11,Aralez Announces Issuance Of Additional U.S. Patent For Yosprala
ARLZ,YOSPRALA,2017-01-09,Aralez Provides Update On PBM Formulary Status For Yosprala
ARLZ,YOSPRALA,2016-12-15,Aralez Provides Update On PBM Formulary Status For Yosprala
ARLZ,YOSPRALA,2016-10-03,Aralez Announces U.S. Commercial Launch Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
ARLZ,YOSPRALA,2016-09-15,Aralez Pharmaceuticals (ARLZ) Stock Closed Higher on Yosprala FDA Approval
ARLZ,YOSPRALA,2016-09-15,Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
ARLZ,YOSPRALA,2016-03-28,Aralez Announces FDA Acceptance Of New Drug Application For YOSPRALA™
ARLZ,YOSPRALA,2016-03-15,Aralez Resubmits To FDA New Drug Application For YOSPRALA
TGTX,TG-1101,2017-03-06,TG Therapeutics Announces Positive Topline Data From Phase 3 GENUINE Study Of TG-1101 In Combination With Ibrutinib In Patients With High Risk Chronic Lymphocytic Leukemia (CLL)
TGTX,TG-1101,2017-02-21,TG Therapeutics, Inc. Announces Publication of Clinical Data From The Phase 1/2 Trial Of TG-1101 (ublituximab) Monotherapy In The British Journal Of Haematology
TGTX,TG-1101,2017-01-24,TG Therapeutics Announces Orphan Drug Designation For The Combination Of TG-1101 And TGR-1202 For The Treatment Of Diffuse Large B-cell Lymphoma
TGTX,TG-1101,2017-01-09,TG Therapeutics Announces Orphan Drug Designation For The Combination Of TG-1101 And TGR-1202 For Treatment Of Chronic Lymphocytic Leukemia
TGTX,TG-1101,2016-12-16,TG Therapeutics, Inc. Announces Publication Of Clinical Data From The Phase 2 Trial Of TG-1101 (ublituximab) In Combination With Ibrutinib In The British Journal Of Haematology
TGTX,TG-1101,2016-09-16,TG Therapeutics, Inc. Announces Presentation Of Data From A Phase Ib Clinical Trial Of TG-1101 In Patients With Neuromyelitis Optica (NMO) At The 32nd Congress Of The European Committee For Treatment And Research In Multiple Sclerosis
TGTX,TG-1101,2016-08-26,TG Therapeutics Announces Orphan Drug Designation For TG-1101 For The Treatment Of Neuromyelitis Optica And Neuromyelitis Optica Spectrum Disorder
TGTX,TG-1101,2016-05-03,TG Therapeutics, Inc. Launches First Clinical Trial In Multiple Sclerosis (MS) For TG-1101 (Ublituximab)
TGTX,TG-1101,2016-04-13,TG Therapeutics, Inc. Announces Issuance Of Composition Of Matter Patent For TG-1101 In The United States
TGTX,TG-1101,2015-12-07,TG Therapeutics, Inc. Announces Data Presentations For TGR-1202 And TG-1101 In Combination With Ibrutinib At The 57th American Society Of Hematology Annual Meeting
TGTX,TG-1101,2015-09-17,TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With The FDA For The First Phase 3 Clinical Trial Of Its Proprietary Combination Regimen Of TG-1101 (ublituximab) In Combination With TGR-1202 For Patients With Chronic Lymphocytic Leukemia (CLL)
TGTX,TG-1101,2015-09-09,TG Therapeutics, Inc. Launches Phase 1/2 "Triple-Therapy" Study With TGR-1202 + TG-1101 + The PD-1 Checkpoint Inhibitor Pembrolizumab In Patients With Advanced Chronic Lymphocytic Leukemia (CLL) At The University Of Pennsylvania's Abramson Cancer Center
TGTX,TG-1101,2015-06-18,Updated Results From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) In Combination With Ibrutinib Confirms Robust Clinical Activity With A Favorable Safety Profile In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)
TGTX,TG-1101,2015-06-11,TG Therapeutics To Present Clinical Data On TG-1101 And TGR-1202 At The 20th Congress Of The European Hematology Association And The 13th International Congress On Malignant Lymphoma
TGTX,TG-1101,2015-06-01,TG Therapeutics Announces The Triple Combination Of TG-1101, TGR-1202 And Ibrutinib Is Safe And Highly Active In Patients With Advanced B-Cell Malignancies
TGTX,TG-1101,2015-05-31,TG Therapeutics, Inc. Announces Presentations Of Its Proprietary Combination Of TG-1101 Plus TGR-1202 As Well As TGR-1202 As A Single Agent In Ongoing Phase I/Ib Dose Escalation Clinical Studies
ACHN,Odalasvir,2016-09-23,Achillion Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen's Phase 2 Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naive HCV
ACHN,Odalasvir,2016-09-09,Achillion Announces 100% SVR Reported In Janssen's Phase 2a Trial Evaluating Triple Combination Of Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naive HCV
ACHN,Odalasvir,2016-08-11,Achillion Announces Upcoming Presentation Of Interim Phase 2a Results From The Janssen Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference
ACHN,Odalasvir,2015-10-16,Achillion Announces That Janssen Has Initiated A Phase 2a Study To Evaluate The Combination Of AL-335, Odalasvir (ACH-3102), And Simeprevir For The Treatment Of Genotype 1 Chronic HCV
ACHN,Odalasvir,2015-08-03,Achillion Announces That Janssen Has Initiated A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir (ACH-3102) On AL-335 Pharmacokinetics
ACHN,Odalasvir,2016-09-23,Achillion Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen's Phase 2 Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naive HCV
ACHN,Odalasvir,2016-09-09,Achillion Announces 100% SVR Reported In Janssen's Phase 2a Trial Evaluating Triple Combination Of Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naive HCV
ACHN,Odalasvir,2016-08-11,Achillion Announces Upcoming Presentation Of Interim Phase 2a Results From The Janssen Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference
ACHN,Odalasvir,2015-10-16,Achillion Announces That Janssen Has Initiated A Phase 2a Study To Evaluate The Combination Of AL-335, Odalasvir (ACH-3102), And Simeprevir For The Treatment Of Genotype 1 Chronic HCV
ACHN,Odalasvir,2015-08-03,Achillion Announces That Janssen Has Initiated A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir (ACH-3102) On AL-335 Pharmacokinetics
ALNY,ALN-GO1,2016-09-24,Alnylam Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1
ALNY,ALN-GO1,2016-03-09,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
ALNY,ALN-GO1,2015-12-21,Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
ALNY,ALN-GO1,2015-09-08,Alnylam Accelerates Development Of ALN-GO1, A Subcutaneously Administered Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
ALNY,ALN-GO1,2016-09-24,Alnylam Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1
ALNY,ALN-GO1,2016-03-09,Alnylam Initiates Phase 1/2 Clinical Trial For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
ALNY,ALN-GO1,2015-12-21,Alnylam Files Clinical Trial Application (CTA) For ALN-GO1, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
ALNY,ALN-GO1,2015-09-08,Alnylam Accelerates Development Of ALN-GO1, A Subcutaneously Administered Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
DRRX,Remoxy,2016-09-26,DURECT's Licensee Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY® ER (oxycodone) Extended-Release Capsules CII
DRRX,Remoxy,2016-07-01,DURECT Provides REMOXY® Update
DRRX,Remoxy,2016-05-19,DURECT Announces FDA Advisory Committee Meeting For REMOXY®
DRRX,Remoxy,2016-05-11,DURECT Announces New REMOXY® Data Being Presented At American Pain Society Meeting
DRRX,Remoxy,2016-04-12,DURECT Announces FDA Acceptance Of REMOXY® NDA, PDUFA Date Of September 25, 2016
DRRX,Remoxy,2016-03-29,DURECT Announces Resubmission Of REMOXY® New Drug Application To The U.S. Food And Drug Administration
DRRX,Remoxy,2014-10-27,DURECT Provides Update On REMOXY® And POSIDUR™ Programs
DRRX,Remoxy,2013-10-22,Pfizer Proceeding With REMOXY® Development
DRRX,Remoxy,2013-05-10,DURECT Announces Update On Remoxy®
DRRX,Remoxy,2011-06-24,Pfizer Receives Complete Response Letter From FDA For REMOXY®
DRRX,Remoxy,2011-01-27,REMOXY® New Drug Application Accepted By The FDA With PDUFA Goal Date Of June 23, 2011
DRRX,Remoxy,2010-12-27,REMOXY® New Drug Application Resubmitted
DRRX,Remoxy,2016-09-26,DURECT's Licensee Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY® ER (oxycodone) Extended-Release Capsules CII
DRRX,Remoxy,2016-07-01,DURECT Provides REMOXY® Update
DRRX,Remoxy,2016-05-19,DURECT Announces FDA Advisory Committee Meeting For REMOXY®
DRRX,Remoxy,2016-05-11,DURECT Announces New REMOXY® Data Being Presented At American Pain Society Meeting
DRRX,Remoxy,2016-04-12,DURECT Announces FDA Acceptance Of REMOXY® NDA, PDUFA Date Of September 25, 2016
DRRX,Remoxy,2016-03-29,DURECT Announces Resubmission Of REMOXY® New Drug Application To The U.S. Food And Drug Administration
DRRX,Remoxy,2014-10-27,DURECT Provides Update On REMOXY® And POSIDUR™ Programs
DRRX,Remoxy,2013-10-22,Pfizer Proceeding With REMOXY® Development
DRRX,Remoxy,2013-05-10,DURECT Announces Update On Remoxy®
DRRX,Remoxy,2011-06-24,Pfizer Receives Complete Response Letter From FDA For REMOXY®
DRRX,Remoxy,2011-01-27,REMOXY® New Drug Application Accepted By The FDA With PDUFA Goal Date Of June 23, 2011
DRRX,Remoxy,2010-12-27,REMOXY® New Drug Application Resubmitted
PTIE,Remoxy,2017-03-20,Pain Therapeutics Announces Positive Regulatory Guidance For REMOXY™ ER
PTIE,Remoxy,2016-12-20,Pain Therapeutics To Discuss REMOXY® ER With FDA
PTIE,Remoxy,2016-09-26,DURECT's Licensee Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY® ER (oxycodone) Extended-Release Capsules CII
PTIE,Remoxy,2016-09-26,Complete Response Letter For REMOXY®
PTIE,Remoxy,2016-07-01,DURECT Provides REMOXY® Update
PTIE,Remoxy,2016-07-01,Pain Therapeutics Announces Advisory Committee Meeting For REMOXY® Is Not Needed
PTIE,Remoxy,2016-05-19,DURECT Announces FDA Advisory Committee Meeting For REMOXY®
PTIE,Remoxy,2016-05-19,Pain Therapeutics Announces FDA Advisory Committee Meeting For REMOXY®
PTIE,Remoxy,2016-05-11,Pain Therapeutics To Present New REMOXY Data At American Pain Society Meeting
PTIE,Remoxy,2016-05-11,DURECT Announces New REMOXY® Data Being Presented At American Pain Society Meeting
PTIE,Remoxy,2016-04-12,DURECT Announces FDA Acceptance Of REMOXY® NDA, PDUFA Date Of September 25, 2016
PTIE,Remoxy,2016-04-12,FDA Accepts REMOXY NDA For Review, Sets PDUFA Date Of September 25, 2016
PTIE,Remoxy,2016-03-29,DURECT Announces Resubmission Of REMOXY® New Drug Application To The U.S. Food And Drug Administration
PTIE,Remoxy,2016-03-29,Pain Therapeutics Resubmits REMOXY New Drug Application To The U.S. Food And Drug Administration
PTIE,Remoxy,2015-11-09,Pain Therapeutics Reports Q3 2015 Financial Results And Update On REMOXY
PTIE,Remoxy,2015-05-12,Pain Therapeutics Announces Positive Top-Line Results From Human Abuse Potential Study With REMOXY
PTIE,Remoxy,2015-04-21,Pain Therapeutics Resumes Responsibility For REMOXY
PTIE,Remoxy,2014-10-27,DURECT Provides Update On REMOXY® And POSIDUR™ Programs
PTIE,Remoxy,2014-10-27,Pain Therapeutics To Regain Full Rights To REMOXY(R)
PTIE,Remoxy,2013-10-22,Pfizer Proceeding With REMOXY® Development
PTIE,Remoxy,2013-10-22,Pain Therapeutics Reports Pfizer Elects To Continue Development Of REMOXY(R)
PTIE,Remoxy,2011-06-24,Pfizer Receives Complete Response Letter From FDA For REMOXY®
PTIE,Remoxy,2011-06-24,FDA Complete Response Letter Received For REMOXY
PTIE,Remoxy,2011-01-27,REMOXY® New Drug Application Accepted By The FDA With PDUFA Goal Date Of June 23, 2011
PTIE,Remoxy,2011-01-27,REMOXY New Drug Application Accepted By FDA
PTIE,Remoxy,2010-12-27,King Pharmaceuticals And Pain Therapeutics Announce Resubmission Of New Drug Application For REMOXY(R)
PTIE,Remoxy,2010-12-27,REMOXY® New Drug Application Resubmitted
PTIE,Remoxy,2010-06-28,Pain Therapeutics Modifies Strategic Alliance For REMOXY(R) In Europe
ABUS,ARB-1467,2016-12-12,Arbutus Provides Additional Data From The ARB-1467 Phase II Clinical Trial In HBV Patients
ABUS,ARB-1467,2016-09-29,Arbutus Reports Interim Multi-Dose Results From Phase II Clinical Trial Of ARB-1467 In Patients With Chronic HBV Infection
ACRS,A-101,2017-02-27,Aclaris Therapeutics Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis - A Common Skin Condition
ACRS,A-101,2016-11-15,Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition
ACRS,A-101,2016-08-18,Aclaris Therapeutics Announces Positive Results In Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts  
ACRS,A-101,2016-07-25,Aclaris Therapeutics Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs
ACRS,A-101,2016-01-19,Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis
ACRS,A-101,2015-12-07,Aclaris Therapeutics Initiates Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts
ACRS,A-101,2017-02-27,Aclaris Therapeutics Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis - A Common Skin Condition
ACRS,A-101,2016-11-15,Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition
ACRS,A-101,2016-08-18,Aclaris Therapeutics Announces Positive Results In Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts  
ACRS,A-101,2016-07-25,Aclaris Therapeutics Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs
ACRS,A-101,2016-01-19,Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis
ACRS,A-101,2015-12-07,Aclaris Therapeutics Initiates Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts
ACRX,ARX-04,2017-01-08,AcelRx Pharmaceuticals Provides Guidance On 2017 Milestones For ARX-04, Now Known As DSUVIA™ In The United States, For The Treatment Of Moderate-to-Severe Acute Pain
ACRX,ARX-04,2017-01-08,AcelRx Pharmaceuticals Announces DSUVIA™ As Brand Name For ARX-04 In The United States
ACRX,ARX-04,2016-12-13,AcelRx Pharmaceuticals Submits New Drug Application For ARX-04 For The Treatment Of Moderate-To-Severe Acute Pain
ACRX,ARX-04,2016-12-06,AcelRx Pharmaceuticals Reports On ARX-04 Market And Landscape Presented At Analyst & Investor Event
ACRX,ARX-04,2016-09-15,AcelRx Reports Positive Results For ARX-04 (sufentanil Sublingual Tablet, 30 Mcg), Including In Elderly Patients And Patients With Organ Impairment, In Third Phase 3 Registration Trial, SAP303
ACRX,ARX-04,2016-09-14,AcelRx Pharmaceuticals To Announce Topline Results In Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain
ACRX,ARX-04,2016-08-15,AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met Its Primary Endpoint, Reduced Pain Intensity In ER Patients With Moderate-to-Severe Acute Pain
ACRX,ARX-04,2016-06-28,AcelRx Pharmaceuticals Completes Patient Enrollment In Remaining Phase 3 Studies Of ARX-04 As A Potential Treatment Of Moderate-to-Severe Acute Pain
ACRX,ARX-04,2016-03-14,AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
ACRX,ARX-04,2016-03-07,AcelRx Pharmaceuticals Initiates Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain
ACRX,ARX-04,2016-02-25,AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores In ER Patients In Interim Phase 3 Analysis
ACRX,ARX-04,2016-01-21,AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery
ACRX,ARX-04,2015-12-23,AcelRx Pharmaceuticals Receives Notice Of Eligibility For Centralized Review Of ARX-04 From European Medicines Agency
ACRX,ARX-04,2015-12-14,AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
ACRX,ARX-04,2015-10-23,AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 Mcg Program At The American Society Of Anesthesiology Meeting
ACRX,ARX-04,2015-10-06,AcelRx Pharmaceuticals Announces Initiation Of Clinical Study With ARX-04 In Emergency Room Patients With Moderate-to-Severe Acute Pain
ACRX,ARX-04,2015-09-09,AcelRx Pharmaceuticals' ARX-04 Meets All Endpoints In Pivotal Phase 3 Study For Moderate-to-Severe Acute Pain
ACRX,ARX-04,2015-05-14,AcelRx Awarded Contract From Department Of Defense To Advance ARX-04
ACRX,ARX-04,2015-03-16,AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
ACRX,ARX-04,2014-05-01,AcelRx Pharmaceuticals Announces Zalviso&#8482; And ARX-04 Data Presentations At The American Pain Society 33rd Annual Scientific Meeting
ACRX,ARX-04,2013-12-13,AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data At Anesthesia Medical Conference
ACRX,ARX-04,2017-01-08,AcelRx Pharmaceuticals Provides Guidance On 2017 Milestones For ARX-04, Now Known As DSUVIA™ In The United States, For The Treatment Of Moderate-to-Severe Acute Pain
ACRX,ARX-04,2017-01-08,AcelRx Pharmaceuticals Announces DSUVIA™ As Brand Name For ARX-04 In The United States
ACRX,ARX-04,2016-12-13,AcelRx Pharmaceuticals Submits New Drug Application For ARX-04 For The Treatment Of Moderate-To-Severe Acute Pain
ACRX,ARX-04,2016-12-06,AcelRx Pharmaceuticals Reports On ARX-04 Market And Landscape Presented At Analyst & Investor Event
ACRX,ARX-04,2016-09-15,AcelRx Reports Positive Results For ARX-04 (sufentanil Sublingual Tablet, 30 Mcg), Including In Elderly Patients And Patients With Organ Impairment, In Third Phase 3 Registration Trial, SAP303
ACRX,ARX-04,2016-09-14,AcelRx Pharmaceuticals To Announce Topline Results In Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain
ACRX,ARX-04,2016-08-15,AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met Its Primary Endpoint, Reduced Pain Intensity In ER Patients With Moderate-to-Severe Acute Pain
ACRX,ARX-04,2016-06-28,AcelRx Pharmaceuticals Completes Patient Enrollment In Remaining Phase 3 Studies Of ARX-04 As A Potential Treatment Of Moderate-to-Severe Acute Pain
ACRX,ARX-04,2016-03-14,AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
ACRX,ARX-04,2016-03-07,AcelRx Pharmaceuticals Initiates Phase 3 Study Of ARX-04 In Patients With Post-Operative Moderate-to-Severe Acute Pain
ACRX,ARX-04,2016-02-25,AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores In ER Patients In Interim Phase 3 Analysis
ACRX,ARX-04,2016-01-21,AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery
ACRX,ARX-04,2015-12-23,AcelRx Pharmaceuticals Receives Notice Of Eligibility For Centralized Review Of ARX-04 From European Medicines Agency
ACRX,ARX-04,2015-12-14,AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
ACRX,ARX-04,2015-10-23,AcelRx Pharmaceuticals Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 Mcg Program At The American Society Of Anesthesiology Meeting
ACRX,ARX-04,2015-10-06,AcelRx Pharmaceuticals Announces Initiation Of Clinical Study With ARX-04 In Emergency Room Patients With Moderate-to-Severe Acute Pain
ACRX,ARX-04,2015-09-09,AcelRx Pharmaceuticals' ARX-04 Meets All Endpoints In Pivotal Phase 3 Study For Moderate-to-Severe Acute Pain
ACRX,ARX-04,2015-05-14,AcelRx Awarded Contract From Department Of Defense To Advance ARX-04
ACRX,ARX-04,2015-03-16,AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
ACRX,ARX-04,2014-05-01,AcelRx Pharmaceuticals Announces Zalviso&#8482; And ARX-04 Data Presentations At The American Pain Society 33rd Annual Scientific Meeting
ACRX,ARX-04,2013-12-13,AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data At Anesthesia Medical Conference
AERI,Roclatan,2016-12-07,Aerie Pharmaceuticals Completes Enrollment Of Mercury 2 Phase 3 Registration Trial Of Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
AERI,Roclatan,2016-09-14,Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
AERI,Roclatan,2016-05-05,Aerie Pharmaceuticals Completes Enrollment Of Mercury 1 Phase 3 Registration Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
AERI,Roclatan,2016-03-28,Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
AERI,Roclatan,2015-09-21,Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial Of RoclatanTM
AERI,Roclatan,2016-12-07,Aerie Pharmaceuticals Completes Enrollment Of Mercury 2 Phase 3 Registration Trial Of Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
AERI,Roclatan,2016-09-14,Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
AERI,Roclatan,2016-05-05,Aerie Pharmaceuticals Completes Enrollment Of Mercury 1 Phase 3 Registration Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
AERI,Roclatan,2016-03-28,Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial Of RoclatanTM (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
AERI,Roclatan,2015-09-21,Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial Of RoclatanTM
AERI,Rhopressa,2017-03-01,Aerie Pharmaceuticals Announces Resubmission Of NDA For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-12-23,Aerie Pharmaceuticals Provides Update On Timing Of NDA Filing For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-10-27,Aerie Pharmaceuticals Reports Positive Topline Efficacy Results Of Rocket 4 Phase 3 Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-09-06,Aerie Pharmaceuticals Submits New Drug Application To U.S. Food And Drug Administration For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-06-16,Aerie Pharmaceuticals Completes Enrollment Of Rocket 4 Phase 3 Clinical Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-03-17,Aerie Pharmaceuticals Reports Update On Positive Safety Results For RhopressaTM QD (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-02-17,Aerie Pharmaceuticals Reports Positive RhopressaTM QD (netarsudil Ophthalmic Solution) 0.02% 12 Month Interim Safety Results For Rocket 2
AERI,Rhopressa,2015-09-24,Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial Of RhopressaTM
AERI,Rhopressa,2015-09-16,Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results
AERI,Rhopressa,2015-04-27,Aerie Pharmaceuticals (AERI) Stock Hits 52-Week Low on Rhopressa Trial Results
AERI,Rhopressa,2015-04-23,Aerie Pharmaceuticals Reports Initial RhopressaTM Phase 3 Efficacy Results
AERI,Rhopressa,2015-03-24,Aerie Pharmaceuticals Completes Enrollment In Second Phase 3 Registration Trial ("Rocket 2") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
AERI,Rhopressa,2015-02-17,Aerie Pharmaceuticals Announces Rhopressa™ Presentation At 2015 Meeting Of The Association For Ocular Pharmacology And Therapeutics
AERI,Rhopressa,2015-01-12,Aerie Pharmaceuticals Announces Acceleration Of Expected Timeline For Reporting Efficacy Results From Phase 3 Registration Trial ("Rocket 1") Of RhopressaTM
AERI,Rhopressa,2014-12-02,Aerie Pharmaceuticals Completes Enrollment In Phase 3 Registration Trial ("Rocket 1") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
AERI,Rhopressa,2014-09-03,Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial In Canada Of RhopressaTM In Patients With Glaucoma
AERI,Rhopressa,2014-07-24,Aerie Pharmaceuticals, Inc. Receives Health Canada &#8220;No Objection Letter&#8221; To Commence Phase 3 Registration Trial Of RhopressaTM In Patients With Glaucoma In Canada
AERI,Rhopressa,2014-07-14,Aerie Pharmaceuticals Initiates Phase 3 Registration Trials Of RhopressaTM, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
AERI,Rhopressa,2017-03-01,Aerie Pharmaceuticals Announces Resubmission Of NDA For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-12-23,Aerie Pharmaceuticals Provides Update On Timing Of NDA Filing For RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-10-27,Aerie Pharmaceuticals Reports Positive Topline Efficacy Results Of Rocket 4 Phase 3 Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-09-06,Aerie Pharmaceuticals Submits New Drug Application To U.S. Food And Drug Administration For Rhopressa™ (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-06-16,Aerie Pharmaceuticals Completes Enrollment Of Rocket 4 Phase 3 Clinical Trial Of RhopressaTM (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-03-17,Aerie Pharmaceuticals Reports Update On Positive Safety Results For RhopressaTM QD (netarsudil Ophthalmic Solution) 0.02%
AERI,Rhopressa,2016-02-17,Aerie Pharmaceuticals Reports Positive RhopressaTM QD (netarsudil Ophthalmic Solution) 0.02% 12 Month Interim Safety Results For Rocket 2
AERI,Rhopressa,2015-09-24,Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial Of RhopressaTM
AERI,Rhopressa,2015-09-16,Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results
AERI,Rhopressa,2015-04-27,Aerie Pharmaceuticals (AERI) Stock Hits 52-Week Low on Rhopressa Trial Results
AERI,Rhopressa,2015-04-23,Aerie Pharmaceuticals Reports Initial RhopressaTM Phase 3 Efficacy Results
AERI,Rhopressa,2015-03-24,Aerie Pharmaceuticals Completes Enrollment In Second Phase 3 Registration Trial ("Rocket 2") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
AERI,Rhopressa,2015-02-17,Aerie Pharmaceuticals Announces Rhopressa™ Presentation At 2015 Meeting Of The Association For Ocular Pharmacology And Therapeutics
AERI,Rhopressa,2015-01-12,Aerie Pharmaceuticals Announces Acceleration Of Expected Timeline For Reporting Efficacy Results From Phase 3 Registration Trial ("Rocket 1") Of RhopressaTM
AERI,Rhopressa,2014-12-02,Aerie Pharmaceuticals Completes Enrollment In Phase 3 Registration Trial ("Rocket 1") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
AERI,Rhopressa,2014-09-03,Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial In Canada Of RhopressaTM In Patients With Glaucoma
AERI,Rhopressa,2014-07-24,Aerie Pharmaceuticals, Inc. Receives Health Canada &#8220;No Objection Letter&#8221; To Commence Phase 3 Registration Trial Of RhopressaTM In Patients With Glaucoma In Canada
AERI,Rhopressa,2014-07-14,Aerie Pharmaceuticals Initiates Phase 3 Registration Trials Of RhopressaTM, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma
ALDR,ALD403,2016-09-15,Alder Presents Positive ALD403 Clinical Data At European Headache And Migraine Trust International Congress
ALDR,ALD403,2016-09-08,Alder Announces Presentations At The European Headache And Migraine Trust International Congress Supporting Development Of ALD403 For Migraine Prevention
ALDR,ALD403,2016-07-25,Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention In Phase 2b Study Of ALD403 In Patients With Chronic Migraine
ALDR,ALD403,2016-06-09,Alder Presents Positive Clinical Data For ALD403 At The Annual Meeting Of The American Headache Society
ALDR,ALD403,2016-06-02,Alder Announces Presentations At Annual Meeting Of The American Headache Society Supporting Development Of ALD403 For Migraine Prevention
ALDR,ALD403,2016-05-25,Alder BioPharmaceuticals Continues To Strengthen And Expand Leadership Team To Support Advancement Of ALD403 For Migraine Prevention
ALDR,ALD403,2016-03-28,Alder Reports Phase 2b Trial Of ALD403 Meets Primary And Secondary Endpoints Demonstrating Migraine Prevention In Patients With Chronic Migraine
ALDR,ALD403,2016-02-09,Alder BioPharmaceuticals Strengthens And Expands Leadership Team Supporting Advancement Of ALD403 Toward Future Commercialization
ALDR,ALD403,2015-10-13,Alder BioPharmaceuticals Initiates Pivotal Clinical Trial Of ALD403 For Preventative Treatment Of Frequent Episodic Migraine
ALDR,ALD403,2015-05-15,Alder Presents Positive Clinical Data For ALD403 At The 17th Congress Of The International Headache Society
ALDR,ALD403,2015-05-06,Alder Announces Presentations At 17th Congress Of The International Headache Society On Data From ALD403 Clinical Trials
ALDR,ALD403,2014-11-03,Alder BioPharmaceuticals Initiates Phase 2b Clinical Trial Of ALD403 For Preventative Treatment Of Chronic Migraine
ALDR,ALD403,2014-10-06,Data From Alder BioPharmaceuticals' Proof-of-Concept Clinical Trial Of ALD403 Published In Lancet Neurology Demonstrates ALD403 Effective In The Preventive Treatment Of Migraine
ARRY,Binimetinib,2015-06-01,Binimetinib And Encorafenib Combination Shows Promising Clinical Activity And Potential Differentiated Safety In BRAF-Mutant Melanoma
ATRS,VIBEX,2014-02-20,Antares Pharma Announces Positive Results From The VIBEX QuickShot Pharmacokinetic Study In Testosterone Deficient Men
ATRS,VIBEX,2013-10-25,Antares Pharma Announces The Issuance Of A New U.S. Patent On The VIBEX&#174; Device Platform
ATRS,VIBEX,2013-09-16,Antares Pharma Announces First Patients Dosed In VIBEX&#8482; QS T Study Evaluating Testosterone Deficient Males
DPRX,Locilex,2016-10-25,Dipexium Announces Top-line Data From OneStep Phase 3 Trials With Locilex® In Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint Of Superiority Versus Vehicle Plus Standardized Wound Care
DPRX,Locilex,2016-10-20,Dipexium Provides Update On Availability Of Results From Pivotal Phase 3 Clinical Trials With Locilex®
DPRX,Locilex,2016-09-07,Dipexium Pharmaceuticals Announces Issuance of Locilex® Patent by European Union
DPRX,Locilex,2016-06-20,Dipexium Pharmaceuticals' Locilex® Microbiology Data Presented At ASM Microbe 2016 Conference
DPRX,Locilex,2016-03-28,Dipexium Pharmaceuticals Announces Issuance Of Locilex® Patent In Japan
DPRX,Locilex,2016-02-01,Dipexium Pharmaceuticals Announces Issuance Of Locilex® Patents In Australia And New Zealand
DPRX,Locilex,2015-09-21,Dipexium Pharmaceuticals Presents Locilex® Microbiology Data At ICAAC/ICC 2015 Conference
DPRX,Locilex,2015-06-02,Dipexium Receives European Medicines Agency Scientific Advice On Clinical And Regulatory Pathway For Locilex® Marketing Approval In European Union
DPRX,Locilex,2015-02-25,Dipexium Pharmaceuticals Passes 25% Enrollment In Locilex® Pivotal Phase 3 Clinical Trials
DPRX,Locilex,2015-02-17,Dipexium Pharmaceuticals Announces Successful Completion And Initial Results Of Phase 1 Skin Sensitization Trial Of Locilex®
DPRX,Locilex,2014-09-08,Dipexium Pharmaceuticals Presents Updated Locilex® Microbiology Data At 54th ICAAC Conference
DPRX,Locilex,2014-07-21,Dipexium Pharmaceuticals Initiates Second Of Two Pivotal Phase 3 Clinical Trials Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers
DPRX,Locilex,2014-07-17,Dipexium Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers
DPRX,Locilex,2014-07-17,Dipexium Pharmaceuticals Announces Successful Completion Of Phase 1 Skin Irritation Trial Of Locilex®
DRRX,DUR-928,2017-01-30,DURECT Corporation Announces Update On DUR-928 Development Program
DRRX,DUR-928,2016-10-31,DURECT Corporation Announces Update On DUR-928 Development Program
DRRX,DUR-928,2016-01-11,DURECT Announces Initiation Of DUR-928 Dosing In Patients
DRRX,DUR-928,2016-01-06,DURECT Announces Positive Phase 1 Data For DUR-928
DRRX,DUR-928,2015-05-18,DURECT Announces Positive Results From DUR-928 Multi-Dose Phase 1 Study
DRRX,DUR-928,2015-03-30,DURECT Announces Initiation Of DUR-928 Multi-Dose Phase 1 Study
DRRX,DUR-928,2017-01-30,DURECT Corporation Announces Update On DUR-928 Development Program
DRRX,DUR-928,2016-10-31,DURECT Corporation Announces Update On DUR-928 Development Program
DRRX,DUR-928,2016-01-11,DURECT Announces Initiation Of DUR-928 Dosing In Patients
DRRX,DUR-928,2016-01-06,DURECT Announces Positive Phase 1 Data For DUR-928
DRRX,DUR-928,2015-05-18,DURECT Announces Positive Results From DUR-928 Multi-Dose Phase 1 Study
DRRX,DUR-928,2015-03-30,DURECT Announces Initiation Of DUR-928 Multi-Dose Phase 1 Study
ESPR,Bempedoic,2017-03-20,Esperion Announces FDA Confirmation Regarding Regulatory Pathway To Approval For An LDL-C Lowering Indication For Bempedoic Acid
ESPR,Bempedoic,2017-03-07,Esperion Announces Initiation Of Phase 2 Triplet Oral Therapy Study Of Bempedoic Acid/Ezetimibe/Atorvastatin
ESPR,Bempedoic,2017-02-22,Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter And Full Year 2016 Financial Results
ESPR,Bempedoic,2017-01-25,Esperion Completes Enrollment Of Pivotal Phase 3 Long-Term Safety And Tolerability Study Of Bempedoic Acid In Patients With Hypercholesterolemia
ESPR,Bempedoic,2017-01-09,Esperion Announces Initiation Of Global Cardiovascular Outcomes Trial For Bempedoic Acid
ESPR,Bempedoic,2017-01-08,Esperion Announces Initiation Of Three Pivotal Phase 3 Studies For Bempedoic Acid
ESPR,Bempedoic,2016-11-28,Esperion Therapeutics Announces Publication Of Definitive Paper On Bempedoic Acid Mechanism Of Action In Nature Communications
ESPR,Bempedoic,2016-11-03,Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
ESPR,Bempedoic,2016-10-13,Bempedoic Acid Global Phase 3 Clinical Program To Include Patients On Any Statin At Any Dose
ESPR,Bempedoic,2016-08-04,Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
ESPR,Bempedoic,2016-06-28,Esperion Therapeutics Provides Clinical Development And Regulatory Update For Bempedoic Acid
ESPR,Bempedoic,2016-05-04,Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
ESPR,Bempedoic,2016-02-25,Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter And Full Year 2015 Financial Results
ESPR,Bempedoic,2016-01-12,Esperion Therapeutics Announces Initiation Of Phase 2 Clinical Study Of Bempedoic Acid In Patients Treated With High-Dose Statin Therapy
FOLD,Migalastat,2017-03-08,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In Italy
FOLD,Migalastat,2017-02-27,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In The United Kingdom
FOLD,Migalastat,2017-01-04,National Institute For Health And Care Excellence (NICE) Issues Final Positive Recommendation For Galafold™ (migalastat) For Fabry Disease In England
FOLD,Migalastat,2016-11-28,Amicus Therapeutics Announces U.S. Regulatory Pathway For Migalastat For Fabry Disease
FOLD,Migalastat,2016-11-11,Journal Of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-10,UPDATE -- New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-10,New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-03,Amicus Therapeutics To Submit Japanese New Drug Application For Migalastat For Fabry Disease In 1H17
FOLD,Migalastat,2016-05-31,Amicus Therapeutics Announces European Commission Approval For Galafold™ (Migalastat) In Patients With Fabry Disease In European Union
FOLD,Migalastat,2016-04-01,Amicus Therapeutics Receives Positive CHMP Opinion For Approval Of Migalastat In Patients With Fabry Disease In European Union
FOLD,Migalastat,2016-03-22,Amicus Therapeutics Announces Expanded Access Program For Migalastat
FOLD,Migalastat,2015-10-02,Amicus Therapeutics Provides U.S. Regulatory Update For Migalastat Monotherapy
FOLD,Migalastat,2015-09-15,Amicus Therapeutics Plans To Submit New Drug Application (NDA) For Migalastat For Fabry Disease Following Positive Pre-NDA Meeting With FDA
FOLD,Migalastat,2015-06-03,Amicus Therapeutics Submits Marketing Authorization Application (MAA) For Full Approval Of Fabry Monotherapy Galafold(TM) (Migalastat) In European Union
FOLD,Migalastat,2017-03-08,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In Italy
FOLD,Migalastat,2017-02-27,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In The United Kingdom
FOLD,Migalastat,2017-01-04,National Institute For Health And Care Excellence (NICE) Issues Final Positive Recommendation For Galafold™ (migalastat) For Fabry Disease In England
FOLD,Migalastat,2016-11-28,Amicus Therapeutics Announces U.S. Regulatory Pathway For Migalastat For Fabry Disease
FOLD,Migalastat,2016-11-11,Journal Of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-10,UPDATE -- New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-10,New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-03,Amicus Therapeutics To Submit Japanese New Drug Application For Migalastat For Fabry Disease In 1H17
FOLD,Migalastat,2016-05-31,Amicus Therapeutics Announces European Commission Approval For Galafold™ (Migalastat) In Patients With Fabry Disease In European Union
FOLD,Migalastat,2016-04-01,Amicus Therapeutics Receives Positive CHMP Opinion For Approval Of Migalastat In Patients With Fabry Disease In European Union
FOLD,Migalastat,2016-03-22,Amicus Therapeutics Announces Expanded Access Program For Migalastat
FOLD,Migalastat,2015-10-02,Amicus Therapeutics Provides U.S. Regulatory Update For Migalastat Monotherapy
FOLD,Migalastat,2015-09-15,Amicus Therapeutics Plans To Submit New Drug Application (NDA) For Migalastat For Fabry Disease Following Positive Pre-NDA Meeting With FDA
FOLD,Migalastat,2015-06-03,Amicus Therapeutics Submits Marketing Authorization Application (MAA) For Full Approval Of Fabry Monotherapy Galafold(TM) (Migalastat) In European Union
FOLD,Migalastat,2017-03-08,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In Italy
FOLD,Migalastat,2017-02-27,Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In The United Kingdom
FOLD,Migalastat,2017-01-04,National Institute For Health And Care Excellence (NICE) Issues Final Positive Recommendation For Galafold™ (migalastat) For Fabry Disease In England
FOLD,Migalastat,2016-11-28,Amicus Therapeutics Announces U.S. Regulatory Pathway For Migalastat For Fabry Disease
FOLD,Migalastat,2016-11-11,Journal Of Medical Genetics Publishes Pivotal Phase 3 ATTRACT Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-10,UPDATE -- New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-10,New England Journal Of Medicine Publishes Pivotal Phase 3 FACETS Study Of Migalastat For Patients With Fabry Disease
FOLD,Migalastat,2016-08-03,Amicus Therapeutics To Submit Japanese New Drug Application For Migalastat For Fabry Disease In 1H17
FOLD,Migalastat,2016-05-31,Amicus Therapeutics Announces European Commission Approval For Galafold™ (Migalastat) In Patients With Fabry Disease In European Union
FOLD,Migalastat,2016-04-01,Amicus Therapeutics Receives Positive CHMP Opinion For Approval Of Migalastat In Patients With Fabry Disease In European Union
FOLD,Migalastat,2016-03-22,Amicus Therapeutics Announces Expanded Access Program For Migalastat
FOLD,Migalastat,2015-10-02,Amicus Therapeutics Provides U.S. Regulatory Update For Migalastat Monotherapy
FOLD,Migalastat,2015-09-15,Amicus Therapeutics Plans To Submit New Drug Application (NDA) For Migalastat For Fabry Disease Following Positive Pre-NDA Meeting With FDA
FOLD,Migalastat,2015-06-03,Amicus Therapeutics Submits Marketing Authorization Application (MAA) For Full Approval Of Fabry Monotherapy Galafold(TM) (Migalastat) In European Union
GNCA,GEN-003,2017-01-05,Genocea Announces Positive 6-Month Results From GEN-003 Phase 2b Clinical Trial
GNCA,GEN-003,2016-12-14,Genocea R&D Day Highlighted Lead Program, GEN-003, For The Treatment Of Genital Herpes And Introduced Immuno-Oncology Programs & Strategy
GNCA,GEN-003,2016-10-28,Genocea Presents New 12 Month Data On Genital Herpes Immunotherapy GEN-003 At IDWeek 2016
GNCA,GEN-003,2016-09-29,Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction Of Viral Shedding In Phase 2b Clinical Trial
GNCA,GEN-003,2016-06-09,Genocea Showcases Potential Of Genital Herpes Immunotherapy GEN-003 At ASM Microbe 2016
GNCA,GEN-003,2016-03-31,Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction Of Viral Shedding Rate, Durable Impact On Clinical Disease 12 Months Post-Dosing
GNCA,GEN-003,2016-01-29,Genocea Commences Dosing In Phase 2b Study For Genital Herpes Treatment, GEN-003
GNCA,GEN-003,2015-10-07,Genocea Announces Positive Durability Data From 6-Month Analysis Of Phase 2 Clinical Trial Of Genital Herpes Immunotherapy GEN-003
GNCA,GEN-003,2015-05-20,Genocea Announces Positive Top-Line Phase 2 Data For Genital Herpes Immunotherapy GEN-003
GNCA,GEN-003,2015-01-07,Genocea Completes Enrollment Early In Phase 2 Dose Optimization Trial Of GEN-003 For Treatment Of Genital Herpes
GNCA,GEN-003,2014-07-22,Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects
GNCA,GEN-003,2014-07-21,Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy
GWPH,Epidiolex,2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
GWPH,Epidiolex,2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
GWPH,Epidiolex,2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
GWPH,Epidiolex,2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
GWPH,Epidiolex,2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
GWPH,Epidiolex,2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
GWPH,Epidiolex,2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
GWPH,Epidiolex,2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
GWPH,Epidiolex,2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
GWPH,Epidiolex,2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
GWPH,Epidiolex,2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
GWPH,Epidiolex,2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
GWPH,Epidiolex,2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
GWPH,Epidiolex,2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
GWPH,Epidiolex,2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
GWPH,Epidiolex,2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
INFI,Duvelisib,2016-11-02,Verastem Licenses Duvelisib From Infinity Pharmaceuticals
INFI,Duvelisib,2016-11-02,Verastem Licenses Duvelisib From Infinity Pharmaceuticals
INFI,Duvelisib,2016-06-28,Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration
INFI,Duvelisib,2016-06-14,Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma
INFI,Duvelisib,2016-05-19,Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings
INFI,Duvelisib,2015-11-17,Infinity Announces Completion Of Target Enrollment In DUO™, A Phase 3 Study Evaluating Duvelisib In Chronic Lymphocytic Leukemia
INFI,Duvelisib,2015-10-06,Infinity To Provide Update On Duvelisib And Immuno-Oncology Development Candidate IPI-549 During 2015 Research And Development Day
INFI,Duvelisib,2015-09-30,Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma
INFI,Duvelisib,2015-05-31,Infinity Reports Phase 1 Data Showing Clinical Activity Of Duvelisib In Treatment-Naïve Patients With Chronic Lymphocytic Leukemia
INFI,Duvelisib,2015-05-26,Infinity Reports Preclinical Data For Duvelisib Demonstrating Synergy With Standard-of-Care Therapies And Emerging Agents In Development For The Treatment Of Hematologic Malignancies
INFI,Duvelisib,2015-05-13,Infinity Announces New Data For Duvelisib To Be Presented At The 2015 American Society Of Clinical Oncology Annual Meeting
INFI,Duvelisib,2015-04-20,Infinity Reports Preclinical Data For Duvelisib In Combination With Venetoclax At The 2015 American Association For Cancer Research Annual Meeting
INFI,Duvelisib,2015-03-31,Infinity Exercises Option To Buy Out All Future Royalty Obligations To Takeda For Duvelisib Sales In Oncology
INFI,Duvelisib,2015-01-08,Infinity Reports Topline Results From Phase 2 Study Of Duvelisib In Rheumatoid Arthritis
INFI,Duvelisib,2014-12-09,Infinity Reports New Results From Phase 1 Study Of Investigational Oncology Compound Duvelisib At The American Society Of Hematology Annual Meeting
INFI,Duvelisib,2014-12-08,Infinity Reports New Translational Research And Updated Phase 1 Data Of Investigational Oncology Compound Duvelisib At American Society Of Hematology Annual Meeting
INFI,Duvelisib,2014-11-06,Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented At ASH 2014 Annual Meeting
INFI,Duvelisib,2014-10-16,Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
INFI,Duvelisib,2014-09-03,Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
INFI,Duvelisib,2014-09-03,Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology
KERX,Auryxia,2017-03-20,Keryx Announces The Largest Medicare Part D Plan Sponsor Added Auryxia® To Its Medicare Part D Plan Formularies
KERX,Auryxia,2017-03-08,Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Auryxia® (ferric Citrate) Tablets
KERX,Auryxia,2017-01-12,Keryx Biopharmaceuticals Announces Publication Of Auryxia® (ferric Citrate) Phase 3 Trial Results For Iron Deficiency Anemia (IDA) In Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) In Journal Of The American Society Of Nephrology
KERX,Auryxia,2016-11-18,Keryx Biopharmaceuticals Announces Case Study Data Of Auryxia® Presented At ASN's Kidney Week
KERX,Auryxia,2016-11-09,Keryx Biopharmaceuticals Announces U.S. FDA Approval Of Second Contract Manufacturer For Auryxia® (ferric Citrate)
KERX,Auryxia,2016-08-02,Keryx Biopharmaceuticals Inc. Investigated For Securities Fraud By Block & Leviton After Keryx Halts The Distribution Of Auryxia And Withdraws Its Full-Year Financial Forecast
KERX,Auryxia,2016-08-01,Keryx Biopharmaceuticals Announces Interruption In Supply Of Auryxia® (ferric Citrate) And Second Quarter 2016 Financial Results
KERX,Auryxia,2015-06-24,Keryx Announces Two National Insurance Providers Added Auryxia(TM) To Their Medicare Part D Formularies
KERX,Auryxia,2015-03-04,Keryx Biopharmaceuticals Announces Publication Of Auryxia(TM) (ferric Citrate) Analysis In Journal Of The American Society Of Nephrology
KITE,KTE-C19,2017-01-09,Kite Pharma Establishes A Strategic Partnership With Daiichi Sankyo To Develop And Commercialize Axicabtagene Ciloleucel (KTE-C19) In Japan
KITE,KTE-C19,2016-12-06,Kite Pharma Presents Results Of Multi-Center Pivotal ZUMA-1 Trial Of Axicabtagene Ciloleucel (KTE-C19) In Aggressive Non-Hodgkin Lymphoma As Late-Breaking Abstract At Annual Meeting Of American Society Of Hematology
KITE,KTE-C19,2016-12-04,Kite Pharma Reports 82 Percent Of Patients Achieved Complete Remission In Preliminary Analysis From Phase 1 ZUMA-3 And ZUMA-4 Trials Of KTE-C19 In Adult And Pediatric Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia
KITE,KTE-C19,2016-11-21,Kite Pharma To Present Interim Results From The ZUMA-1 Pivotal Trial Of KTE-C19 In A Late-Breaking Session At The 2016 American Society Of Hematology Annual Meeting
KITE,KTE-C19,2016-11-03,Kite Pharma To Present KTE-C19 Data From Interim Analysis Of The ZUMA-1 Pivotal Trial In Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) And Transformed Follicular Lymphoma (TFL) At The 2016 American Society Hematology Annual Meeting
KITE,KTE-C19,2016-10-19,Kite Pharma Details KTE-C19 Launch Preparedness And Near-Term, Next Generation CAR/TCR Product Candidates At Investor Day
KITE,KTE-C19,2016-10-11,Kite Pharma To Host Investor Day On October 18, 2016 Spotlighting An Industry-Leading CAR/TCR Pipeline, Next Generation Research And Development, And KTE-C19 Launch Readiness
KITE,KTE-C19,2016-10-06,Kite Pharma Initiates Phase 1b/2 Combination Study For KTE-C19 And Atezolizumab In Patients With Refractory Diffuse Large B-cell Lymphoma (DLBCL)
KITE,KTE-C19,2016-09-26,Kite Pharma Announces Positive Topline KTE-C19 Data From ZUMA-1 Pivotal Trial In Patients With Aggressive Non-Hodgkin Lymphoma (NHL)
KITE,KTE-C19,2016-07-07,Kite Pharma Completes Enrollment Of All Patients With Diffuse Large B-Cell Lymphoma (DLBCL) In Pivotal Multi-Center Phase 2 Study Of KTE-C19 (ZUMA-1)
KITE,KTE-C19,2016-06-01,Kite Pharma Granted Access To Priority Medicines (PRIME) Regulatory Support For KTE-C19 In The Treatment Of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL)
KITE,KTE-C19,2016-05-02,Kite Pharma Announces FDA Orphan Drug Designations For KTE-C19 In Five Additional Indications
KITE,KTE-C19,2016-04-15,Kite Pharma Announces Key Presentations On KTE-C19 And Engineered Cell Therapy Pipeline Programs At The Annual Meeting Of The American Association For Cancer Research (AACR)
KITE,KTE-C19,2016-03-16,Kite Pharma Announces Clinical And Manufacturing Updates On KTE-C19 And MAGE-A3 Product Candidates At The Annual Meeting Of The American Association For Cancer Research (AACR)
KITE,KTE-C19,2015-12-07,Kite Pharma Receives FDA Breakthrough Therapy Designation For KTE-C19 For The Treatment Of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)
KITE,KTE-C19,2015-12-07,Kite Pharma Initiates The ZUMA-4 Study To Support Registration Of KTE-C19 For Relapsed Or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) In Children And Young Adults
KITE,KTE-C19,2015-12-02,Kite Pharma Initiates The ZUMA-3 Study To Support Registration Of KTE-C19 For Relapsed Or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) In Adult Subjects
KITE,KTE-C19,2015-11-09,Kite Pharma Initiates Phase 2 Clinical Study Of KTE-C19 (ZUMA-2) In Patients With Relapsed Or Refractory Mantle Cell Lymphoma (r/r MCL) To Support Registration For A Second Indication
KITE,KTE-C19,2015-11-05,Kite Pharma To Present Four Abstracts, Including Safety And Efficacy Data From The KTE-C19 Phase 1 Study In Patients With Refractory, Aggressive NHL (ZUMA-1), At The 57th American Society Of Hematology Annual Meeting (ASH)
KITE,KTE-C19,2015-11-02,Kite Pharma Initiates ZUMA-1 Phase 2 In Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (NHL) To Support Registration Of KTE-C19
KITE,KTE-C19,2015-10-15,Kite Pharma Receives Positive Opinions For Orphan Drug Designation In The European Union (EU) For KTE-C19 In Three Additional Hematological Indications
KITE,KTE-C19,2015-09-11,Kite Pharma Receives Positive Opinion For Orphan Drug Designation In The European Union For KTE-C19, Kite's Lead Cancer T-Cell Immunotherapy
KITE,KTE-C19,2015-08-17,Kite Pharma Provides Update On KTE-C19 Clinical Trial
KITE,KTE-C19,2015-07-01,Kite Pharma And The Leukemia & Lymphoma Society(R) Enter Into Collaboration To Enhance The Development Of KTE-C19 In Refractory Aggressive Non-Hodgkin Lymphoma And Launch CAR T-Cell Therapy Educational Programs
MRNS,Ganaxolone,2017-02-14,Ganaxolone Reduces Seizures And Improves Behaviors In Angelman Syndrome Preclinical Model
MRNS,Ganaxolone,2017-01-03,Marinus Pharmaceuticals Receives FDA Orphan Drug Designation For Ganaxolone To Treat Fragile X Syndrome
MRNS,Ganaxolone,2016-11-15,Ganaxolone And Diazepam Administered Intravenously Synergistically Block Seizures In Animal Model Of Status Epilepticus
MRNS,Ganaxolone,2016-10-19,Ganaxolone Phase 1 Data Supports Progressing To Phase 2 In Patients With Status Epilepticus
MRNS,Ganaxolone,2016-09-29,Ganaxolone Reduces Seizures In Females With PCDH19 Pediatric Epilepsy
MRNS,Ganaxolone,2016-06-28,Results From Phase 2 Exploratory Clinical Study Support Continued Development Of Ganaxolone In Fragile X Syndrome
MRNS,Ganaxolone,2016-06-22,Marinus Pharmaceuticals Doses First Subject In Phase 1 Clinical Trial For Ganaxolone IV
MRNS,Ganaxolone,2016-04-19,Marinus Pharmaceuticals' Ganaxolone IV Demonstrates Robust Efficacy In Benzodiazepine-Resistant Model Of Status Epilepticus
MRNS,Ganaxolone,2016-04-15,Marinus Pharmaceuticals Receives FDA Orphan Drug Designation For Ganaxolone IV To Treat Status Epilepticus
MRNS,Ganaxolone,2016-04-12,Marinus Pharmaceuticals To Present Ganaxolone IV Data At American Academy Of Neurology Annual Meeting
MRNS,Ganaxolone,2015-12-16,Marinus Pharmaceuticals Completes Patient Recruitment In Phase 3 Clinical Trial Of Ganaxolone In Focal Onset Seizures
MRNS,Ganaxolone,2015-12-07,Marinus Presents Additional Responder Analysis Data For Ganaxolone In Focal Onset Seizures At The American Epilepsy Society Annual Meeting
MRNS,Ganaxolone,2015-11-19,Marinus's Ganaxolone To Be Featured In Two Poster Presentations At The 69th Annual Meeting Of The American Epilepsy Society
MRNS,Ganaxolone,2015-10-29,Marinus Announces Clinical Development Plans For Ganaxolone Intravenous Formulation
MRNS,Ganaxolone,2015-09-09,Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA For Ganaxolone In Focal Onset Seizures
MRNS,Ganaxolone,2015-07-06,Published Data Support Scientific Basis For Ganaxolone Use In PCDH19 Female Epilepsy
MRNS,Ganaxolone,2015-05-18,Marinus Pharmaceuticals Presents Clinical Data Of Ganaxolone In Pediatric Epilepsies At Antiepileptic Drug And Device Trials XIII Conference
MRNS,Ganaxolone,2015-03-25,Marinus Pharmaceuticals' Ganaxolone Receives FDA Orphan Drug Designation In PCDH19 Female Epilepsy
MRNS,Ganaxolone,2015-02-03,Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone In PCDH19 Female Pediatric Epilepsy
MRNS,Ganaxolone,2014-08-12,Marinus Pharmaceuticals, Inc. Enters Into Use Agreement With CyDex Pharmaceuticals, Inc. For Use Of Captisol(R) For Ganaxolone IV
NVAX,RSV,2017-01-19,Novavax Initiates Phase 2 Safety And Immunogenicity Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2016-09-15,Novavax Announces Topline RSV F Vaccine Data From Two Clinical Trials In Older Adults
NVAX,RSV,2016-05-25,U.S. FDA Grants Fast Track Designation To Novavax' RSV F Vaccine For Older Adults
NVAX,RSV,2015-12-14,Novavax Completes Enrollment Of Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-12-03,Novavax Initiates Global Pivotal Phase 3 Trial Of The RSV F Vaccine To Protect Infants Via Maternal Immunization
NVAX,RSV,2015-11-16,Novavax To Make Multiple Presentations At RSV Vaccines For The World
NVAX,RSV,2015-11-09,Novavax Initiates Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-10-22,Novavax Initiates Phase 2 Safety And Immunogenicity Trial To Evaluate Annual Re-Dosing Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-09-29,Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial In Pediatrics
NVAX,RSV,2015-09-29,Novavax Announces Grant Of Up To $89 Million To Support Development Of RSV F Vaccine To Protect Infants Via Maternal Immunization
NVAX,RSV,2015-09-15,Novavax RSV F Vaccine Is Highly Immunogenic With Robust Transplacental Antibody Transfer In Preclinical Maternal Immunization Model
NVAX,RSV,2015-09-10,Novavax RSV F Vaccine Clinical Trial Data In Women Of Child Bearing Age Published In The Journal Of Infectious Disease
NVAX,RSV,2017-01-19,Novavax Initiates Phase 2 Safety And Immunogenicity Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2016-09-15,Novavax Announces Topline RSV F Vaccine Data From Two Clinical Trials In Older Adults
NVAX,RSV,2016-05-25,U.S. FDA Grants Fast Track Designation To Novavax' RSV F Vaccine For Older Adults
NVAX,RSV,2015-12-14,Novavax Completes Enrollment Of Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-12-03,Novavax Initiates Global Pivotal Phase 3 Trial Of The RSV F Vaccine To Protect Infants Via Maternal Immunization
NVAX,RSV,2015-11-16,Novavax To Make Multiple Presentations At RSV Vaccines For The World
NVAX,RSV,2015-11-09,Novavax Initiates Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-10-22,Novavax Initiates Phase 2 Safety And Immunogenicity Trial To Evaluate Annual Re-Dosing Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-09-29,Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial In Pediatrics
NVAX,RSV,2015-09-29,Novavax Announces Grant Of Up To $89 Million To Support Development Of RSV F Vaccine To Protect Infants Via Maternal Immunization
NVAX,RSV,2015-09-15,Novavax RSV F Vaccine Is Highly Immunogenic With Robust Transplacental Antibody Transfer In Preclinical Maternal Immunization Model
NVAX,RSV,2015-09-10,Novavax RSV F Vaccine Clinical Trial Data In Women Of Child Bearing Age Published In The Journal Of Infectious Disease
OGXI,Custirsen,2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
OGXI,Custirsen,2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
OGXI,Custirsen,2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
OGXI,Custirsen,2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
OGXI,Custirsen,2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
OGXI,Custirsen,2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
OGXI,Custirsen,2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
OGXI,Custirsen,2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
OGXI,Custirsen,2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
OGXI,Custirsen,2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
OGXI,Custirsen,2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
OGXI,Custirsen,2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
OGXI,Custirsen,2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
OGXI,Custirsen,2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
OGXI,Custirsen,2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
OGXI,Custirsen,2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
OGXI,Custirsen,2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
OGXI,Custirsen,2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
OGXI,Custirsen,2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
OGXI,Custirsen,2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
OGXI,Custirsen,2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
OGXI,Custirsen,2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
OGXI,Custirsen,2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
OGXI,Custirsen,2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
OGXI,Custirsen,2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
OGXI,Custirsen,2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
OGXI,Custirsen,2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
OGXI,Custirsen,2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
OGXI,Custirsen,2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
OGXI,Custirsen,2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
OGXI,Custirsen,2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
OGXI,Custirsen,2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
OGXI,Custirsen,2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
OGXI,Custirsen,2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
OGXI,Custirsen,2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
OGXI,Custirsen,2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
OGXI,Custirsen,2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
OGXI,Custirsen,2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
OGXI,Custirsen,2016-10-13,OncoGenex Announces Results From The Phase 3 ENSPIRIT Trial Of Custirsen In Non-Small Cell Lung Cancer
OGXI,Custirsen,2016-08-16,OncoGenex Announces Results From The Phase 3 AFFINITY Trial Of Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2015-12-01,OncoGenex Announces Phase 3 AFFINITY Trial With Custirsen Continues Following Interim Analyses
OGXI,Custirsen,2015-09-28,OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels In Metastatic Prostate Cancer Patients; Low Levels Correlate With Improved Survival In Those At Increased Risk For Poor Outcomes
OGXI,Custirsen,2015-07-13,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion Of Final Futility Survival Analysis
OGXI,Custirsen,2015-05-30,OncoGenex Announces Data From The Phase 3 SYNERGY Trial Showing A Survival Benefit With Custirsen In Patients With Poor Prognosis
OGXI,Custirsen,2015-04-30,OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
OGXI,Custirsen,2015-04-27,OncoGenex Regains Rights To Custirsen From Teva
OGXI,Custirsen,2015-01-16,OncoGenex Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-12-30,OncoGenex To Regain Rights To Custirsen From Teva
OGXI,Custirsen,2014-09-16,OncoGenex Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-08-21,OncoGenex Announces Update On Phase 3 ENSPIRIT Trial Evaluating Custirsen In Advanced Non-Small Cell Lung Cancer
OGXI,Custirsen,2014-04-28,OncoGenex Announces Top-Line Survival Results Of Phase 3 SYNERGY Trial Evaluating Custirsen For Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-04-28,Teva And OncoGenex Announce Top-Line Survival Results Of Phase III SYNERGY Trial Evaluating Custirsen In Combination With First-line Docetaxel And Prednisone For Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-04-23,OncoGenex Announces Fast Track Designation Granted For Custirsen In Combination With Cabazitaxel/Prednisone As Second-line Chemotherapy In Phase 3 AFFINITY Trial Of Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2014-02-11,OncoGenex Announces Target Number Of Events Reached In Phase 3 SYNERGY Trial Of Custirsen In Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2013-11-19,OncoGenex Announces Update On Phase 3 SYNERGY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer
OGXI,Custirsen,2012-11-06,OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
OGXI,Custirsen,2012-09-27,OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer
OGXI,Custirsen,2012-07-10,OncoGenex Announces Clinical Development Plans For Custirsen In Non-Small Cell Lung Cancer
OGXI,Custirsen,2012-03-08,Teva And OncoGenex Announce Updates To Custirsen Development Program In Advanced Prostate Cancer
OGXI,Custirsen,2012-01-04,OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology
OGXI,Custirsen,2011-09-19,OncoGenex Announces Completion Of A Special Protocol Assessment (SPA) Amendment With The FDA Increasing Patient Eligibility For The Custirsen Phase III Prostate Cancer SATURN Clinical Trial
OGXI,Custirsen,2011-09-06,OncoGenex Announces Publication Of Custirsen Phase II Clinical And Pre-Clinical Data In Leading Cancer Journals
OGXI,Custirsen,2011-06-06,Data From Pre-Clinical Studies Presented At The 2011 ASCO Annual Meeting Show Potential Combinability Of Custirsen With MDV3100 And Hsp90 Inhibitors To Enhance Anti-Tumor Activity In Prostate Cancer
OGXI,Custirsen,2011-05-19,Teva And OncoGenex To Present Data On Custirsen In Prostate Cancer At The 2011 ASCO Annual Meeting
OGXI,Custirsen,2011-04-06,Teva And OncoGenex Present Preclinical Data On The Activity Of Its Antisense Compound Custirsen (OGX-011/TV-1011) At The American Association Of Cancer Research (AACR) Annual Meeting 2011
RPRX,Enclomiphene,2016-10-05,Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities
RPRX,Enclomiphene,2016-09-12,Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism
RPRX,Enclomiphene,2016-08-15,Repros Provides Six Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-06-01,Repros Provides Update On EU Submission Of Enclomiphene For The Treatment Of Secondary Hypogonadism And 3 Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-02-16,Repros Completes Randomization Of Enclomiphene Phase 2 Proof Of Concept Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-02-08,Repros Holds Meeting With FDA To Discuss Complete Response Letter For Enclomiphene In The Treatment Of Secondary Hypogonadism
RPRX,Enclomiphene,2016-01-04,Repros Updates Enclomiphene Program
RPRX,Enclomiphene,2015-12-01,Repros Therapeutics Receives Complete Response Letter From FDA For Enclomiphene
RPRX,Enclomiphene,2015-10-29,Repros Therapeutics Announces Cancellation Of FDA Advisory Committee Meeting To Review Enclomiphene For The Treatment Of Secondary Hypogonadism
RPRX,Enclomiphene,2016-10-05,Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities
RPRX,Enclomiphene,2016-09-12,Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism
RPRX,Enclomiphene,2016-08-15,Repros Provides Six Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-06-01,Repros Provides Update On EU Submission Of Enclomiphene For The Treatment Of Secondary Hypogonadism And 3 Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-02-16,Repros Completes Randomization Of Enclomiphene Phase 2 Proof Of Concept Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-02-08,Repros Holds Meeting With FDA To Discuss Complete Response Letter For Enclomiphene In The Treatment Of Secondary Hypogonadism
RPRX,Enclomiphene,2016-01-04,Repros Updates Enclomiphene Program
RPRX,Enclomiphene,2015-12-01,Repros Therapeutics Receives Complete Response Letter From FDA For Enclomiphene
RPRX,Enclomiphene,2015-10-29,Repros Therapeutics Announces Cancellation Of FDA Advisory Committee Meeting To Review Enclomiphene For The Treatment Of Secondary Hypogonadism
RPRX,Enclomiphene,2016-10-05,Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities
RPRX,Enclomiphene,2016-09-12,Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism
RPRX,Enclomiphene,2016-08-15,Repros Provides Six Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-06-01,Repros Provides Update On EU Submission Of Enclomiphene For The Treatment Of Secondary Hypogonadism And 3 Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-02-16,Repros Completes Randomization Of Enclomiphene Phase 2 Proof Of Concept Study In Obese Secondary Hypogonadal Men
RPRX,Enclomiphene,2016-02-08,Repros Holds Meeting With FDA To Discuss Complete Response Letter For Enclomiphene In The Treatment Of Secondary Hypogonadism
RPRX,Enclomiphene,2016-01-04,Repros Updates Enclomiphene Program
RPRX,Enclomiphene,2015-12-01,Repros Therapeutics Receives Complete Response Letter From FDA For Enclomiphene
RPRX,Enclomiphene,2015-10-29,Repros Therapeutics Announces Cancellation Of FDA Advisory Committee Meeting To Review Enclomiphene For The Treatment Of Secondary Hypogonadism
RTRX,Sparsentan,2017-03-01,Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter And Full Year 2016 Financial Results
RTRX,Sparsentan,2016-11-19,Retrophin Reports Additional Positive Data From Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis At ASN Kidney Week 2016
RTRX,Sparsentan,2016-10-21,Retrophin To Present Additional Data From Phase 2 DUET Study Of Sparsentan In Late-Breaking Oral Session At ASN Kidney Week 2016
RTRX,Sparsentan,2016-09-07,Retrophin Announces Positive Top-Line Results From Phase 2 DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis
RTRX,Sparsentan,2016-03-30,Retrophin Completes Enrollment Of Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis
RTRX,Sparsentan,2015-11-16,Retrophin Receives European Orphan Drug Designation For Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis
RTRX,Sparsentan,2015-01-09,Ligand Partner Retrophin Receives Orphan Drug Designation For Sparsentan
THLD,Tarloxotinib,2016-09-29,Threshold Pharmaceuticals Announces Interim Results From Tarloxotinib Program And Its Plans To Focus On Evofosfamide And Earlier-Stage Opportunities
THLD,Tarloxotinib,2016-09-29,Threshold Pharmaceuticals Announces Interim Results From Tarloxotinib Program And Its Plans To Focus On Evofosfamide And Earlier-Stage Opportunities
THLD,Tarloxotinib,2016-09-29,Threshold Pharmaceuticals Announces Interim Results From Tarloxotinib Program And Its Plans To Focus On Evofosfamide And Earlier-Stage Opportunities
THLD,Tarloxotinib,2016-09-29,Threshold Pharmaceuticals Announces Interim Results From Tarloxotinib Program And Its Plans To Focus On Evofosfamide And Earlier-Stage Opportunities
TNXP,TNX-102,2017-03-14,Tonix Pharmaceuticals Receives Notice Of Allowance For New U.S. Patent Covering Composition And Manufacture Of TNX-102 SL
TNXP,TNX-102,2016-12-19,Tonix Pharmaceuticals' PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation By The FDA
TNXP,TNX-102,2016-09-06,Tonix Pharmaceuticals Reports Topline Results From Phase 3 AFFIRM Study Of TNX-102 SL In Fibromyalgia And Provides Corporate Update
TNXP,TNX-102,2016-08-29,Tonix Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA For TNX-102 SL In Post-Traumatic Stress Disorder
TNXP,TNX-102,2016-08-15,Tonix Pharmaceuticals Presents Poster On The Development Of TNX-102 SL For Post-Traumatic Stress Disorder (PTSD) At The 2016 Military Health System Research Symposium
TNXP,TNX-102,2016-07-26,Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study Of TNX-102 SL In Fibromyalgia
TNXP,TNX-102,2016-06-09,Tonix Pharmaceuticals Presents At EULAR Results Of A Retrospective Analysis From The Phase 2b BESTFIT Clinical Study Of TNX-102 SL In Fibromyalgia
TNXP,TNX-102,2016-05-31,Tonix Pharmaceuticals Presents Positive Results From Phase 2 AtEase Study Of TNX-102 SL In Post-Traumatic Stress Disorder (PTSD) At The American Society Of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting
TNXP,TNX-102,2016-05-26,Tonix Pharmaceuticals To Present Positive Results From Phase 2 AtEase Study Of TNX-102 SL In Post-Traumatic Stress Disorder At The ASCP 2016 Annual Meeting
TNXP,TNX-102,2016-05-19,Tonix Pharmaceuticals Reports Positive Topline Results From Phase 2 AtEase Study Of TNX-102 SL In Post-Traumatic Stress Disorder (PTSD)
TNXP,TNX-102,2016-05-02,Tonix Pharmaceuticals Completes Enrollment In Phase 3 Clinical Trial Of TNX-102 SL In Fibromyalgia
TNXP,TNX-102,2016-03-09,Tonix Pharmaceuticals Presents Pharmacokinetic Data On TNX-102 SL As A Potential Treatment For The Management Of Fibromyalgia And Treatment Of Post-Traumatic Stress Disorder At The ASCPT 2016 Annual Meeting
TNXP,TNX-102,2015-12-23,Tonix Pharmaceuticals Completes Enrollment In Phase 2 Clinical Trial Of TNX-102 SL In Post-Traumatic Stress Disorder (PTSD)
TNXP,TNX-102,2015-12-07,Tonix Pharmaceuticals And U.S. Department Of Defense Military Developer In Partnership To Expand Efforts To Examine TNX-102 SL For Post-Traumatic Stress Disorder
TNXP,TNX-102,2015-08-18,Tonix Pharmaceuticals Presents On The Development Of TNX-102 SL For Post-Traumatic Stress Disorder (PTSD) At The 2015 Military Health System Research Symposium
TNXP,TNX-102,2015-05-20,Tonix Pharmaceuticals To Present Additional Data From Completed Phase 2b Study Of TNX-102 SL In Fibromyalgia At EULAR
TNXP,TNX-102,2015-05-13,Tonix Pharmaceuticals Launches Phase 3 Clinical Study Of TNX-102 SL In Fibromyalgia
TNXP,TNX-102,2015-01-15,Tonix Pharmaceuticals Commences Phase 2 Trial Of TNX-102 SL In Post-Traumatic Stress Disorder
TNXP,TNX-102,2015-01-06,Tonix Pharmaceuticals Provides Clinical And Regulatory Update On Its Continued Development Of TNX-102 SL In Fibromyalgia
TNXP,TNX-102,2014-09-29,Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial Of TNX-102 SL In Patients With Fibromyalgia
TNXP,TNX-102,2014-06-10,Tonix Pharmaceuticals Receives IND Clearance From U.S. Food And Drug Administration For TNX-102 SL In Post-Traumatic Stress Disorder
TNXP,TNX-102,2014-05-12,Tonix Pharmaceuticals Completes Enrollment In BESTFIT Trial Of TNX-102 SL For Fibromyalgia
TNXP,TNX-102,2012-07-30,Tonix Pharmaceuticals Announces Completion Of Clinical Trial Of Sublingual TNX-102
TNXP,TNX-102,2012-07-09,Tonix Pharmaceuticals Reports Positive Preclinical Data On Sublingual TNX-102
VICL,ASP0113,2016-09-19,Vical And Astellas Announce Topline Results From A Phase 2 Study Of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) In Kidney Transplant Patients
VICL,ASP0113,2013-12-10,Astellas And Vical Announce Initiation Of Phase 2 Trial Of ASP0113, A Cytomegalovirus Vaccine, In Solid Organ Transplant Recipients
VICL,ASP0113,2013-06-25,Vical And Astellas Announce Initiation Of Phase 3 Trial Of ASP0113 Cytomegalovirus Vaccine
VRTX,ORKAMBI,2016-12-19,Vertex Announces German Reimbursement Agreement For ORKAMBI® (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation
VRTX,ORKAMBI,2016-11-07,Positive Phase 3 Study Of ORKAMBI® In Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies Of The F508del Mutation Supports A Submission To The European Medicines Agency In The First Half Of 2017
VRTX,ORKAMBI,2016-10-27,Vertex Presents Long-Term Data Demonstrating That ORKAMBI® (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) Show The Potential To Modify The Progression Of CF
VRTX,ORKAMBI,2016-09-28,U.S. Food And Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) For Use In Children With Cystic Fibrosis Ages 6 Through 11 Who Have Two Copies Of The F508del Mutation
VRTX,ORKAMBI,2016-06-10,Vertex Announces Presentations Of Data For KALYDECO® (ivacaftor) And ORKAMBI® (lumacaftor/ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference
VRTX,ORKAMBI,2016-05-31,U.S. FDA Accepts For Priority Review Supplemental New Drug Application For The Use Of ORKAMBI® (lumacaftor/ivacaftor) In Children With Cystic Fibrosis Ages 6 To 11 Who Have Two Copies Of The F508del Mutation
VRTX,ORKAMBI,2016-04-04,Reasons for Vertex's Stock Slump Since Last Summer Center on Orkambi Launch
VRTX,ORKAMBI,2016-03-08,Vertex Receives Australian Approval For ORKAMBI® (lumacaftor/ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation
VRTX,ORKAMBI,2016-01-26,Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis For People Ages 12 And Older With Two Copies Of The F508del Mutation
VRTX,ORKAMBI,2016-01-10,Vertex Takes a Pass on 2016 Orkambi Cystic Fibrosis Sales Guidance
VRTX,ORKAMBI,2015-11-20,Vertex Receives EU Approval For ORKAMBI® (lumacaftor/ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation
VRTX,ORKAMBI,2015-09-25,Vertex Receives CHMP Positive Opinions For ORKAMBI™ (lumacaftor/ivacaftor) And KALYDECO® (ivacaftor) In The European Union
VRTX,ORKAMBI,2015-07-02,FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis For People Ages 12 And Older With Two Copies Of The F508del Mutation
VRTX,ORKAMBI,2015-05-17,New England Journal Of Medicine Publishes Data From Two Phase 3 Studies Of ORKAMBITM (lumacaftor/ivacaftor) in People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation
VRTX,ORKAMBI,2015-05-12,Food And Drug Administration Advisory Panel Voted 12 To 1 To Recommend Approval Of ORKAMBI™ (lumacaftor/ivacaftor) To Treat People With Cystic Fibrosis Ages 12 And Older Who Have Two Copies Of The F508del Mutation
CERU,CRLX101,2016-08-17,Cerulean Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin® Combination In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2016-07-19,Cerulean Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer
CERU,CRLX101,2016-05-19,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
CERU,CRLX101,2016-05-10,Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA™
CERU,CRLX101,2016-04-25,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
CERU,CRLX101,2016-03-23,Cerulean Announces Publication Showing CRLX101 Localizes Selectively In Human Tumors, Sparing Adjacent Healthy Tissue
CERU,CRLX101,2015-11-17,Cerulean Announces Clinical Collaboration With AstraZeneca And The National Cancer Institute To Evaluate The Combination Of LYNPARZA™ And CRLX101
CERU,CRLX101,2015-10-19,Cerulean Announces First Patient Dosed In Clinical Trial To Evaluate Weekly Dosing Schedule With CRLX101
CERU,CRLX101,2015-10-15,Cerulean Announces Completion Of Enrollment Of Randomized Phase 2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2015-09-30,Cerulean Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin® In Relapsed Ovarian Cancer
CERU,CRLX101,2015-07-21,Cerulean Announces First Patient Dosed In Phase 1b Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
CERU,CRLX101,2015-06-01,Cerulean Announces Presentation Of Full Data From Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Metastatic Renal Cell Carcinoma At The Annual Meeting Of The American Society For Clinical Oncology
CERU,CRLX101,2015-05-26,Cerulean's CRLX101 Receives Orphan Drug Designation From The FDA For The Treatment Of Ovarian Cancer
CERU,CRLX101,2015-04-28,Cerulean Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma
CERU,CRLX101,2015-04-16,Cerulean Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association For Cancer Research Annual Meeting
CERU,CRLX101,2015-04-13,Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells And Impedes Resistance To Anti-angiogenic Therapy In Preclinical Models
CERU,CRLX101,2015-03-19,Cerulean Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma Meets Primary Endpoint
CERU,CRLX101,2015-03-03,Cerulean Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
CERU,CRLX101,2015-02-19,CRLX101 Selected For Oral Presentation At 17th Annual Symposium On Anti-Angiogenesis And Immune Therapies For Cancer
CERU,CRLX101,2015-01-19,CRLX101 Rectal Cancer Data Presented At ASCO 2015 Gastrointestinal Cancers Symposium
CERU,CRLX101,2015-01-06,Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models
CERU,CRLX101,2014-12-15,Cerulean Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2016-08-17,Cerulean Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin® Combination In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2016-07-19,Cerulean Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer
CERU,CRLX101,2016-05-19,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
CERU,CRLX101,2016-05-10,Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA™
CERU,CRLX101,2016-04-25,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
CERU,CRLX101,2016-03-23,Cerulean Announces Publication Showing CRLX101 Localizes Selectively In Human Tumors, Sparing Adjacent Healthy Tissue
CERU,CRLX101,2015-11-17,Cerulean Announces Clinical Collaboration With AstraZeneca And The National Cancer Institute To Evaluate The Combination Of LYNPARZA™ And CRLX101
CERU,CRLX101,2015-10-19,Cerulean Announces First Patient Dosed In Clinical Trial To Evaluate Weekly Dosing Schedule With CRLX101
CERU,CRLX101,2015-10-15,Cerulean Announces Completion Of Enrollment Of Randomized Phase 2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2015-09-30,Cerulean Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin® In Relapsed Ovarian Cancer
CERU,CRLX101,2015-07-21,Cerulean Announces First Patient Dosed In Phase 1b Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
CERU,CRLX101,2015-06-01,Cerulean Announces Presentation Of Full Data From Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Metastatic Renal Cell Carcinoma At The Annual Meeting Of The American Society For Clinical Oncology
CERU,CRLX101,2015-05-26,Cerulean's CRLX101 Receives Orphan Drug Designation From The FDA For The Treatment Of Ovarian Cancer
CERU,CRLX101,2015-04-28,Cerulean Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma
CERU,CRLX101,2015-04-16,Cerulean Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association For Cancer Research Annual Meeting
CERU,CRLX101,2015-04-13,Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells And Impedes Resistance To Anti-angiogenic Therapy In Preclinical Models
CERU,CRLX101,2015-03-19,Cerulean Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma Meets Primary Endpoint
CERU,CRLX101,2015-03-03,Cerulean Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
CERU,CRLX101,2015-02-19,CRLX101 Selected For Oral Presentation At 17th Annual Symposium On Anti-Angiogenesis And Immune Therapies For Cancer
CERU,CRLX101,2015-01-19,CRLX101 Rectal Cancer Data Presented At ASCO 2015 Gastrointestinal Cancers Symposium
CERU,CRLX101,2015-01-06,Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models
CERU,CRLX101,2014-12-15,Cerulean Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
CLDX,Glembatumumab,2016-10-09,Phase 2 Study Of Single-agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint And Demonstrates Clinically Meaningful Duration Of Response
CLDX,Glembatumumab,2016-04-27,Celldex Therapeutics Initiates Phase 1/2 Study Of Glembatumumab Vedotin In Squamous Cell Lung Cancer
CLDX,Glembatumumab,2016-04-20,Celldex Therapeutics Presents Data Supporting The Clinical Development Of Glembatumumab Vedotin And The Preclinical CD40 Program At The AACR Annual Meeting 2016
CLDX,Glembatumumab,2015-04-06,Celldex Therapeutics' Phase 2 EMERGE Study Of Glembatumumab Vedotin In Metastatic Breast Cancer Published In Journal Of Clinical Oncology
CLDX,Glembatumumab,2014-12-04,Celldex Therapeutics Initiates A Phase 2 Study Of Glembatumumab Vedotin In Patients With Advanced Melanoma
EGLT,Egalet-001,2015-06-29,Egalet Announces Positive Top-Line Results From Intranasal Human Abuse Liability Study Of Abuse-Deterrent Morphine, Egalet-001
EGLT,Egalet-001,2015-01-22,Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study Of Abuse-Deterrent Morphine, Egalet-001
EGLT,Egalet-001,2014-09-23,Egalet Announces Update On Clinical Development Plan For Abuse-Deterrent Morphine Egalet-001
EGLT,Egalet-001,2014-08-06,Egalet Announces Topline Results From Bioequivalence Studies Of Abuse-Deterrent Morphine, Egalet-001
EGLT,Egalet-001,2014-07-15,Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical And Chemical Manipulation
WINT,Aerosurf,2016-11-28,Windtree Therapeutics' AEROSURF® (lucinactant For Inhalation) Phase 2a Data Presented At The 2016 International Congress Of Union Of European Neonatal And Perinatal Societies
WINT,Aerosurf,2016-09-19,Windtree Therapeutics Announces FDA Fast Track Designation For AEROSURF®
WINT,Aerosurf,2016-08-08,Windtree Receives $2.6 Million SBIR Grant To Support AEROSURF® Phase 2b Clinical Trial
WINT,Aerosurf,2016-11-28,Windtree Therapeutics' AEROSURF® (lucinactant For Inhalation) Phase 2a Data Presented At The 2016 International Congress Of Union Of European Neonatal And Perinatal Societies
WINT,Aerosurf,2016-09-19,Windtree Therapeutics Announces FDA Fast Track Designation For AEROSURF®
WINT,Aerosurf,2016-08-08,Windtree Receives $2.6 Million SBIR Grant To Support AEROSURF® Phase 2b Clinical Trial
MDVN,XTANDI,2016-04-07,CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI® (enzalutamide)
MDVN,XTANDI,2016-02-22,FDA Accepts For Review Supplemental New Drug Application For XTANDI® (enzalutamide) Capsules In Metastatic Castration-resistant Prostate Cancer With Data From Head-to-Head Studies Of Enzalutamide Versus Bicalutamide
MDVN,XTANDI,2016-04-07,CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI® (enzalutamide)
MDVN,XTANDI,2016-02-22,FDA Accepts For Review Supplemental New Drug Application For XTANDI® (enzalutamide) Capsules In Metastatic Castration-resistant Prostate Cancer With Data From Head-to-Head Studies Of Enzalutamide Versus Bicalutamide
PRQR,QR-010,2016-10-27,ProQR Announces That QR-010 Meets The Primary Endpoint In A Proof Of Concept Study Of Homozygous F508del Cystic Fibrosis Patients
PRQR,QR-010,2016-07-19,ProQR Receives Fast Track Designation From FDA For QR-010 For Cystic Fibrosis
PRQR,QR-010,2016-06-21,ProQR To Release Topline Data From Proof Of Concept Study Of QR-010 In Cystic Fibrosis Patients At NACFC
PRQR,QR-010,2015-10-01,ProQR Announces An Investor And Analyst Event And Pre-Clinical Data Presentations For QR-010 For Cystic Fibrosis At Two Upcoming Scientific Conferences
PRQR,QR-010,2015-09-14,ProQR Announces A Proof-of-Concept Nasal Potential Difference Study Of QR-010 Is Open For Enrollment
PRQR,QR-010,2015-06-26,ProQR Announces Enrollment Has Started In Global Phase 1b Study Of QR-010 In Cystic Fibrosis Patients
AMRN,Vascepa,2016-11-14,Pure EPA Vascepa® (icosapent Ethyl) Showed Reductions In Potentially Atherogenic Lipid And Inflammatory Parameters In Statin-Treated Women With Persistent High Triglycerides
AMRN,Vascepa,2016-10-25,Pure EPA Vascepa® Now Available In New, Smaller Half-Gram Capsule Size
AMRN,Vascepa,2016-09-12,Amarin's REDUCE-IT Cardiovascular Outcomes Study Of Vascepa To Continue As Planned At Recommendation Of Independent Data Monitoring Committee
AMRN,Vascepa,2016-08-31,Amarin Randomizes Final Patient Into REDUCE-IT Cardiovascular Outcomes Study Of Vascepa
AMRN,Vascepa,2015-05-28,Amarin Surges After Court Sides With Company On Vascepa Exclusivity
AMRN,Vascepa,2014-09-12,Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal
AMRN,Vascepa,2014-05-02,Amarin Announces Presentation Of New MARINE And ANCHOR Post-Hoc Analyses At National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels
AMRN,Vascepa,2014-03-31,Amarin And Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement For Vascepa(R) (icosapent Ethyl) Capsules
AMRN,Vascepa,2014-02-24,Amarin Loses Bid for Vascepa 5-Year Market Exclusivity
AMRN,Vascepa,2014-02-21,Amarin Announces FDA Award Of Three-Year Exclusivity For Vascepa(R) (icosapent Ethyl) Capsules
AMRN,Vascepa,2013-10-17,Amarin: Dead Stock Walking With Negative Vascepa Panel Vote
AMRN,Vascepa,2013-10-16,Amarin Announces FDA Advisory Committee Outcome For The Use Of Vascepa In The Treatment Of High Triglycerides With Mixed Dyslipidemia
AMRN,Vascepa,2013-10-16,Amarin Vascepa FDA Panel Live Blog
AMRN,Vascepa,2013-10-16,Amarin Corporation (NASDAQ: AMRN) Stock Trading Halted Today; FDA Advisory Committee To Review SNDA For Vascepa(R) ANCHOR Indication
AMRN,Vascepa,2013-10-15,The Essential Investor Guide to Amarin's Vascepa FDA Panel
AMRN,Vascepa,2013-10-09,Amarin To Host Conference Call On October 16, 2013 To Discuss Results Of FDA Advisory Committee Meeting On ANCHOR Supplemental New Drug Application (sNDA) For Vascepa(R)
AMRN,Vascepa,2013-09-09,Amarin Announces 30th Patent For Vascepa(R)
AMRN,Vascepa,2013-08-26,Amarin Announces Submission Of Supplemental New Drug Application For Novasep As Fourth Vascepa(R) Active Pharmaceutical Ingredient Supplier
AMRN,Vascepa,2013-06-21,Amarin Announces Positive Results Of Phase 1 Clinical Trial Measuring The Bioavailability Of A Fixed-Dose Combination Of Vascepa(R) And A Statin Compared To Concomitant Administration
AMRN,Vascepa,2013-06-19,Amarin Informed By FDA Of October 16th Advisory Committee Date In Connection With Supplemental New Drug Application (sNDA) For Vascepa(R) In The Treatment Of Patients With High Triglycerides (>200 Mg/dL And 
AMRN,Vascepa,2013-06-06,As If Amarin Needs Another Worry, Here Comes A Vascepa FDA Panel
AMRN,Vascepa,2013-05-30,Amarin Announces Additional Effects Of Vascepa(R) On Lipoprotein Particle Concentration From The ANCHOR Study Presented At The National Lipid Association 2013 Annual Scientific Sessions
AMRN,Vascepa,2013-05-22,Amarin Announces Notification Of Patent Allowance For U.S. Application 13/417,899 Related To Combination Product Of Vascepa(R) And Statin Therapy
AMRN,Vascepa,2013-04-30,Amarin Announces Approval Of Supplemental New Drug Application For BASF As Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
AMRN,Vascepa,2013-04-23,Amarin Announces FDA Acceptance Of Supplemental New Drug Application (sNDA) For Vascepa(R) For The Treatment Of Patients With High Triglycerides (>200 Mg/dL And 
AMRN,Vascepa,2013-04-18,Amarin Announces Approval Of Supplemental New Drug Application For Chemport As Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
ANTH,Blisibimod,2016-12-06,Anthera Announces Leadership Transition In Preparation Of Commercialization Of Sollpura And Future Development Of Blisibimod For IgA Nephropathy
ANTH,Blisibimod,2016-12-06,Anthera Reports Blisibimod BRIGHT-SC IgA Nephropathy Continues To Demonstrate Positive Trends In The Week 48 Analysis
ANTH,Blisibimod,2016-11-10,Anthera Announces That The Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve The Primary Endpoint In Patients With Active Systemic Lupus Erythematosus
ANTH,Blisibimod,2016-08-03,Anthera Pharmaceuticals Announces Completion Of Dosing In CHABLIS-SC1 Phase 3 Clinical Study With Blisibimod
ANTH,Blisibimod,2016-06-28,Anthera Provides Clinical Program Updates For Blisibimod And Sollpura®
ANTH,Blisibimod,2015-09-14,Anthera Announces Termination Of Blisibimod Partnership In Japan By Zenyaku
ANTH,Blisibimod,2015-06-16,Anthera Pharmaceuticals Has Reached Enrollment Target In CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod
ANTH,Blisibimod,2015-06-04,Anthera Pharmaceuticals Announces Additional Data On Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study
ANTH,Blisibimod,2015-03-16,Anthera Pharmaceuticals Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy
ANTH,Blisibimod,2015-02-10,Anthera Pharmaceuticals Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For Systemic Lupus Erythematosus
ANTH,Blisibimod,2014-12-15,Anthera Pharmaceuticals Licenses Japan Rights For Blisibimod To Zenyaku Kogyo Co., Ltd.
ANTH,Blisibimod,2014-10-01,Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod
ANTH,Blisibimod,2013-06-24,Anthera Announces Initiation Of BRIGHT-SC Phase 2 Clinical Study In IgA Nephropathy With Blisibimod
ANTH,Blisibimod,2013-05-07,Anthera Pharmaceuticals Announces Additional Data From Phase 2b PEARL-SC Blisibimod Study
ANTH,Blisibimod,2013-03-27,Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study In Lupus With Blisibimod
ANTH,Blisibimod,2012-09-17,Anthera Announces The Advancement Of Blisibimod Into Phase 3 Development For Patients With Systemic Lupus Erythematosus (SLE)
ANTH,Blisibimod,2012-03-05,Anthera Pharmaceuticals Completes Interim Analysis Of PEARL-SC Clinical Trial With Blisibimod
ANTH,Blisibimod,2016-12-06,Anthera Announces Leadership Transition In Preparation Of Commercialization Of Sollpura And Future Development Of Blisibimod For IgA Nephropathy
ANTH,Blisibimod,2016-12-06,Anthera Reports Blisibimod BRIGHT-SC IgA Nephropathy Continues To Demonstrate Positive Trends In The Week 48 Analysis
ANTH,Blisibimod,2016-11-10,Anthera Announces That The Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve The Primary Endpoint In Patients With Active Systemic Lupus Erythematosus
ANTH,Blisibimod,2016-08-03,Anthera Pharmaceuticals Announces Completion Of Dosing In CHABLIS-SC1 Phase 3 Clinical Study With Blisibimod
ANTH,Blisibimod,2016-06-28,Anthera Provides Clinical Program Updates For Blisibimod And Sollpura®
ANTH,Blisibimod,2015-09-14,Anthera Announces Termination Of Blisibimod Partnership In Japan By Zenyaku
ANTH,Blisibimod,2015-06-16,Anthera Pharmaceuticals Has Reached Enrollment Target In CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod
ANTH,Blisibimod,2015-06-04,Anthera Pharmaceuticals Announces Additional Data On Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study
ANTH,Blisibimod,2015-03-16,Anthera Pharmaceuticals Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy
ANTH,Blisibimod,2015-02-10,Anthera Pharmaceuticals Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For Systemic Lupus Erythematosus
ANTH,Blisibimod,2014-12-15,Anthera Pharmaceuticals Licenses Japan Rights For Blisibimod To Zenyaku Kogyo Co., Ltd.
ANTH,Blisibimod,2014-10-01,Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod
ANTH,Blisibimod,2013-06-24,Anthera Announces Initiation Of BRIGHT-SC Phase 2 Clinical Study In IgA Nephropathy With Blisibimod
ANTH,Blisibimod,2013-05-07,Anthera Pharmaceuticals Announces Additional Data From Phase 2b PEARL-SC Blisibimod Study
ANTH,Blisibimod,2013-03-27,Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study In Lupus With Blisibimod
ANTH,Blisibimod,2012-09-17,Anthera Announces The Advancement Of Blisibimod Into Phase 3 Development For Patients With Systemic Lupus Erythematosus (SLE)
ANTH,Blisibimod,2012-03-05,Anthera Pharmaceuticals Completes Interim Analysis Of PEARL-SC Clinical Trial With Blisibimod
INNL,Cogenzia,2016-11-03,Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA And NDA Submission For XARACOLL
INNL,Cogenzia,2016-06-23,Innocoll Holdings Plc Announces The Completion Of Enrollment In Two Pivotal Phase 3 Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections
INNL,Cogenzia,2015-06-30,Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation For Cogenzia For The Adjunctive Treatment Of Moderate And Severe Diabetic Foot Infection
INNL,Cogenzia,2015-06-15,Innocoll AG Announces First Patient Dosed In The Cogenzia COACT-2 Phase 3 Study For The Treatment Of Diabetic Foot Infection
INNL,Cogenzia,2015-05-15,Innocoll AG Announces First Patient Dosed In The Cogenzia COACT-1 Phase 3 Study For The Treatment Of Diabetic Foot Infection
INNL,Cogenzia,2016-11-03,Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA And NDA Submission For XARACOLL
INNL,Cogenzia,2016-06-23,Innocoll Holdings Plc Announces The Completion Of Enrollment In Two Pivotal Phase 3 Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections
INNL,Cogenzia,2015-06-30,Innocoll AG Announces Qualified Infectious Disease Product (QIDP) Designation For Cogenzia For The Adjunctive Treatment Of Moderate And Severe Diabetic Foot Infection
INNL,Cogenzia,2015-06-15,Innocoll AG Announces First Patient Dosed In The Cogenzia COACT-2 Phase 3 Study For The Treatment Of Diabetic Foot Infection
INNL,Cogenzia,2015-05-15,Innocoll AG Announces First Patient Dosed In The Cogenzia COACT-1 Phase 3 Study For The Treatment Of Diabetic Foot Infection
INNL,XaraColl,2016-12-29,Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL® (bupivacaine HCl collagen-matrix implants) New Drug Application
INNL,XaraColl,2016-11-03,Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA And NDA Submission For XARACOLL
INNL,XaraColl,2016-05-25,Innocoll Announces XARACOLL® (bupivacaine-collagen Bioresorbable Implant) Meets Primary Endpoint In Both Pivotal Phase 3 Trials In Postoperative Pain Relief
INNL,XaraColl,2016-05-24,Innocoll To Host Live Webcast On Top-Line Results From Two Pivotal Phase 3 Trials Of XARACOLL® (bupivacaine-collagen Bioresorbable Implant) In Postoperative Pain Relief
INNL,XaraColl,2015-09-16,Innocoll AG Announces First Patient Dosed In The XaraColl MATRIX-2 Phase 3 Study For The Treatment Of Postoperative Pain
INNL,XaraColl,2015-09-02,Innocoll AG Announces First Patient Dosed In The XaraColl MATRIX-1 Phase 3 Study For The Treatment Of Postoperative Pain
INNL,XaraColl,2015-04-01,Pivotal Pharmacokinetic Study Of Innocoll's XaraColl(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain
INNL,XaraColl,2016-12-29,Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL® (bupivacaine HCl collagen-matrix implants) New Drug Application
INNL,XaraColl,2016-11-03,Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA And NDA Submission For XARACOLL
INNL,XaraColl,2016-05-25,Innocoll Announces XARACOLL® (bupivacaine-collagen Bioresorbable Implant) Meets Primary Endpoint In Both Pivotal Phase 3 Trials In Postoperative Pain Relief
INNL,XaraColl,2016-05-24,Innocoll To Host Live Webcast On Top-Line Results From Two Pivotal Phase 3 Trials Of XARACOLL® (bupivacaine-collagen Bioresorbable Implant) In Postoperative Pain Relief
INNL,XaraColl,2015-09-16,Innocoll AG Announces First Patient Dosed In The XaraColl MATRIX-2 Phase 3 Study For The Treatment Of Postoperative Pain
INNL,XaraColl,2015-09-02,Innocoll AG Announces First Patient Dosed In The XaraColl MATRIX-1 Phase 3 Study For The Treatment Of Postoperative Pain
INNL,XaraColl,2015-04-01,Pivotal Pharmacokinetic Study Of Innocoll's XaraColl(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain
OPXA,Tovaxin,2011-11-14,Opexa Announces Publication In Multiple Sclerosis Journal Of Tovaxin&#174; Phase IIb Clinical Trial Results
OPXA,Tovaxin,2011-11-08,Opexa&#8217;s Tovaxin&#174; For The Treatment Of Multiple Sclerosis Granted Fast Track Designation By FDA
OPXA,Tovaxin,2011-04-15,Opexa Presents Tovaxin&#174; Data At American Academy Of Neurology 2011 Annual Meeting
OPXA,Tovaxin,2011-03-23,Opexa To Present Tovaxin&#174; Data At 2011 American Academy Of Neurology Annual Meeting
OPXA,Tovaxin,2011-01-05,Opexa Completes Successful Meetings With FDA To Pursue Phase 3 Clinical Study For Tovaxin&#174; In Multiple Sclerosis
OPXA,Tovaxin,2010-05-11,Opexa Strengthens Tovaxin&#174; Patent Estate Through Issuance Of Key Patents
OPXA,Tovaxin,2010-04-14,Opexa Presents Tovaxin&#174; Data At The American Academy Of Neurology 2010 Annual Meeting
OPXA,Tovaxin,2010-04-06,Opexa To Present Tovaxin&#174; Data At The American Academy Of Neurology 2010 Annual Meeting
PTN,Bremelanotide,2017-03-20,Palatin Technologies Receives Notice Of Allowance On Bremelanotide Methods Of Use Patent For Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women
PTN,Bremelanotide,2016-11-01,Bremelanotide Meets Co-Primary Endpoints In Palatin's Phase 3 Trials For Hypoactive Sexual Desire Disorder
PTN,Bremelanotide,2016-09-23,Palatin Technologies Presents Bremelanotide Neurobiology And Treatment Efficacy Review At World Meeting On Sexual Medicine
PTN,Bremelanotide,2016-08-04,Palatin Technologies Announces Completion Of All Patient Visits In Phase 3 Clinical Trials Of Bremelanotide For Hypoactive Sexual Desire Disorder
PTN,Bremelanotide,2016-02-26,Palatin Technologies Presents Bremelanotide Alcohol Interaction Study At International Society For The Study Of Women's Sexual Health Annual Meeting
PTN,Bremelanotide,2016-02-08,Palatin Technologies Strengthens Intellectual Property Surrounding Use Of Bremelanotide For Female Sexual Dysfunction
PTN,Bremelanotide,2015-12-10,Palatin Technologies Achieves Target Patient Enrollment In Pivotal Phase 3 Studies For Bremelanotide For Female Sexual Dysfunction
PTN,Bremelanotide,2015-09-21,Palatin Technologies And Richter Terminate License Agreement For Bremelanotide For Female Sexual Dysfunction
PTN,Bremelanotide,2015-02-20,Palatin Launches Reconnectstudy.com In Support Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
PTN,Bremelanotide,2014-12-29,Palatin Announces Start Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction
PTN,Bremelanotide,2014-09-03,Palatin Technologies Licenses Bremelanotide In Europe And Other Selected Countries To Richter
PTN,Bremelanotide,2014-05-01,Palatin Technologies Announces Option Exercise By Specialty Pharmaceutical Company To License Bremelanotide In Europe
PTN,Bremelanotide,2014-03-31,Palatin Technologies Announces Option Extension For License To Bremelanotide In Europe
PTN,Bremelanotide,2014-02-24,Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy Of Bremelanotide In Female Hypoactive Sexual Desire Disorder
PTN,Bremelanotide,2013-11-13,Palatin Technologies Announces Option For License To Bremelanotide In Europe
PTN,Bremelanotide,2012-11-08,Palatin Technologies Reports Positive Results For Phase 2B Bremelanotide Female Sexual Dysfunction Trial
PTN,Bremelanotide,2012-09-10,Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
PTN,Bremelanotide,2012-03-08,Palatin Technologies Completes Enrollment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
PTN,Bremelanotide,2011-06-28,Palatin Technologies, Inc. Initiates Enrollment In Phase 2b Trial With Bremelanotide In Women With Female Sexual Dysfunction
PTN,Bremelanotide,2010-08-17,Palatin Technologies, Inc. Announces Positive Safety Results In Subcutaneous Bremelanotide Trial In Men
PTN,Bremelanotide,2010-06-24,Palatin Technologies, Inc. Announces Last Patient Dosed And Database Lock In Subcutaneous Bremelanotide Trial In Men
PTN,Bremelanotide,2010-02-09,Palatin Technologies, Inc. Announces Dosing Of Subcutaneous Bremelanotide Trial In Men
TBPH,Revefenacin,2016-10-20,Theravance Biopharma And Mylan Announce Positive Results From Two Pivotal Phase 3 Studies Of Revefenacin (TD-4208) For The Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
TBPH,Revefenacin,2015-09-14,Theravance Biopharma And Mylan Initiate Phase 3 Program For Revefenacin (TD-4208) For Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
EIGR,Lonafarnib,2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
EIGR,Lonafarnib,2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
MDCO,MDCO-216,2016-11-07,The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter
MDCO,MDCO-216,2015-12-14,The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy
MDCO,MDCO-216,2015-06-01,The Medicines Company To Hold Conference Call On Tuesday, June 2 To Discuss Clinical Trial Results Of ABP-700 And MDCO-216
MDCO,MDCO-216,2015-05-26,The Medicines Company Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients
MDCO,MDCO-216,2014-11-16,The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients
MDCO,MDCO-216,2014-11-14,The Medicines Company To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association (AHA) Annual Scientific Sessions In Chicago
MDCO,MDCO-216,2016-11-07,The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter
MDCO,MDCO-216,2015-12-14,The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy
MDCO,MDCO-216,2015-06-01,The Medicines Company To Hold Conference Call On Tuesday, June 2 To Discuss Clinical Trial Results Of ABP-700 And MDCO-216
MDCO,MDCO-216,2015-05-26,The Medicines Company Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients
MDCO,MDCO-216,2014-11-16,The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients
MDCO,MDCO-216,2014-11-14,The Medicines Company To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association (AHA) Annual Scientific Sessions In Chicago
MDCO,MDCO-216,2016-11-07,The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter
MDCO,MDCO-216,2015-12-14,The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy
MDCO,MDCO-216,2015-06-01,The Medicines Company To Hold Conference Call On Tuesday, June 2 To Discuss Clinical Trial Results Of ABP-700 And MDCO-216
MDCO,MDCO-216,2015-05-26,The Medicines Company Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients
MDCO,MDCO-216,2014-11-16,The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients
MDCO,MDCO-216,2014-11-14,The Medicines Company To Present New Data On Investigational Lipid-Modifying Agent MDCO-216 And Investigational Antiplatelet Agent Cangrelor At 2014 American Heart Association (AHA) Annual Scientific Sessions In Chicago
LXRX,Telotristat,2017-02-28,FDA Approves Lexicon Drug XERMELO™ (telotristat Ethyl) 250 Mg As First And Only Oral Treatment For Carcinoid Syndrome Diarrhea In Cancer Patients With Metastatic Neuroendocrine Tumors
LXRX,Telotristat,2016-11-21,Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl
LXRX,Telotristat,2016-10-31,Lexicon Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology
LXRX,Telotristat,2016-09-14,FDA Extends PDUFA Date For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
LXRX,Telotristat,2016-07-18,Lexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
LXRX,Telotristat,2016-05-31,Lexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
LXRX,Telotristat,2016-03-30,Lexicon Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
LXRX,Telotristat,2016-03-08,Lexicon Announces Telotristat Etiprate Data To Be Presented At European Neuroendocrine Tumor Society Conference
LXRX,Telotristat,2015-12-01,Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial
LXRX,Telotristat,2015-10-19,Cancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being
LXRX,Telotristat,2015-10-09,Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium
LXRX,Telotristat,2015-09-29,Lexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care
LXRX,Telotristat,2015-08-26,Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress
LXRX,Telotristat,2015-08-03,Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome
LXRX,Telotristat,2015-03-18,Lexicon And Ipsen Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada
LXRX,Telotristat,2015-03-09,Lexicon Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate
LXRX,Telotristat,2014-10-22,Lexicon And Ipsen Enter Into Ex-North America/Japan Licensing And Commercialization Agreement For Telotristat Etiprate
LXRX,Telotristat,2014-10-22,Lexicon And Ipsen Enter Into Ex-North America/Japan Licensing And Commercialization Agreement For Telotristat Etiprate
LXRX,Telotristat,2013-10-09,Lexicon Completes Pilot Study Of Telotristat Etiprate In Ulcerative Colitis
LXRX,Telotristat,2012-10-12,Lexicon Initiates Phase 3 Clinical Trial Of Telotristat Etiprate In Patients With Carcinoid Syndrome
LXRX,Telotristat,2012-10-12,Second Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
BLUE,LentiGlobin,2017-02-03,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product Under Amended Study Protocol In HGB-206 Phase 1 Study Of Patients With Severe Sickle Cell Disease
BLUE,LentiGlobin,2016-12-14,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product In Northstar-2 (HGB-207) Phase 3 Trial Of Patients With Transfusion-Dependent ß-Thalassemia
BLUE,LentiGlobin,2016-12-03,Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting
BLUE,LentiGlobin,2016-11-03,Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting
BLUE,LentiGlobin,2016-10-13,Bluebird Bio Provides Update On LentiGlobin™ Programs And Research And Development Strategy At Gene Therapy Day
BLUE,LentiGlobin,2016-09-21,LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program
BLUE,LentiGlobin,2016-09-08,Bluebird Bio Opens Phase 3 Study Of LentiGlobin™ Drug Product In Patients With Transfusion-Dependent Beta-Thalassemia
BLUE,LentiGlobin,2015-12-06,Bluebird Bio Reports New Beta-thalassemia Major And Severe Sickle Cell Disease Data From HGB-205 And HGB-206 Studies Of LentiGlobin® At ASH Annual Meeting
BLUE,LentiGlobin,2015-12-05,Bluebird Bio Reports New Beta-thalassemia Major Data From Northstar Study Of LentiGlobin® At ASH Annual Meeting
BLUE,LentiGlobin,2015-11-05,Bluebird Bio To Present LentiGlobin® BB305 Clinical Data And Bb2121 Preclinical Data At Annual Meeting Of The American Society Of Hematology
BLUE,LentiGlobin,2017-02-03,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product Under Amended Study Protocol In HGB-206 Phase 1 Study Of Patients With Severe Sickle Cell Disease
BLUE,LentiGlobin,2016-12-14,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product In Northstar-2 (HGB-207) Phase 3 Trial Of Patients With Transfusion-Dependent ß-Thalassemia
BLUE,LentiGlobin,2016-12-03,Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting
BLUE,LentiGlobin,2016-11-03,Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting
BLUE,LentiGlobin,2016-10-13,Bluebird Bio Provides Update On LentiGlobin™ Programs And Research And Development Strategy At Gene Therapy Day
BLUE,LentiGlobin,2016-09-21,LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program
BLUE,LentiGlobin,2016-09-08,Bluebird Bio Opens Phase 3 Study Of LentiGlobin™ Drug Product In Patients With Transfusion-Dependent Beta-Thalassemia
BLUE,LentiGlobin,2015-12-06,Bluebird Bio Reports New Beta-thalassemia Major And Severe Sickle Cell Disease Data From HGB-205 And HGB-206 Studies Of LentiGlobin® At ASH Annual Meeting
BLUE,LentiGlobin,2015-12-05,Bluebird Bio Reports New Beta-thalassemia Major Data From Northstar Study Of LentiGlobin® At ASH Annual Meeting
BLUE,LentiGlobin,2015-11-05,Bluebird Bio To Present LentiGlobin® BB305 Clinical Data And Bb2121 Preclinical Data At Annual Meeting Of The American Society Of Hematology
BLUE,LentiGlobin,2017-02-03,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product Under Amended Study Protocol In HGB-206 Phase 1 Study Of Patients With Severe Sickle Cell Disease
BLUE,LentiGlobin,2016-12-14,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product In Northstar-2 (HGB-207) Phase 3 Trial Of Patients With Transfusion-Dependent ß-Thalassemia
BLUE,LentiGlobin,2016-12-03,Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting
BLUE,LentiGlobin,2016-11-03,Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting
BLUE,LentiGlobin,2016-10-13,Bluebird Bio Provides Update On LentiGlobin™ Programs And Research And Development Strategy At Gene Therapy Day
BLUE,LentiGlobin,2016-09-21,LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program
BLUE,LentiGlobin,2016-09-08,Bluebird Bio Opens Phase 3 Study Of LentiGlobin™ Drug Product In Patients With Transfusion-Dependent Beta-Thalassemia
BLUE,LentiGlobin,2015-12-06,Bluebird Bio Reports New Beta-thalassemia Major And Severe Sickle Cell Disease Data From HGB-205 And HGB-206 Studies Of LentiGlobin® At ASH Annual Meeting
BLUE,LentiGlobin,2015-12-05,Bluebird Bio Reports New Beta-thalassemia Major Data From Northstar Study Of LentiGlobin® At ASH Annual Meeting
BLUE,LentiGlobin,2015-11-05,Bluebird Bio To Present LentiGlobin® BB305 Clinical Data And Bb2121 Preclinical Data At Annual Meeting Of The American Society Of Hematology
BLUE,LentiGlobin,2017-02-03,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product Under Amended Study Protocol In HGB-206 Phase 1 Study Of Patients With Severe Sickle Cell Disease
BLUE,LentiGlobin,2016-12-14,Bluebird Bio Announces First Patient Treated With LentiGlobinTM Drug Product In Northstar-2 (HGB-207) Phase 3 Trial Of Patients With Transfusion-Dependent ß-Thalassemia
BLUE,LentiGlobin,2016-12-03,Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting
BLUE,LentiGlobin,2016-11-03,Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting
BLUE,LentiGlobin,2016-10-13,Bluebird Bio Provides Update On LentiGlobin™ Programs And Research And Development Strategy At Gene Therapy Day
BLUE,LentiGlobin,2016-09-21,LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program
BLUE,LentiGlobin,2016-09-08,Bluebird Bio Opens Phase 3 Study Of LentiGlobin™ Drug Product In Patients With Transfusion-Dependent Beta-Thalassemia
BLUE,LentiGlobin,2015-12-06,Bluebird Bio Reports New Beta-thalassemia Major And Severe Sickle Cell Disease Data From HGB-205 And HGB-206 Studies Of LentiGlobin® At ASH Annual Meeting
BLUE,LentiGlobin,2015-12-05,Bluebird Bio Reports New Beta-thalassemia Major Data From Northstar Study Of LentiGlobin® At ASH Annual Meeting
BLUE,LentiGlobin,2015-11-05,Bluebird Bio To Present LentiGlobin® BB305 Clinical Data And Bb2121 Preclinical Data At Annual Meeting Of The American Society Of Hematology
SPPI,Apaziquone,2016-09-14,FDA Advisory Committee Votes That Qapzola™ (apaziquone) Has Not Shown Substantial Evidence Of A Treatment Effect Over Placebo
SPPI,Apaziquone,2016-05-06,Spectrum Pharmaceuticals Highlights An Oral Presentation On Apaziquone At The 2016 Annual Meeting Of The American Urological Association Education And Research Inc. (AUA) In San Diego, California, May 6-10, 2016
SPPI,Apaziquone,2016-02-19,Spectrum Pharmaceuticals Announces FDA's Acceptance Of NDA Filing For EOquin® (apaziquone For Intravesical Instillation)
SPPI,Apaziquone,2015-10-26,Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial For The Treatment Of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement
SPPI,Apaziquone,2015-08-17,Spectrum Pharmaceuticals Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Upcoming Apaziquone Phase 3 Trial In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
CEMP,Solithera,2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithera,2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithera,2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
AAAP,Lutathera,2017-01-12,Advanced Accelerator Applications Announces New England Journal Of Medicine Publication Of Lutathera® NETTER-1 Phase III Results
AAAP,Lutathera,2017-01-09,Advanced Accelerator Applications CEO Provides Progress Report On Corporate Developments Of 2016; Asserts Confidence In Ability To Address FDA Comments On Lutathera® NDA
AAAP,Lutathera,2016-12-21,Advanced Accelerator Applications Receives Complete Response Letter From FDA For Lutathera®, An Investigational Treatment For Neuroendocrine Tumors
AAAP,Lutathera,2016-11-28,Advanced Accelerator Applications Reports 15.4% Sales Growth In The Third Quarter Of 2016 And Feedback From The FDA For Lutathera®, An Investigational Treatment For Neuroendocrine Tumors
AAAP,Lutathera,2016-10-11,Advanced Accelerator Applications Announces Presentations On Lutathera® NETTER-1 Phase III And NeoBOMB1 At EANM
AAAP,Lutathera,2016-09-20,Advanced Accelerator Applications Announces Revised EMA Review Timeline For Lutathera®
AAAP,Lutathera,2016-08-02,Advanced Accelerator Applications Announces Clinical Trial Agreement With National Cancer Institute For Study Of Lutathera In Patients With Inoperable Pheochromocytoma And Paraganglioma
AAAP,Lutathera,2016-07-26,Advanced Accelerator Applications Announces Opening Of First U.S. Manufacturing Facility; Preparation For Anticipated Lutathera Launch
AAAP,Lutathera,2016-06-27,Advanced Accelerator Applications Announces FDA Priority Review For Lutathera
AAAP,Lutathera,2016-05-23,Advanced Accelerator Applications Preparing For Lutathera Launch By Scaling Up Production In Ivrea, Italy
AAAP,Lutathera,2016-03-23,Advanced Accelerator Applications Provides Lutathera Update
AAAP,Lutathera,2016-02-25,Advanced Accelerator Applications Provides Update On Lutathera And Somakit
AAAP,Lutathera,2016-01-10,Advanced Accelerator Applications To Present New Data From Lutathera NETTER-1 Phase 3 Study At 2016 Gastrointestinal Cancer Symposium (ASCO GI)
CEMP,Solithera,2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithera,2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithera,2016-07-05,Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
BLRX,BL-8040,2017-03-20,BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2017-01-17,BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
BLRX,BL-8040,2016-12-05,BioLineRx Presents Positive Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
BLRX,BL-8040,2016-11-03,BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
BLRX,BL-8040,2016-10-05,BioLineRx Announces Acceptance Of BL-8040 Abstracts For Oral And Poster Presentations At 58th American Society Of Hematology (ASH) Annual Meeting
BLRX,BL-8040,2016-09-20,BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
BLRX,BL-8040,2016-09-07,BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications
BLRX,BL-8040,2016-08-08,BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
BLRX,BL-8040,2016-06-28,BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
BLRX,BL-8040,2016-05-19,BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences
BLRX,BL-8040,2016-03-23,BioLineRx Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2016-01-12,BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer
BLRX,BL-8040,2015-12-14,BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2014-12-12,BioLineRx Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform
BLRX,BL-8040,2014-09-03,BioLineRx Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2014-03-14,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 In Immunotherapy
BLRX,BL-8040,2013-09-09,BioLineRx's BL-8040 Receives Orphan Drug Designation For Treatment Of AML
BLRX,BL-8040,2013-09-03,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 For Obtaining Stem Cells
BLRX,BL-8040,2013-08-05,BioLineRx Announces Publication Of Positive Pre-Clinical Results For BL-8040 In Treatment Of Thrombocytopenia
BLRX,BL-8040,2012-11-07,BioLineRx Announces BL-8040, For The Treatment Of Leukemia And Other Types Of Hematological Cancer, To Be Presented At 2012 ASH Annual Meeting
BLRX,BL-8040,2017-03-20,BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2017-01-17,BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
BLRX,BL-8040,2016-12-05,BioLineRx Presents Positive Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
BLRX,BL-8040,2016-11-03,BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-of-Action Data For BL-8040 Oncology Platform At ASH 2016
BLRX,BL-8040,2016-10-05,BioLineRx Announces Acceptance Of BL-8040 Abstracts For Oral And Poster Presentations At 58th American Society Of Hematology (ASH) Annual Meeting
BLRX,BL-8040,2016-09-20,BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
BLRX,BL-8040,2016-09-07,BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications
BLRX,BL-8040,2016-08-08,BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
BLRX,BL-8040,2016-06-28,BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA® (pembrolizumab) For Treatment Of Pancreatic Cancer
BLRX,BL-8040,2016-05-19,BioLineRx's BL-8040 To Be Presented At Upcoming Scientific Conferences
BLRX,BL-8040,2016-03-23,BioLineRx Announces Initiation Of Phase 2 Trial For BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2016-01-12,BioLineRx Announces Collaboration With MSD To Investigate The Combination Of KEYTRUDA (pembrolizumab) And BL-8040 In Pancreatic Cancer
BLRX,BL-8040,2015-12-14,BioLineRx Announces Regulatory Submission For Phase 2 Trial Of BL-8040 As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2014-12-12,BioLineRx Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform
BLRX,BL-8040,2014-09-03,BioLineRx Doses First Patient For BL-8040’s Second Indication As Novel Stem Cell Mobilization Treatment
BLRX,BL-8040,2014-03-14,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 In Immunotherapy
BLRX,BL-8040,2013-09-09,BioLineRx's BL-8040 Receives Orphan Drug Designation For Treatment Of AML
BLRX,BL-8040,2013-09-03,BioLineRx Announces Issuance Of United States Patent Covering Use Of BL-8040 For Obtaining Stem Cells
BLRX,BL-8040,2013-08-05,BioLineRx Announces Publication Of Positive Pre-Clinical Results For BL-8040 In Treatment Of Thrombocytopenia
BLRX,BL-8040,2012-11-07,BioLineRx Announces BL-8040, For The Treatment Of Leukemia And Other Types Of Hematological Cancer, To Be Presented At 2012 ASH Annual Meeting
ACAD,Pimavanserin,2016-12-20,ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study Of Pimavanserin For Alzheimer's Disease Psychosis
ACAD,Pimavanserin,2016-12-01,ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder
ACAD,Pimavanserin,2016-11-15,ACADIA Pharmaceuticals Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia
ACAD,Pimavanserin,2016-11-03,ACADIA Pharmaceuticals Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia
ACAD,Pimavanserin,2016-10-31,ACADIA Pharmaceuticals Initiates Phase II Study Of Pimavanserin In Alzheimer's Disease Agitation
ACAD,Pimavanserin,2016-05-31,ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available For The Treatment Of Hallucinations And Delusions Associated With Parkinson's Disease Psychosis
ACAD,Pimavanserin,2016-04-29,NUPLAZID™ (pimavanserin) Bottle (Photo: Business Wire)
ACAD,Pimavanserin,2016-03-29,FDA Advisory Committee Votes 12 To 2 That Benefits Of ACADIA Pharmaceuticals' NUPLAZID™ (Pimavanserin) For The Treatment Of Psychosis Associated With Parkinson's Disease Outweigh The Risks
ACAD,Pimavanserin,2016-01-29,ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting To Review NUPLAZID™ (Pimavanserin) For The Treatment Of Parkinson's Disease Psychosis
ACAD,Pimavanserin,2015-11-02,ACADIA Pharmaceuticals Announces FDA Priority Review Of NUPLAZID™ (Pimavanserin) New Drug Application For Parkinson's Disease Psychosis
ACHN,ACH-4471,2016-06-10,Achillion Presents Interim Phase 1 Results For ACH-4471, A Novel Orally-Administered Factor D Inhibitor, At The 21st Congress Of The European Hematology Association
ACHN,ACH-4471,2016-05-19,Achillion Announces Acceptance Of Late Breaking Abstract For ACH-4471 At The 21st Congress Of The European Hematology Association
ACHN,ACH-4471,2016-02-11,Achillion Initiates Phase 1 Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
ACHN,ACH-4471,2015-12-05,Achillion Announces Upcoming Oral Presentation At The 57th Annual Meeting Of The American Society Of Hematology And Nomination Of ACH-4471, A Novel Small Molecule Factor D Inhibitor, For Clinical Development
ACHN,ACH-4471,2016-06-10,Achillion Presents Interim Phase 1 Results For ACH-4471, A Novel Orally-Administered Factor D Inhibitor, At The 21st Congress Of The European Hematology Association
ACHN,ACH-4471,2016-05-19,Achillion Announces Acceptance Of Late Breaking Abstract For ACH-4471 At The 21st Congress Of The European Hematology Association
ACHN,ACH-4471,2016-02-11,Achillion Initiates Phase 1 Study Of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
ACHN,ACH-4471,2015-12-05,Achillion Announces Upcoming Oral Presentation At The 57th Annual Meeting Of The American Society Of Hematology And Nomination Of ACH-4471, A Novel Small Molecule Factor D Inhibitor, For Clinical Development
ACOR,Dalfampridine,2016-11-21,Acorda To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties
ACOR,Dalfampridine,2015-10-07,Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
ACOR,Dalfampridine,2014-12-15,Acorda Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits
ACOR,Dalfampridine,2016-11-21,Acorda To Discontinue Development Of Dalfampridine For Treatment Of Post-Stroke Walking Difficulties
ACOR,Dalfampridine,2015-10-07,Acorda to Present New rHIgM22 and AMPYRA® (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
ACOR,Dalfampridine,2014-12-15,Acorda Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits
ACRS,A-101,2017-02-27,Aclaris Therapeutics Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis - A Common Skin Condition
ACRS,A-101,2016-11-15,Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition
ACRS,A-101,2016-08-18,Aclaris Therapeutics Announces Positive Results In Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts  
ACRS,A-101,2016-07-25,Aclaris Therapeutics Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs
ACRS,A-101,2016-01-19,Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis
ACRS,A-101,2015-12-07,Aclaris Therapeutics Initiates Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts
ACRS,A-101,2017-02-27,Aclaris Therapeutics Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis - A Common Skin Condition
ACRS,A-101,2016-11-15,Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition
ACRS,A-101,2016-08-18,Aclaris Therapeutics Announces Positive Results In Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts  
ACRS,A-101,2016-07-25,Aclaris Therapeutics Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs
ACRS,A-101,2016-01-19,Aclaris Therapeutics Initiates Phase 3 Clinical Trials Of A-101 For The Treatment Of Seborrheic Keratosis
ACRS,A-101,2015-12-07,Aclaris Therapeutics Initiates Phase 2 Clinical Trial Of A-101 For Treatment Of Common Warts
ACRX,Zalviso,2016-09-27,AcelRx Initiates Phase 3 Study Of Zalviso® In Patients With Moderate-to-Severe Acute Post-Operative Pain
ACRX,Zalviso,2016-01-08,AcelRx Completes Protocol Review With FDA And Plans To Initiate Phase 3 Open-Label Study (IAP312) For Zalviso™ In 1Q 2016
ACRX,Zalviso,2015-11-04,AcelRx Pharmaceuticals Presents Data From Phase 3 Clinical Trials Evaluating The Safety And Efficacy Of Zalviso In Obese Surgical Patients
ACRX,Zalviso,2015-10-08,AcelRx Pharmaceuticals Provides Regulatory Update On Zalviso
ACRX,Zalviso,2015-09-22,AcelRx Pharmaceuticals Reports That The European Commission Has Granted Marketing Authorization For Zalviso™ For Treatment Of Acute Moderate-to-Severe Post-Operative Pain In Adult Patients
ACRX,Zalviso,2015-09-21,PDL BioPharma Acquires A Portion Of AcelRx Pharmaceuticals' Expected Royalties And Commercial Milestones From Zalviso™ For $65 Million
ACRX,Zalviso,2015-09-21,AcelRx Pharmaceuticals Receives $65 Million From The Partial Sale Of Zalviso™ European Royalties And Commercial Milestones To PDL BioPharma
ACRX,Zalviso,2015-07-24,AcelRx Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-to-Severe Post-Operative Pain In Adult Patients
ACRX,Zalviso,2015-07-02,Zalviso™ Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
ACRX,Zalviso,2015-03-09,AcelRx Pharmaceuticals (ACRX) Stock Tanks Today on FDA Demand For Further Zalviso Trials
ACRX,Zalviso,2015-03-09,AcelRx Provides Regulatory Update On Zalviso
ACRX,Zalviso,2014-12-02,AcelRx Pharmaceuticals Receives CE Mark Approval For Zalviso
ACRX,Zalviso,2014-10-22,AcelRx Announces Publication Of Zalviso Phase 3 Abdominal Trial Results
ACRX,Zalviso,2014-10-16,AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies
ACRX,Zalviso,2014-09-26,AcelRx Pharmaceuticals Provides Regulatory Update On Zalviso™
ACRX,Zalviso,2014-07-25,AcelRx Pharmaceuticals Receives Complete Response Letter From FDA For New Drug Application For Zalviso™
ACRX,Zalviso,2014-07-24,AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date For Zalviso
ACRX,Zalviso,2014-07-07,AcelRx And Grunenthal Announce Submission Of European Marketing Authorization Application For ZALVISO™
ACRX,Zalviso,2014-05-01,AcelRx Pharmaceuticals Announces Zalviso&#8482; And ARX-04 Data Presentations At The American Pain Society 33rd Annual Scientific Meeting
ACRX,Zalviso,2013-12-16,AcelRx And Grunenthal Announce Collaboration For EU Commercialization Of ZALVISO&#8482;
ACRX,Zalviso,2013-12-02,Zalviso&#8482; New Drug Application Accepted For Filing By FDA
ACRX,Zalviso,2013-10-15,AcelRx Pharmaceuticals Announces Data Presentations For Zalviso™ At US And International Medical Meetings
ACRX,Zalviso,2013-10-08,AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies
ACRX,Zalviso,2013-09-30,AcelRx Pharmaceuticals Submits New Drug Application To The FDA For Zalviso™
ACRX,Zalviso,2016-09-27,AcelRx Initiates Phase 3 Study Of Zalviso® In Patients With Moderate-to-Severe Acute Post-Operative Pain
ACRX,Zalviso,2016-01-08,AcelRx Completes Protocol Review With FDA And Plans To Initiate Phase 3 Open-Label Study (IAP312) For Zalviso™ In 1Q 2016
ACRX,Zalviso,2015-11-04,AcelRx Pharmaceuticals Presents Data From Phase 3 Clinical Trials Evaluating The Safety And Efficacy Of Zalviso In Obese Surgical Patients
ACRX,Zalviso,2015-10-08,AcelRx Pharmaceuticals Provides Regulatory Update On Zalviso
ACRX,Zalviso,2015-09-22,AcelRx Pharmaceuticals Reports That The European Commission Has Granted Marketing Authorization For Zalviso™ For Treatment Of Acute Moderate-to-Severe Post-Operative Pain In Adult Patients
ACRX,Zalviso,2015-09-21,PDL BioPharma Acquires A Portion Of AcelRx Pharmaceuticals' Expected Royalties And Commercial Milestones From Zalviso™ For $65 Million
ACRX,Zalviso,2015-09-21,AcelRx Pharmaceuticals Receives $65 Million From The Partial Sale Of Zalviso™ European Royalties And Commercial Milestones To PDL BioPharma
ACRX,Zalviso,2015-07-24,AcelRx Announces Positive CHMP Opinion For Zalviso In The Management Of Acute Moderate-to-Severe Post-Operative Pain In Adult Patients
ACRX,Zalviso,2015-07-02,Zalviso™ Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
ACRX,Zalviso,2015-03-09,AcelRx Pharmaceuticals (ACRX) Stock Tanks Today on FDA Demand For Further Zalviso Trials
ACRX,Zalviso,2015-03-09,AcelRx Provides Regulatory Update On Zalviso
ACRX,Zalviso,2014-12-02,AcelRx Pharmaceuticals Receives CE Mark Approval For Zalviso
ACRX,Zalviso,2014-10-22,AcelRx Announces Publication Of Zalviso Phase 3 Abdominal Trial Results
ACRX,Zalviso,2014-10-16,AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies
ACRX,Zalviso,2014-09-26,AcelRx Pharmaceuticals Provides Regulatory Update On Zalviso™
ACRX,Zalviso,2014-07-25,AcelRx Pharmaceuticals Receives Complete Response Letter From FDA For New Drug Application For Zalviso™
ACRX,Zalviso,2014-07-24,AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date For Zalviso
ACRX,Zalviso,2014-07-07,AcelRx And Grunenthal Announce Submission Of European Marketing Authorization Application For ZALVISO™
ACRX,Zalviso,2014-05-01,AcelRx Pharmaceuticals Announces Zalviso&#8482; And ARX-04 Data Presentations At The American Pain Society 33rd Annual Scientific Meeting
ACRX,Zalviso,2013-12-16,AcelRx And Grunenthal Announce Collaboration For EU Commercialization Of ZALVISO&#8482;
ACRX,Zalviso,2013-12-02,Zalviso&#8482; New Drug Application Accepted For Filing By FDA
ACRX,Zalviso,2013-10-15,AcelRx Pharmaceuticals Announces Data Presentations For Zalviso™ At US And International Medical Meetings
ACRX,Zalviso,2013-10-08,AcelRx Pharmaceuticals Provides Update On Its Patent Portfolio For Zalviso™ And Its Proprietary Platform Technologies
ACRX,Zalviso,2013-09-30,AcelRx Pharmaceuticals Submits New Drug Application To The FDA For Zalviso™
ADMS,ADS-5102,2017-02-28,Adamas Presents Additional Open-Label, Long-Term Safety And Efficacy Data On ADS-5102 At The First Pan American Parkinson's Disease And Movement Disorders Congress
ADMS,ADS-5102,2017-02-17,Adamas To Present New ADS-5102 Data From Phase 2 Trial In Walking Impairment Associated With Multiple Sclerosis At ACTRIMS Forum 2017
ADMS,ADS-5102,2017-01-06,Adamas Announces U.S. FDA Acceptance Of ADS-5102 New Drug Application For The Treatment Of Levodopa-induced Dyskinesia In Patients With Parkinson's Disease
ADMS,ADS-5102,2016-10-27,Adamas Submits New Drug Application To U.S. FDA For ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia In Patients With Parkinson's Disease
ADMS,ADS-5102,2016-09-20,Adamas Announces Results Of EASE LID 3, A Pivotal Trial Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) In Parkinson's Disease Patients At The 4th World Parkinson Congress
ADMS,ADS-5102,2016-09-12,Adamas Announces Two Data Presentations On ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) At The 4th World Parkinson Congress
ADMS,ADS-5102,2016-06-22,Adamas Announces Additional ADS-5102 Data For The Treatment Of Levodopa-induced Dyskinesia At The International Congress Of Parkinson's Disease And Movement Disorders
ADMS,ADS-5102,2016-06-13,Adamas Announces Positive Results From Its Phase 2 Proof-of-Concept Study Of ADS-5102 For The Treatment Of Walking Impairment In Multiple Sclerosis (MS) Patients
ADMS,ADS-5102,2016-05-16,Adamas Announces Two Data Presentations On ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) At The 20th International Congress Of Parkinson's And Movement Disorders
ADMS,ADS-5102,2016-04-28,Adamas Announces Positive Top-line Results From Its Phase 3 EASE LID 3 Trial Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) In Patients With Parkinson's Disease
ADMS,ADS-5102,2016-04-19,Adamas Presents Positive Findings From The Phase 3 EASE LID Clinical Trial Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) Associated With Parkinson's Disease At The American Academy Of Neurology Annual Meeting
ADMS,ADS-5102,2015-12-23,Adamas Announces Positive Top-Line Phase 3 Results Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia In Patients With Parkinson's Disease
ADMS,ADS-5102,2015-12-14,Adamas Completes Enrollment Of Its Phase 3 EASE LID 3 Study Evaluating ADS-5102 For Treatment Of Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease
ADMS,ADS-5102,2015-10-12,Adamas Presents Nonclinical Findings Supporting The Potential Use Of ADS-5102 For The Treatment Of Multiple Sclerosis Gait
ADMS,ADS-5102,2015-07-09,Adamas Completes Recruitment Of Its Phase 3 EASE LID Study Evaluating ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia Associated With Parkinson's Disease
ADMS,ADS-5102,2015-07-07,Adamas Pharmaceuticals Issued U.S. Patent Relating To ADS-5102 Program
ADMS,ADS-5102,2015-06-15,Adamas Announces Additional Findings From Its Phase 2/3 Trial Of ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) Associated With Parkinson's Disease
ADMS,ADS-5102,2015-06-11,Adamas Begins Phase 2 Clinical Trial Assessing ADS-5102 For Treating Multiple Sclerosis Symptoms In Patients With Walking Impairment
ADMS,ADS-5102,2015-04-10,Adamas Pharmaceuticals Receives Orphan Drug Designation For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease
ADMS,ADS-5102,2014-10-28,Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 For The Treatment Of Levodopa-induced Dyskinesia (LID) In Patients With Parkinson's Disease
ADMS,ADS-5102,2014-06-10,Adamas Pharmaceuticals Announces Rater Training Data On ADS-5102 For Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
ADMS,ADS-5102,2014-06-09,Adamas Pharmaceuticals Initiates Phase 3 Trial For ADS-5102 In Parkinson's Disease Patients With Levodopa-Induced Dyskinesia
ADMS,ADS-5102,2014-04-30,Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting
ADRO,CRS-207,2017-01-09,Aduro Biotech Announces Clinical Collaboration With Merck To Evaluate The Combination Of Aduro's CRS-207 With Merck's KEYTRUDA® (pembrolizumab) For The Treatment Of Gastric Cancer
ADRO,CRS-207,2016-03-24,Aduro Biotech Announces First Patient Dosed In Combination Clinical Trial Of CRS-207 And Epacadostat To Treat Ovarian Cancer
ADRO,CRS-207,2015-12-14,Aduro Biotech Receives Orphan Drug Designation In The European Union For CRS-207 And GVAX Pancreas For The Treatment Of Pancreatic Cancer
ADRO,CRS-207,2015-11-23,Aduro Biotech Receives Orphan Drug Designation In The European Union For CRS-207 For The Treatment Of Mesothelioma
ADRO,CRS-207,2015-08-10,Aduro Biotech Completes Enrollment In Phase 1b Clinical Trial Of CRS-207 Immunotherapy For The Treatment Of Mesothelioma
AEZS,Macimorelin,2014-01-06,Aeterna Zentaris NDA For Macimorelin Acetate In AGHD Accepted For Filing By The FDA
AEZS,Macimorelin,2013-11-05,Aeterna Zentaris Submits New Drug Application To FDA For Macimorelin Acetate (AEZS-130) For Evaluation Of AGHD
AEZS,Macimorelin,2014-01-06,Aeterna Zentaris NDA For Macimorelin Acetate In AGHD Accepted For Filing By The FDA
AEZS,Macimorelin,2013-11-05,Aeterna Zentaris Submits New Drug Application To FDA For Macimorelin Acetate (AEZS-130) For Evaluation Of AGHD
AEZS,Zoptrex,2017-02-14,Aeterna Zentaris Announces Zoptrex™ Presentation In Prostate Cancer At 2017 Genitourinary Cancers Symposium
AEZS,Zoptrex,2017-01-30,Aeterna Zentaris Announces Completion Of Zoptrex™ Pivotal Phase 3 Clinical Trial In Advanced Endometrial Cancer; Expects To Report Top-Line Results In April 2017
AEZS,Zoptrex,2016-10-12,Aeterna Zentaris And Specialised Therapeutics Asia Sign Exclusive License Agreement For The Potential Marketing Of Zoptrex™ In Australia And New Zealand
AEZS,Zoptrex,2016-08-01,Aeterna Zentaris And Rafa Laboratories Sign Exclusive License Agreement For Zoptrex™ In Israel
AEZS,Zoptrex,2016-07-01,Aeterna Zentaris And Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement For Zoptrex™ In Taiwan And Southeast Asia
AEZS,Zoptrex,2016-06-06,Aeterna Zentaris Reconfirms Commitment To LHRH-receptor Targeting Zoptrex™ During 2016 ASCO Annual Meeting
AEZS,Zoptrex,2016-03-01,Aeterna Zentaris Reports On Zoptrex™ Development Progress In China
AEZS,Zoptrex,2016-01-26,Aeterna Zentaris Files International Patent Application For Novel Method Of Manufacturing Zoptrex™
AEZS,Zoptrex,2017-02-14,Aeterna Zentaris Announces Zoptrex™ Presentation In Prostate Cancer At 2017 Genitourinary Cancers Symposium
AEZS,Zoptrex,2017-01-30,Aeterna Zentaris Announces Completion Of Zoptrex™ Pivotal Phase 3 Clinical Trial In Advanced Endometrial Cancer; Expects To Report Top-Line Results In April 2017
AEZS,Zoptrex,2016-10-12,Aeterna Zentaris And Specialised Therapeutics Asia Sign Exclusive License Agreement For The Potential Marketing Of Zoptrex™ In Australia And New Zealand
AEZS,Zoptrex,2016-08-01,Aeterna Zentaris And Rafa Laboratories Sign Exclusive License Agreement For Zoptrex™ In Israel
AEZS,Zoptrex,2016-07-01,Aeterna Zentaris And Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement For Zoptrex™ In Taiwan And Southeast Asia
AEZS,Zoptrex,2016-06-06,Aeterna Zentaris Reconfirms Commitment To LHRH-receptor Targeting Zoptrex™ During 2016 ASCO Annual Meeting
AEZS,Zoptrex,2016-03-01,Aeterna Zentaris Reports On Zoptrex™ Development Progress In China
AEZS,Zoptrex,2016-01-26,Aeterna Zentaris Files International Patent Application For Novel Method Of Manufacturing Zoptrex™
AGRX,Twirla,2016-11-07,Agile Therapeutics Reports Third Quarter 2016 Financial Results And Announces Completion Of Subject Visits For Twirla® Phase 3 SECURE Clinical Trial
AGRX,Twirla,2015-10-19,Agile Therapeutics Announces Completion Of Patient Enrollment In Twirla(R) Phase 3 SECURE Clinical Trial
AGRX,Twirla,2015-08-31,Agile Therapeutics Announces Completion Of Patient Recruitment In Twirla(R) Phase 3 SECURE Clinical Trial
AGRX,Twirla,2015-06-12,Agile Therapeutics Announces Issuance Of Patent For Twirla(R) Patch Design
AGRX,Twirla,2014-09-29,Agile Announces Dosing Of First Patients In Twirla(R) Phase 3 SECURE Study
AGRX,Twirla,2014-09-16,Agile Initiates Phase 3 SECURE Study For Twirla(TM)
ALKS,ALKS,2017-03-16,Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study Of ALKS 8700 For Treatment Of Multiple Sclerosis
ALKS,ALKS,2016-11-28,Short Interest Makes 14% Move For ALKS
ALKS,ALKS,2016-11-15,Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election
ALKS,ALKS,2016-10-21,Alkermes (ALKS) Stock Soars on Trial Results, Upgrades
ALKS,ALKS,2016-10-20,Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study Of ALKS 5461 For Major Depressive Disorder
ALKS,ALKS,2016-10-03,Alkermes Announces Initiation Of Clinical Study Evaluating Metabolic Profile Of ALKS 3831 For Treatment Of Schizophrenia
ALKS,ALKS,2016-07-29,Alkermes (ALKS) Is Today's Dead Cat Bounce Stock
ALKS,ALKS,2016-07-28,Water-Logged And Getting Wetter: Alkermes (ALKS)
ALKS,ALKS,2016-05-25,Alkermes Announces Initiation Of Phase 1 Clinical Study Of Immuno-Oncology Drug Candidate ALKS 4230
ALKS,ALKS,2016-05-24,Alkermes To Present Data On ALKS 5461 At Upcoming American Society Of Clinical Psychopharmacology Annual Meeting
ALKS,ALKS,2016-04-28,Alkermes Announces Plan To Initiate Second Clinical Trial Of ALKS 7119 Based On Preliminary Phase 1 Results
ALKS,ALKS,2016-03-09,Weak On High Volume: Alkermes (ALKS)
ALKS,ALKS,2016-03-07,Insider Trading Alert - HAFC, ALKS And PRGO Traded By Insiders
ALKS,ALKS,2016-03-04,Trade-Ideas: Alkermes (ALKS) Is Today's Post-Market Leader Stock
ALKS,ALKS,2016-02-19,Alkermes (ALKS) Is Today's Dead Cat Bounce Stock
ALKS,ALKS,2016-02-10,Alkermes Announces Initiation Of Second Phase 3 Study Of ALKS 3831 For Schizophrenia
ALKS,ALKS,2016-01-25,Alkermes Announces Initiation Of Phase 1 Clinical Study Of New CNS Drug Candidate ALKS 7119
ALKS,ALKS,2016-01-21,Alkermes (ALKS) Stock Plunges on Depression Treatment's Trial Results
ALKS,ALKS,2016-01-21,Trade-Ideas: Alkermes (ALKS) Is Today's Pre-Market Mover With Heavy Volume Stock
ALKS,ALKS,2016-01-21,Alkermes Announces Topline Results Of FORWARD-3 And FORWARD-4, Two Phase 3 Studies Of ALKS 5461 In Major Depressive Disorder
ALKS,ALKS,2016-01-20,Weak On High Volume: Alkermes (ALKS)
ALKS,ALKS,2016-01-12,Alkermes (ALKS) Showing Signs Of Being Water-Logged And Getting Wetter
ALKS,ALKS,2016-01-04,Alkermes (ALKS) Is Today's Water-Logged And Getting Wetter Stock
ALKS,ALKS,2015-11-17,Trade-Ideas: Alkermes (ALKS) Is Today's Post-Market Leader Stock
ALKS,ALKS,2015-11-05,Insider Trading Alert - ALKS, REIS And LAD Traded By Insiders
ALKS,ALKS,2015-10-29,Alkermes Announces Positive Clinical Trial Results And Streamlined Registration Pathway For ALKS 8700 For Treatment Of Multiple Sclerosis
ALKS,ALKS,2015-10-23,Alkermes (ALKS) Flagged As Strong On High Volume
ALKS,ALKS,2015-10-07,Alkermes (ALKS) Stock Price Target Upped at Barclays
ALKS,ALKS,2015-10-06,Insider Trading Alert - ALKS, ED And TRC Traded By Insiders
ALKS,ALKS,2015-09-30,Alkermes (ALKS) Strong On High Relative Volume Today
ALKS,ALKS,2015-09-24,Alkermes (ALKS) Marked As Today's Roof Leaker Stock
ALKS,ALKS,2015-09-03,Insider Trading Alert - GMCR, ALKS And INUV Traded By Insiders
ALKS,ALKS,2015-09-01,Today's Dead Cat Bounce Stock Is Alkermes (ALKS)
ALKS,ALKS,2015-07-03,Insider Trading Alert - BXMT, ALKS And FRME Traded By Insiders
ALKS,ALKS,2015-06-16,Alkermes (ALKS) Stock Gains After Announcing Presentation at Annual ASCP Meeting
ALKS,ALKS,2015-06-16,Strong On High Relative Volume: Alkermes (ALKS)
ALKS,ALKS,2015-06-02,Insider Trading Alert - ALKS, CUBI And WLFC Traded By Insiders
ALKS,ALKS,2015-05-29,Alkermes To Present Clinical Data On ALKS 8700 At Annual Meeting Of The Consortium Of Multiple Sclerosis Centers
ALKS,ALKS,2015-04-06,Alkermes Announces Positive Topline Results From Complete Six-Month Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia
ALKS,ALKS,2015-03-23,Alkermes To Present Data On Aripiprazole Lauroxil And ALKS 3831 At 15th International Congress On Schizophrenia Research
ALKS,ALKS,2015-03-05,Trade-Ideas: Alkermes (ALKS) Is Today's Strong On High Relative Volume Stock
ALKS,ALKS,2015-03-04,Alkermes Plc (ALKS) Downgraded From Hold to Sell
ALKS,ALKS,2015-03-02,Alkermes Announces New Drug Candidate, ALKS 7119, For Treatment Of Alzheimer's Agitation, Depression And Other CNS Diseases
ALKS,ALKS,2015-02-24,Alkermes Announces Results From Phase 1 Study Of ALKS 7106
ALKS,ALKS,2015-02-11,Jim Cramer's Top Stock Picks: GM HAS SAVE ALKS
ALKS,ALKS,2015-02-09,Alkermes Announces Positive Topline Results From Phase 1 Study Of ALKS 8700 For Treatment Of Multiple Sclerosis
ALKS,ALKS,2015-01-07,Alkermes Announces Positive Results Of Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia
ALKS,ALKS,2015-01-06,Alkermes Announces Positive Results From Study Of ALKS 5461 For Treatment Of Major Depressive Disorder
ALKS,ALKS,2014-11-19,Jim Cramer's Top Stock Picks: MMM UNH CELG AMZN HD ALKS PPG
ALKS,ALKS,2014-09-03,Alkermes Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic
ALKS,ALKS,2014-08-26,Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 7106 For Treatment Of Pain
ALKS,ALKS,2014-07-30,Alkermes Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder
ALKS,ALKS,2014-07-17,Alkermes Announces Initiation Of Phase 1 Clinical Study Of ALKS 8700 For Treatment Of Multiple Sclerosis
ALNY,ALN-TTRsc02,2016-06-09,Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis
ALNY,ALN-TTRsc02,2015-10-14,Alnylam Demonstrates Continued Commitment To Transthyretin-Mediated Amyloidosis Patients With Advancement Of ALN-TTRsc02, An Investigational RNAi Therapeutic With Potential For Low Volume, Once Quarterly, Subcutaneous Dose Regimen
ALNY,ALN-TTRsc02,2016-06-09,Alnylam Initiates Phase 1 Clinical Trial For ALN-TTRsc02, An Investigational RNAi Therapeutic For The Treatment Of TTR-Mediated Amyloidosis
ALNY,ALN-TTRsc02,2015-10-14,Alnylam Demonstrates Continued Commitment To Transthyretin-Mediated Amyloidosis Patients With Advancement Of ALN-TTRsc02, An Investigational RNAi Therapeutic With Potential For Low Volume, Once Quarterly, Subcutaneous Dose Regimen
ANTH,Sollpura,2016-12-27,Anthera Announces The Phase 3 SOLUTION Study With Sollpura™ In Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed
ANTH,Sollpura,2016-12-13,Anthera Pharmaceuticals Announces Continuation Of SIMPLICITY Study Of Sollpura™ Following Positive DMC Review
ANTH,Sollpura,2016-12-06,Anthera Announces Leadership Transition In Preparation Of Commercialization Of Sollpura And Future Development Of Blisibimod For IgA Nephropathy
ANTH,Sollpura,2016-08-16,Anthera Pharmaceuticals Announces Positive DSMB Review In Phase 3 SOLUTION Study Of Sollpura™
ANTH,Sollpura,2016-06-28,Anthera Provides Clinical Program Updates For Blisibimod And Sollpura®
ANTH,Sollpura,2015-10-02,Anthera Announces Initiation Of The SOLUTION Clinical Study Of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy Of Non-Porcine Origin In People With Cystic Fibrosis
ANTH,Sollpura,2015-03-19,Anthera Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics For Development Of Sollpura - A Novel Enzyme Therapy
ANTH,Sollpura,2014-07-14,Anthera Pharmaceuticals Announces Acquisition Of Sollpura® (liprotamase) For Exocrine Pancreatic Insufficiency From Eli Lilly And Company
ANTH,Sollpura,2016-12-27,Anthera Announces The Phase 3 SOLUTION Study With Sollpura™ In Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed
ANTH,Sollpura,2016-12-13,Anthera Pharmaceuticals Announces Continuation Of SIMPLICITY Study Of Sollpura™ Following Positive DMC Review
ANTH,Sollpura,2016-12-06,Anthera Announces Leadership Transition In Preparation Of Commercialization Of Sollpura And Future Development Of Blisibimod For IgA Nephropathy
ANTH,Sollpura,2016-08-16,Anthera Pharmaceuticals Announces Positive DSMB Review In Phase 3 SOLUTION Study Of Sollpura™
ANTH,Sollpura,2016-06-28,Anthera Provides Clinical Program Updates For Blisibimod And Sollpura®
ANTH,Sollpura,2015-10-02,Anthera Announces Initiation Of The SOLUTION Clinical Study Of Oral Sollpura(R) (liprotamase) Unit-Matched Therapy Of Non-Porcine Origin In People With Cystic Fibrosis
ANTH,Sollpura,2015-03-19,Anthera Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics For Development Of Sollpura - A Novel Enzyme Therapy
ANTH,Sollpura,2014-07-14,Anthera Pharmaceuticals Announces Acquisition Of Sollpura® (liprotamase) For Exocrine Pancreatic Insufficiency From Eli Lilly And Company
APRI,Vitaros,2017-03-08,Apricus Biosciences Announces Sale Of Ex-U.S. Vitaros Assets And Rights To Ferring Pharmaceuticals
APRI,Vitaros,2017-01-18,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Mexico
APRI,Vitaros,2016-12-27,Apricus Biosciences Announces The Launch Of Vitaros® For The Treatment Of Erectile Dysfunction In Lebanon By Elis Pharmaceuticals
APRI,Vitaros,2016-11-18,Apricus Biosciences Provides Update On Vitaros NDA Following Receipt Of FDA Feedback
APRI,Vitaros,2016-10-26,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Greece
APRI,Vitaros,2016-09-21,Apricus Biosciences Announces The Launch Of Vitaros® In The Czech Republic And Slovakia By Recordati
APRI,Vitaros,2016-09-20,Apricus Biosciences Announces Completion Of Transfer Of The Marketing Authorizations For Vitaros® In Finland And Denmark To Ferring Pharmaceuticals
APRI,Vitaros,2016-09-08,Apricus Biosciences Announces Approval Of Vitaros® For The Treatment Of Erectile Dysfunction In Argentina
APRI,Vitaros,2016-08-15,Apricus Biosciences Announces Completion Of Transfer Of The United Kingdom Marketing Authorization For Vitaros® To Ferring Pharmaceuticals
APRI,Vitaros,2016-08-10,Apricus Biosciences Announces Completion Of Transfer Of Vitaros® German Marketing Authorization To Ferring Pharmaceuticals
APRI,Vitaros,2016-07-27,Apricus Biosciences Announces Approval Of Vitaros(R) For The Treatment Of Erectile Dysfunction In Lebanon
APRI,Vitaros,2016-07-25,Apricus Biosciences Further Expands Existing Vitaros® Partnership With Ferring Pharmaceuticals In Europe And Asia
APRI,Vitaros,2016-05-03,CORRECTING And REPLACING -- Apricus Biosciences To Host Live Webcast KOL Event On May 9th Addressing Vitaros® And Erectile Dysfunction Population
APRI,Vitaros,2016-05-03,Apricus Biosciences To Host Live Webcast KOL Event On May 9th Addressing Vitaros® And Erectile Dysfunction Population
APRI,Vitaros,2015-10-01,Apricus Biosciences And Ferring Pharmaceuticals Sign Exclusive Distribution Agreement To Market Topical Erectile Dysfunction Cream Vitaros(TM) In Latin American Countries
APRI,Vitaros,2015-09-10,Apricus Biosciences Enters Into License Agreement With Allergan For The U.S. Rights To Vitaros(TM)
APRI,Vitaros,2015-08-10,Apricus Biosciences Announces Approval Of Vitaros(R) For The Treatment Of Erectile Dysfunction In Twelve Additional Countries
APRI,Vitaros,2015-02-03,Apricus Biosciences Expands Exclusive License Agreement With An Existing Partner To Market Vitaros(R) In Select Asia-Pacific Countries
APRI,Vitaros,2014-12-22,Apricus Biosciences Announces Year-End 2014 Update And 2015 Plans To Advance Its Clinical Pipeline And Further Commercialize Its Erectile Dysfunction Drug Vitaros(R)
APRI,Vitaros,2014-08-18,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In Germany By Hexal
APRI,Vitaros,2014-08-04,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In Sweden By Sandoz
APRI,Vitaros,2014-06-16,Apricus Biosciences Announces The Launch Of Its Topical Treatment For Erectile Dysfunction Vitaros(R) In The United Kingdom
APRI,Vitaros,2014-04-24,Apricus Biosciences Announces National Phase Approval For Vitaros(R) In Spain
APRI,Vitaros,2014-04-16,Apricus Biosciences' Partner In The United Kingdom Accepts First Shipment Of Vitaros(R)
APRI,Vitaros,2014-04-07,Apricus Biosciences And Its European Partners To Sponsor Symposium On Vitaros(R) At The European Association Of Urology (EAU) Congress, Stockholm
APRI,Vitaros,2014-04-03,Apricus Biosciences Announces National Phase Approval For Vitaros(R) In Luxembourg
APRI,Vitaros,2014-02-10,Apricus And Recordati Sign Exclusive License Agreement To Market Topical Erectile Dysfunction Cream - Vitaros(R) In Spain, Russia, Turkey And Other Global Territories
APRI,Vitaros,2014-01-23,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Belgium
APRI,Vitaros,2013-12-19,Apricus Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In France
APRI,Vitaros,2013-12-16,Apricus Expands Exclusive License Agreement With Its Partner In Germany To Market Vitaros(R) In Additional European Countries
APRI,Vitaros,2013-11-25,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Italy
APRI,Vitaros,2013-11-13,Apricus And Laboratoires Majorelle Sign Exclusive License Agreement To Market Topical Erectile Dysfunction Cream Vitaros(R) In France, Monaco And Certain African Countries
APRI,Vitaros,2013-10-07,Apricus Biosciences Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros(R) In Germany
APRI,Vitaros,2013-08-29,Apricus Biosciences Provides Vitaros(R) Swissmedic Update
APRI,Vitaros,2013-08-15,Apricus Biosciences Receives National Phase Approvals For Vitaros(R) In Ireland And The Netherlands
APRI,Vitaros,2013-06-21,Apricus Biosciences Presents Vitaros(R) Poster At The International Symposium On Prostate, Androgens And Men's Sexual Health
APRI,Vitaros,2013-06-10,Apricus Biosciences Receives European Approval For Vitaros(R) For The Treatment Of Erectile Dysfunction
APRI,Vitaros,2013-05-07,Apricus Biosciences Announces Poster Presentation Of Vitaros(R) Data In Men Previously Unresponsive To PDE-5 Inhibitors At American Urological Association Annual Meeting
APRI,Vitaros,2012-10-18,Apricus Biosciences Receives $2.5 Million Payment From Abbott Laboratories For Vitaros(R) In Canada
APRI,Vitaros,2012-09-13,Apricus Biosciences' Wholly-Owned Subsidiary NexMed (U.S.A.) And Takeda Pharmaceuticals International GmbH Sign Exclusive License Agreement To Market Vitaros(R) In The United Kingdom
APRI,Vitaros,2012-08-20,Apricus Biosciences Announces Podium Presentation Of Vitaros(R) Clinical Data At 2012 World Meeting On Sexual Medicine
APRI,Vitaros,2011-08-08,Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America
APRI,Vitaros,2011-02-14,Apricus Biosciences And Neopharm Group Sign Licensing Agreement For Vitaros(R) In Israel For Up To $4.35 Million, Plus Royalties
ARDM,Pulmaquin,2016-12-01,Aradigm Announces Top-Line Results From Two Phase 3 Studies Evaluating Pulmaquin For The Chronic Treatment Of Non-Cystic Fibrosis Bronchiectasis Patients With Lung Infections With Pseudomonas Aeruginosa
ARDM,Pulmaquin,2016-09-22,Aradigm Announces Last Patient Dosing Visit In ORBIT-3 And ORBIT-4 Phase 3 Studies Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis Patients
ARDM,Pulmaquin,2016-03-17,Aradigm Announces Decision For Centralized Review Of Pulmaquin By The European Medicines Agency
ARDM,Pulmaquin,2015-10-13,Aradigm Corporation Completes Enrollment In The Second Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
ARDM,Pulmaquin,2015-09-22,Aradigm Corporation Completes Enrollment In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
ARDM,Pulmaquin,2015-01-14,Aradigm Granted Key Composition Of Matter Patents For Pulmaquin In Europe And Australia
ARDM,Pulmaquin,2014-09-04,FDA Grants Fast Track Designation To Aradigm’s Pulmaquin For Non-Cystic Fibrosis Bronchiectasis
ARDM,Pulmaquin,2014-06-23,Aradigm Corporation Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4)
ARDM,Pulmaquin,2014-06-03,Aradigm Receives $5 Million Milestone For Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis
ARDM,Pulmaquin,2014-04-30,Aradigm Corporation Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
ARDM,Pulmaquin,2013-09-16,Sigma-Tau PharmaSource, Inc. And Aradigm Corporation Sign Manufacturing Agreement For The Clinical And Commercial Supply Of Pulmaquin
ARDM,Pulmaquin,2013-08-28,Grifols And Aradigm Corporation Complete The Closing Of Worldwide Licensing Agreement To Develop And Commercialize Pulmaquin&#174;
ARDM,Pulmaquin,2013-08-01,Aradigm Awarded NIH Grant To Investigate The Treatment Of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections With Pulmaquin And Lipoquin
ARDM,Pulmaquin,2013-07-16,Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. To Develop And Commercialize Pulmaquin
ARDM,Pulmaquin,2012-09-18,New U.S. Composition Of Matter Patent For Aradigm&#8217;s Pulmaquin&#8482; And Lipoquin&#8482; Provides Protection Until 2031
ARDM,Pulmaquin,2012-03-12,Aradigm Receives U.S. FDA Clearance For Phase 3 Clinical Trial Of Pulmaquin&#8482; In Patients With Non-Cystic Fibrosis Bronchiectasis
ARDM,Pulmaquin,2012-02-21,US Patent Protection For Pulmaquin&#8482; Is Extended With Issuance Of A Composition Of Matter Patent
ARDM,Pulmaquin,2011-12-07,Aradigm Selects Pulmaquin&#8482; For Phase 3 Development And Announces Issuance Of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
ARGS,AGS-003,2016-11-03,Argos Therapeutics Announces Publication Of A Case Report On Long-term Survival Of Kidney Cancer Patients Treated With AGS-003 Individualized Immunotherapy Featured In The Kidney Cancer Journal
ARGS,AGS-003,2016-06-13,Independent Data Monitoring Committee Recommends Continuation Of ADAPT Phase 3 Clinical Trial Of AGS-003 In Metastatic Renal Cell Carcinoma Following Interim Data Review
ARGS,AGS-003,2016-03-23,Argos Therapeutics Announces Initiation Of A Phase 2 Clinical Trial Of AGS-003 For The Treatment Of Non-small Cell Lung Cancer In Combination With Standard-of-Care Chemotherapy
ARGS,AGS-003,2015-12-10,Independent Data Monitoring Committee Recommends Continuation Of ADAPT Phase 3 Clinical Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis
ARGS,AGS-003,2015-08-10,Argos Therapeutics Announces Pilot Clinical Trial Of AGS-003 As Neoadjuvant Immunotherapy For Localized Renal Cell Carcinoma
ARGS,AGS-003,2015-07-15,Argos Therapeutics Announces Completion Of Patient Enrollment In Pivotal Phase 3 ADAPT Clinical Trial Of AGS-003
ARGS,AGS-003,2015-06-04,Independent Data Monitoring Committee Recommends Continuation Of Pivotal ADAPT Phase 3 Clinical Trial Of AGS-003 For Metastatic Renal Cell Carcinoma
ARGS,AGS-003,2015-04-21,Argos Therapeutics Announces Publication Of Data From Phase 2 Clinical Trial Of AGS-003 Fully Personalized Immunotherapy For Treatment Of Metastatic Renal Cell Carcinoma (mRCC)
ARGS,AGS-003,2014-09-18,Enrollment In Argos Therapeutics' Pivotal Phase III ADAPT Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent
ARGS,AGS-003,2014-06-02,Treatment With AGS-003 And Sunitinib Associated With Doubling Of Expected Survival In Patients With Unfavorable Risk Metastatic Renal Cell Carcinoma (mRCC)
ARGS,AGS-003,2014-05-12,Argos Therapeutics To Present Data Related To Clinical Development Program For AGS-003 During 2014 ASCO Annual Meeting
ARIA,Iclusig,2016-11-29,ARIAD Announces FDA Full Approval And Label Update For Iclusig® (ponatinib) Based On Long-Term Efficacy And Safety Data From Phase 2 PACE Clinical Trial
ARIA,Iclusig,2016-06-17,ARIAD Announces Distribution Agreements For Iclusig® In Latin America And The Middle East/North Africa
ARIA,Iclusig,2016-06-02,ARIAD Completes The Sale Of Its European Operations And Out-License Of European Rights To Iclusig®
ARIA,Iclusig,2016-05-19,ARIAD Announces Pricing And Reimbursement For Iclusig In France
ARIA,Iclusig,2015-12-11,ARIAD Announces Pricing And Reimbursement Negotiations For Iclusig In France To Continue Into 2016
ARIA,Iclusig,2015-11-05,ARIAD Announces Iclusig Data Presentations At Annual American Society Of Hematology Meeting
ARIA,Iclusig,2015-08-10,ARIAD Announces First Patient Treated In Phase 2 Dose-Ranging Optic Trial Of Iclusig (Ponatinib)
ARIA,Iclusig,2015-07-29,ARIAD To Receive Up To $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing With PDL BioPharma
ARIA,Iclusig,2015-06-10,ARIAD And Paladin Announce Commercial Distribution Agreement For Iclusig (Ponatinib) In Canada
ARIA,Iclusig,2015-05-06,ARIAD Announces Commercial Distribution Agreement For Iclusig (ponatinib) In Turkey
AVIR,Vapendavir,2017-02-13,Aviragen Therapeutics Announces Top-Line Results From Phase 2b SPIRITUS Trial Of Vapendavir
AXON,Nelotanserin,2017-02-13,Axovant Sciences Announces Preliminary Results From Interim Analysis Of Phase 2 Study Testing Investigational Drug Nelotanserin In Lewy Body Dementia Patients
BDSI,Clonidine,2016-12-13,BioDelivery Sciences Announces Clonidine Topical Gel For Painful Diabetic Neuropathy Phase 2b Trial Fails To Meet Its Primary Efficacy Endpoint
BDSI,Clonidine,2016-08-04,BioDelivery Sciences Announces Randomization Target Reached In Clinical Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy
BDSI,Clonidine,2015-03-30,BioDelivery Sciences Announces Primary Endpoint In Phase 3 Study Of Clonidine Topical Gel For Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
BDSI,Clonidine,2014-12-08,BioDelivery Sciences Announces Completion Of Randomization In Phase 3 Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy
BDSI,Clonidine,2014-08-06,BioDelivery Sciences Provides Update On Ongoing Phase 3 Pivotal Trial For Clonidine Topical Gel For Painful Diabetic Neuropathy
BDSI,Clonidine,2014-06-26,BioDelivery Sciences Announces Completion Of Patient Enrollment In Its Initial Phase 3 Trial Of Clonidine Topical Gel For Painful Diabetic Neuropathy
BDSI,Clonidine,2014-05-06,BioDelivery Sciences Announces Randomization Of Over 50% Of Subjects In Its Initial Phase 3 Study Of Clonidine Topical Gel For Painful Diabetic Neuropathy
BDSI,Clonidine,2014-04-03,BioDelivery Sciences Announces Enrollment Of The First Patient In A Phase 3 Clinical Study Of Clonidine Topical Gel For Painful Diabetic Neuropathy
BLPH,INOpulse,2017-01-04,Bellerophon Therapeutics Announces FDA Acceptance Of Modifications To INOpulse Pulmonary Arterial Hypertension Phase 3 Program
BLPH,INOpulse,2016-02-09,Bellerophon Therapeutics Announces Positive Data From The Final Analysis Of The Phase 2 Long-Term Extension Study Of INOpulse For Treatment Of Pulmonary Arterial Hypertension
BLPH,INOpulse,2016-01-21,Bellerophon Therapeutics Announces Notice Of Intention To Grant A European Patent Supporting Its INOpulse Program
BLPH,INOpulse,2016-01-19,Bellerophon Therapeutics Receives EC Certification For New INOpulse® Drug-Device Delivery System
BLPH,INOpulse,2015-09-30,Bellerophon Announces Functional Respiratory Imaging Data From Company Sponsored Clinical Trial Of INOpulse(R) In COPD Patients With Pulmonary Hypertension Presented Today At The European Respiratory Society (ERS) International Congress
BLPH,INOpulse,2015-09-24,Bellerophon Therapeutics Announces Positive Data From Interim Analysis Of Phase 2 Long-Term Extension Study Of INOpulse(R) For Treatment Of Pulmonary Arterial Hypertension
BLPH,INOpulse,2015-07-29,Bellerophon Therapeutics Expands License Agreement With INO Therapeutics To Develop INOpulse(R) For Three Additional Cardiopulmonary Diseases
BLPH,INOpulse,2015-05-07,Bellerophon Therapeutics Forms Scientific Advisory Board For INOpulse(R) Programs
BLPH,INOpulse,2015-03-25,Bellerophon Therapeutics Selects Flextronics To Manufacture The Mark2, Next-Generation INOpulse(R) Device
CASC,ONT-380,2016-06-29,Cascadian Therapeutics Receives ONT-380 Fast Track Designation From FDA For The Treatment Of Advanced HER2+ Metastatic Breast Cancer
CASC,ONT-380,2016-06-14,Cascadian Therapeutics Reports Topline ONT-380 "Triplet" Data And Outlines Key Development Strategies
CATB,CAT-1004,2017-01-31,Catabasis Pharmaceuticals Announces Top-Line Results For Part B Of The MoveDMD® Trial For Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy
CATB,CAT-1004,2017-01-19,Catabasis Pharmaceuticals Phase 1 Data On Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy Being Developed For Duchenne Muscular Dystrophy, Published In The Journal Of Clinical Pharmacology
CATB,CAT-1004,2017-01-04,Positive Preclinical Research On The Edasalonexent (CAT-1004) Program, A Potential Disease-Modifying Therapy For Duchenne Muscular Dystrophy, Published In JCI Insight
CATB,CAT-1004,2016-10-11,Catabasis Pharmaceuticals To Present The MoveDMD® Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The American Neurological Association's 2016 Annual Meeting
CATB,CAT-1004,2016-10-06,Catabasis Pharmaceuticals Presents Positive Data From Part A Of The MoveDMD® Trial Of Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy For DMD, At The World Muscle Society Congress
CATB,CAT-1004,2016-10-04,Catabasis Pharmaceuticals Completes Target Enrollment For Part B Of The MoveDMD® Trial, A Phase 2 Trial Of Edasalonexent (CAT-1004) For The Potential Treatment Of Duchenne Muscular Dystrophy
CATB,CAT-1004,2016-07-07,Catabasis Pharmaceuticals Announces The Initiation Of An Open-Label Extension For The MoveDMD® Trial Studying Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy
CATB,CAT-1004,2016-06-20,Catabasis Pharmaceuticals To Present Edasalonexent (CAT-1004), An Oral Agent Targeting NF-kB: MoveDMDSM Trial In Duchenne Muscular Dystrophy (DMD) At The 2016 PPMD Annual Connect Conference
CATB,CAT-1004,2016-06-08,Catabasis Pharmaceuticals And Parent Project Muscular Dystrophy To Host A Webinar On MoveDMDSM: A Clinical Trial Of Edasalonexent (CAT-1004) In Boys With Duchenne Muscular Dystrophy
CATB,CAT-1004,2016-04-12,Catabasis Pharmaceuticals Initiates Part B Of The MoveDMDSM Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
CATB,CAT-1004,2016-03-21,Catabasis Pharmaceuticals Presents Positive CAT-1004 Data From Part A Of The MoveDMDSM Trial At The 2016 Muscular Dystrophy Association Clinical Conference
CATB,CAT-1004,2016-03-18,Catabasis Pharmaceuticals To Present CAT-1004 Data From Part A Of The MoveDMDSM Trial At The 2016 Muscular Dystrophy Association Clinical Conference
CATB,CAT-1004,2016-02-10,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The XIV International Conference On Duchenne And Becker Muscular Dystrophy
CATB,CAT-1004,2016-02-05,Muscular Dystrophy Association To Collaborate With Catabasis Pharmaceuticals On Development Of CAT-1004, A Potential Novel Oral Disease-Modifying Treatment For Duchenne Muscular Dystrophy
CATB,CAT-1004,2016-01-25,Catabasis Pharmaceuticals Announces Positive Top-Line Results From Part A Of The MoveDMD¿ Trial, A Phase 1 / 2 Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
CATB,CAT-1004,2015-12-18,Catabasis Pharmaceuticals Completes Enrollment For Part A Of The MoveDMDSM Trial, A Phase 1/2 Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
CATB,CAT-1004,2015-10-27,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The Action Duchenne International Conference
CATB,CAT-1004,2015-10-26,European Commission Grants Orphan Medicinal Product Designation For CAT-1004, Catabasis Pharmaceuticals' Investigational Therapy For The Treatment Of Duchenne Muscular Dystrophy
CATB,CAT-1004,2015-09-25,Catabasis Pharmaceuticals Will Present CAT-1004, A Potential Disease-Modifying Agent In Development For The Treatment Of Duchenne Muscular Dystrophy, At The World Muscle Society Congress
CATB,CAT-1004,2015-09-14,Catabasis Pharmaceuticals Receives Rare Pediatric Disease Designation From FDA For CAT-1004 For The Potential Treatment Of Duchenne Muscular Dystrophy
CATB,CAT-1004,2015-07-06,Catabasis Pharmaceuticals Receives FDA Fast Track Designation For CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy
CCXI,CCX872,2017-01-20,ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer
CCXI,CCX872,2016-10-18,ChemoCentryx's CCR2 Inhibitor CCX872 Shown To Reduce Liver Fibrosis In NASH Models
CCXI,CCX872,2016-09-01,ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer
CCXI,CCX872,2015-04-20,ChemoCentryx Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer
CCXI,CCX872,2012-10-02,ChemoCentryx Reports Data For CCX872, The Company's Orally Bioavailable, Next-Generation CCR2 Inhibitor, In A Preclinical Model Of Diabetic Nephropathy
CCXI,CCX872,2017-01-20,ChemoCentryx Announces Presentation Of Data From Ongoing Phase Ib Clinical Trial Of CCR2 Inhibitor CCX872 In Patients With Advanced Non-Resectable Pancreatic Cancer
CCXI,CCX872,2016-10-18,ChemoCentryx's CCR2 Inhibitor CCX872 Shown To Reduce Liver Fibrosis In NASH Models
CCXI,CCX872,2016-09-01,ChemoCentryx Reports Initial Results From Ongoing Phase Ib Clinical Trial Of CCX872 In Patients With Advanced Pancreatic Cancer
CCXI,CCX872,2015-04-20,ChemoCentryx Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer
CCXI,CCX872,2012-10-02,ChemoCentryx Reports Data For CCX872, The Company's Orally Bioavailable, Next-Generation CCR2 Inhibitor, In A Preclinical Model Of Diabetic Nephropathy
CCXI,CCX168,2016-11-07,ChemoCentryx Announces Presentations Of Positive Results From Phase II ANCA-Associated Vasculitis Trials ('CLEAR' And 'CLASSIC') Of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan')
CCXI,CCX168,2016-10-17,ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016
CCXI,CCX168,2016-06-16,ChemoCentryx Announces Positive Top-Line Results For CCX168 From The Phase II ANCA-Associated Vasculitis CLASSIC Study And Advances Plans To Initiate Phase III Development
CCXI,CCX168,2016-06-01,ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis
CCXI,CCX168,2016-05-23,ChemoCentryx Announces Presentation Of Positive Results From Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168 At The 53rd ERA-EDTA Congress
CCXI,CCX168,2016-05-10,Vifor Pharma Licenses Rights To Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 For Orphan And Rare Renal Diseases In Europe And Certain Other Major Markets
CCXI,CCX168,2016-04-28,ChemoCentryx Receives FDA Orphan Products Development Grant For Orally Administered Complement 5a Receptor Inhibitor CCX168 For Treatment Of ANCA-Associated Vasculitis
CCXI,CCX168,2016-01-06,ChemoCentryx Announces Positive Results In Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168
CCXI,CCX168,2014-12-04,ChemoCentryx Granted EU Orphan Drug Designation For CCX168, An Orally Administered Complement C5a Receptor Inhibitor, For The Treatment Of Microscopic Polyangiitis And Granulomatosis With Polyangiitis, Two Forms Of ANCA-Associated Vasculitis
CCXI,CCX168,2014-11-20,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA
CCXI,CCX168,2014-11-17,ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
CCXI,CCX168,2014-06-03,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In ANCA-Associated Diseases By The FDA
CCXI,CCX168,2014-06-02,ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit In ANCA-Associated Vasculitis Based On Birmingham Vasculitis Activity Score And Renal Disease Measurements
CCXI,CCX168,2013-12-03,ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data In ANCA-Associated Renal Vasculitis
CCXI,CCX168,2016-11-07,ChemoCentryx Announces Presentations Of Positive Results From Phase II ANCA-Associated Vasculitis Trials ('CLEAR' And 'CLASSIC') Of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan')
CCXI,CCX168,2016-10-17,ChemoCentryx Announces Presentation Of Positive Data From Ongoing Pilot Phase II Trial Of CCX168 (Avacopan) In Atypical Hemolytic Uremic Syndrome (aHUS) At ASN Kidney Week 2016
CCXI,CCX168,2016-06-16,ChemoCentryx Announces Positive Top-Line Results For CCX168 From The Phase II ANCA-Associated Vasculitis CLASSIC Study And Advances Plans To Initiate Phase III Development
CCXI,CCX168,2016-06-01,ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation For Accelerated Assessment Of Complement 5a Receptor Inhibitor CCX168 For Treatment Of Patients With ANCA-Associated Vasculitis
CCXI,CCX168,2016-05-23,ChemoCentryx Announces Presentation Of Positive Results From Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168 At The 53rd ERA-EDTA Congress
CCXI,CCX168,2016-05-10,Vifor Pharma Licenses Rights To Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 For Orphan And Rare Renal Diseases In Europe And Certain Other Major Markets
CCXI,CCX168,2016-04-28,ChemoCentryx Receives FDA Orphan Products Development Grant For Orally Administered Complement 5a Receptor Inhibitor CCX168 For Treatment Of ANCA-Associated Vasculitis
CCXI,CCX168,2016-01-06,ChemoCentryx Announces Positive Results In Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168
CCXI,CCX168,2014-12-04,ChemoCentryx Granted EU Orphan Drug Designation For CCX168, An Orally Administered Complement C5a Receptor Inhibitor, For The Treatment Of Microscopic Polyangiitis And Granulomatosis With Polyangiitis, Two Forms Of ANCA-Associated Vasculitis
CCXI,CCX168,2014-11-20,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA
CCXI,CCX168,2014-11-17,ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements
CCXI,CCX168,2014-06-03,ChemoCentryx's CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In ANCA-Associated Diseases By The FDA
CCXI,CCX168,2014-06-02,ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit In ANCA-Associated Vasculitis Based On Birmingham Vasculitis Activity Score And Renal Disease Measurements
CCXI,CCX168,2013-12-03,ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data In ANCA-Associated Renal Vasculitis
CEMP,Solithromycin,2016-12-29,Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
CEMP,Solithromycin,2016-12-05,Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) Begins Phase 3 Studies In Japan With Cempra's Solithromycin
CEMP,Solithromycin,2016-11-04,FDA Advisory Committee Votes That Efficacy Results Of Cempra's Solithromycin Outweigh Risks For Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-11-04,Cempra Stock Trading Halted Today; FDA Advisory Committee To Discuss Solithromycin
CEMP,Solithromycin,2016-11-01,Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) As Solithromycin Progresses To Phase 3 Studies In Japan
CEMP,Solithromycin,2016-09-29,Cempra Announces Anti-NASH Effects Of Solithromycin: Interim Results From Phase 2 Study
CEMP,Solithromycin,2016-08-30,Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016
CEMP,Solithromycin,2016-08-25,Cempra's Pivotal Phase 3 SOLITAIRE-IV Study Of IV To Oral Solithromycin Published In Clinical Infectious Diseases
CEMP,Solithromycin,2016-08-23,Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP
CEMP,Solithromycin,2016-06-28,Cempra Submits Marketing Authorization Application To EMA For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-06-10,Cempra Announces Solithromycin Presentations At ASM Microbe 2016 Conference
CEMP,Solithromycin,2016-05-12,Cempra To Present Solithromycin IV Data At ATS 2016
CEMP,Solithromycin,2016-05-01,Cempra Completes NDA Submissions For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-04-04,Cempra To Present Data On Solithromycin At ECCMID
CEMP,Solithromycin,2016-03-07,Cempra Authorized To Receive Funds From BARDA For A Phase 2/3 Clinical Trial Of Solithromycin In Pediatric Patients
CEMP,Solithromycin,2016-02-05,The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results For Cempra's Oral Solithromycin In Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-02-01,Cempra And Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement For Solithromycin
CEMP,Solithromycin,2016-01-05,Cempra Doses Initial Patient In Phase 2 Clinical Trial Of Solithromycin In NASH
CEMP,Solithromycin,2015-12-22,Cempra Enters Into A CRADA With The NIAID And Expands The Phase 3 Solithromycin Clinical Trial In Urogenital Gonorrhea To Include Additional Female Patients And Adolescents
CEMP,Solithromycin,2015-11-11,Cempra To Present Anti-NASH Data For Solithromycin At The Liver Meeting(R) 2015
CEMP,Solithromycin,2015-10-23,Cempra To Present Solithromycin Oral Data At CHEST 2015
CEMP,Solithromycin,2015-10-16,Cempra Announces Positive Topline Phase 3 Clinical Results For Intravenous Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2015-10-05,Cempra To Present Solithromycin Data At ID Week 2015
CEMP,Solithromycin,2015-09-24,Cempra To Present Solithromycin Data In COPD Patient Subgroup At European Respiratory Society International Congress
CEMP,Solithromycin,2015-08-19,FDA Grants Fast Track Designation To Cempra For Solithromycin In The Treatment Of Community Acquired Bacterial Pneumonia
CEMP,Solithromycin,2015-05-19,Cempra Presenting Additional Data From The Phase 3 Oral Solithromycin Study In Community Acquired Bacterial Pneumonia At The American Thoracic Society Conference
CEMP,Solithromycin,2015-05-12,Cempra To Present Solithromycin Data At Two Upcoming Medical Conferences
CEMP,Solithromycin,2016-12-29,Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
CEMP,Solithromycin,2016-12-05,Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) Begins Phase 3 Studies In Japan With Cempra's Solithromycin
CEMP,Solithromycin,2016-11-04,FDA Advisory Committee Votes That Efficacy Results Of Cempra's Solithromycin Outweigh Risks For Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-11-04,Cempra Stock Trading Halted Today; FDA Advisory Committee To Discuss Solithromycin
CEMP,Solithromycin,2016-11-01,Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) As Solithromycin Progresses To Phase 3 Studies In Japan
CEMP,Solithromycin,2016-09-29,Cempra Announces Anti-NASH Effects Of Solithromycin: Interim Results From Phase 2 Study
CEMP,Solithromycin,2016-08-30,Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016
CEMP,Solithromycin,2016-08-25,Cempra's Pivotal Phase 3 SOLITAIRE-IV Study Of IV To Oral Solithromycin Published In Clinical Infectious Diseases
CEMP,Solithromycin,2016-08-23,Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP
CEMP,Solithromycin,2016-06-28,Cempra Submits Marketing Authorization Application To EMA For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-06-10,Cempra Announces Solithromycin Presentations At ASM Microbe 2016 Conference
CEMP,Solithromycin,2016-05-12,Cempra To Present Solithromycin IV Data At ATS 2016
CEMP,Solithromycin,2016-05-01,Cempra Completes NDA Submissions For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-04-04,Cempra To Present Data On Solithromycin At ECCMID
CEMP,Solithromycin,2016-03-07,Cempra Authorized To Receive Funds From BARDA For A Phase 2/3 Clinical Trial Of Solithromycin In Pediatric Patients
CEMP,Solithromycin,2016-02-05,The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results For Cempra's Oral Solithromycin In Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-02-01,Cempra And Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement For Solithromycin
CEMP,Solithromycin,2016-01-05,Cempra Doses Initial Patient In Phase 2 Clinical Trial Of Solithromycin In NASH
CEMP,Solithromycin,2015-12-22,Cempra Enters Into A CRADA With The NIAID And Expands The Phase 3 Solithromycin Clinical Trial In Urogenital Gonorrhea To Include Additional Female Patients And Adolescents
CEMP,Solithromycin,2015-11-11,Cempra To Present Anti-NASH Data For Solithromycin At The Liver Meeting(R) 2015
CEMP,Solithromycin,2015-10-23,Cempra To Present Solithromycin Oral Data At CHEST 2015
CEMP,Solithromycin,2015-10-16,Cempra Announces Positive Topline Phase 3 Clinical Results For Intravenous Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2015-10-05,Cempra To Present Solithromycin Data At ID Week 2015
CEMP,Solithromycin,2015-09-24,Cempra To Present Solithromycin Data In COPD Patient Subgroup At European Respiratory Society International Congress
CEMP,Solithromycin,2015-08-19,FDA Grants Fast Track Designation To Cempra For Solithromycin In The Treatment Of Community Acquired Bacterial Pneumonia
CEMP,Solithromycin,2015-05-19,Cempra Presenting Additional Data From The Phase 3 Oral Solithromycin Study In Community Acquired Bacterial Pneumonia At The American Thoracic Society Conference
CEMP,Solithromycin,2015-05-12,Cempra To Present Solithromycin Data At Two Upcoming Medical Conferences
CEMP,Solithromycin,2016-12-29,Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs
CEMP,Solithromycin,2016-12-05,Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) Begins Phase 3 Studies In Japan With Cempra's Solithromycin
CEMP,Solithromycin,2016-11-04,FDA Advisory Committee Votes That Efficacy Results Of Cempra's Solithromycin Outweigh Risks For Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-11-04,Cempra Stock Trading Halted Today; FDA Advisory Committee To Discuss Solithromycin
CEMP,Solithromycin,2016-11-01,Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary Of FUJIFILM Holdings Corporation) As Solithromycin Progresses To Phase 3 Studies In Japan
CEMP,Solithromycin,2016-09-29,Cempra Announces Anti-NASH Effects Of Solithromycin: Interim Results From Phase 2 Study
CEMP,Solithromycin,2016-08-30,Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016
CEMP,Solithromycin,2016-08-25,Cempra's Pivotal Phase 3 SOLITAIRE-IV Study Of IV To Oral Solithromycin Published In Clinical Infectious Diseases
CEMP,Solithromycin,2016-08-23,Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP
CEMP,Solithromycin,2016-06-28,Cempra Submits Marketing Authorization Application To EMA For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-06-10,Cempra Announces Solithromycin Presentations At ASM Microbe 2016 Conference
CEMP,Solithromycin,2016-05-12,Cempra To Present Solithromycin IV Data At ATS 2016
CEMP,Solithromycin,2016-05-01,Cempra Completes NDA Submissions For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-04-04,Cempra To Present Data On Solithromycin At ECCMID
CEMP,Solithromycin,2016-03-07,Cempra Authorized To Receive Funds From BARDA For A Phase 2/3 Clinical Trial Of Solithromycin In Pediatric Patients
CEMP,Solithromycin,2016-02-05,The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results For Cempra's Oral Solithromycin In Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2016-02-01,Cempra And Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement For Solithromycin
CEMP,Solithromycin,2016-01-05,Cempra Doses Initial Patient In Phase 2 Clinical Trial Of Solithromycin In NASH
CEMP,Solithromycin,2015-12-22,Cempra Enters Into A CRADA With The NIAID And Expands The Phase 3 Solithromycin Clinical Trial In Urogenital Gonorrhea To Include Additional Female Patients And Adolescents
CEMP,Solithromycin,2015-11-11,Cempra To Present Anti-NASH Data For Solithromycin At The Liver Meeting(R) 2015
CEMP,Solithromycin,2015-10-23,Cempra To Present Solithromycin Oral Data At CHEST 2015
CEMP,Solithromycin,2015-10-16,Cempra Announces Positive Topline Phase 3 Clinical Results For Intravenous Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
CEMP,Solithromycin,2015-10-05,Cempra To Present Solithromycin Data At ID Week 2015
CEMP,Solithromycin,2015-09-24,Cempra To Present Solithromycin Data In COPD Patient Subgroup At European Respiratory Society International Congress
CEMP,Solithromycin,2015-08-19,FDA Grants Fast Track Designation To Cempra For Solithromycin In The Treatment Of Community Acquired Bacterial Pneumonia
CEMP,Solithromycin,2015-05-19,Cempra Presenting Additional Data From The Phase 3 Oral Solithromycin Study In Community Acquired Bacterial Pneumonia At The American Thoracic Society Conference
CEMP,Solithromycin,2015-05-12,Cempra To Present Solithromycin Data At Two Upcoming Medical Conferences
CERC,CERC-501,2016-09-06,Cerecor Announces Last Patient Enrolled In Phase 2 Clinical Trial With CERC-501 For Smoking Cessation
CERC,CERC-501,2016-08-29,Cerecor Inc. Announces Initiation Of Second CERC-501 Phase 2 Clinical Trial In Smokers
CERC,CERC-501,2016-07-25,Cerecor Announces Research Grant From The Department Of Defense To Study CERC-501 In Animal Models For Co-Morbid Post-Traumatic Stress Disorder And Alcohol Use Disorder
CERC,CERC-501,2016-02-02,Cerecor Announces Initiation Of Phase 2 Clinical Trial With CERC-501 For Smoking Cessation
CERC,CERC-501,2015-12-11,Publication Reports Human Brain Penetration And Target Engagement Of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
CERU,CRLX101,2016-08-17,Cerulean Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin® Combination In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2016-07-19,Cerulean Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer
CERU,CRLX101,2016-05-19,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
CERU,CRLX101,2016-05-10,Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA™
CERU,CRLX101,2016-04-25,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
CERU,CRLX101,2016-03-23,Cerulean Announces Publication Showing CRLX101 Localizes Selectively In Human Tumors, Sparing Adjacent Healthy Tissue
CERU,CRLX101,2015-11-17,Cerulean Announces Clinical Collaboration With AstraZeneca And The National Cancer Institute To Evaluate The Combination Of LYNPARZA™ And CRLX101
CERU,CRLX101,2015-10-19,Cerulean Announces First Patient Dosed In Clinical Trial To Evaluate Weekly Dosing Schedule With CRLX101
CERU,CRLX101,2015-10-15,Cerulean Announces Completion Of Enrollment Of Randomized Phase 2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2015-09-30,Cerulean Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin® In Relapsed Ovarian Cancer
CERU,CRLX101,2015-07-21,Cerulean Announces First Patient Dosed In Phase 1b Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
CERU,CRLX101,2015-06-01,Cerulean Announces Presentation Of Full Data From Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Metastatic Renal Cell Carcinoma At The Annual Meeting Of The American Society For Clinical Oncology
CERU,CRLX101,2015-05-26,Cerulean's CRLX101 Receives Orphan Drug Designation From The FDA For The Treatment Of Ovarian Cancer
CERU,CRLX101,2015-04-28,Cerulean Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma
CERU,CRLX101,2015-04-16,Cerulean Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association For Cancer Research Annual Meeting
CERU,CRLX101,2015-04-13,Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells And Impedes Resistance To Anti-angiogenic Therapy In Preclinical Models
CERU,CRLX101,2015-03-19,Cerulean Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma Meets Primary Endpoint
CERU,CRLX101,2015-03-03,Cerulean Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
CERU,CRLX101,2015-02-19,CRLX101 Selected For Oral Presentation At 17th Annual Symposium On Anti-Angiogenesis And Immune Therapies For Cancer
CERU,CRLX101,2015-01-19,CRLX101 Rectal Cancer Data Presented At ASCO 2015 Gastrointestinal Cancers Symposium
CERU,CRLX101,2015-01-06,Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models
CERU,CRLX101,2014-12-15,Cerulean Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2016-08-17,Cerulean Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin® Combination In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2016-07-19,Cerulean Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer
CERU,CRLX101,2016-05-19,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
CERU,CRLX101,2016-05-10,Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA™
CERU,CRLX101,2016-04-25,Cerulean Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference
CERU,CRLX101,2016-03-23,Cerulean Announces Publication Showing CRLX101 Localizes Selectively In Human Tumors, Sparing Adjacent Healthy Tissue
CERU,CRLX101,2015-11-17,Cerulean Announces Clinical Collaboration With AstraZeneca And The National Cancer Institute To Evaluate The Combination Of LYNPARZA™ And CRLX101
CERU,CRLX101,2015-10-19,Cerulean Announces First Patient Dosed In Clinical Trial To Evaluate Weekly Dosing Schedule With CRLX101
CERU,CRLX101,2015-10-15,Cerulean Announces Completion Of Enrollment Of Randomized Phase 2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
CERU,CRLX101,2015-09-30,Cerulean Announces CRLX101 Advances To Second Stage Of Phase 2 Clinical Trial Of CRLX101 In Combination With Avastin® In Relapsed Ovarian Cancer
CERU,CRLX101,2015-07-21,Cerulean Announces First Patient Dosed In Phase 1b Trial Of CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
CERU,CRLX101,2015-06-01,Cerulean Announces Presentation Of Full Data From Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Metastatic Renal Cell Carcinoma At The Annual Meeting Of The American Society For Clinical Oncology
CERU,CRLX101,2015-05-26,Cerulean's CRLX101 Receives Orphan Drug Designation From The FDA For The Treatment Of Ovarian Cancer
CERU,CRLX101,2015-04-28,Cerulean Announces Fast Track Designation Granted For CRLX101 In Metastatic Renal Cell Carcinoma
CERU,CRLX101,2015-04-16,Cerulean Announces Three Posters To Be Presented With Preclinical CRLX101 Data At The American Association For Cancer Research Annual Meeting
CERU,CRLX101,2015-04-13,Cerulean Announces Publication Showing CRLX101 Targets Breast Cancer Stem Cells And Impedes Resistance To Anti-angiogenic Therapy In Preclinical Models
CERU,CRLX101,2015-03-19,Cerulean Announces Phase 1b/2 Trial Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma Meets Primary Endpoint
CERU,CRLX101,2015-03-03,Cerulean Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer
CERU,CRLX101,2015-02-19,CRLX101 Selected For Oral Presentation At 17th Annual Symposium On Anti-Angiogenesis And Immune Therapies For Cancer
CERU,CRLX101,2015-01-19,CRLX101 Rectal Cancer Data Presented At ASCO 2015 Gastrointestinal Cancers Symposium
CERU,CRLX101,2015-01-06,Cerulean Announces Publication Describing Synergistic Anti-Tumor Activity Of CRLX101 With Avastin In Advanced Metastatic Ovarian Tumor Models
CERU,CRLX101,2014-12-15,Cerulean Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma
CHRS,CHS-1420,2017-03-02,Coherus Announces CHS-1420 Pharmacokinetic Clinical Bioequivalence Study Meets Primary Endpoint
CHRS,CHS-1420,2017-01-10,Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results For CHS-1420 (HUMIRA® Biosimilar Candidate) In Patients With Psoriasis
CHRS,CHS-1420,2016-08-08,Coherus BioSciences Announces Positive Topline Phase Three Results For CHS-1420 (Humira® Biosimilar Candidate) In Patients With Psoriasis
CLBS,CLBS03,2017-02-23,Caladrius Biosciences Awarded $12.2 Million Grant From CIRM In Support Of Phase 2 Clinical Trial Of CLBS03 To Treat Type 1 Diabetes
CLBS,CLBS03,2017-01-25,Caladrius Biosciences Announces Addition Of Three Clinical Sites, Including University Of California, San Francisco, For The Ongoing Phase 2 Study Of CLBS03 In T1D
CLBS,CLBS03,2016-10-31,Caladrius Biosciences Begins Enrollment Of Second Cohort Of Phase 2 Trial Of CLBS03 As A Treatment For Type 1 Diabetes Following Favorable Safety Data From First Cohort
CLBS,CLBS03,2016-09-06,Caladrius Biosciences Completes Enrollment Of First Patient Cohort In Phase 2 Trial Of CLBS03 To Treat Type 1 Diabetes
CLBS,CLBS03,2016-07-28,Caladrius Biosciences Receives FDA Fast Track Designation For CLBS03 To Treat Recent Onset Type 1 Diabetes
CLBS,CLBS03,2016-05-12,Caladrius Biosciences Receives Orphan Drug Designation For CLBS03 To Treat Type 1 Diabetes
CLBS,CLBS03,2016-03-29,Caladrius Biosciences Announces First Subject Treated In CLBS03 Type 1 Diabetes Phase 2 Trial
CRBP,Resunab,2016-09-23,Corbus CEO on Resunab and the Pharma's Unstoppable Stock
CRBP,Resunab,2016-09-23,Resunab Results Keeping Corbus on Fast Track Says CEO
CRBP,Resunab,2016-09-23,Corbus CEO on Resunab and the Pharma's Unstoppable Stock
CRBP,Resunab,2016-09-23,Resunab Results Keeping Corbus on Fast Track Says CEO
CRBP,Resunab,2016-09-23,Corbus CEO on Resunab and the Pharma's Unstoppable Stock
CRBP,Resunab,2016-09-23,Resunab Results Keeping Corbus on Fast Track Says CEO
CRBP,Resunab,2016-09-23,Corbus CEO on Resunab and the Pharma's Unstoppable Stock
CRBP,Resunab,2016-09-23,Resunab Results Keeping Corbus on Fast Track Says CEO
CRMD,Neutrolin,2016-04-12,CorMedix Inc. To Present Post-Market Clinical Utility Data From Neutrolin® Usage Monitoring Program On May 23, 2016
CRMD,Neutrolin,2015-12-14,CorMedix Announces Enrollment And Dosing Of First Patient In Phase 3 Neutrolin® Trial In Hemodialysis
CRMD,Neutrolin,2015-06-17,CorMedix (CRMD) Stock Gains After Receiving Positive FDA Feedback for Neutrolin
CRMD,Neutrolin,2015-06-17,CorMedix Inc. Receives Positive Feedback From FDA For Neutrolin® Clinical Trial Protocol For Oncology Patients
CRMD,Neutrolin,2015-06-01,CorMedix Presents Neutrolin® Post Marketing Surveillance Data At European Renal Association - European Dialysis And Transplant Association (ERA-EDTA) Conference
CRMD,Neutrolin,2015-04-23,CorMedix Presents Data From Neutrolin® Post Marketing Surveillance Study At Two Medical Conferences
CRMD,Neutrolin,2015-04-09,CorMedix Institutes Program To Reduce Neutrolin® Cost Of Goods; Reports On Strategic Review Process Managed By Evercore
CRMD,Neutrolin,2015-01-29,FDA Grants QIDP Designation To Neutrolin®, CorMedix Inc.'s Lead Product Candidate In The U.S.
CRMD,Neutrolin,2015-01-15,CorMedix Inc. Receives Fast Track Designation For Neutrolin®
CRMD,Neutrolin,2014-12-23,CorMedix Inc. Finalizes First Middle East Neutrolin® Sales/Distribution Agreement In The Kingdom Of Saudi Arabia
CRMD,Neutrolin,2014-12-04,CorMedix Inc. Files Request With FDA For QIDP Designation For Neutrolin®
CRMD,Neutrolin,2014-12-03,Neutrolin Label Expansion Approved In Germany
CRMD,Neutrolin,2014-09-25,CorMedix Announces FDA IND Filing For Neutrolin® In United States
CRMD,Neutrolin,2014-09-22,Neutrolin Label Expansion Approved For The European Union
CRMD,Neutrolin,2014-01-13,CorMedix Expands NeutrolinA® Sales With Middle East Distribution Agreements
CRMD,Neutrolin,2014-01-10,CorMedix Awarded European Patent For Neutrolin
CRMD,Neutrolin,2013-12-23,CorMedix Receives Minutes From Neutrolin Pre-IND Meeting With FDA
CRMD,Neutrolin,2013-12-12,CorMedix Announces First Sales Of NeutrolinA® In The European Union
CRMD,Neutrolin,2013-07-05,CorMedix Receives CE Mark For Neutrolin&#174; Catheter Lock Solution
CRMD,Neutrolin,2013-01-15,CorMedix Signs Sales And Marketing Agreement With MKM Co-Pharma, Bolsters Commercial Management Team To Ready Neutrolin&#174; Catheter Lock Solution For European Market
CRMD,Neutrolin,2012-06-14,CorMedix Provides An Update On CE Marking Process For Neutrolin&#174; In The EU
CRMD,Neutrolin,2011-09-29,CorMedix Announces FDA Designation For Neutrolin (CRMD003)
CRMD,Neutrolin,2011-07-07,CorMedix Submits Design Dossier For Neutrolin&#174; (CRMD003) To Start European Approval Process
CRMD,Neutrolin,2011-06-23,CorMedix Provides Regulatory Update For CRMD003 (Neutrolin&#174;)
CTRV,CMX157,2016-12-19,ContraVir Expands Phase 2a Trial Of Tenofovir Exalidex (Formerly CMX157) To Include Doses Above 100 Mg
CTRV,CMX157,2016-10-17,CMX157 Advances Head-to-Head Phase 2a Clinical Study In Hepatitis B Patients With Favorable Recommendation From DSMB
CTRV,CMX157,2016-10-13,CMX157 Demonstrates 99% Viral Load Reduction In Ongoing Head-to-Head Phase 2a Clinical Study Vs. Viread® In Hepatitis B Patients
CTRV,CMX157,2016-09-12,ContraVir Reports New CRV431 Data Highlighting Synergistic Activity With CMX157 Against Hepatitis B
CTRV,CMX157,2016-08-02,ContraVir Reports Positive Data From Phase 1b Study Of CMX157
CTRV,CMX157,2016-06-21,ContraVir Doses First Patients In Head-to-Head Study Of CMX157 Vs. Viread® For Treating Hepatitis B
CTRV,CMX157,2016-06-01,ContraVir Initiates Head-to-Head Phase 2a Clinical Study Of CMX157 Vs. Viread® For Treating Hepatitis B
CTRV,CMX157,2016-05-25,ContraVir To Showcase CMX157 Data In Poster At The 3rd ANRS HBV Cure Workshop
CTRV,CMX157,2016-04-19,ContraVir Doses First Subject In Phase 1b Clinical Study Of CMX157 For Treating Chronic Hepatitis B Infection
CTRV,CMX157,2016-03-29,ContraVir's CMX157 Outperforms Gilead's Tenofovir AF (TAF) Against Hepatitis B Virus In Independent Head-to-Head In-Vitro Study
CTRV,CMX157,2016-03-21,ContraVir Initiates Phase 1/2a Clinical Study Of CMX157 For Treating Chronic Hepatitis B Infection
CTRV,CMX157,2015-12-08,ContraVir Reports Key CMX157 Data At HEP DART 2015 Demonstrating Enhanced In Vitro Safety Profile Compared To Viread®
CTRV,CMX157,2015-12-01,ContraVir To Present New CMX157 Data At HEP DART 2015
CTRV,CMX157,2015-10-05,ContraVir Reports New Data Demonstrating CMX157 To Be 60-Fold More Potent Against Hepatitis B Virus Than Gilead's Viread®
CTRV,CMX157,2015-06-03,ContraVir Engages The Baruch S. Blumberg Institute To Further Research And Develop CMX157
CTRV,CMX157,2015-02-04,ContraVir Pharmaceuticals' HBV Compound CMX157 Receives Extended Patent Life
CTRV,CMX157,2014-12-18,Chimerix And ContraVir Pharmaceuticals Establish Strategic Collaboration For Antiviral Drug Candidate CMX157
CYCC,Sapacitabine,2016-06-06,Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO
CYCC,Sapacitabine,2016-05-19,Cyclacel's Seliciclib-Sapacitabine Abstract Selected For Oral Presentation At The 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting
CYCC,Sapacitabine,2014-12-16,Cyclacel Announces Enrollment Of 486 Patients, DSMB Recommendations And That The Seamless Phase 3 Trial Of Sapacitabine In AML Will Continue To Final Analysis
CYCC,Sapacitabine,2014-10-09,Cyclacel Announces Data Safety Monitoring Board Recommendation To Continue The Seamless Phase 3 Trial Of Sapacitabine In AML
CYCC,Sapacitabine,2014-05-31,Cyclacel Pharmaceuticals Provides Update On Its Clinical Development Plan Of Sapacitabine For Myelodysplastic Syndromes (MDS)
CYCC,Sapacitabine,2014-05-28,Cyclacel Pharmaceuticals To Webcast Institutional Investor And Analyst Presentation On Clinical Development Plan Of Sapacitabine For MDS
CYCC,Sapacitabine,2014-05-05,New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations And Combination Treatments
CYCC,Sapacitabine,2014-04-10,Independent Investigators Present Non-Clinical Data Providing Rationale For Sapacitabine Combination Treatment With Bcr-Abl Inhibitors In CML
CYCC,Sapacitabine,2013-12-09,Cyclacel Reports New Phase 2 Data Of Sapacitabine For MDS At ASH
CYCC,Sapacitabine,2013-11-25,Cyclacel Announces Data Safety Monitoring Board Recommendation To Continue The SEAMLESS Phase 3 Trial Of Sapacitabine In AML
CYCC,Sapacitabine,2013-11-07,Researchers To Present New Phase 2 Data On Sapacitabine As A Treatment For Patients With MDS At ASH Annual Meeting
CYCC,Sapacitabine,2013-11-05,New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents And Sapacitabine Dosing Regimens
CYCC,Sapacitabine,2013-09-19,Cyclacel's Sapacitabine Reported To Have Anti-Tumor Activity Against Ovarian Cancer
CYCC,Sapacitabine,2013-04-30,Cyclacel Reports Updated Phase 2 Survival Data Of Sapacitabine For MDS
CYCC,Sapacitabine,2013-04-09,Combination Potential Of Cyclacel's Sapacitabine And Seliciclib Reported At AACR
CYCC,Sapacitabine,2013-02-12,Cyclacel Announces Grants Of New U.S. & European Patents Covering Sapacitabine Used In Combination With HDAC Inhibitors
CYCC,Sapacitabine,2012-10-15,Cyclacel's Sapacitabine Nearly Doubles Expected Survival Of Elderly Patients With MDS After Front-Line Therapy Failure
CYCC,Sapacitabine,2012-10-12,Updated Phase 2 Survival Data Of Cyclacel's Sapacitabine For MDS Presented At The Eighth Annual Hematologic Malignancies 2012 Conference
CYCC,Sapacitabine,2011-01-11,Cyclacel Begins Pivotal Phase 3 "SEAMLESS" Trial Of Sapacitabine As Front-Line Treatment For AML Under A Special Protocol Assessment
CYCC,Sapacitabine,2010-12-04,Cyclacel Reports Phase 2 Survival Data With Sapacitabine In Myelodysplastic Syndromes At 2010 ASH Annual Meeting
CYCC,Sapacitabine,2010-11-19,Cyclacel Pharmaceuticals To Present Sapacitabine Phase 2 MDS Data At The Upcoming American Society Of Hematology Meeting
CYCC,Sapacitabine,2010-11-10,Publications Highlight Novel Combinations Of Sapacitabine With Targeted Agents For The Treatment Of Cancer
CYNA,APL-130277,2016-08-29,Cynapsus Receives FDA Fast Track Designation For APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
CYNA,APL-130277,2016-07-18,Cynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results With APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
CYNA,APL-130277,2016-07-18,Cynapsus Therapeutics Provides European Clinical Update For APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
CYNA,APL-130277,2016-06-30,Cynapsus Therapeutics Enrolls Last Patient In Pivotal Phase 3 Efficacy Trial Of APL-130277 To Treat OFF Episodes In Patients With Parkinson's Disease
CYNA,APL-130277,2015-09-02,Cynapsus Therapeutics Enrolls First Patient In Pivotal Phase 3 Safety Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
CYTR,Aldoxorubicin,2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
CYTR,Aldoxorubicin,2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
CYTR,Aldoxorubicin,2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
CYTR,Aldoxorubicin,2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
CYTR,Aldoxorubicin,2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
CYTR,Aldoxorubicin,2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
CYTR,Aldoxorubicin,2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
CYTR,Aldoxorubicin,2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
CYTR,Aldoxorubicin,2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
CYTR,Aldoxorubicin,2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
CYTR,Aldoxorubicin,2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
CYTR,Aldoxorubicin,2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
CYTR,Aldoxorubicin,2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
CYTR,Aldoxorubicin,2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
CYTR,Aldoxorubicin,2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
CYTR,Aldoxorubicin,2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
CYTR,Aldoxorubicin,2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
CYTR,Aldoxorubicin,2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
CYTR,Aldoxorubicin,2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
CYTR,Aldoxorubicin,2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
CYTR,Aldoxorubicin,2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
CYTR,Aldoxorubicin,2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
CYTR,Aldoxorubicin,2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
CYTR,Aldoxorubicin,2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
CYTR,Aldoxorubicin,2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
CYTR,Aldoxorubicin,2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
CYTR,Aldoxorubicin,2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
CYTR,Aldoxorubicin,2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
CYTR,Aldoxorubicin,2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
CYTR,Aldoxorubicin,2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
DMTX,DTX101,2017-01-31,Dimension Announces Interim Topline Results From Ongoing Phase 1/2 Clinical Program For DTX101, Dimension's Lead AAV Product Candidate In Development For Adult Patients With Moderate/Severe To Severe Hemophilia B
DMTX,DTX101,2016-05-05,Dimension Therapeutics Announces Preclinical Data Supporting Ongoing DTX101 Phase 1/2 Clinical Trial At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting
DMTX,DTX101,2016-01-07,Dimension Therapeutics Announces Initiation Of Phase 1/2 Study For DTX101 For The Treatment Of Hemophilia B
DRNA,DCR-MYC,2015-12-21,Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors
DRNA,DCR-MYC,2015-06-01,Dicerna Presents Preliminary Safety And Efficacy Data From DCR-MYC Phase 1 Study In Patients With Advanced Solid Tumors At The 2015 ASCO Annual Meeting
DRNA,DCR-MYC,2015-05-14,Dicerna Announces Expansion Of Ongoing DCR-MYC Phase 1 Study To Evaluate Safety And Efficacy In Patients With Advanced Pancreatic Neuroendocrine Tumors (PNETs)
DRNA,DCR-MYC,2015-05-13,Dicerna To Present Interim Clinical Data From First DCR-MYC Phase 1 Study In Patients With Advanced Solid Tumors At The 2015 ASCO Annual Meeting
DRNA,DCR-MYC,2015-02-02,Dicerna Pharmaceuticals Announces First Patient Dosed In Phase 1b/2 Clinical Trial Of DCR-MYC, An Investigational RNAi Therapeutic Targeting The MYC Oncogene, In Patients With Advanced Hepatocellular Carcinoma
EARS,AM-101,2016-06-07,Auris Medical To Host Key Opinion Leader Event Focused On Acute Inner Ear Tinnitus And AM-101's Phase 3 Program On June 14 In New York City
EARS,AM-101,2016-03-30,Auris Medical Completes Enrollment Of TACTT2 Phase 3 Trial Of AM-101 In Acute Inner Ear Tinnitus
EARS,AM-101,2015-04-20,Auris Medical Announces Publications Related To AM-101 In Peer-Reviewed Scientific And Medical Journals
EARS,AM-101,2015-03-10,Auris Medical Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101
EIGR,Subcutaneous,2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
EIGR,Subcutaneous,2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
EIGR,Subcutaneous,2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
EIGR,Subcutaneous,2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
EIGR,Subcutaneous,2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
EIGR,Subcutaneous,2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
EIGR,Subcutaneous,2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
EIGR,Subcutaneous,2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
FLXN,Zilretta,2017-02-23,Flexion Therapeutics Initiates Clinical Trial To Evaluate The Safety Of Repeat Administration Of Zilretta™ (FX006) In Patients With Osteoarthritis Of The Knee
FLXN,Zilretta,2017-02-07,Flexion Therapeutics Announces New Drug Application For Zilretta™ (FX006) Accepted By U.S. Food And Drug Administration
FLXN,Zilretta,2016-12-12,Flexion Therapeutics Submits New Drug Application For Zilretta™ To Treat Knee Osteoarthritis Pain
FLXN,Zilretta,2016-11-11,Flexion Therapeutics Announces Presentation Of Phase 3 Data Demonstrating That Extended-Release Zilretta™ Achieves Clinically Significant Improvement Of Pain, Stiffness And Function In Patients With Osteoarthritis Of The Knee
FLXN,Zilretta,2016-11-03,Flexion Therapeutics Announces That Analysis From Phase 3 Clinical Trial Of Zilretta™ For Osteoarthritis Of The Knee To Be Presented At AAHKS
FLXN,Zilretta,2016-11-01,Flexion Therapeutics Reports Primary Endpoint Met In Clinical Trial Evaluating Investigational Drug Candidate Zilretta™ In Type 2 Diabetes Patients With Knee Osteoarthritis
FLXN,Zilretta,2016-07-06,Flexion Therapeutics Adds Three New Executives In Key Roles To Support The Planned Commercial Launch Of Zilretta™
FLXN,Zilretta,2016-05-26,Flexion Therapeutics Receives Positive Guidance From FDA On New Drug Application (NDA) Submission For Zilretta™ For Osteoarthritis Of The Knee
FLXN,Zilretta,2016-04-28,Flexion Therapeutics Enrolls First Patient In Phase 2 Trial Of Zilretta™ Among Type 2 Diabetes Patients With Knee Osteoarthritis
FLXN,Zilretta,2016-04-04,Flexion Therapeutics Announces Presentation Of Results From Pivotal Phase 2b And Phase 3 Clinical Trials For Zilretta™ At Osteoarthritis Research Society International (OARSI) 2016 World Congress
FLXN,Zilretta,2016-04-01,Flexion To Present Pivotal Phase 2b And Phase 3 Results For Zilretta™ At Osteoarthritis Research Society International (OARSI) 2016 World Congress
FLXN,Zilretta,2016-02-16,Flexion Therapeutics Reports Primary Endpoint Met In Pivotal Phase 3 Trial Of Zilretta™ In Knee Osteoarthritis
FLXN,Zilretta,2015-12-01,Flexion Therapeutics Enrolls First Patient In Pharmacokinetic Study Of Zilretta™ For Osteoarthritis Of The Knee
GALE,NeuVax,2017-02-06,Galena Biopharma Reports Positive Outcome From The Data Safety Monitoring Board On The Two NeuVax™ (nelipepimut-S) Clinical Trials In Combination With Trastuzumab
GALE,NeuVax,2016-12-14,Galena Biopharma Announces The Phase 2 Clinical Trial Of NeuVax™ (nelipepimut-S) In Ductal Carcinoma In Situ (DCIS) Is Open For Enrollment And Screening Patients
GALE,NeuVax,2016-10-10,Galena Biopharma To Present NeuVax™ (nelipepimut-S) Plus Trastuzumab Interim Safety Data At The European Society For Medical Oncology (ESMO) 2016 Congress
GALE,NeuVax,2016-09-29,Galena Biopharma To Present NeuVax™ (nelipepimut-S) Interim Safety Data At The European Society For Medical Oncology (ESMO) 2016 Congress
GALE,NeuVax,2016-09-13,Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data In Ovarian And Pancreatic Cancer At The Progress In Vaccination Against Cancer (PIVAC) Conference
GALE,NeuVax,2016-06-29,Galena Biopharma Discontinues NeuVax™ (nelipepimut-S) Phase 3, PRESENT Interim Analysis Based On Independent Data Monitoring Committee Recommendation
GALE,NeuVax,2016-06-01,Galena Biopharma Receives Fast Track Designation For NeuVax™ (nelipepimut-S) PRESENT Clinical Trial
GALE,NeuVax,2016-03-29,Galena Biopharma Phase 3 PRESENT Clinical Trial With NeuVax™ (nelipepimut-S) Achieves 70th Qualifying Disease Free Survival Event
GALE,NeuVax,2016-02-08,Galena Biopharma Announces Notice Of Allowance Of U.S. Patent For NeuVax™ (nelipepimut-S)
GALE,NeuVax,2015-10-22,Galena Biopharma To Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, And The Phase 2 NeuVax(TM) Data Impact On Cancer Survivorship At Two Upcoming Medical Conferences
GALE,NeuVax,2015-09-30,Galena Biopharma Collaborates With The National Cancer Institute On A Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) In Ductal Carcinoma In Situ Patients
GALE,NeuVax,2015-08-24,Galena Biopharma Announces Independent Data Safety Monitoring Committee Recommends Reduction Of Cardiac Toxicity Monitoring For NeuVax(TM) PRESENT Trial
GALE,NeuVax,2015-04-14,Galena Biopharma Completes Over-Enrollment Of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
GALE,NeuVax,2015-03-26,Galena Biopharma Expands Patient Population In NeuVax(TM) (nelipepimut-S) And Trastuzumab Phase 2b Combination Clinical Trial In HER2 1+/2+ Patients
GALE,NeuVax,2015-02-09,Galena Biopharma Enrolls 700th Patient In NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
GALE,NeuVax,2014-12-11,Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle(TM) Results From The Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial At The 2014 San Antonio Breast Cancer Symposium (SABCS)
GALE,NeuVax,2014-12-05,Galena Biopharma To Present HER2 Screening Data From The Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial At The 2014 San Antonio Breast Cancer Symposium (SABCS)
GALE,NeuVax,2014-11-11,Galena Biopharma Doses First Patient In Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) In Combination With Herceptin(R) (trastuzumab) To Treat High-Risk HER2 3+ Or HER2 Gene-Amplified Breast Cancer Patients
GALE,NeuVax,2014-10-14,Galena Biopharma Receives Notice Of Allowance Of Improvement Patent For NeuVax(TM) (nelipepimut-S) In Japan
GTXI,Enobosarm,2016-12-08,GTx Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-11-28,Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-11-16,GTx Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-09-08,GTx Achieves Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-01-13,GTx Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence
GTXI,Enobosarm,2015-10-06,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer
GTXI,Enobosarm,2015-09-29,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2014-12-08,GTx To Present Results On Enobosarm 9mg In Women With Metastatic Breast Cancer At 2014 San Antonio Breast Cancer Symposium
GTXI,Enobosarm,2014-06-02,GTx Reports Positive Clinical Data From Open Label Phase 2 Study Of Enobosarm In Patients With Androgen And Estrogen Receptor Positive Metastatic Breast Cancer
GTXI,Enobosarm,2014-05-19,GTx To Present Clinical Data On Enobosarm In Breast Cancer And NSCLC At ASCO 2014 Annual Meeting
GTXI,Enobosarm,2013-12-12,GTx Presents On Enobosarm As Targeted Therapy For The Treatment Of Androgen Receptor-Positive Breast Cancer At The San Antonio Breast Cancer Symposium
GTXI,Enobosarm,2013-10-24,GTx Presents Results From Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer At 15th World Conference On Lung Cancer
GTXI,Enobosarm,2013-09-24,GTx Announces Late Breaker Presentation On Results From The Two Phase 3 POWER Trials Of Enobosarm, A Selective Androgen Receptor Modulator (SARM), For The Prevention And Treatment Of Muscle Wasting In NSCLC Patients During 2013 European Cancer Congress
GTXI,Enobosarm,2013-08-19,GTx: Survival Spin Job Follows Enobosarm Study Flop
GTXI,Enobosarm,2013-08-19,GTx Reports Results For Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
GTXI,Enobosarm,2013-06-28,GTx Presents On Enobosarm For The Prevention And Treatment Of Muscle Wasting In Cancer Patients At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
GTXI,Enobosarm,2013-06-24,GTx Announces Symposium And Presentation Of Scientific Poster Presentations On Enobosarm At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
GTXI,Enobosarm,2013-03-14,Enobosarm Phase 2 Trial For Muscle Wasting And Physical Function In Patients With Cancer Published In The Lancet Oncology
GTXI,Enobosarm,2013-01-08,GTx Announces FDA&#8217;s Grant Of Fast Track Designation To Enobosarm For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
GTXI,Enobosarm,2012-12-17,GTx Attains Enrollment Goal For Its Enobosarm POWER 1 And POWER 2 Phase III Clinical Studies
GTXI,Enobosarm,2012-10-29,GTx's Phase III Clinical Development Of Enobosarm (GTx-024) For Muscle Wasting In Lung Cancer Patients On Course Following Planned Safety Review
GTXI,Enobosarm,2012-10-08,GTx To Present Scientific Poster Presentations On Enobosarm To Prevent And Treat Muscle Wasting In Cancer Patients
GTXI,Enobosarm,2012-06-26,GTx Announces Presentations On The Effect Of Enobosarm On Improving Physical Function In Cancer Patients
GTXI,Enobosarm,2012-06-25,GTx Announces Presentation On Enobosarm&#8217;s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels
GTXI,Enobosarm,2012-06-13,GTx Announces Poster Presentation On The Prevalence And Impact Of Hypogonadism In Cancer Patients With Muscle Wasting From Its Phase IIb Enobosarm Clinical Trial At The Endocrine Society&#8217;s 2012 Annual Meeting
GTXI,Enobosarm,2016-12-08,GTx Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-11-28,Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-11-16,GTx Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-09-08,GTx Achieves Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-01-13,GTx Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence
GTXI,Enobosarm,2015-10-06,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer
GTXI,Enobosarm,2015-09-29,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2014-12-08,GTx To Present Results On Enobosarm 9mg In Women With Metastatic Breast Cancer At 2014 San Antonio Breast Cancer Symposium
GTXI,Enobosarm,2014-06-02,GTx Reports Positive Clinical Data From Open Label Phase 2 Study Of Enobosarm In Patients With Androgen And Estrogen Receptor Positive Metastatic Breast Cancer
GTXI,Enobosarm,2014-05-19,GTx To Present Clinical Data On Enobosarm In Breast Cancer And NSCLC At ASCO 2014 Annual Meeting
GTXI,Enobosarm,2013-12-12,GTx Presents On Enobosarm As Targeted Therapy For The Treatment Of Androgen Receptor-Positive Breast Cancer At The San Antonio Breast Cancer Symposium
GTXI,Enobosarm,2013-10-24,GTx Presents Results From Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer At 15th World Conference On Lung Cancer
GTXI,Enobosarm,2013-09-24,GTx Announces Late Breaker Presentation On Results From The Two Phase 3 POWER Trials Of Enobosarm, A Selective Androgen Receptor Modulator (SARM), For The Prevention And Treatment Of Muscle Wasting In NSCLC Patients During 2013 European Cancer Congress
GTXI,Enobosarm,2013-08-19,GTx: Survival Spin Job Follows Enobosarm Study Flop
GTXI,Enobosarm,2013-08-19,GTx Reports Results For Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
GTXI,Enobosarm,2013-06-28,GTx Presents On Enobosarm For The Prevention And Treatment Of Muscle Wasting In Cancer Patients At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
GTXI,Enobosarm,2013-06-24,GTx Announces Symposium And Presentation Of Scientific Poster Presentations On Enobosarm At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
GTXI,Enobosarm,2013-03-14,Enobosarm Phase 2 Trial For Muscle Wasting And Physical Function In Patients With Cancer Published In The Lancet Oncology
GTXI,Enobosarm,2013-01-08,GTx Announces FDA&#8217;s Grant Of Fast Track Designation To Enobosarm For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
GTXI,Enobosarm,2012-12-17,GTx Attains Enrollment Goal For Its Enobosarm POWER 1 And POWER 2 Phase III Clinical Studies
GTXI,Enobosarm,2012-10-29,GTx's Phase III Clinical Development Of Enobosarm (GTx-024) For Muscle Wasting In Lung Cancer Patients On Course Following Planned Safety Review
GTXI,Enobosarm,2012-10-08,GTx To Present Scientific Poster Presentations On Enobosarm To Prevent And Treat Muscle Wasting In Cancer Patients
GTXI,Enobosarm,2012-06-26,GTx Announces Presentations On The Effect Of Enobosarm On Improving Physical Function In Cancer Patients
GTXI,Enobosarm,2012-06-25,GTx Announces Presentation On Enobosarm&#8217;s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels
GTXI,Enobosarm,2012-06-13,GTx Announces Poster Presentation On The Prevalence And Impact Of Hypogonadism In Cancer Patients With Muscle Wasting From Its Phase IIb Enobosarm Clinical Trial At The Endocrine Society&#8217;s 2012 Annual Meeting
GTXI,Enobosarm,2016-12-08,GTx Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-11-28,Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-11-16,GTx Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-09-08,GTx Achieves Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-01-13,GTx Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence
GTXI,Enobosarm,2015-10-06,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer
GTXI,Enobosarm,2015-09-29,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2014-12-08,GTx To Present Results On Enobosarm 9mg In Women With Metastatic Breast Cancer At 2014 San Antonio Breast Cancer Symposium
GTXI,Enobosarm,2014-06-02,GTx Reports Positive Clinical Data From Open Label Phase 2 Study Of Enobosarm In Patients With Androgen And Estrogen Receptor Positive Metastatic Breast Cancer
GTXI,Enobosarm,2014-05-19,GTx To Present Clinical Data On Enobosarm In Breast Cancer And NSCLC At ASCO 2014 Annual Meeting
GTXI,Enobosarm,2013-12-12,GTx Presents On Enobosarm As Targeted Therapy For The Treatment Of Androgen Receptor-Positive Breast Cancer At The San Antonio Breast Cancer Symposium
GTXI,Enobosarm,2013-10-24,GTx Presents Results From Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer At 15th World Conference On Lung Cancer
GTXI,Enobosarm,2013-09-24,GTx Announces Late Breaker Presentation On Results From The Two Phase 3 POWER Trials Of Enobosarm, A Selective Androgen Receptor Modulator (SARM), For The Prevention And Treatment Of Muscle Wasting In NSCLC Patients During 2013 European Cancer Congress
GTXI,Enobosarm,2013-08-19,GTx: Survival Spin Job Follows Enobosarm Study Flop
GTXI,Enobosarm,2013-08-19,GTx Reports Results For Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
GTXI,Enobosarm,2013-06-28,GTx Presents On Enobosarm For The Prevention And Treatment Of Muscle Wasting In Cancer Patients At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
GTXI,Enobosarm,2013-06-24,GTx Announces Symposium And Presentation Of Scientific Poster Presentations On Enobosarm At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
GTXI,Enobosarm,2013-03-14,Enobosarm Phase 2 Trial For Muscle Wasting And Physical Function In Patients With Cancer Published In The Lancet Oncology
GTXI,Enobosarm,2013-01-08,GTx Announces FDA&#8217;s Grant Of Fast Track Designation To Enobosarm For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
GTXI,Enobosarm,2012-12-17,GTx Attains Enrollment Goal For Its Enobosarm POWER 1 And POWER 2 Phase III Clinical Studies
GTXI,Enobosarm,2012-10-29,GTx's Phase III Clinical Development Of Enobosarm (GTx-024) For Muscle Wasting In Lung Cancer Patients On Course Following Planned Safety Review
GTXI,Enobosarm,2012-10-08,GTx To Present Scientific Poster Presentations On Enobosarm To Prevent And Treat Muscle Wasting In Cancer Patients
GTXI,Enobosarm,2012-06-26,GTx Announces Presentations On The Effect Of Enobosarm On Improving Physical Function In Cancer Patients
GTXI,Enobosarm,2012-06-25,GTx Announces Presentation On Enobosarm&#8217;s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels
GTXI,Enobosarm,2012-06-13,GTx Announces Poster Presentation On The Prevalence And Impact Of Hypogonadism In Cancer Patients With Muscle Wasting From Its Phase IIb Enobosarm Clinical Trial At The Endocrine Society&#8217;s 2012 Annual Meeting
GTXI,Enobosarm,2016-12-08,GTx Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-11-28,Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-11-16,GTx Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-09-08,GTx Achieves Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2016-01-13,GTx Announces Initiation Of Phase 2 Clinical Trial Of Enobosarm In Stress Urinary Incontinence
GTXI,Enobosarm,2015-10-06,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In Triple Negative Breast Cancer
GTXI,Enobosarm,2015-09-29,GTx Announces Enrollment Of First Patient In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer
GTXI,Enobosarm,2014-12-08,GTx To Present Results On Enobosarm 9mg In Women With Metastatic Breast Cancer At 2014 San Antonio Breast Cancer Symposium
GTXI,Enobosarm,2014-06-02,GTx Reports Positive Clinical Data From Open Label Phase 2 Study Of Enobosarm In Patients With Androgen And Estrogen Receptor Positive Metastatic Breast Cancer
GTXI,Enobosarm,2014-05-19,GTx To Present Clinical Data On Enobosarm In Breast Cancer And NSCLC At ASCO 2014 Annual Meeting
GTXI,Enobosarm,2013-12-12,GTx Presents On Enobosarm As Targeted Therapy For The Treatment Of Androgen Receptor-Positive Breast Cancer At The San Antonio Breast Cancer Symposium
GTXI,Enobosarm,2013-10-24,GTx Presents Results From Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer At 15th World Conference On Lung Cancer
GTXI,Enobosarm,2013-09-24,GTx Announces Late Breaker Presentation On Results From The Two Phase 3 POWER Trials Of Enobosarm, A Selective Androgen Receptor Modulator (SARM), For The Prevention And Treatment Of Muscle Wasting In NSCLC Patients During 2013 European Cancer Congress
GTXI,Enobosarm,2013-08-19,GTx: Survival Spin Job Follows Enobosarm Study Flop
GTXI,Enobosarm,2013-08-19,GTx Reports Results For Enobosarm POWER Trials For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
GTXI,Enobosarm,2013-06-28,GTx Presents On Enobosarm For The Prevention And Treatment Of Muscle Wasting In Cancer Patients At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
GTXI,Enobosarm,2013-06-24,GTx Announces Symposium And Presentation Of Scientific Poster Presentations On Enobosarm At The 2013 MASCC/ISOO International Symposium On Supportive Care In Cancer
GTXI,Enobosarm,2013-03-14,Enobosarm Phase 2 Trial For Muscle Wasting And Physical Function In Patients With Cancer Published In The Lancet Oncology
GTXI,Enobosarm,2013-01-08,GTx Announces FDA&#8217;s Grant Of Fast Track Designation To Enobosarm For The Prevention And Treatment Of Muscle Wasting In Patients With Non-Small Cell Lung Cancer
GTXI,Enobosarm,2012-12-17,GTx Attains Enrollment Goal For Its Enobosarm POWER 1 And POWER 2 Phase III Clinical Studies
GTXI,Enobosarm,2012-10-29,GTx's Phase III Clinical Development Of Enobosarm (GTx-024) For Muscle Wasting In Lung Cancer Patients On Course Following Planned Safety Review
GTXI,Enobosarm,2012-10-08,GTx To Present Scientific Poster Presentations On Enobosarm To Prevent And Treat Muscle Wasting In Cancer Patients
GTXI,Enobosarm,2012-06-26,GTx Announces Presentations On The Effect Of Enobosarm On Improving Physical Function In Cancer Patients
GTXI,Enobosarm,2012-06-25,GTx Announces Presentation On Enobosarm&#8217;s Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels
GTXI,Enobosarm,2012-06-13,GTx Announces Poster Presentation On The Prevalence And Impact Of Hypogonadism In Cancer Patients With Muscle Wasting From Its Phase IIb Enobosarm Clinical Trial At The Endocrine Society&#8217;s 2012 Annual Meeting
GWPH,Epidiolex,2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
GWPH,Epidiolex,2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
GWPH,Epidiolex,2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
GWPH,Epidiolex,2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
GWPH,Epidiolex,2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
GWPH,Epidiolex,2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
GWPH,Epidiolex,2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
GWPH,Epidiolex,2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
GWPH,Epidiolex,2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
GWPH,Epidiolex,2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
GWPH,Epidiolex,2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-05,GW Announces New Epidiolex® (CBD) Positive Phase 3 Data In Dravet Syndrome And Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-12-01,GW Pharmaceuticals Plc Announces Epidiolex® (cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting
GWPH,Epidiolex,2016-09-26,GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-27,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results For Epidiolex® (cannabidiol) In The Treatment Of Lennox-Gastaut Syndrome
GWPH,Epidiolex,2016-06-21,GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol Or CBD) Development Program In Infantile Spasms (IS)
GWPH,Epidiolex,2016-03-14,GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results For Epidiolex® (cannabidiol)
GWPH,Epidiolex,2015-12-24,The Lancet Neurology Publishes Data From The Epidiolex® Expanded Access Program In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-12-07,GW Pharmaceuticals Announces New Physician Reports Of Epidiolex(R) Treatment Effect In Children And Young Adults With Treatment-Resistant Epilepsy
GWPH,Epidiolex,2015-11-25,New Epidiolex(R) (CBD) Data Accepted For Presentation At The 69th Annual Meeting Of The American Epilepsy Society
GWPH,Epidiolex,2015-10-27,GW Pharmaceuticals And The Government Of New South Wales Announce A Strategic Agreement To Study Epidiolex(R) And CBDV In A Clinical Trial And Research Program For Children With Epilepsy
GWPH,Epidiolex,2015-06-11,GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Epidiolex,2015-05-11,GW Pharmaceuticals Initiates Phase 3 Pivotal Study Of Epidiolex(R) (CBD) In Lennox-Gastaut Syndrome
GWPH,Sativex,2015-10-27,GW Pharmaceuticals And Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials
GWPH,Sativex,2015-10-27,GW Pharmaceuticals And Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials
GWPH,Sativex,2015-10-27,GW Pharmaceuticals And Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials
HALO,PEGPH20,2017-02-13,MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 With Halozyme PEGPH20
HALO,PEGPH20,2016-11-10,Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types
HALO,PEGPH20,2016-10-04,PEGPH20 Selected For Inclusion In Groundbreaking Clinical Trial Initiative Designed To Transform Outcomes For Pancreatic Cancer Patients
HALO,PEGPH20,2016-07-26,Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20
HALO,PEGPH20,2016-07-25,Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA
HALO,PEGPH20,2016-06-04,Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
HALO,PEGPH20,2016-03-16,Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine
HALO,PEGPH20,2015-11-05,First Patient Dosed In Clinical Trial Of Halozyme Investigational Drug PEGPH20 In Combination With Merck Immuno-oncology Drug KEYTRUDA
HALO,PEGPH20,2015-08-06,UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery
HALO,PEGPH20,2015-05-31,Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients
HALO,PEGPH20,2015-02-17,Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics
HALO,PEGPH20,2014-10-09,Halozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences
HALO,PEGPH20,2014-10-07,Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20
HALO,PEGPH20,2014-09-18,SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer
HALO,PEGPH20,2014-09-03,Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation
HALO,PEGPH20,2014-07-22,Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
HALO,PEGPH20,2014-06-04,Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer
HRTX,HTX-019,2015-05-14,Heron Therapeutics Announces Positive Outcome From Meeting With FDA For HTX-019
HTBX,HS-410,2017-02-17,Heat Biologics Presents Immune Data On Its HS-410 Phase 2 Bladder Cancer Trial At The Genitourinary Cancers Symposium
HTBX,HS-410,2016-11-30,Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
HTBX,HS-410,2016-11-16,Heat Biologics To Present Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
HTBX,HS-410,2016-02-25,Heat Biologics Provides Update On Its HS-410 Phase 2 Monotherapy Bladder Cancer Trial Arm
HTBX,HS-410,2016-02-03,Heat Biologics Reports Update On Its HS-410 Phase 2 Bladder Cancer Trial
HTBX,HS-410,2016-01-26,Heat Biologics CSO To Present Interim Results From The Monotherapy Arm In Its Ongoing HS-410 Phase 2 Bladder Cancer Trial At The Phacilitate Immunotherapy World Conference
HTBX,HS-410,2015-11-06,Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
HTBX,HS-410,2015-11-03,Results Of Heat Biologics' HS-410 Phase 1 Safety Trial In Non-Muscle Invasive Bladder Cancer To Be Presented At SITC Annual Meeting
HTBX,HS-410,2015-10-08,Heat Biologics Completes Patient Enrollment For Randomized Arms Of Its Phase 2 HS-410 Bladder Cancer Trial
HTBX,HS-410,2015-03-09,Heat Biologics, Inc. Receives US FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer
HTBX,HS-410,2015-01-26,Heat Biologics, Inc. Presents Positive Immunological Data On HS-410 In Non-Muscle Invasive Bladder Cancer At The 7th Annual Phacilitate Immunotherapy Forum 2015
HTBX,HS-410,2017-02-17,Heat Biologics Presents Immune Data On Its HS-410 Phase 2 Bladder Cancer Trial At The Genitourinary Cancers Symposium
HTBX,HS-410,2016-11-30,Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
HTBX,HS-410,2016-11-16,Heat Biologics To Present Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
HTBX,HS-410,2016-02-25,Heat Biologics Provides Update On Its HS-410 Phase 2 Monotherapy Bladder Cancer Trial Arm
HTBX,HS-410,2016-02-03,Heat Biologics Reports Update On Its HS-410 Phase 2 Bladder Cancer Trial
HTBX,HS-410,2016-01-26,Heat Biologics CSO To Present Interim Results From The Monotherapy Arm In Its Ongoing HS-410 Phase 2 Bladder Cancer Trial At The Phacilitate Immunotherapy World Conference
HTBX,HS-410,2015-11-06,Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
HTBX,HS-410,2015-11-03,Results Of Heat Biologics' HS-410 Phase 1 Safety Trial In Non-Muscle Invasive Bladder Cancer To Be Presented At SITC Annual Meeting
HTBX,HS-410,2015-10-08,Heat Biologics Completes Patient Enrollment For Randomized Arms Of Its Phase 2 HS-410 Bladder Cancer Trial
HTBX,HS-410,2015-03-09,Heat Biologics, Inc. Receives US FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer
HTBX,HS-410,2015-01-26,Heat Biologics, Inc. Presents Positive Immunological Data On HS-410 In Non-Muscle Invasive Bladder Cancer At The 7th Annual Phacilitate Immunotherapy Forum 2015
HTBX,HS-110,2017-03-21,Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results In Patients Treated With HS-110 In Combination With A Checkpoint Inhibitor
HTBX,HS-110,2016-12-06,Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
HTBX,HS-110,2016-11-17,Heat Biologics To Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results At The International Society For The Study Of Lung Cancer Annual Meeting
HTBX,HS-110,2016-06-06,Heat Biologics Presents A Poster On Its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial At ASCO Annual Meeting
HTBX,HS-110,2015-09-01,Heat Biologics Announces Clinical Trial Combining HS-110 And PD-1 Checkpoint Inhibitor In NSCLC
HTBX,HS-110,2015-05-29,Heat Biologics, Inc. To Present Interim Immune Response Data From Ongoing Phase II Trial With HS-110 In Advanced NSCLC At ASCO
HTBX,HS-110,2015-05-11,CORRECTING And REPLACING -- Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
HTBX,HS-110,2015-05-11,Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
HTBX,HS-110,2017-03-21,Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results In Patients Treated With HS-110 In Combination With A Checkpoint Inhibitor
HTBX,HS-110,2016-12-06,Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
HTBX,HS-110,2016-11-17,Heat Biologics To Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results At The International Society For The Study Of Lung Cancer Annual Meeting
HTBX,HS-110,2016-06-06,Heat Biologics Presents A Poster On Its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial At ASCO Annual Meeting
HTBX,HS-110,2015-09-01,Heat Biologics Announces Clinical Trial Combining HS-110 And PD-1 Checkpoint Inhibitor In NSCLC
HTBX,HS-110,2015-05-29,Heat Biologics, Inc. To Present Interim Immune Response Data From Ongoing Phase II Trial With HS-110 In Advanced NSCLC At ASCO
HTBX,HS-110,2015-05-11,CORRECTING And REPLACING -- Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
HTBX,HS-110,2015-05-11,Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
HZNP,ACTIMMUNE,2016-12-08,Horizon Pharma Plc Announces Topline Results From Phase 3 Study Of  ACTIMMUNE® (interferon Gamma-1b) In Friedreich's Ataxia
IDRA,IMO-2125,2017-02-24,Idera Pharmaceuticals Presents Update From Ongoing Phase 1 Dose Escalation Clinical Trial Of Intratumoral IMO-2125 In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment At The 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
IDRA,IMO-2125,2016-11-11,Idera Pharmaceuticals Reports Translational Data Supporting The Mechanism Of Action Of Intratumoral IMO-2125 From Ongoing Phase 1 Dose Escalation In Clinical Trial In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment
IDRA,IMO-2125,2016-11-09,Idera Pharmaceuticals To Provide Multiple Presentations On Intratumoral IMO-2125 At The 2016 Society For Immunotherapy Of Cancer (SITC) Annual Meeting
IDRA,IMO-2125,2016-09-26,Idera Pharmaceuticals Reports Promising Data From Ongoing Phase 1 Dose Escalation In Clinical Trial Of Intra-tumoral IMO-2125 In Combination With Ipilimumab In Patients With PD-1 Refractory Metastatic Melanoma
IDRA,IMO-2125,2016-04-19,Idera Presents Preclinical Data Demonstrating Enhanced Systemic Anti-Tumor Activity From Combination Treatment With Intra-tumoral IMO-2125 And IDO-1 Inhibitor At AACR Annual Meeting 2016
IDRA,IMO-2125,2015-12-14,Idera Pharmaceuticals Announces Initiation Of Phase 1/2 Clinical Trial Of Intra-tumoral IMO-2125 In Combination With Ipilimumab In Patients With Metastatic Melanoma
IDRA,IMO-2125,2015-11-05,Idera Pharmaceuticals Presents Preclinical Data Demonstrating Potent Anti-Tumor Response From Combination Treatment With Intra-Tumoral IMO-2125 And Anti-PD-1 Monoclonal Antibody At AACR-NCI-EORTC International Conference
IDRA,IMO-2125,2015-09-16,Idera Pharmaceuticals Presents New Intratumoral IMO-2125 Preclinical Data At CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference
IMGN,Kadcyla,2015-03-31,Immunogen (IMGN) Stock Gains Today After Selling Kadcyla Royalty Rights for $200 Million
INCY,Ruxolitinib,2016-12-30,Incyte Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi®) In Graft-versus-Host Disease
INCY,Ruxolitinib,2016-12-04,Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi® (ruxolitinib)
INCY,Ruxolitinib,2016-09-27,NCCN Guidelines® Recommend Jakafi® (ruxolitinib) For The Treatment Of Myelofibrosis
INCY,Ruxolitinib,2016-06-23,FDA Grants Breakthrough Therapy Designation For Incyte's Ruxolitinib (Jakafi®) In Acute Graft-Versus-Host Disease (GVHD)
INCY,Ruxolitinib,2016-06-10,New Phase 3 Data Show Jakafi® (ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)
INCY,Ruxolitinib,2016-06-06,Five-year Results From Phase 3 Study Of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF)
INCY,Ruxolitinib,2016-05-19,Incyte Highlights Jakafi® (ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And EHA Annual Meetings
INCY,Ruxolitinib,2016-04-06,Incyte Acquires Rights From Lilly To Develop And Commercialize Ruxolitinib (Jakafi®) For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)
INCY,Ruxolitinib,2016-02-11,Incyte Announces Decision To Discontinue JANUS Studies Of Ruxolitinib Plus Capecitabine In Patients With Advanced Or Metastatic Pancreatic Cancer
INCY,Ruxolitinib,2016-01-27,Incyte Announces Decision To Stop Phase 2 Sub-study Of Ruxolitinib Plus Regorafenib In Patients With Metastatic Colorectal Cancer And High CRP
INCY,Ruxolitinib,2015-12-05,Two Phase 3 Studies Reinforce Sustained Benefits Of Treatment With Jakafi® (ruxolitinib) In Patients With Myeloproliferative Neoplasms (MPNs)
INCY,Ruxolitinib,2015-12-05,Phase 3 RESPONSE-2 Study Of Jakafi® (ruxolitinib) Meets Primary Endpoint
INCY,Ruxolitinib,2015-11-30,Incyte's Jakafi® (ruxolitinib) To Be Featured In Over 60 Abstracts At ASH Annual Meeting
INCY,Ruxolitinib,2016-12-30,Incyte Announces First Patient Treated In Pivotal Clinical Trial Program For Ruxolitinib (Jakafi®) In Graft-versus-Host Disease
INCY,Ruxolitinib,2016-12-04,Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi® (ruxolitinib)
INCY,Ruxolitinib,2016-09-27,NCCN Guidelines® Recommend Jakafi® (ruxolitinib) For The Treatment Of Myelofibrosis
INCY,Ruxolitinib,2016-06-23,FDA Grants Breakthrough Therapy Designation For Incyte's Ruxolitinib (Jakafi®) In Acute Graft-Versus-Host Disease (GVHD)
INCY,Ruxolitinib,2016-06-10,New Phase 3 Data Show Jakafi® (ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)
INCY,Ruxolitinib,2016-06-06,Five-year Results From Phase 3 Study Of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF)
INCY,Ruxolitinib,2016-05-19,Incyte Highlights Jakafi® (ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And EHA Annual Meetings
INCY,Ruxolitinib,2016-04-06,Incyte Acquires Rights From Lilly To Develop And Commercialize Ruxolitinib (Jakafi®) For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)
INCY,Ruxolitinib,2016-02-11,Incyte Announces Decision To Discontinue JANUS Studies Of Ruxolitinib Plus Capecitabine In Patients With Advanced Or Metastatic Pancreatic Cancer
INCY,Ruxolitinib,2016-01-27,Incyte Announces Decision To Stop Phase 2 Sub-study Of Ruxolitinib Plus Regorafenib In Patients With Metastatic Colorectal Cancer And High CRP
INCY,Ruxolitinib,2015-12-05,Two Phase 3 Studies Reinforce Sustained Benefits Of Treatment With Jakafi® (ruxolitinib) In Patients With Myeloproliferative Neoplasms (MPNs)
INCY,Ruxolitinib,2015-12-05,Phase 3 RESPONSE-2 Study Of Jakafi® (ruxolitinib) Meets Primary Endpoint
INCY,Ruxolitinib,2015-11-30,Incyte's Jakafi® (ruxolitinib) To Be Featured In Over 60 Abstracts At ASH Annual Meeting
INSY,Buprenorphine,2016-08-24,Insys Therapeutics Reports Phase 3 Trial Of Sublingual Buprenorphine Spray Met Primary Endpoint In Patients With Moderate-to-Severe Postoperative Pain After Bunionectomy
IRWD,Linaclotide,2017-01-29,Astellas And Ironwood Report Positive Top-Line Results From Phase III Linaclotide Trial For Patients With Chronic Constipation Conducted In Japan
IRWD,Linaclotide,2016-12-22,Ironwood And Allergan Report Topline Phase IIb Data Supporting Advancement Of Linaclotide Colonic Release-1 (CR1) In IBS-C
IRWD,Linaclotide,2016-12-22,Ironwood And Allergan Report Topline Phase IIb Data Supporting Further Investigation Of Linaclotide Colonic Release-2 (CR2) For Abdominal Pain In Non-Constipation Subtypes Of IBS
IRWD,Linaclotide,2016-12-19,Ironwood Pharmaceuticals Announces Approval Of LINZESS® (linaclotide) In Japan For The Treatment Of Adults With IBS-C
IRWD,Linaclotide,2016-05-17,Ironwood Pharmaceuticals To Present Linaclotide Data At Digestive Disease Week® 2016
IRWD,Linaclotide,2016-02-29,Updated 2016 Direct-to-Consumer Awareness Campaign For LINZESS® (linaclotide)
IRWD,Linaclotide,2016-02-24,Ironwood Pharmaceuticals Announces Filing By Astellas Of New Drug Application In Japan With Linaclotide For The Treatment Of Adults With IBS-C
IRWD,Linaclotide,2015-11-30,Ironwood Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation
IRWD,Linaclotide,2015-11-02,Ironwood And Allergan Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation
IRWD,Linaclotide,2015-10-27,Allergan Acquires Rights To Ironwood's CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countries
IRWD,Linaclotide,2015-10-13,Ironwood Reports Positive Top-Line Results From Phase III Trial Of 72 Mcg Linaclotide In Adults With Chronic Idiopathic Constipation
IRWD,Linaclotide,2015-07-08,AstraZeneca And Ironwood Report Positive Top-Line Data From Phase III IBS-C Trial Designed To Support Linaclotide Approval In China
IRWD,Linaclotide,2014-11-20,Ironwood Earns $15 Million Milestone From Astellas Upon Initiation Of Enrollment In Linaclotide Phase III IBS-C Clinical Trial In Japan
IRWD,Linaclotide,2014-11-04,Ironwood Pharmaceuticals Initiates Phase III Trial Of 72 Mcg Linaclotide In Adult Patients With Chronic Idiopathic Constipation
IRWD,Linaclotide,2014-10-16,Ironwood Pharmaceuticals Announces Initiation Of Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation
IRWD,Linaclotide,2014-10-09,Ironwood And Actavis To Present Linaclotide Data At The American College Of Gastroenterology 2014 Annual Scientific Meeting
IRWD,Linaclotide,2014-05-01,Ironwood And Forest To Present Linaclotide Data At Digestive Disease Week&#174; 2014
ITCI,ITI-007-302,2016-06-30,Intra-Cellular Therapies Reports Completion Of Enrollment Of ITI-007-302 Phase 3 Clinical Trial For The Treatment Of Schizophrenia
ITCI,ITI-007-302,2015-06-23,Intra-Cellular Therapies Reports Initiation Of Randomization For ITI-007-302 Phase 3 Trial In Schizophrenia
ITEK,Trabodenoson,2017-02-24,Inotek Pharmaceuticals Announces Poster Presentations On Trabodenoson At The American Glaucoma Society 2017 Annual Meeting
ITEK,Trabodenoson,2017-01-03,Inotek Announces Top-line Results For MATrX-1, First Phase 3 Trial Of Trabodenoson For Glaucoma
ITEK,Trabodenoson,2016-08-24,Inotek Pharmaceuticals Announces The Completion Of The Recruitment Phase Of MATrX-1, The First Phase 3 Clinical Trial Of Trabodenoson For Glaucoma
ITEK,Trabodenoson,2016-07-12,Inotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial Of A Fixed-Dose Combination Of Trabodenoson, A Novel Treatment For Glaucoma, And Latanoprost
ITEK,Trabodenoson,2016-04-26,Inotek Pharmaceuticals Announces Poster Presentations On Trabodenoson At The ARVO 2016 Annual Meeting
ITEK,Trabodenoson,2016-04-21,Inotek Pharmaceuticals Corporation Announces Publication Of Phase 1 Data For Trabodenoson In Healthy Adult Volunteers In The Journal Of Ocular Pharmacology And Therapeutics
ITEK,Trabodenoson,2016-04-11,Inotek Pharmaceuticals Announces The Journal Of Ocular Pharmacology And Therapeutics Has Published Its Phase 2 Data For Trabodenoson In Patients With Glaucoma And Ocular Hypertension
ITEK,Trabodenoson,2016-03-09,Inotek Pharmaceuticals Strengthens Patent Estate For Lead Product Candidate Trabodenoson
ITEK,Trabodenoson,2015-10-16,Inotek Pharmaceuticals Initiates Dosing Of MATRx-1, The First Pivotal Phase 3 Clinical Trial Of Trabodenoson, A Novel Treatment For Glaucoma
ITEK,Trabodenoson,2015-07-23,Inotek Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA And Phase 3 Development Strategy For Trabodenoson, A Novel Treatment For Glaucoma
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KTOV,KIT-302,2017-03-08,Kitov Announces License Agreement For KIT-302 In South Korea
KTOV,KIT-302,2017-02-01,Kitov Granted Notice Of Allowance From U.S. Patent & Trademark Office For KIT-302
KTOV,KIT-302,2016-12-07,Kitov Successfully Completes All KIT-302 Testing Required For New Drug Application To U.S. FDA
KTOV,KIT-302,2016-09-27,Kitov Reports Successful Results For Additional KIT-302 Pharmacokinetic Bioequivalence Study
KTOV,KIT-302,2016-09-06,Kitov Pharmaceuticals To Present Data From A U.S. Market Assessment For KIT-302
KTOV,KIT-302,2016-08-10,Kitov Announces Issuance Of U.S. Patent Securing Long-Term Exclusivity For KIT-302 Ahead Of New Drug Application To The FDA
KTOV,KIT-302,2016-06-28,Kitov's Lead Drug KIT-302 Achieves Manufacturing Milestone Ahead Of Planned NDA Filing With U.S. FDA
KTOV,KIT-302,2016-06-24,Kitov Reports New Data Demonstrating KIT-302 Has Beneficial Effects On Kidney Function
KTOV,KIT-302,2016-05-27,Kitov Announces Completion Of Manufacturing Pivotal Batches Of KIT-302 Required For Registration In The U.S.
KTOV,KIT-302,2016-05-12,Kitov Granted Notice Of Allowance From U.S. Patent Office For KIT-302
KTOV,KIT-302,2016-05-12,Kitov Receives Pre-NDA Meeting Response From FDA For KIT-302, Supporting Its NDA Submission
KTOV,KIT-302,2016-05-10,Kitov Reports KIT-302 Study Successfully Meets U.S. Food & Drug Administration Bioequivalence Standards
KTOV,KIT-302,2015-12-17,Kitov Pharmaceuticals Reports Additional Data From Its Phase III Trial On The Beneficial Blood Pressure Effects Of KIT-302
KURA,Tipifarnib,2017-03-06,Kura Oncology Reports Updated Clinical Activity Data In Ongoing Phase 2 Trial For Tipifarnib
KURA,Tipifarnib,2017-02-27,Kura Oncology Announces Presentation Of Preliminary Clinical Data For Tipifarnib In HRAS Mutant Squamous Cell Carcinomas Of The Head And Neck At TAT 2017
KURA,Tipifarnib,2017-01-17,Kura Oncology Doses First Patient In Phase 2 Study Of Tipifarnib In Chronic Myelomonocytic Leukemia
KURA,Tipifarnib,2016-06-16,Kura Oncology Doses First Patient In Phase 2 Study Of Tipifarnib In Lower Risk Myelodysplastic Syndromes
KURA,Tipifarnib,2015-12-03,Kura Oncology Announces Data Presentation On Lead Product Candidate Tipifarnib At The Upcoming ASH Meeting
KURA,Tipifarnib,2015-11-30,Kura Oncology Announces First Patient Dosed In An Investigator-Sponsored Phase 2 Trial Of Tipifarnib In Patients With HRAS Mutant Urothelial Cancer
LIFE,Resolaris,2017-03-03,ATyr Pharma Receives EMA Orphan Drug Designation For The Treatment Of Limb Girdle Muscular Dystrophy With Resolaris™
LIFE,Resolaris,2017-02-28,ATyr Pharma Receives U.S. FDA Orphan Drug Designation For The Treatment Of Limb Girdle Muscular Dystrophy With Resolaris™
LIFE,Resolaris,2016-12-13,ATyr Pharma Reports Promising Signals Of Clinical Activity In Multiple Rare Genetically Distinct Myopathies With Resolaris™ In Exploratory Trials
LIFE,Resolaris,2016-10-24,ATyr Pharma Receives FDA Fast Track Designation For Resolaris™ To Treat Facioscapulohumeral Muscular Dystrophy (FSHD)
LIFE,Resolaris,2016-10-06,ATyr Pharma Presents Additional Data For Resolaris™ Phase 1b/2 Trial In Adult Patients With Facioscapulohumeral Muscular Dystrophy At The 21st International Annual Congress Of The World Muscle Society
LIFE,Resolaris,2015-09-10,ATyr Pharma Doses First Patient In Long-Term Safety Extension Study Of Resolaris™ For Treatment Of Adult Patients With FSHD
MATN,OXi4503,2017-03-15,Mateon Therapeutics Announces Initial Data From Third Cohort Of Phase 1b Study Of OXi4503 In Relapsed/Refractory AML
MATN,OXi4503,2016-12-06,Mateon Announces Presentation Of OXi4503 AML Study Data At 58th Annual Meeting Of American Society Of Hematology
MATN,OXi4503,2017-03-15,Mateon Therapeutics Announces Initial Data From Third Cohort Of Phase 1b Study Of OXi4503 In Relapsed/Refractory AML
MATN,OXi4503,2016-12-06,Mateon Announces Presentation Of OXi4503 AML Study Data At 58th Annual Meeting Of American Society Of Hematology
MATN,CA4P,2017-02-13,Mateon Therapeutics Announces Initial Pre-clinical Data On Combination Of CA4P With Checkpoint Inhibitors
MATN,CA4P,2016-10-31,Mateon Announces Presentation Of CA4P Posters At Meeting Of The International Gynecologic Cancer Society
MATN,CA4P,2017-02-13,Mateon Therapeutics Announces Initial Pre-clinical Data On Combination Of CA4P With Checkpoint Inhibitors
MATN,CA4P,2016-10-31,Mateon Announces Presentation Of CA4P Posters At Meeting Of The International Gynecologic Cancer Society
MDGN,NFC-1,2015-09-09,Medgenics Acquires Phase 2-Ready CNS Program: NFC-1
MDVN,Enzalutamide,2016-06-02,Astellas And Medivation Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer
MDVN,Enzalutamide,2016-04-07,CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI® (enzalutamide)
MDVN,Enzalutamide,2016-03-24,Pivotal Phase III Trial Of Enzalutamide Initiated In Metastatic Hormone Sensitive Prostate Cancer
MDVN,Enzalutamide,2016-02-22,FDA Accepts For Review Supplemental New Drug Application For XTANDI® (enzalutamide) Capsules In Metastatic Castration-resistant Prostate Cancer With Data From Head-to-Head Studies Of Enzalutamide Versus Bicalutamide
MDVN,Enzalutamide,2016-01-26,Journal Of Clinical Oncology Publishes Results From The STRIVE Trial Of Enzalutamide Compared To Bicalutamide In Castration-resistant Prostate Cancer
MDVN,Enzalutamide,2016-01-13,Lancet Oncology Publishes Results From The Phase 2 TERRAIN Trial Of Enzalutamide Compared To Bicalutamide In Metastatic Castration-Resistant Prostate Cancer
MDVN,Enzalutamide,2016-06-02,Astellas And Medivation Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer
MDVN,Enzalutamide,2016-04-07,CHMP Issues Positive Opinion To Include New Data In European Label For XTANDI® (enzalutamide)
MDVN,Enzalutamide,2016-03-24,Pivotal Phase III Trial Of Enzalutamide Initiated In Metastatic Hormone Sensitive Prostate Cancer
MDVN,Enzalutamide,2016-02-22,FDA Accepts For Review Supplemental New Drug Application For XTANDI® (enzalutamide) Capsules In Metastatic Castration-resistant Prostate Cancer With Data From Head-to-Head Studies Of Enzalutamide Versus Bicalutamide
MDVN,Enzalutamide,2016-01-26,Journal Of Clinical Oncology Publishes Results From The STRIVE Trial Of Enzalutamide Compared To Bicalutamide In Castration-resistant Prostate Cancer
MDVN,Enzalutamide,2016-01-13,Lancet Oncology Publishes Results From The Phase 2 TERRAIN Trial Of Enzalutamide Compared To Bicalutamide In Metastatic Castration-Resistant Prostate Cancer
MNOV,Progressive,2016-12-19,MediciNova Announces Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS Will Continue As Planned Following DSMB Review Of Interim Efficacy Analysis
MNOV,Progressive,2016-07-13,MediciNova Announces Initiation Of Interim Efficacy Analysis In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
MNOV,Progressive,2016-03-22,FDA Grants Fast Track Designation For MediciNova's MN-166 (ibudilast) For Progressive Multiple Sclerosis
MNOV,Progressive,2015-06-12,MediciNova Announces Randomization Of 255 Subjects Completed In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
MNOV,Progressive,2015-05-07,MediciNova Announces Full Enrollment In Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
MNOV,Progressive,2015-04-23,Baseline Characteristics Of 228 Subjects Enrolled In MediciNova's Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS Presented At The American Academy Of Neurology (AAN) 67th Annual Meeting
MNOV,Progressive,2015-02-01,MN-166 (ibudilast) Progressive MS Abstract Accepted For Presentation At The American Academy Of Neurology (AAN) 67th Annual Meeting In Washington, DC
MNOV,Progressive,2014-09-23,MediciNova Provides Update On Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS
MNOV,Progressive,2013-07-18,MediciNova Announces Initiation Of A Cooperative Phase 2b Trial Of MN-166 In Progressive Multiple Sclerosis
NBIX,NBI-98854,2016-05-06,Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data To Be Presented At The American Psychiatric Association's 2016 Annual Meeting In Atlanta
NBIX,NBI-98854,2016-03-02,Neurocrine Biosciences Announces The Acceptance Of Three Scientific Abstracts For Valbenazine (NBI-98854) At The 68th Annual Meeting Of The American Academy Of Neurology In Vancouver April 2016
NBIX,NBI-98854,2015-12-16,Neurocrine Announces Successful Completion Of Phase Ib T-Force Study Of VMAT2 Inhibitor NBI-98854 In Adolescents And Children With Tourette Syndrome
NBIX,NBI-98854,2015-10-20,Neurocrine Announces Initiation Of Phase II Clinical Study Of VMAT2 Inhibitor NBI-98854 In Adults With Tourette Syndrome
NBIX,NBI-98854,2015-03-31,Neurocrine Biosciences And Mitsubishi Tanabe Pharma Announce Agreement To Develop And Commercialize VMAT2 Inhibitor NBI-98854 For Movement Disorders In Japan And Other Select Asian Markets
NBIX,NBI-98854,2014-10-30,Neurocrine Biosciences Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia
NBIX,NBI-98854,2014-10-20,Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
NBIX,NBI-98854,2014-06-11,Neurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International Parkinson And Movement Disorder Society's 18th Annual Congress
NBIX,NBI-98854,2014-02-25,Neurocrine Biosciences Announces NBI-98854 Scientific Presentations At The International Parkinson And Movement Disorder Society's 18th Annual Congress
NBIX,NBI-98854,2014-01-09,Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
NDRM,ND0612H,2017-03-01,NeuroDerm Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson's Disease; Seeks Broader EU Label Based On INDiGO Trial Following EMA Meeting
NDRM,ND0612H,2016-12-22,NeuroDerm Announces Completion Of Patient Enrollment And Treatment In A Phase II Trial Of ND0612H For Advanced Parkinson's Disease
NDRM,ND0612H,2016-06-30,NeuroDerm Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson's Disease
NDRM,ND0612H,2016-06-28,NeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA® In Head-To-Head Pilot PK Comparison Trial
NDRM,ND0612H,2016-06-16,NeuroDerm To Present Design Of The First Clinical Efficacy Study Of ND0612H And Other Clinical Data At The 20th International Congress Of Parkinson's Disease And Movement Disorders
NDRM,ND0612H,2015-12-30,NeuroDerm Announces Start Of Patient Enrollment In Phase II Trial Of ND0612H For Advanced Parkinson's Disease
NDRM,ND0612H,2015-11-11,NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback On ND0612H And ND0612L For The Treatment Of Parkinson's Disease
NDRM,ND0612H,2015-06-11,NeuroDerm Announces Start Of A Pharmacokinetic, Head-To-Head Comparison Study Of ND0612H And Duodopa(R)
NDRM,ND0612H,2014-12-30,NeuroDerm Announces Topline Results Of Phase IIa Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease
NKTR,Cipro,2014-11-24,FDA Grants QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation
NKTR,Cipro,2014-11-24,FDA Grants QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation
NKTR,Cipro,2014-11-24,FDA Grants QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation
NKTR,Cipro,2014-11-24,FDA Grants QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation
NKTR,NKTR-214,2017-02-18,Clinical Data From Phase 1 Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium
NKTR,NKTR-214,2016-11-09,Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting
NKTR,NKTR-214,2016-09-27,Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214
NKTR,NKTR-214,2016-06-06,Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity
NKTR,NKTR-214,2016-04-18,Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration
NKTR,NKTR-214,2016-02-01,Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research
NKTR,NKTR-214,2015-12-08,Nektar Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
NKTR,NKTR-214,2015-10-07,Nektar Submits Investigational New Drug Application (IND) For NKTR-214 To Treat Solid Tumor Malignancies
NKTR,NKTR-214,2015-09-21,Nektar Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models
NKTR,NKTR-214,2015-06-02,Nektar And MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration For NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
NKTR,NKTR-214,2017-02-18,Clinical Data From Phase 1 Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium
NKTR,NKTR-214,2016-11-09,Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting
NKTR,NKTR-214,2016-09-27,Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214
NKTR,NKTR-214,2016-06-06,Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity
NKTR,NKTR-214,2016-04-18,Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration
NKTR,NKTR-214,2016-02-01,Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research
NKTR,NKTR-214,2015-12-08,Nektar Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
NKTR,NKTR-214,2015-10-07,Nektar Submits Investigational New Drug Application (IND) For NKTR-214 To Treat Solid Tumor Malignancies
NKTR,NKTR-214,2015-09-21,Nektar Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models
NKTR,NKTR-214,2015-06-02,Nektar And MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration For NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
NKTR,NKTR-214,2017-02-18,Clinical Data From Phase 1 Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium
NKTR,NKTR-214,2016-11-09,Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting
NKTR,NKTR-214,2016-09-27,Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214
NKTR,NKTR-214,2016-06-06,Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity
NKTR,NKTR-214,2016-04-18,Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration
NKTR,NKTR-214,2016-02-01,Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research
NKTR,NKTR-214,2015-12-08,Nektar Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
NKTR,NKTR-214,2015-10-07,Nektar Submits Investigational New Drug Application (IND) For NKTR-214 To Treat Solid Tumor Malignancies
NKTR,NKTR-214,2015-09-21,Nektar Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models
NKTR,NKTR-214,2015-06-02,Nektar And MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration For NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
NKTR,NKTR-214,2017-02-18,Clinical Data From Phase 1 Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium
NKTR,NKTR-214,2016-11-09,Nektar Therapeutics Presents New Clinical Data From Ongoing Phase 1 Dose-Escalation Study Of NKTR-214 At The Society For Immunotherapy Of Cancer (SITC) 2016 Annual Meeting
NKTR,NKTR-214,2016-09-27,Bristol-Myers Squibb And Nektar Therapeutics Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo (nivolumab) And NKTR-214
NKTR,NKTR-214,2016-06-06,Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity
NKTR,NKTR-214,2016-04-18,Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration
NKTR,NKTR-214,2016-02-01,Nektar Publishes Pre-clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research
NKTR,NKTR-214,2015-12-08,Nektar Announces First Patient Dosed In Phase 1/2 Clinical Study Of NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
NKTR,NKTR-214,2015-10-07,Nektar Submits Investigational New Drug Application (IND) For NKTR-214 To Treat Solid Tumor Malignancies
NKTR,NKTR-214,2015-09-21,Nektar Presents Data Demonstrating That NKTR-214, A CD122-Biased Immunostimulatory Cytokine, Induces Durable And Specific Anti-Tumor Immunity As A Single-Agent And When Combined With Checkpoint Inhibitors In Preclinical Models
NKTR,NKTR-214,2015-06-02,Nektar And MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration For NKTR-214, A CD122-Biased Immuno-Stimulatory Cytokine
NVAX,RSV,2017-01-19,Novavax Initiates Phase 2 Safety And Immunogenicity Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2016-09-15,Novavax Announces Topline RSV F Vaccine Data From Two Clinical Trials In Older Adults
NVAX,RSV,2016-05-25,U.S. FDA Grants Fast Track Designation To Novavax' RSV F Vaccine For Older Adults
NVAX,RSV,2015-12-14,Novavax Completes Enrollment Of Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-12-03,Novavax Initiates Global Pivotal Phase 3 Trial Of The RSV F Vaccine To Protect Infants Via Maternal Immunization
NVAX,RSV,2015-11-16,Novavax To Make Multiple Presentations At RSV Vaccines For The World
NVAX,RSV,2015-11-09,Novavax Initiates Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-10-22,Novavax Initiates Phase 2 Safety And Immunogenicity Trial To Evaluate Annual Re-Dosing Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-09-29,Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial In Pediatrics
NVAX,RSV,2015-09-29,Novavax Announces Grant Of Up To $89 Million To Support Development Of RSV F Vaccine To Protect Infants Via Maternal Immunization
NVAX,RSV,2015-09-15,Novavax RSV F Vaccine Is Highly Immunogenic With Robust Transplacental Antibody Transfer In Preclinical Maternal Immunization Model
NVAX,RSV,2015-09-10,Novavax RSV F Vaccine Clinical Trial Data In Women Of Child Bearing Age Published In The Journal Of Infectious Disease
NVAX,RSV,2017-01-19,Novavax Initiates Phase 2 Safety And Immunogenicity Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2016-09-15,Novavax Announces Topline RSV F Vaccine Data From Two Clinical Trials In Older Adults
NVAX,RSV,2016-05-25,U.S. FDA Grants Fast Track Designation To Novavax' RSV F Vaccine For Older Adults
NVAX,RSV,2015-12-14,Novavax Completes Enrollment Of Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-12-03,Novavax Initiates Global Pivotal Phase 3 Trial Of The RSV F Vaccine To Protect Infants Via Maternal Immunization
NVAX,RSV,2015-11-16,Novavax To Make Multiple Presentations At RSV Vaccines For The World
NVAX,RSV,2015-11-09,Novavax Initiates Pivotal Phase 3 Trial Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-10-22,Novavax Initiates Phase 2 Safety And Immunogenicity Trial To Evaluate Annual Re-Dosing Of The RSV F Vaccine In Older Adults
NVAX,RSV,2015-09-29,Novavax Announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial In Pediatrics
NVAX,RSV,2015-09-29,Novavax Announces Grant Of Up To $89 Million To Support Development Of RSV F Vaccine To Protect Infants Via Maternal Immunization
NVAX,RSV,2015-09-15,Novavax RSV F Vaccine Is Highly Immunogenic With Robust Transplacental Antibody Transfer In Preclinical Maternal Immunization Model
NVAX,RSV,2015-09-10,Novavax RSV F Vaccine Clinical Trial Data In Women Of Child Bearing Age Published In The Journal Of Infectious Disease
NVCR,Tumor,2017-02-15,First Patient Enrolled In Novocure's Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields For The Treatment Of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy
NVCR,Tumor,2016-12-12,Novocure Presents Second Cohort Of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel And Gemcitabine May Be Safe As First-Line Treatment And May Improve One-Year Survival Rate Of Patients With Advanced Pancreatic Cancer
NVCR,Tumor,2016-12-12,Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel May Be Safe As First-Line Treatment And May Improve Survival Of Patients With Recurrent Ovarian Cancer
NVCR,Tumor,2016-11-17,Novocure Presents Interim STELLAR Results At IASLC Suggesting Treatment With Tumor Treating Fields Plus Chemotherapy May Extend Survival Of Patients With Mesothelioma
NVCR,Tumor,2016-11-07,Novocure Announces 38 Presentations On Tumor Treating Fields At 21st Annual Scientific Meeting Of The Society Of Neuro-Oncology
NVCR,Tumor,2016-09-19,CNS Oncology Publishes Tumor Treating Fields Treatment Planning And Patient Follow-up Guidelines In Glioblastoma
NVCR,Tumor,2016-09-15,Novocure's Executive Chairman William Doyle To Present On Tumor Treating Fields At New York Academy Of Sciences' Symposium On Bioelectronic Medicine
NVCR,Tumor,2016-09-14,Two Institutions Publish Independent Data On Novocure's Tumor Treating Fields
NVCR,Tumor,2016-09-01,International Journal Of Cancer Publishes Data Showing Tumor Treating Fields In Combination With Paclitaxel Is Therapeutically Effective Against Ovarian Cancer Cells In Vitro And In Vivo
NVCR,Tumor,2016-05-23,Novocure Enrolls Last Patient In PANOVA Trial Of Tumor Treating Fields Plus Chemotherapy In Advanced Pancreatic Cancer
NVCR,Tumor,2016-05-19,Novocure Enrolls Last Patient In INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel In Recurrent Ovarian Cancer
NVCR,Tumor,2016-05-18,Novocure Announces Presentation Of Subgroup Analysis Of PANOVA Data Showing Overall Survival Benefit Of Tumor Treating Fields Plus Gemcitabine In Advanced Pancreatic Cancer Patients
NVCR,Tumor,2016-05-13,Novocure To Present New Preclinical Data Showing Additive Efficacy Of Tumor Treating Fields And PD-1 Inhibitors At The American Association Of Immunologists' Annual Meeting 2016
NVCR,Tumor,2016-05-06,Novocure Kicks Off Brain Tumor Awareness Month With New Activities To Support And Inspire Those Affected By Glioblastoma
NVCR,Tumor,2016-04-07,Novocure To Present New Preclinical Data On Tumor Treating Fields At American Association For Cancer Research Annual Meeting 2016
NVCR,Tumor,2016-01-19,Novocure Presents Phase 2 PANOVA Results At ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy May Be Safe As First-Line Treatment And Improve Survival Of Patients With Advanced Pancreatic Cancer
NVCR,Tumor,2015-12-14,New Data On Tumor Treating Fields' Anti-Mitotic Mechanism Of Action Published In Scientific Reports
NVCR,Tumor,2015-12-02,Preliminary Phase 2 Data Demonstrate Tumor Treating Fields Is Safe In Patients With Brain Metastases Originating From Non-Small Cell Lung Cancer
NVCR,Tumor,2015-11-17,Novocure Announces Webcast To Discuss New EF-14 Clinical Trial Analyses And Tumor Treating Fields Presentations From SNO 2015
NVCR,Tumor,2015-11-17,Novocure Announces 18 Presentations On Tumor Treating Fields At SNO 2015 Including New Analyses Of The EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data
OCUL,DEXTENZA,2017-03-15,New Publication Describes Positive Patient Experience In Study Of Ocular Therapeutix' DEXTENZA™ Following Cataract Surgery
OCUL,DEXTENZA,2017-02-22,Ocular Therapeutix™ Announces FDA Acceptance Of NDA Resubmission For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery
OCUL,DEXTENZA,2017-01-23,Ocular Therapeutix™ Resubmits NDA For DEXTENZA™ For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery
OCUL,DEXTENZA,2017-01-04,Ocular Therapeutix™ Announces Additional Successful Results For Phase 3 Clinical Trial Of DEXTENZA™
OCUL,DEXTENZA,2016-11-14,Ocular Therapeutix™ Announces Successful Topline Results For Both Inflammation And Pain Primary Efficacy Endpoints From Phase 3 Clinical Trial Of DEXTENZA™
OCUL,DEXTENZA,2016-08-03,Ocular Therapeutix™ Provides Update On NDA For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
OCUL,DEXTENZA,2016-07-25,Ocular Therapeutix™ Receives Complete Response Letter From FDA For Its NDA For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
OCUL,DEXTENZA,2016-06-06,Ocular Therapeutix™ Announces Topline Results Of Second Phase 3 Clinical Trial Of DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
OCUL,DEXTENZA,2015-12-14,Ocular Therapeutix™ Announces Encouraging Top-Line Results From Exploratory Phase 2 Trial For DEXTENZA™ In Patients With Inflammatory Dry Eye Disease
OCUL,DEXTENZA,2015-12-09,Ocular Therapeutix™ Announces FDA Acceptance Of NDA Filing For DEXTENZA™ For The Treatment Of Post-Surgical Ocular Pain
OCUL,DEXTENZA,2015-11-24,Ocular Therapeutix™ Begins Enrollment In Its Second Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
OCUL,DEXTENZA,2015-10-22,Ocular Therapeutix™ Announces Topline Results Of Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
OCUL,DEXTENZA,2015-10-14,Ocular Therapeutix™ Begins Enrollment In Third Phase 3 Clinical Trial For DEXTENZA™ for The Treatment Of Post-Surgical Ocular Inflammation And Pain
OCUL,DEXTENZA,2015-09-28,Ocular Therapeutix™ Submits New Drug Application To U.S. Food And Drug Administration For DEXTENZA® For The Treatment Of Post-Surgical Ocular Pain
OCUL,DEXTENZA,2015-06-16,Ocular Therapeutix™ Begins Enrollment In Phase 3 Clinical Trial For DEXTENZA™ For The Treatment Of Allergic Conjunctivitis
OGXI,Apatorsen,2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
OGXI,Apatorsen,2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
OGXI,Apatorsen,2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
OGXI,Apatorsen,2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
OGXI,Apatorsen,2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
OGXI,Apatorsen,2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
OGXI,Apatorsen,2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
OGXI,Apatorsen,2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
OGXI,Apatorsen,2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
OGXI,Apatorsen,2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
OGXI,Apatorsen,2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
OGXI,Apatorsen,2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
OGXI,Apatorsen,2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
OGXI,Apatorsen,2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
OGXI,Apatorsen,2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
OGXI,Apatorsen,2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
OGXI,Apatorsen,2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
OGXI,Apatorsen,2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
OGXI,Apatorsen,2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
ONCE,SPK-RPE65,2015-11-14,Spark Therapeutics Announces Presentation Of Additional Phase 3 Data On SPK-RPE65 At The American Academy Of Ophthalmology 2015 Annual Meeting
ONCE,SPK-RPE65,2015-10-10,Spark Therapeutics Announces Presentation Of Additional Phase 3 And Durability Data On SPK-RPE65 At The Retina Society 48th Annual Scientific Meeting
ONCE,SPK-RPE65,2015-10-05,Spark Therapeutics Announces Positive Top-line Results From Pivotal Phase 3 Trial Of SPK-RPE65 For Genetic Blinding Conditions
ONCE,SPK-RPE65,2015-09-09,Spark Therapeutics Announces Database Lock For SPK-RPE65 Phase 3 Clinical Trial And Expected Release Of Top-Line Data In October
ONCE,SPK-RPE65,2015-11-14,Spark Therapeutics Announces Presentation Of Additional Phase 3 Data On SPK-RPE65 At The American Academy Of Ophthalmology 2015 Annual Meeting
ONCE,SPK-RPE65,2015-10-10,Spark Therapeutics Announces Presentation Of Additional Phase 3 And Durability Data On SPK-RPE65 At The Retina Society 48th Annual Scientific Meeting
ONCE,SPK-RPE65,2015-10-05,Spark Therapeutics Announces Positive Top-line Results From Pivotal Phase 3 Trial Of SPK-RPE65 For Genetic Blinding Conditions
ONCE,SPK-RPE65,2015-09-09,Spark Therapeutics Announces Database Lock For SPK-RPE65 Phase 3 Clinical Trial And Expected Release Of Top-Line Data In October
OPHT,Fovista,2016-12-12,Ophthotech Announces Results From Pivotal Phase 3 Trials Of Fovista® In Wet Age-Related Macular Degeneration
OPHT,Fovista,2016-10-31,Ophthotech Announces The Publication Of Fovista® In Combination With Lucentis® Phase 2b Study Results In Ophthalmology®, The Journal Of The American Academy Of Ophthalmology
OPHT,Fovista,2016-06-20,Ophthotech Completes Patient Recruitment In Phase 3 Trial Of Fovista® Anti-PDGF Therapy In Combination With Eylea® Or Avastin® In Wet Age-Related Macular Degeneration
OPHT,Fovista,2015-11-17,Ophthotech Announces That Genentech, A Roche Wholly-Owned Subsidiary, Elects To Exercise Its Right To Opt-in To The Novartis Portion Of The Ophthotech / Novartis Ex-US Agreement For Fovista® To Treat Wet Age-Related Macular Degeneration
OPHT,Fovista,2015-10-26,Ophthotech Completes Patient Recruitment Of The Second Phase 3 Pivotal Trial Of Fovista® Anti-PDGF Therapy In Combination With Lucentis® In Wet Age-Related Macular Degeneration
OPHT,Fovista,2015-05-11,Ophthotech Completes Patient Recruitment Of The First Phase 3 Pivotal Trial Of Fovista® Anti-PDGF Therapy In Combination With Lucentis® In Wet Age-Related Macular Degeneration Program
OPHT,Fovista,2015-03-10,Ophthotech Corporation Achieves Second $50 Million Enrollment Milestone Under Ex-US Licensing And Commercial Agreement With Novartis For Fovista®
OPHT,Fovista,2014-09-16,Ophthotech Announces Fovista® Phase 2b Independent Analysis Shows That Fovista® Anti-PDGF Therapy, Combined With Anti-VEGF Therapy, Is Associated With A Reduction Of Sub-retinal Fibrosis In Wet AMD Patients
OPHT,Fovista,2014-09-08,Ophthotech Corporation Achieves $50 Million Milestone Under Ex-US Licensing And Commercial Agreement With Novartis For Fovista®
OPHT,Fovista,2014-08-05,Ophthotech Initiates First Of Several Expansion Studies To Further Evaluate Fovista® (Anti-PDGF) Therapy In Patients With Wet Age-Related Macular Degeneration
OPK,hGH-CTP,2016-12-30,OPKO Health Provides Update On HGH-CTP Clinical Programs
OPK,hGH-CTP,2016-09-06,OPKO To Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data At The 55th Annual Meeting Of The European Society For Paediatric Endocrinology
OPK,hGH-CTP,2016-03-24,OPKO To Present 18-24 Month Clinical Data On Its Long-acting Human Growth Hormone (hGH-CTP) From Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study In Oral Presentation At ENDO 2016
OPK,hGH-CTP,2015-10-07,OPKO Presents Clinical Data On Its Long-acting Human Growth Hormone (hGH-CTP) In Two Oral Presentations At The 54th Annual Meeting Of The European Society For Pediatric Endocrinology (ESPE)
OPK,hGH-CTP,2015-08-05,Two Reports On HGH-CTP Pediatric Phase 2 Clinical Data Accepted For Oral Presentation At The 54th Annual Meeting Of The European Society For Paediatric Endocrinology (ESPE Conference)
OPK,hGH-CTP,2016-12-30,OPKO Health Provides Update On HGH-CTP Clinical Programs
OPK,hGH-CTP,2016-09-06,OPKO To Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data At The 55th Annual Meeting Of The European Society For Paediatric Endocrinology
OPK,hGH-CTP,2016-03-24,OPKO To Present 18-24 Month Clinical Data On Its Long-acting Human Growth Hormone (hGH-CTP) From Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study In Oral Presentation At ENDO 2016
OPK,hGH-CTP,2015-10-07,OPKO Presents Clinical Data On Its Long-acting Human Growth Hormone (hGH-CTP) In Two Oral Presentations At The 54th Annual Meeting Of The European Society For Pediatric Endocrinology (ESPE)
OPK,hGH-CTP,2015-08-05,Two Reports On HGH-CTP Pediatric Phase 2 Clinical Data Accepted For Oral Presentation At The 54th Annual Meeting Of The European Society For Paediatric Endocrinology (ESPE Conference)
OTIC,OTIPRIO,2017-01-05,Otonomy Announces Positive Top-Line Results From Phase 3 Clinical Trial Of OTIPRIO® In Patients With Acute Otitis Externa
OTIC,OTIPRIO,2016-11-02,Otonomy Announces Assignment Of J Code For OTIPRIO®
OTIC,OTIPRIO,2016-10-04,Otonomy Successfully Completes Phase 2 Clinical Trial Of OTIPRIO® In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
OTIC,OTIPRIO,2016-09-15,Otonomy Successfully Completes Open-Label Clinical Trial For OTIPRIO® in Patients With History Of Otitis Media Requiring Tympanostomy Tubes
OTIC,OTIPRIO,2016-09-13,Otonomy Announces OTIPRIO® Data Presentation And Symposium At American Academy Of Otolaryngology - Head And Neck Surgery Foundation Annual Meeting
OTIC,OTIPRIO,2016-06-09,Otonomy Initiates Patient Enrollment In Single Phase 3 Clinical Trial Of OTIPRIO™ In Patients With Acute Otitis Externa
OTIC,OTIPRIO,2016-05-20,Otonomy Announces Assignment Of C Code And Pass-Through Payment Status For OTIPRIO™
OTIC,OTIPRIO,2016-05-16,Otonomy Announces OTIPRIO™ Data Presentation And Symposium At Combined Otolaryngology Spring Meetings
OTIC,OTIPRIO,2016-04-18,Otonomy Announces Phase 3 Clinical Trial Plan For OTIPRIO™ In Otitis Externa Patients Based On Successful End-of-Phase 2 Review By FDA
OTIC,OTIPRIO,2016-03-18,Otonomy Announces Publication Of OTIPRIO™ Phase 3 Clinical Trial Results In JAMA Otolaryngology
OTIC,OTIPRIO,2016-03-03,Otonomy Initiates Phase 2 Clinical Trial Of OTIPRIO™ In Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
OTIC,OTIPRIO,2016-03-02,Otonomy Announces Commercial Availability Of OTIPRIO™
OTIC,OTIPRIO,2015-12-11,Otonomy Announces FDA Approval Of OTIPRIO(TM) For The Treatment Of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
OTIC,OTIPRIO,2015-12-01,Otonomy Completes Enrollment In OTIPRIO(TM) Phase 2 Trial And Demonstrates Clinical Feasibility In Patients With Acute Otitis Externa
OTIC,OTIPRIO,2015-11-03,Otonomy Initiates Open-Label Clinical Trial For OTIPRIO(TM) In Pediatric Patients With History Of Otitis Media Requiring Tympanostomy Tubes
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PGNX,1404,2017-03-24,Data From Phase 2 Study Of Progenics' PSMA-Targeted Imaging Agent 1404 Published In Journal Of Nuclear Medicine
PGNX,1404,2016-12-22,Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation For Continuation Of Phase 3 Clinical Trial Of SPECT/CT Imaging Agent 1404
PGNX,1404,2016-01-07,Progenics Pharmaceuticals Commences Pivotal Phase 3 Study Of PSMA Targeted Imaging Agent 1404 For Prostate Cancer
PGNX,1404,2015-10-12,Data From Phase 2 Study Of Progenics' 1404 Imaging Agent Presented At EANM Congress 2015
PGNX,1404,2015-07-07,Progenics Pharmaceuticals Announces Plans To Move Forward With 1404 Phase 3 Trial
PGNX,1404,2015-04-07,Progenics Announces The Initiation Of Fuji's Phase 2 Trial For 1404 In Japan
PGNX,1404,2014-10-20,Phase 2 Data For Progenics' 1404 Imaging Agent Presented At EANM Congress
PGNX,1404,2017-03-24,Data From Phase 2 Study Of Progenics' PSMA-Targeted Imaging Agent 1404 Published In Journal Of Nuclear Medicine
PGNX,1404,2016-12-22,Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation For Continuation Of Phase 3 Clinical Trial Of SPECT/CT Imaging Agent 1404
PGNX,1404,2016-01-07,Progenics Pharmaceuticals Commences Pivotal Phase 3 Study Of PSMA Targeted Imaging Agent 1404 For Prostate Cancer
PGNX,1404,2015-10-12,Data From Phase 2 Study Of Progenics' 1404 Imaging Agent Presented At EANM Congress 2015
PGNX,1404,2015-07-07,Progenics Pharmaceuticals Announces Plans To Move Forward With 1404 Phase 3 Trial
PGNX,1404,2015-04-07,Progenics Announces The Initiation Of Fuji's Phase 2 Trial For 1404 In Japan
PGNX,1404,2014-10-20,Phase 2 Data For Progenics' 1404 Imaging Agent Presented At EANM Congress
PLX,PRX-106,2016-11-30,Protalix BioTherapeutics Enrolls First Patient In Phase II Clinical Trial Of OPRX-106 For The Treatment Of Ulcerative Colitis
PLX,PRX-106,2015-08-03,Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF
PLX,PRX-106,2016-11-30,Protalix BioTherapeutics Enrolls First Patient In Phase II Clinical Trial Of OPRX-106 For The Treatment Of Ulcerative Colitis
PLX,PRX-106,2015-08-03,Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF
PRTO,Vonapanitase,2016-12-13,Proteon Therapeutics Announces Top-Line Data From Phase 3 PATENCY-1 Clinical Trial Of Investigational Vonapanitase In Patients With CKD
PRTO,Vonapanitase,2016-11-10,Proteon Therapeutics Announces First Patient Dosed In Phase 1 Study Evaluating Vonapanitase For The Treatment Of Peripheral Artery Disease Below The Knee
PRTO,Vonapanitase,2016-10-25,Proteon Therapeutics Announces Overview Of Phase 1 Clinical Program Of Investigational Vonapanitase In Peripheral Artery Disease To Be Presented At The 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
PRTO,Vonapanitase,2016-04-13,Proteon Therapeutics Announces Publication In The Journal Of Cardiovascular Pharmacology Of Promising Nonclinical Results For Vonapanitase In Peripheral Artery Disease
PRTO,Vonapanitase,2015-11-02,Proteon Therapeutics Completes Enrollment In PATENCY-1, First Phase 3 Clinical Study Of Investigational Vonapanitase
PRTO,Vonapanitase,2015-10-12,Proteon Therapeutics Announces Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease Presented At TCT 2015
PRTO,Vonapanitase,2015-08-13,Proteon Therapeutics Announces Top-Line Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease
PRTO,Vonapanitase,2015-08-12,Proteon Therapeutics Initiates Second Phase 3 Clinical Study Of Investigational Drug Vonapanitase
PRTO,Vonapanitase,2015-03-26,Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis
PRTO,Vonapanitase,2016-12-13,Proteon Therapeutics Announces Top-Line Data From Phase 3 PATENCY-1 Clinical Trial Of Investigational Vonapanitase In Patients With CKD
PRTO,Vonapanitase,2016-11-10,Proteon Therapeutics Announces First Patient Dosed In Phase 1 Study Evaluating Vonapanitase For The Treatment Of Peripheral Artery Disease Below The Knee
PRTO,Vonapanitase,2016-10-25,Proteon Therapeutics Announces Overview Of Phase 1 Clinical Program Of Investigational Vonapanitase In Peripheral Artery Disease To Be Presented At The 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
PRTO,Vonapanitase,2016-04-13,Proteon Therapeutics Announces Publication In The Journal Of Cardiovascular Pharmacology Of Promising Nonclinical Results For Vonapanitase In Peripheral Artery Disease
PRTO,Vonapanitase,2015-11-02,Proteon Therapeutics Completes Enrollment In PATENCY-1, First Phase 3 Clinical Study Of Investigational Vonapanitase
PRTO,Vonapanitase,2015-10-12,Proteon Therapeutics Announces Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease Presented At TCT 2015
PRTO,Vonapanitase,2015-08-13,Proteon Therapeutics Announces Top-Line Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease
PRTO,Vonapanitase,2015-08-12,Proteon Therapeutics Initiates Second Phase 3 Clinical Study Of Investigational Drug Vonapanitase
PRTO,Vonapanitase,2015-03-26,Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis
PTLA,Betrixaban,2017-03-07,Portola Pharmaceuticals Announces Betrixaban And AndexXa™ (andexanet Alfa) Presentations At ACC.17
PTLA,Betrixaban,2017-02-08,FDA Informs Portola Pharmaceuticals At Mid-Cycle Review For Betrixaban That It Has Not Identified Issues That Require An Advisory Committee Meeting
PTLA,Betrixaban,2016-12-23,Portola Pharmaceuticals Announces FDA Accepts New Drug Application For Priority Review And EMA Validates Marketing Authorization Application For Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
PTLA,Betrixaban,2016-11-28,Portola Pharmaceuticals Announces AndexXa™ (andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society Of Hematology Annual Meeting And Exposition
PTLA,Betrixaban,2016-11-14,Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban
PTLA,Betrixaban,2016-10-25,Portola Pharmaceuticals Submits New Drug Application To U.S. FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients
PTLA,Betrixaban,2016-05-27,Portola Pharmaceuticals Announces Full Results Of Phase 3 APEX Study Of Betrixaban Presented At International Society On Thrombosis And Haemostasis (ISTH) Meeting
PTLA,Betrixaban,2016-05-23,Portola Pharmaceuticals Announces Upcoming Data Presentations On Betrixaban And AndexXa™ (andexanet Alfa) At International Society On Thrombosis And Haemostasis (ISTH) 2016 Scientific And Standardization Committee Meeting
PTLA,Betrixaban,2016-03-24,Portola Pharmaceuticals Announces Topline Results From Phase 3 APEX Trial Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
PTLA,Betrixaban,2015-10-30,Portola Pharmaceuticals Completes Enrollment In Pivotal Phase 3 APEX Study Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
PTLA,Betrixaban,2015-10-13,Portola Pharmaceuticals Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
PTLA,Betrixaban,2015-02-05,Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis In Phase 3 APEX Study; Trial Continues As Planned And Remains On Track For Enrollment Completion By Year-End
PTLA,Betrixaban,2017-03-07,Portola Pharmaceuticals Announces Betrixaban And AndexXa™ (andexanet Alfa) Presentations At ACC.17
PTLA,Betrixaban,2017-02-08,FDA Informs Portola Pharmaceuticals At Mid-Cycle Review For Betrixaban That It Has Not Identified Issues That Require An Advisory Committee Meeting
PTLA,Betrixaban,2016-12-23,Portola Pharmaceuticals Announces FDA Accepts New Drug Application For Priority Review And EMA Validates Marketing Authorization Application For Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
PTLA,Betrixaban,2016-11-28,Portola Pharmaceuticals Announces AndexXa™ (andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society Of Hematology Annual Meeting And Exposition
PTLA,Betrixaban,2016-11-14,Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban
PTLA,Betrixaban,2016-10-25,Portola Pharmaceuticals Submits New Drug Application To U.S. FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients
PTLA,Betrixaban,2016-05-27,Portola Pharmaceuticals Announces Full Results Of Phase 3 APEX Study Of Betrixaban Presented At International Society On Thrombosis And Haemostasis (ISTH) Meeting
PTLA,Betrixaban,2016-05-23,Portola Pharmaceuticals Announces Upcoming Data Presentations On Betrixaban And AndexXa™ (andexanet Alfa) At International Society On Thrombosis And Haemostasis (ISTH) 2016 Scientific And Standardization Committee Meeting
PTLA,Betrixaban,2016-03-24,Portola Pharmaceuticals Announces Topline Results From Phase 3 APEX Trial Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
PTLA,Betrixaban,2015-10-30,Portola Pharmaceuticals Completes Enrollment In Pivotal Phase 3 APEX Study Of Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
PTLA,Betrixaban,2015-10-13,Portola Pharmaceuticals Announces FDA Grants Fast Track Designation To Betrixaban For Prevention Of Blood Clots In Acute Medically Ill Patients
PTLA,Betrixaban,2015-02-05,Portola's Factor Xa Inhibitor Betrixaban Successfully Passes Futility Analysis In Phase 3 APEX Study; Trial Continues As Planned And Remains On Track For Enrollment Completion By Year-End
PTLA,Cerdulatinib,2016-11-28,Portola Pharmaceuticals Announces AndexXa™ (andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society Of Hematology Annual Meeting And Exposition
PTLA,Cerdulatinib,2016-06-01,Portola Pharmaceuticals Announces Dosing Of First Patient In Phase 2a Study Of Cerdulatinib For Treatment Of Hematologic Cancer And Upcoming Presentations Of New Phase 1 Clinical Data At ASCO And EHA Annual Meetings
PTLA,Cerdulatinib,2016-04-14,Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation At American Association For Cancer Research (AACR) Annual Meeting 2016
PTLA,Cerdulatinib,2015-12-05,Portola Pharmaceuticals Announces Andexanet Alfa And Cerdulatinib Data Presentations At The 2015 American Society Of Hematology Annual Meeting And Exposition
PTLA,Cerdulatinib,2015-05-29,Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study Of Dual Kinase Inhibitor Cerdulatinib
PTLA,Cerdulatinib,2015-05-18,Portola Pharmaceuticals Announces Upcoming Data Presentation On Dual Kinase Inhibitor Cerdulatinib At American Society Of Clinical Oncology (ASCO) Annual Meeting
PTLA,Cerdulatinib,2014-05-14,Portola Pharmaceuticals Announces Two Presentations Of Data On Cerdulatinib, An Oral Dual Syk/JAK Inhibitor, At 2014 ASCO Annual Meeting
PTLA,Cerdulatinib,2016-11-28,Portola Pharmaceuticals Announces AndexXa™ (andexanet Alfa), Betrixaban And Cerdulatinib Data To Be Presented At 2016 American Society Of Hematology Annual Meeting And Exposition
PTLA,Cerdulatinib,2016-06-01,Portola Pharmaceuticals Announces Dosing Of First Patient In Phase 2a Study Of Cerdulatinib For Treatment Of Hematologic Cancer And Upcoming Presentations Of New Phase 1 Clinical Data At ASCO And EHA Annual Meetings
PTLA,Cerdulatinib,2016-04-14,Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation At American Association For Cancer Research (AACR) Annual Meeting 2016
PTLA,Cerdulatinib,2015-12-05,Portola Pharmaceuticals Announces Andexanet Alfa And Cerdulatinib Data Presentations At The 2015 American Society Of Hematology Annual Meeting And Exposition
PTLA,Cerdulatinib,2015-05-29,Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study Of Dual Kinase Inhibitor Cerdulatinib
PTLA,Cerdulatinib,2015-05-18,Portola Pharmaceuticals Announces Upcoming Data Presentation On Dual Kinase Inhibitor Cerdulatinib At American Society Of Clinical Oncology (ASCO) Annual Meeting
PTLA,Cerdulatinib,2014-05-14,Portola Pharmaceuticals Announces Two Presentations Of Data On Cerdulatinib, An Oral Dual Syk/JAK Inhibitor, At 2014 ASCO Annual Meeting
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
RARE,KRN23,2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
RARE,KRN23,2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
RARE,KRN23,2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
RARE,KRN23,2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
RARE,KRN23,2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
RARE,KRN23,2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
RARE,KRN23,2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
RARE,KRN23,2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
RARE,KRN23,2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
RARE,KRN23,2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
RARE,KRN23,2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
RARE,KRN23,2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
RARE,KRN23,2017-01-05,Ultragenyx And Kyowa Kirin International Announce Marketing Authorization Application For KRN23 Filed And Accepted For Review By European Medicines Agency
RARE,KRN23,2016-10-26,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Pediatric Patients With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2016-09-19,Ultragenyx Reports Positive Interim Data From Pediatric And Adult Phase 2 Studies Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2016-09-18,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2016-09-16,Ultragenyx To Host Conference Call To Discuss KRN23 Data Presented At ASBMR 2016 Annual Meeting
RARE,KRN23,2016-08-23,Ultragenyx Announces KRN23 Data Presentations At ASBMR 2016 Annual Meeting
RARE,KRN23,2016-07-28,Ultragenyx Announces Completion Of Enrollment In Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2016-06-28,Ultragenyx Receives Breakthrough Therapy Designation For KRN23 In Pediatric Patients With X-Linked Hypophosphatemia
RARE,KRN23,2016-04-21,Ultragenyx Reports Positive Interim Data From Phase 2 Study Of KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2015-12-03,Ultragenyx Announces First Patient Enrolled In Global Phase 3 Study Of KRN23 In Adults With X-Linked Hypophosphatemia (XLH)
RARE,KRN23,2015-12-02,Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-07-09,Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-06-02,Ultragenyx Releases Positive 16-Week Interim Data From Pediatric Phase 2 Study Of KRN23 In X-Linked Hypophosphatemia
RARE,KRN23,2015-01-06,Ultragenyx Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia
RARE,KRN23,2014-10-30,Ultragenyx Granted EU Orphan Drug Designation For KRN23 For The Treatment Of X-Linked Hypophosphatemia
RARE,KRN23,2014-09-15,Ultragenyx Announces Positive Results From A Long-Term Phase 1/2 Study Of KRN23 In Adult Patients With X-Linked Hypophosphatemia
RARE,UX007,2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
RARE,UX007,2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
RARE,UX007,2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
RARE,UX007,2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
RARE,UX007,2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
RARE,UX007,2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
RARE,UX007,2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
RARE,UX007,2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
RARE,UX007,2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
RARE,UX007,2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
RARE,UX007,2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2017-03-22,Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
RARE,UX007,2016-11-30,Ultragenyx Announces Positive Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RARE,UX007,2015-11-06,Ultragenyx Announces Update To UX007 Development Program In Glucose Transporter Type-1 Deficiency Syndrome
RARE,UX007,2015-10-13,Ultragenyx Announces Positive Interim Data From Phase 2 Study Of UX007 In Long-Chain Fatty Acid Oxidation Disorder Patients
RDHL,RIZAPORT,2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
RDHL,RIZAPORT,2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
RDHL,RIZAPORT,2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
RDHL,RIZAPORT,2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
RDHL,RIZAPORT,2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
RDHL,RIZAPORT,2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
RDHL,RIZAPORT,2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
RDHL,RIZAPORT,2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
RDHL,RIZAPORT,2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
RDHL,RIZAPORT,2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
RDHL,RIZAPORT,2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
RDHL,RIZAPORT,2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
RDHL,RIZAPORT,2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
RDHL,RIZAPORT,2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
RDHL,RIZAPORT,2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
RDHL,RIZAPORT,2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
RDHL,RIZAPORT,2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
RDHL,RIZAPORT,2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
RDHL,RIZAPORT,2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
RDHL,RIZAPORT,2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
RDHL,RIZAPORT,2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
RDHL,RIZAPORT,2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
RDHL,RIZAPORT,2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
RDHL,RIZAPORT,2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
RDHL,RIZAPORT,2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
RDHL,RIZAPORT,2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
RDHL,RIZAPORT,2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
RDHL,RHB-104,2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
RDHL,RHB-104,2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
RDHL,RHB-104,2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
RDHL,RHB-104,2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
RDHL,RHB-104,2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
RDHL,RHB-104,2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
RDHL,RHB-104,2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
RDHL,RHB-104,2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
RDHL,RHB-104,2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
RDHL,RHB-104,2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
RDHL,RHB-104,2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
RDHL,RHB-104,2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
RDHL,RHB-104,2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
RDHL,RHB-104,2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
RDHL,RHB-104,2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
RDHL,RHB-104,2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
RDHL,RHB-104,2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
RDHL,RHB-104,2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
RDHL,RHB-104,2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
RDHL,RHB-104,2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
RDHL,RHB-104,2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
RDHL,RHB-104,2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
RDHL,RHB-104,2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
RDHL,RHB-104,2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
RDHL,RHB-104,2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
RDHL,RHB-104,2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
RDHL,RHB-104,2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
RDHL,RHB-104,2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
RDHL,RHB-104,2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
RDHL,RHB-104,2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
RDHL,RHB-104,2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
RDHL,RHB-104,2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
RDHL,RHB-104,2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
RDHL,RHB-104,2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
RDHL,RHB-104,2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
RDHL,RHB-104,2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
RDHL,RHB-104,2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
RDHL,RHB-104,2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
RDHL,RHB-104,2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
RDHL,RHB-104,2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
RDHL,RHB-104,2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
RDHL,RHB-104,2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
RDHL,RHB-104,2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
RDHL,RHB-104,2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
RDHL,RHB-104,2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
RDHL,RHB-104,2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
RDHL,RHB-104,2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
RDHL,RHB-104,2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
RDHL,RHB-104,2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
RDHL,RHB-104,2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
RDHL,RHB-104,2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
RDHL,RHB-104,2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
RDHL,RHB-104,2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
RDHL,RHB-104,2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
RDHL,RHB-104,2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
RDHL,RHB-104,2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
RDHL,RHB-104,2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
RDHL,RHB-104,2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
RDHL,RHB-104,2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
RDHL,RHB-104,2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
RDHL,RHB-104,2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
RDHL,RHB-104,2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
RDHL,RHB-104,2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
RDHL,RHB-104,2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
RNN,Supinoxin,2017-02-23,Rexahn Pharmaceuticals Doses First Patient In A Phase IIa Trial Of Supinoxin™ In Patients With Metastatic Triple Negative Breast Cancer
RNN,Supinoxin,2016-10-10,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
RNN,Supinoxin,2016-10-04,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
RNN,Supinoxin,2016-03-24,Rexahn Pharmaceuticals Presents Additional Data For Supinoxin For The Treatment Of Triple Negative Breast Cancer At The 2016 Targeted Anticancer Therapeutics Congress
RNN,Supinoxin,2016-01-25,Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium
RNN,Supinoxin,2016-01-12,New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition
RNN,Supinoxin,2015-12-14,Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition
RNN,Supinoxin,2015-09-28,Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015
RNN,Supinoxin,2015-04-21,New Data Show Rexahn's Supinoxin(TM) Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model
RNN,Supinoxin,2015-04-13,Rexahn Pharmaceuticals To Present Data On RX-3117 And Supinoxin(TM) At The 2015 American Association For Cancer Research Annual Meeting
RNN,Supinoxin,2015-02-09,Rexahn Pharmaceuticals Announces The Publication Of Preclinical Data For Supinoxin(TM) (RX-5902) Demonstrating Mechanism Of Action
RNN,Supinoxin,2014-07-18,Rexahn Pharmaceuticals Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors
RNN,Supinoxin,2014-03-11,Rexahn Announces Initial Results From Phase I Trial Of SupinoxinTM (RX-5902) For Solid Cancer Tumors
RNN,Supinoxin,2013-12-11,Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin TM&#160;(RX-5902)
RNN,Supinoxin,2013-08-07,Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors
RNN,Supinoxin,2017-02-23,Rexahn Pharmaceuticals Doses First Patient In A Phase IIa Trial Of Supinoxin™ In Patients With Metastatic Triple Negative Breast Cancer
RNN,Supinoxin,2016-10-10,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
RNN,Supinoxin,2016-10-04,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
RNN,Supinoxin,2016-03-24,Rexahn Pharmaceuticals Presents Additional Data For Supinoxin For The Treatment Of Triple Negative Breast Cancer At The 2016 Targeted Anticancer Therapeutics Congress
RNN,Supinoxin,2016-01-25,Rexahn Pharmaceuticals Announces Supinoxin™ Poster Presentations At The 2016 Gastrointestinal Cancers Symposium
RNN,Supinoxin,2016-01-12,New Preclinical Data For Supinoxin™ Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition
RNN,Supinoxin,2015-12-14,Rexahn Pharmaceuticals Announces New Data For Supinoxin™ Showing Potent Tumor Growth Inhibition
RNN,Supinoxin,2015-09-28,Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015
RNN,Supinoxin,2015-04-21,New Data Show Rexahn's Supinoxin(TM) Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model
RNN,Supinoxin,2015-04-13,Rexahn Pharmaceuticals To Present Data On RX-3117 And Supinoxin(TM) At The 2015 American Association For Cancer Research Annual Meeting
RNN,Supinoxin,2015-02-09,Rexahn Pharmaceuticals Announces The Publication Of Preclinical Data For Supinoxin(TM) (RX-5902) Demonstrating Mechanism Of Action
RNN,Supinoxin,2014-07-18,Rexahn Pharmaceuticals Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors
RNN,Supinoxin,2014-03-11,Rexahn Announces Initial Results From Phase I Trial Of SupinoxinTM (RX-5902) For Solid Cancer Tumors
RNN,Supinoxin,2013-12-11,Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin TM&#160;(RX-5902)
RNN,Supinoxin,2013-08-07,Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors
RNN,RX-3117,2017-01-20,Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
RNN,RX-3117,2016-10-31,Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent
RNN,RX-3117,2016-10-10,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
RNN,RX-3117,2016-10-04,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
RNN,RX-3117,2016-09-12,Rexahn Pharmaceuticals Initiates Stage 2 Of Phase Ib/IIa Clinical Trial Of RX-3117 In Relapsed Or Refractory Metastatic Pancreatic Cancer
RNN,RX-3117,2016-03-29,Rexahn Pharmaceuticals Announces Initiation Of Phase Ib/IIa Clinical Trial Of Its Novel Oral Anti-Cancer Therapeutic RX-3117 In The Treatment Of Pancreatic And Bladder Cancer
RNN,RX-3117,2015-10-26,Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program
RNN,RX-3117,2015-09-28,Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015
RNN,RX-3117,2015-06-09,Data On Rexahn's RX-3117 In Non-Small Cell Lung Cancer Presented At 16th International Symposium Of The Purine And Pyrimidine Society
RNN,RX-3117,2015-04-20,Rexahn Identifies RX-3117 Biomarker & Presents Data At The 2015 American Association For Cancer Research Annual Meeting
RNN,RX-3117,2015-04-13,Rexahn Pharmaceuticals To Present Data On RX-3117 And Supinoxin(TM) At The 2015 American Association For Cancer Research Annual Meeting
RNN,RX-3117,2015-01-06,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells
RNN,RX-3117,2014-09-24,Rexahn Receives FDA Orphan Drug Designation For RX-3117 In Treatment Of Pancreatic Cancer
RNN,RX-3117,2014-05-08,RX-3117 Showed Greater Efficacy (tumor Growth Inhibition) As Compared To Gemcitabine In Four Different Xenograft Animal Models With Gemcitabine Resistant Human Cancer Cell Lines: Colorectal Cancer (Colo205), Small Cell Lung Cancer (H69), Cervical Cancer (CaSki) And Pancreatic Cancer (CTG-0298).
RNN,RX-3117,2014-04-02,Rexahn Pharmaceuticals To Present Data On RX-3117 And RX-21101 At The 2014 American Association For Clinical Research Annual Meeting
RNN,RX-3117,2014-01-08,Rexahn Initiates Phase Ib Clinical Trial Of RX-3117 For Treatment Of Solid Tumors
RNN,RX-3117,2013-09-30,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117
RNN,RX-3117,2013-08-28,Rexahn Pharmaceuticals Announces Teva Will Not Exercise Its Option To License RX-3117
RNN,RX-3117,2013-07-15,Rexahn Pharmaceuticals Announce IND Submission For RX-3117
RNN,RX-3117,2012-08-06,Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study Of RX-3117
RNN,RX-3117,2012-05-30,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anti-Cancer Compound RX-3117
RNN,RX-3117,2012-03-27,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-3117 At AACR 103rd Annual Meeting
RNN,RX-3117,2012-03-13,Rexahn Pharmaceuticals Enrolls First Subject In Exploratory Phase I Clinical Study Of RX-3117
RNN,RX-3117,2012-01-18,Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors
RNN,RX-3117,2011-01-20,Teva Pharmaceutical Increases Its Investment In Rexahn For The Continued Research And Development Of The Pre-Clinical Anti-Cancer Compound, RX-3117
RNN,RX-3117,2017-01-20,Rexahn Pharmaceuticals Presents An Update Of The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Pancreatic Cancer At The American Society Of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
RNN,RX-3117,2016-10-31,Rexahn Pharmaceuticals Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Patent Covering The Manufacturing Of RX-3117 - A Cancer Cell Specific Anticancer Agent
RNN,RX-3117,2016-10-10,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
RNN,RX-3117,2016-10-04,Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From Phase Ib/IIa Trial Of RX-3117 In Metastatic Pancreatic Cancer And Supinoxin™ Phase I Trial At 2016 European Society For Medical Oncology (ESMO) Congress
RNN,RX-3117,2016-09-12,Rexahn Pharmaceuticals Initiates Stage 2 Of Phase Ib/IIa Clinical Trial Of RX-3117 In Relapsed Or Refractory Metastatic Pancreatic Cancer
RNN,RX-3117,2016-03-29,Rexahn Pharmaceuticals Announces Initiation Of Phase Ib/IIa Clinical Trial Of Its Novel Oral Anti-Cancer Therapeutic RX-3117 In The Treatment Of Pancreatic And Bladder Cancer
RNN,RX-3117,2015-10-26,Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program
RNN,RX-3117,2015-09-28,Rexahn Pharmaceuticals Presents Preliminary Clinical Data For Supinoxin(TM) And RX-3117 Oncology Programs At The European Cancer Congress 2015
RNN,RX-3117,2015-06-09,Data On Rexahn's RX-3117 In Non-Small Cell Lung Cancer Presented At 16th International Symposium Of The Purine And Pyrimidine Society
RNN,RX-3117,2015-04-20,Rexahn Identifies RX-3117 Biomarker & Presents Data At The 2015 American Association For Cancer Research Annual Meeting
RNN,RX-3117,2015-04-13,Rexahn Pharmaceuticals To Present Data On RX-3117 And Supinoxin(TM) At The 2015 American Association For Cancer Research Annual Meeting
RNN,RX-3117,2015-01-06,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells
RNN,RX-3117,2014-09-24,Rexahn Receives FDA Orphan Drug Designation For RX-3117 In Treatment Of Pancreatic Cancer
RNN,RX-3117,2014-05-08,RX-3117 Showed Greater Efficacy (tumor Growth Inhibition) As Compared To Gemcitabine In Four Different Xenograft Animal Models With Gemcitabine Resistant Human Cancer Cell Lines: Colorectal Cancer (Colo205), Small Cell Lung Cancer (H69), Cervical Cancer (CaSki) And Pancreatic Cancer (CTG-0298).
RNN,RX-3117,2014-04-02,Rexahn Pharmaceuticals To Present Data On RX-3117 And RX-21101 At The 2014 American Association For Clinical Research Annual Meeting
RNN,RX-3117,2014-01-08,Rexahn Initiates Phase Ib Clinical Trial Of RX-3117 For Treatment Of Solid Tumors
RNN,RX-3117,2013-09-30,Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117
RNN,RX-3117,2013-08-28,Rexahn Pharmaceuticals Announces Teva Will Not Exercise Its Option To License RX-3117
RNN,RX-3117,2013-07-15,Rexahn Pharmaceuticals Announce IND Submission For RX-3117
RNN,RX-3117,2012-08-06,Rexahn Pharmaceuticals Completes Exploratory Phase I Clinical Study Of RX-3117
RNN,RX-3117,2012-05-30,Rexahn Pharmaceuticals Announces Publication Of New Preclinical Research Data For Novel Anti-Cancer Compound RX-3117
RNN,RX-3117,2012-03-27,Rexahn Pharmaceuticals To Present Data On Novel Anti-Cancer Small Molecule RX-3117 At AACR 103rd Annual Meeting
RNN,RX-3117,2012-03-13,Rexahn Pharmaceuticals Enrolls First Subject In Exploratory Phase I Clinical Study Of RX-3117
RNN,RX-3117,2012-01-18,Rexahn Pharmaceuticals Secures Approval In Europe To Conduct A First-in-Human Trial Of RX-3117 In Solid Tumors
RNN,RX-3117,2011-01-20,Teva Pharmaceutical Increases Its Investment In Rexahn For The Continued Research And Development Of The Pre-Clinical Anti-Cancer Compound, RX-3117
RPRX,Proellex,2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
RPRX,Proellex,2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
RPRX,Proellex,2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
RPRX,Proellex,2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2015-12-21,Repros Updates Proellex® Program
RPRX,Proellex,2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
RPRX,Proellex,2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
RPRX,Proellex,2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
RPRX,Proellex,2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
RPRX,Proellex,2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
RPRX,Proellex,2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
RPRX,Proellex,2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
RPRX,Proellex,2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
RPRX,Proellex,2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
RPRX,Proellex,2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
RPRX,Proellex,2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2015-12-21,Repros Updates Proellex® Program
RPRX,Proellex,2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
RPRX,Proellex,2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
RPRX,Proellex,2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
RPRX,Proellex,2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
RPRX,Proellex,2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
RPRX,Proellex,2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
RPRX,Proellex,2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
RPRX,Proellex,2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
RPRX,Proellex,2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
RPRX,Proellex,2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
RPRX,Proellex,2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2015-12-21,Repros Updates Proellex® Program
RPRX,Proellex,2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
RPRX,Proellex,2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
RPRX,Proellex,2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
RPRX,Proellex,2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
RPRX,Proellex,2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
RPRX,Proellex,2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
RPRX,Proellex,2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
RPRX,Proellex,2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
RPRX,Proellex,2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
RPRX,Proellex,2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
RPRX,Proellex,2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2015-12-21,Repros Updates Proellex® Program
RPRX,Proellex,2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
RPRX,Proellex,2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
RPRX,Proellex,2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
RPRX,Proellex,2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
RPRX,Proellex,2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
RPRX,Proellex,2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
RPRX,Proellex,2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
RPRX,Proellex,2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
RPRX,Proellex,2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
RPRX,Proellex,2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
RPRX,Proellex,2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2015-12-21,Repros Updates Proellex® Program
RPRX,Proellex,2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
RPRX,Proellex,2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
RPRX,Proellex,2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
RPRX,Proellex,2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
RPRX,Proellex,2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
RPRX,Proellex,2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
RPRX,Proellex,2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
RPRX,Proellex,2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2017-01-30,FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-12-19,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis
RPRX,Proellex,2016-12-12,Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids
RPRX,Proellex,2016-11-14,Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids
RPRX,Proellex,2016-09-07,Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis
RPRX,Proellex,2016-05-18,Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2016-04-12,Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids
RPRX,Proellex,2015-12-21,Repros Updates Proellex® Program
RPRX,Proellex,2015-11-12,Repros Therapeutics Completes Randomization Of Phase 2b Study Of Vaginal Proellex(R) In Women With Symptomatic Uterine Fibroid Bleeding
RPRX,Proellex,2014-03-17,Repros Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex(R) In The Treatment Of Uterine Fibroids And Endometriosis
RPRX,Proellex,2013-11-04,Repros Receives FDA Guidance For Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program
RPRX,Proellex,2013-05-22,FDA Recommends Running Phase 2b Trial Of Proellex(R)-V In The Treatment Of Severe Menstrual Bleeding Associated With Uterine Fibroids
RPRX,Proellex,2013-04-29,Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University
RPRX,Proellex,2013-02-28,FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design
RPRX,Proellex,2013-01-03,Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids
RPRX,Proellex,2012-10-08,FDA Reclassifies Proellex(R) Clinical Hold Status: Repros To Proceed With Phase 2 Study Of Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RPRX,Proellex,2012-08-27,FDA Provides Recommendations For Phase 2 Protocol For Low Dose Oral Proellex(R) In The Treatment Of Endometriosis
RVNC,RT002,2017-03-07,Revance Completes Enrollment In Phase 3 Pivotal Trials Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines
RVNC,RT002,2017-01-18,Revance Presents Clinical Data For RT002 Injectable At TOXINS 2017
RVNC,RT002,2016-12-07,Revance Announces Initiation Of Subject Dosing In The SAKURA Phase 3 Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines
RVNC,RT002,2016-11-03,Revance Announces Initiation Of Phase 2 Trial Of RT002 Injectable To Treat Plantar Fasciitis
RVNC,RT002,2016-07-14,Revance Announces Completion Of Pre-Phase 3 Meeting With FDA For RT002 Injectable To Treat Glabellar Lines
RVNC,RT002,2016-03-05,Revance Announces Late-Breaking Podium Presentation Of Positive 6-Month Duration Results For BELMONT Phase 2 Active Comparator Study Of Injectable RT002 At The 74th Annual Meeting Of The American Academy Of Dermatology
RVNC,RT002,2015-01-08,Revance Therapeutics Announces Publication Of Positive Results From RT002 Phase 1/2 Study
RVNC,RT002,2015-01-05,Revance Therapeutics Announces Initiation Of BELMONT Phase 2 Active Comparator Trial Of Injectable RT002
RXII,Samcyprone,2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
RXII,Samcyprone,2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
RXII,Samcyprone,2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
RXII,Samcyprone,2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
RXII,Samcyprone,2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
RXII,Samcyprone,2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
RXII,Samcyprone,2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
RXII,Samcyprone,2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
RXII,Samcyprone,2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
RXII,Samcyprone,2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
RXII,Samcyprone,2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
RXII,Samcyprone,2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
RXII,Samcyprone,2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
RXII,Samcyprone,2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
RXII,Samcyprone,2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
RXII,Samcyprone,2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
RXII,Samcyprone,2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
RXII,Samcyprone,2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
RXII,Samcyprone,2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
RXII,Samcyprone,2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
RXII,Samcyprone,2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
RXII,Samcyprone,2015-12-21,RXi Pharmaceuticals Announces The Initiation Of A Phase 2 Trial In Dermatology With Samcyprone For Cutaneous Warts
RXII,Samcyprone,2015-04-17,RXi Pharmaceuticals Receives Orphan Drug Designation For Samcyprone™ From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb To IV
RXII,Samcyprone,2015-02-05,RXi Pharmaceuticals Announces Closing Of The Exclusive Global Licensing Agreement To Samcyprone™ With Hapten Pharmaceuticals
SAGE,SAGE-547,2016-12-06,Sage Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting
SAGE,SAGE-547,2016-11-16,SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression
SAGE,SAGE-547,2016-09-27,Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting
SAGE,SAGE-547,2016-09-06,Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression
SAGE,SAGE-547,2016-07-12,Sage Reports Positive Top-line Results Including Demonstration Of 30-Day Durability From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression
SAGE,SAGE-547,2016-05-26,Sage Therapeutics Announces Completion Of Enrollment For Phase 2 Proof-of-Concept Trial Of SAGE-547 In Severe Postpartum Depression
SAGE,SAGE-547,2016-04-17,Sage Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting
SAGE,SAGE-547,2016-03-03,Sage Therapeutics To Present SAGE-547 Clinical Data And SRSE Health Economic Data In Five Abstracts At The American Academy Of Neurology 2016 Annual Meeting
SAGE,SAGE-547,2015-12-15,SAGE Updates Guidance For Top-Line Results Of Phase 3 STATUS Trial Of SAGE-547
SAGE,SAGE-547,2015-08-17,SAGE Announces First Patient Treated In Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus
SAGE,SAGE-547,2015-08-06,SAGE Receives Special Protocol Assessment For Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus
SAGE,SAGE-547,2015-06-09,SAGE Therapeutics Announces Positive Top-Line Data In Exploratory Trial Of SAGE-547 In Postpartum Depression
SAGE,SAGE-547,2015-05-14,SAGE Therapeutics Announces SAGE-547 Progress And First Quarter 2015 Financial Results
SAGE,SAGE-547,2015-05-14,SAGE Therapeutics Achieves 77 Percent Response Rate In Completed Phase 1/2 Clinical Trial Of SAGE-547 In Super-Refractory Status Epilepticus
SAGE,SAGE-547,2015-04-20,SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus
SAGE,SAGE-547,2015-04-02,SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA And Planned Initiation Of SAGE-547 Global Phase 3 Trial In Mid-2015
SAGE,SAGE-547,2015-01-12,SAGE Therapeutics Initiates Phase 2a Trial Of SAGE-547 In Postpartum Depression
SAGE,SAGE-547,2015-01-09,SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial And Emergency Use Program Of SAGE-547 In Patients With Super-Refractory Status Epilepticus
SAGE,SAGE-547,2014-11-10,SAGE Therapeutics Reports Positive Top-Line Phase 2 Data Of SAGE-547 In Patients With Super-Refractory Status Epilepticus
SAGE,SAGE-547,2014-11-03,First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology
SAGE,SAGE-547,2014-10-23,SAGE Therapeutics Initiates Exploratory Study Of SAGE-547 In Essential Tremor
SAGE,SAGE-547,2014-07-22,SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus
SCMP,Lubiprostone,2015-06-15,China Food And Drug Administration Accepts IND For Pivotal Study Of AMITIZA(R) (lubiprostone)
SCMP,Lubiprostone,2015-05-15,Sucampo Announces Clinical Data On Lubiprostone To Be Presented At Digestive Disease Week
SCMP,Lubiprostone,2015-05-11,Sucampo And Harbin Gloria Pharmaceuticals Enter Into Licensing Agreement For AMITIZA(R) (lubiprostone) In China
SCMP,Lubiprostone,2015-01-30,AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation For Approval In European Countries
SCMP,Lubiprostone,2014-12-30,Sucampo Announces Acceptance Of New Drug Submission For AMITIZA(R) (lubiprostone) By Health Canada
SCMP,Lubiprostone,2014-10-21,Takeda And Sucampo Enter Into Global Licensing Agreement For AMITIZA(R) (lubiprostone)
SCMP,Lubiprostone,2014-10-14,Sucampo Announces Extension Of AMITIZA(R) (lubiprostone) License And Collaboration Agreement With Takeda
SCMP,Lubiprostone,2014-10-13,Clinical Data For AMITIZA(R) Lubiprostone To Be Presented At The American College Of Gastroenterology 2014 Annual Scientific Meeting
SCMP,Lubiprostone,2014-09-29,Sucampo And Takeda Launch Direct-to-Consumer Advertising Campaign For AMITIZA(R) (lubiprostone) For Chronic Idiopathic Constipation
SCMP,Lubiprostone,2014-08-21,Sucampo Announces New Exclusive Global Manufacturing And Supply Agreement For Lubiprostone
SCMP,Lubiprostone,2014-07-23,Sucampo Announces Publication Of NICE Recommendation For AMITIZA(R) (Lubiprostone)
SCMP,Lubiprostone,2014-07-07,Swissmedic Approves AMITIZA(R) (Lubiprostone) For The Treatment Of Opioid-Induced Constipation
SCMP,Lubiprostone,2014-06-17,AMITIZA(R) (Lubiprostone) Receives NICE Recommendation
SCMP,Lubiprostone,2014-05-01,Sucampo Announces Clinical Data On Lubiprostone To Be Presented At Two Upcoming Scientific Conferences
SCMP,Lubiprostone,2014-04-25,Preclinical Data For Lubiprostone And Unoprostone Isopropyl To Be Presented At Experimental Biology Conference 2014
SCMP,Lubiprostone,2014-03-14,Sucampo And Takeda Announce Update On Liquid Formulation Program For AMITIZA(R) (lubiprostone)
SCMP,Lubiprostone,2013-12-17,Sucampo And Takeda Initiate Global Pivotal Phase 3 Program Of Lubiprostone In Pediatric Functional Constipation
SCMP,Lubiprostone,2013-10-23,Sucampo And Takeda Initiate Pivotal Trial Of Lubiprostone Liquid Formulation In Adults With Chronic Idiopathic Constipation
SCMP,Lubiprostone,2013-10-11,Sucampo Announces Presentation Of Results On AMITIZA(R) (lubiprostone) In Opioid-Induced Constipation At Two Upcoming Scientific Conferences
SCMP,Lubiprostone,2013-10-10,Sucampo Announces Presentation Of Results On Lubiprostone In Pediatric Functional Constipation At NASPGHAN 2013
SCMP,Lubiprostone,2013-10-08,Clinical Data Show That Lubiprostone Is Efficacious And Well Tolerated In Children And Adolescents With Functional Constipation
SCMP,Lubiprostone,2013-09-27,Sucampo To Present Data On AMITIZA(R) (Lubiprostone) In Opioid-Induced Constipation At 24th Annual AAPM Meeting
SGYP,Plecanatide,2017-02-07,Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology
SGYP,Plecanatide,2017-01-19,Synergy Pharmaceuticals' TRULANCE™ (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation
SGYP,Plecanatide,2016-12-22,Synergy Pharmaceuticals Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
SGYP,Plecanatide,2016-12-09,Synergy Pharmaceuticals Announces Positive Results In First Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
SGYP,Plecanatide,2016-10-17,Synergy Pharmaceuticals Presents Long-Term Data For Plecanatide In Chronic Idiopathic Constipation At The American College Of Gastroenterology (ACG) Annual Scientific Meeting
SGYP,Plecanatide,2016-09-28,Synergy Pharmaceuticals Announces New Plecanatide Data Presentations At Upcoming Scientific Meeting And Provides Update On IBS-C Program
SGYP,Plecanatide,2016-07-15,Synergy Pharmaceuticals Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program
SGYP,Plecanatide,2016-05-24,Synergy Pharmaceuticals Presents New In Vitro Data Showing The PH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin
SGYP,Plecanatide,2016-05-22,Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data In Chronic Idiopathic Constipation At Digestive Disease Week
SGYP,Plecanatide,2016-05-21,Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week
SGYP,Plecanatide,2016-05-16,Synergy Pharmaceuticals To Present New Plecanatide Data At Digestive Disease Week 2016
SGYP,Plecanatide,2016-04-19,Synergy Pharmaceuticals Announces Acceptance Of New Drug Application For Plecanatide, A Novel Uroguanylin Analog, In Chronic Idiopathic Constipation
SGYP,Plecanatide,2016-01-29,Synergy Pharmaceuticals Files New Drug Application For Plecanatide In Chronic Idiopathic Constipation
SGYP,Plecanatide,2015-07-30,Synergy Pharmaceuticals Announces Positive Results In The Second Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
SGYP,Plecanatide,2015-06-23,Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2015-06-17,Synergy Pharmaceuticals Announces Positive Results In The First Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
SGYP,Plecanatide,2015-01-29,Synergy Pharmaceuticals Completes Patient Enrollment For The Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2015-01-08,Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2014-12-18,Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2014-10-21,Synergy Pharmaceuticals Presents Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2014-10-07,Synergy Pharmaceuticals To Present Additional Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation At ACG 2014 Annual Scientific Meeting
SGYP,Plecanatide,2014-09-18,Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2017-02-07,Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology
SGYP,Plecanatide,2017-01-19,Synergy Pharmaceuticals' TRULANCE™ (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation
SGYP,Plecanatide,2016-12-22,Synergy Pharmaceuticals Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
SGYP,Plecanatide,2016-12-09,Synergy Pharmaceuticals Announces Positive Results In First Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
SGYP,Plecanatide,2016-10-17,Synergy Pharmaceuticals Presents Long-Term Data For Plecanatide In Chronic Idiopathic Constipation At The American College Of Gastroenterology (ACG) Annual Scientific Meeting
SGYP,Plecanatide,2016-09-28,Synergy Pharmaceuticals Announces New Plecanatide Data Presentations At Upcoming Scientific Meeting And Provides Update On IBS-C Program
SGYP,Plecanatide,2016-07-15,Synergy Pharmaceuticals Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program
SGYP,Plecanatide,2016-05-24,Synergy Pharmaceuticals Presents New In Vitro Data Showing The PH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin
SGYP,Plecanatide,2016-05-22,Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data In Chronic Idiopathic Constipation At Digestive Disease Week
SGYP,Plecanatide,2016-05-21,Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week
SGYP,Plecanatide,2016-05-16,Synergy Pharmaceuticals To Present New Plecanatide Data At Digestive Disease Week 2016
SGYP,Plecanatide,2016-04-19,Synergy Pharmaceuticals Announces Acceptance Of New Drug Application For Plecanatide, A Novel Uroguanylin Analog, In Chronic Idiopathic Constipation
SGYP,Plecanatide,2016-01-29,Synergy Pharmaceuticals Files New Drug Application For Plecanatide In Chronic Idiopathic Constipation
SGYP,Plecanatide,2015-07-30,Synergy Pharmaceuticals Announces Positive Results In The Second Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
SGYP,Plecanatide,2015-06-23,Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2015-06-17,Synergy Pharmaceuticals Announces Positive Results In The First Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
SGYP,Plecanatide,2015-01-29,Synergy Pharmaceuticals Completes Patient Enrollment For The Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2015-01-08,Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2014-12-18,Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2014-10-21,Synergy Pharmaceuticals Presents Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2014-10-07,Synergy Pharmaceuticals To Present Additional Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation At ACG 2014 Annual Scientific Meeting
SGYP,Plecanatide,2014-09-18,Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SNGX,SGX301,2017-02-02,Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation From The UK Medicines And Healthcare Products Regulatory Agency
SNGX,SGX301,2015-12-14,Soligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma
SNGX,SGX301,2015-08-04,Soligenix Receives Orphan Drug Designation From The European Commission For SGX301 As A Treatment For Cutaneous T-Cell Lymphoma
SNGX,SGX301,2015-06-23,Soligenix Announces Collaboration With The National Organization For Rare Disorders And The Cutaneous Lymphoma Foundation In Advancing Its Phase 3 Study Of SGX301 For The Treatment Of Cutaneous T-Cell Lymphoma
SNGX,SGX301,2015-01-07,FDA Grants Soligenix "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma
SNGX,SGX301,2014-11-10,Soligenix Reports Third Quarter 2014 Financial Results, Highlighted With The Acquisition Of SGX301, Synthetic Hypericin, For The Treatment Of Cutaneous T-Cell Lymphoma
SNGX,SGX301,2014-09-17,Soligenix Announces FDA Clearance Of Phase 3 Clinical Protocol Of SGX301 In Cutaneous T-Cell Lymphoma
TCON,TRC105,2017-02-16,TRACON Pharmaceuticals Announces First Patient Dosed In Phase 3 TAPPAS Trial Of TRC105 In Angiosarcoma
TCON,TRC105,2017-02-09,TRACON Pharmaceuticals Announces Top-line Results From NCI-Sponsored Phase 2 Trial Of TRC105 In Recurrent Glioblastoma
TCON,TRC105,2017-01-03,TRACON Pharmaceuticals Receives Special Protocol Assessment (SPA) Agreement From FDA For Phase 3 Clinical Trial Of TRC105 In Angiosarcoma
TCON,TRC105,2016-11-11,TRACON Pharmaceuticals Announces Presentation Of Updated Data From Phase 1b/2 Study Of TRC105 And Votrient® In Patients With Angiosarcoma
TCON,TRC105,2016-10-09,TRACON Pharmaceuticals Presents Final Updated Phase 1b Results For TRC105 In Combination With Inlyta® In Renal Cell Carcinoma At The ESMO 2016 Congress
TCON,TRC105,2016-10-03,TRACON Pharmaceuticals Announces Successful Meetings With FDA And EMA For TRC105 (carotuximab) In Angiosarcoma
TCON,TRC105,2016-06-06,TRACON Pharmaceuticals Announces Positive Results From TRC105 And TRC102 Clinical Trials At American Society Of Clinical Oncology (ASCO) 2016 Annual Meeting
TCON,TRC105,2016-05-18,TRACON Pharmaceuticals Initiates Dosing In Phase 1b/2 Study Of TRC105 In Patients With Hepatocellular Carcinoma
TCON,TRC105,2016-05-09,TRACON Pharmaceuticals Announces Initiation Of Dosing In A Phase 1/2 Neoadjuvant Study Of TRC105 In Patients With Breast Cancer
TCON,TRC105,2016-05-04,TRACON Announces EMA Orphan Drug Designation For TRC105 In Soft Tissue Sarcoma
TCON,TRC105,2016-04-11,TRACON Pharmaceuticals Announces TRC105 Clinical Data Presentation At Upcoming AACR Annual Meeting
TCON,TRC105,2016-03-21,TRACON Pharmaceuticals Reports Updated Positive Data On Ongoing Complete Response In Choriocarcinoma Patient Treated With TRC105
TCON,TRC105,2016-03-14,TRACON Pharmaceuticals Initiates Phase 1b Study Of TRC105 In Patients With Lung Cancer
TCON,TRC105,2016-01-25,TRACON Announces FDA Orphan Drug Designation For TRC105 In Soft Tissue Sarcoma
TCON,TRC105,2015-11-06,TRACON Pharmaceuticals Presents Positive Updated Phase 1b Results For TRC105 In Combination With Inlyta® At The 2015 Kidney Cancer Association Meeting
TCON,TRC105,2015-11-05,TRACON Pharmaceuticals Presents Positive Interim Results From TRC105 Trial In Sarcoma At The Connective Tissue Oncology Society (CTOS) 2015 Annual Meeting
TCON,TRC105,2015-09-18,TRACON Pharmaceuticals Reports Ongoing Complete Response In Choriocarcinoma Patient Treated With Company's TRC105 In Compassionate Use Phase 2 Clinical Trial Conducted At Dana-Farber Cancer Institute
TCON,TRC105,2015-07-01,TRACON Pharmaceuticals Announces IND Filing Of DE-122 (TRC105) For The Treatment Of Wet Age-Related Macular Degeneration By Santen Pharmaceutical
TCON,TRC105,2015-06-01,TRACON Pharmaceuticals Announces Positive Results Of TRC105 Clinical Trials In Sarcoma And Liver Cancer At The American Society Of Clinical Oncology (ASCO) 2015 Annual Meeting
TCON,TRC105,2015-05-14,TRACON's TRC105 Receives FDA Fast Track Designation
TCON,TRC105,2015-02-28,TRACON Pharmaceuticals Announces Positive Phase 1b Results For TRC105 In Combination With Inlyta(R) (axitinib) At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
TCON,TRC105,2015-02-19,TRACON Pharmaceuticals Announces Upcoming Presentation Of Results From A Clinical Trial Of TRC105 In Patients With Renal Cell Carcinoma At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
TENX,Levosimendan,2016-10-05,Tenax Therapeutics Provides Clinical Update For Lead Candidate Levosimendan
TENX,Levosimendan,2015-10-08,Tenax Therapeutics Provides Clinical Update For Lead Candidate Levosimendan
TENX,Levosimendan,2015-07-01,Tenax Therapeutics Spotlights Academic Publication On Levosimendan In Cardiac Surgery
TENX,Levosimendan,2015-06-16,Tenax Therapeutics Highlights New Scientific Publication Regarding The Potential Mortality Benefits Of Levosimendan In Septic Shock Patients
TENX,Levosimendan,2015-03-05,Tenax Therapeutics Highlights Recent Scientific Publications On Levosimendan
TENX,Levosimendan,2014-09-22,Tenax Therapeutics Announces First Patients Enrolled In Phase 3 LEVO-CTS Clinical Trial Of Levosimendan
VSAR,VRS-317,2015-12-16,Versartis' VRS-317 6-Month Data Published In The Journal Of Clinical Endocrinology & Metabolism
VSAR,VRS-317,2015-07-06,Versartis Announces Removal Of FDA Partial Clinical Hold And Continuation Of VRS-317 Phase 3 Clinical Trial
VSAR,VRS-317,2015-04-13,Versartis Initiates Phase 2/3 Trial Of VRS-317 In Japan For Children With Growth Hormone Deficiency
VSAR,VRS-317,2015-03-06,Versartis Presents 12-Month Data For VRS-317 At Late-Breaker Session At Endocrine Society's Annual Meeting
VSAR,VRS-317,2015-01-08,Versartis Initiates Global Phase 3 Study Of VRS-317 In Children With Growth Hormone Deficiency
VSAR,VRS-317,2015-01-05,Versartis Announces Positive 12 Month Data For VRS-317 From Ongoing Extension Study
VSAR,VRS-317,2014-12-29,Versartis To Hold Conference Call To Discuss VRS-317 Clinical Update From Ongoing Extension Study
VSAR,VRS-317,2014-10-30,Versartis Schedules Conference Call To Discuss Plans For Phase 3 Trial For VRS-317 In Pediatric Growth Hormone Deficiency Patients
VTAE,VTP-38543,2015-12-29,Vitae Pharmaceuticals Doses First Patients In Phase 2a Proof-of-Concept Trial Of VTP-38543 In Atopic Dermatitis
VTAE,VTP-38543,2015-12-10,Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial Of VTP-38543 In Atopic Dermatitis Patients
VTVT,TTP273,2016-12-14,VTv Therapeutics Announces Positive Topline Results From Phase 2 Study Of TTP273 In Type 2 Diabetes
VTVT,TTP273,2016-08-16,VTv Therapeutics Completes Enrollment Of Phase 2 Trial Evaluating TTP273 For The Treatment Of Type 2 Diabetes
VTVT,TTP273,2016-04-12,VTv Therapeutics Announces Presentations On Its Diabetes Product Candidates TTP273 And TTP399 At The Keystone Symposia On New Therapeutics For Diabetes And Obesity
VTVT,TTP273,2016-02-22,VTv Therapeutics Reports Preclinical And Clinical Results On Its Diabetes Candidate TTP273
VTVT,TTP273,2016-01-21,VTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 For The Treatment Of Type 2 Diabetes
VYGR,VY-AADC01,2017-01-20,Voyager Therapeutics Announces Updates From Phase 1b Trial Of VY-AADC01 For Advanced Parkinson's Disease
VYGR,VY-AADC01,2016-12-07,Voyager Therapeutics Announces Positive Interim Results From Phase 1b Trial Of VY-AADC01 For Advanced Parkinson's Disease
VYGR,VY-AADC01,2016-08-09,Voyager Therapeutics Initiates Third Cohort In Ongoing Phase 1b Clinical Trial Of VY-AADC01 In Advanced Parkinson's Disease
VYGR,VY-AADC01,2016-06-22,Voyager Therapeutics Announces Interim Phase 1b Surgical Results For VY-AADC01 In Advanced Parkinson's Disease
XENT,RESOLVE,2017-03-08,Intersect ENT Submits New Drug Application To FDA For Office-Based RESOLVE Steroid Releasing Implant For Recurrent Chronic Sinus Disease
XENT,RESOLVE,2016-10-17,Intersect ENT's Investigational RESOLVE Steroid Releasing Implant (Photo: Business Wire)
XENT,RESOLVE,2016-06-01,Intersect ENT Announces Completion Of Enrollment In RESOLVE II Clinical Trial Of New In-Office Implant For Recurrent Chronic Sinusitis
XLRN,Luspatercept,2016-12-05,Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology
XLRN,Luspatercept,2016-12-04,Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology
XLRN,Luspatercept,2016-06-10,Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association
XLRN,Luspatercept,2016-06-10,Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association
XLRN,Luspatercept,2016-06-07,Acceleron Pharma To Host Conference Call And Webcast To Review Updated Luspatercept Results Presented At The 21st Congress Of The European Hematology Association
XLRN,Luspatercept,2016-05-19,Acceleron Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association
XLRN,Luspatercept,2015-12-07,Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Beta-Thalassemia Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
XLRN,Luspatercept,2015-12-07,FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Lower-Risk Myelodysplastic Syndromes
XLRN,Luspatercept,2015-12-05,Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Myelodysplastic Syndromes Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
XLRN,Luspatercept,2015-06-12,Acceleron Announces New Luspatercept Phase 2 Clinical Results At The 20th Congress Of The European Hematology Association
XLRN,Luspatercept,2015-06-09,Acceleron Pharma To Host Conference Call And Webcast To Review New Luspatercept Data Presented At The 20th Congress Of The European Hematology Association
XLRN,Luspatercept,2015-05-21,Acceleron To Present Luspatercept Clinical Trials At The 20th Congress Of The European Hematology Association
XLRN,Luspatercept,2015-05-02,Luspatercept Data Presented At The 13th International Symposium On Myelodysplastic Syndromes
XLRN,Luspatercept,2015-04-30,Celgene And Acceleron Select Luspatercept To Advance To Phase 3 In Myelodysplastic Syndromes
XLRN,Luspatercept,2015-04-07,Acceleron Announces Oral Presentations Of Luspatercept And Sotatercept Data At The 13th International Symposium On Myelodysplastic Syndromes
XLRN,Luspatercept,2014-12-10,Luspatercept Data On Myelodysplastic Syndromes Selected For "Best Of ASH" By The American Society Of Hematology
XLRN,Luspatercept,2014-12-07,New Data From Luspatercept Phase 2 Clinical Trial In Beta-Thalassemia Presented At The 56th American Society Of Hematology (ASH) Annual Meeting And Exposition
XLRN,Luspatercept,2016-12-05,Acceleron And Celgene Announce Updated Results From Phase 2 Studies Of Luspatercept In Beta-Thalassemia Presented At The 58th Annual Meeting Of The American Society Of Hematology
XLRN,Luspatercept,2016-12-04,Acceleron And Celgene Announce Updated Results From Ongoing Phase 2 Studies Of Luspatercept In Myelodysplastic Syndromes At The 58th Annual Meeting Of The American Society Of Hematology
XLRN,Luspatercept,2016-06-10,Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association
XLRN,Luspatercept,2016-06-10,Acceleron And Celgene Announce Updated Results From An Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes At The 21st Congress Of The European Hematology Association
XLRN,Luspatercept,2016-06-07,Acceleron Pharma To Host Conference Call And Webcast To Review Updated Luspatercept Results Presented At The 21st Congress Of The European Hematology Association
XLRN,Luspatercept,2016-05-19,Acceleron Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association
XLRN,Luspatercept,2015-12-07,Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Beta-Thalassemia Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
XLRN,Luspatercept,2015-12-07,FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Lower-Risk Myelodysplastic Syndromes
XLRN,Luspatercept,2015-12-05,Celgene And Acceleron Announce New Results From An Investigational Study With Luspatercept In Myelodysplastic Syndromes Presented At The 57th American Society Of Hematology (ASH) Annual Meeting And Exposition
XLRN,Luspatercept,2015-06-12,Acceleron Announces New Luspatercept Phase 2 Clinical Results At The 20th Congress Of The European Hematology Association
XLRN,Luspatercept,2015-06-09,Acceleron Pharma To Host Conference Call And Webcast To Review New Luspatercept Data Presented At The 20th Congress Of The European Hematology Association
XLRN,Luspatercept,2015-05-21,Acceleron To Present Luspatercept Clinical Trials At The 20th Congress Of The European Hematology Association
XLRN,Luspatercept,2015-05-02,Luspatercept Data Presented At The 13th International Symposium On Myelodysplastic Syndromes
XLRN,Luspatercept,2015-04-30,Celgene And Acceleron Select Luspatercept To Advance To Phase 3 In Myelodysplastic Syndromes
XLRN,Luspatercept,2015-04-07,Acceleron Announces Oral Presentations Of Luspatercept And Sotatercept Data At The 13th International Symposium On Myelodysplastic Syndromes
XLRN,Luspatercept,2014-12-10,Luspatercept Data On Myelodysplastic Syndromes Selected For "Best Of ASH" By The American Society Of Hematology
XLRN,Luspatercept,2014-12-07,New Data From Luspatercept Phase 2 Clinical Trial In Beta-Thalassemia Presented At The 56th American Society Of Hematology (ASH) Annual Meeting And Exposition
XLRN,Dalantercept,2015-06-15,Acceleron Announces Publication In Cancer Research Demonstrating Dalantercept Prevents Metastases In Preclinical Studies Of Breast Cancer
XLRN,Dalantercept,2015-05-13,Acceleron To Present Dalantercept Clinical Data At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
XLRN,Dalantercept,2015-02-19,Acceleron To Present New Dalantercept Clinical Data At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
XLRN,Dalantercept,2014-09-23,Acceleron Provides Update On Externally Sponsored Clinical Trial Of Dalantercept Monotherapy In Ovarian Cancer
XLRN,Dalantercept,2014-05-14,Acceleron To Report New Encouraging Interim Clinical Data From Phase 2 Trial Of Dalantercept In Renal Cell Carcinoma At The 50th Annual Meeting Of The American Society Of Clinical Oncology
XLRN,Dalantercept,2015-06-15,Acceleron Announces Publication In Cancer Research Demonstrating Dalantercept Prevents Metastases In Preclinical Studies Of Breast Cancer
XLRN,Dalantercept,2015-05-13,Acceleron To Present Dalantercept Clinical Data At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting
XLRN,Dalantercept,2015-02-19,Acceleron To Present New Dalantercept Clinical Data At The American Society Of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium
XLRN,Dalantercept,2014-09-23,Acceleron Provides Update On Externally Sponsored Clinical Trial Of Dalantercept Monotherapy In Ovarian Cancer
XLRN,Dalantercept,2014-05-14,Acceleron To Report New Encouraging Interim Clinical Data From Phase 2 Trial Of Dalantercept In Renal Cell Carcinoma At The 50th Annual Meeting Of The American Society Of Clinical Oncology
XOMA,XOMA,2017-03-23,XOMA Announces Four Presentations At The 2017 ENDO Meeting
XOMA,XOMA,2017-03-22,XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation
XOMA,XOMA,2017-03-16,XOMA Reports Fourth Quarter And Full Year 2016 Financial Results
XOMA,XOMA,2017-03-14,XOMA To Announce Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call Focused On Its New Strategic Direction On March 16, 2017
XOMA,XOMA,2017-02-28,XOMA To Present New Strategic Initiatives At The Cowen And Company 37th Annual Health Care Conference
XOMA,XOMA,2017-02-16,XOMA Appoints Matthew Perry To Its Board Of Directors
XOMA,XOMA,2017-02-13,XOMA Announces Pricing Of $25 Million Registered Offering Of Common Stock And Convertible Preferred Stock
XOMA,XOMA,2017-01-31,XOMA Establishes Proof-of-Concept For 358 In Congenital Hyperinsulinism And Hypoglycemia Post-Bariatric Surgery
XOMA,XOMA,2016-12-21,XOMA Announces Up To $22 Million Generated From Sale Of Royalty Streams From Two License Agreements To HealthCare Royalty Partners And Provides Corporate Update
XOMA,XOMA,2016-11-09,XOMA Reports Third Quarter 2016 Achievements And Financial Results
XOMA,XOMA,2016-11-08,New XOMA Antibodies Unveiled At The Society For Immunotherapy Of Cancer 31st Annual Meeting
XOMA,XOMA,2016-10-19,XOMA Reaches Analyst Target Price
XOMA,XOMA,2016-10-19,XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study For XOMA 358 In Children With Congenital Hyperinsulinism
XOMA,XOMA,2016-10-14,XOMA Announces Reverse Stock Split
XOMA,XOMA,2016-09-15,XOMA Provides Update From Ongoing Phase 2 XOMA 358 Clinical Studies
XOMA,XOMA,2016-09-06,XOMA To Host XOMA 358 Clinical Update Webcast And Conference Call On September 15, 2016
XOMA,XOMA,2016-08-11,XOMA To Present At The 2016 Wedbush PacGrow Healthcare Conference
XOMA,XOMA,2016-08-03,XOMA Reports Second Quarter 2016 Achievements And Financial Results
XOMA,XOMA,2016-07-20,XOMA Receives Orphan Drug Designation In The European Union For XOMA 358 For Treatment Of Congenital Hyperinsulinism
XOMA,XOMA,2016-07-05,XOMA To Present At The Cantor Fitzgerald Healthcare Conference
XOMA,XOMA,2016-06-28,XOMA Initiates Phase 2 Proof-of-Concept Study Of XOMA 213
XOMA,XOMA,2016-06-02,XOMA To Present At The Jefferies Global Healthcare Conference
XOMA,XOMA,2016-05-04,XOMA Reports First Quarter 2016 Operational Achievements And Financial Results
XOMA,XOMA,2016-04-27,XOMA Initiates XOMA 358 Proof-of-Concept Study In Patients With Hypoglycemia Post Gastric Bypass Surgery
XOMA,XOMA,2016-04-04,XOMA Presented First Data From Novel Antibody Fragment To Address Severe Acute Hypoglycemia At The ENDO Meeting
XOMA,XOMA,2016-03-11,XOMA (XOMA) Weak On High Volume
XOMA,XOMA,2016-03-10,Xoma Stock Soaring on Q4 Earnings Beat
XOMA,XOMA,2016-03-09,Xoma Stock Surges in After-Hours Trading on Q4 Results
XOMA,XOMA,2016-03-09,XOMA Reports Fourth Quarter And Full-Year 2015 Financial Results
XOMA,XOMA,2016-03-02,XOMA To Present At The Cowen & Company Health Care Conference
XOMA,XOMA,2016-02-24,XOMA To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Webcast On March 9
XOMA,XOMA,2015-12-11,Friday Small-Cap Focus: Xoma
XOMA,XOMA,2015-12-01,Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million
XOMA,XOMA,2015-12-01,XOMA Announces License Agreement With Novo Nordisk For XMetA Program In Diabetes
XOMA,XOMA,2015-11-12,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2015-11-09,Strong On High Volume: XOMA (XOMA)
XOMA,XOMA,2015-11-05,XOMA Announces The Sale Of Its Manufacturing Facilities To Agenus
XOMA,XOMA,2015-11-05,XOMA Provides Corporate Update And Reports Financial Results For Third Quarter 2015
XOMA,XOMA,2015-10-29,XOMA To Announce Third Quarter 2015 Financial Results And Host Webcast On November 5
XOMA,XOMA,2015-10-26,XOMA Initiates Proof-of-Concept Study For XOMA 358 In Patients With Congenital Hyperinsulinism
XOMA,XOMA,2015-10-01,XOMA Announces Development And Commercialization Agreement For First-in-Class Anti-TGF-beta Antibody Program In Immuno-Oncology
XOMA,XOMA,2015-09-08,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against XOMA Corporation And Lead Plaintiff Deadline September 22, 2015
XOMA,XOMA,2015-08-18,TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors Of Important Deadline In Class Action - XOMA
XOMA,XOMA,2015-08-07,XOMA To Present At The 2015 Wedbush PacGrow Healthcare Conference
XOMA,XOMA,2015-08-06,XOMA Reports Financial Results For Second Quarter 2015
XOMA,XOMA,2015-08-03,Robbins Arroyo LLP: XOMA Corporation (XOMA) Misled Shareholders According To A Recently Filed Class Action
XOMA,XOMA,2015-07-30,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against XOMA Corporation
XOMA,XOMA,2015-07-30,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against Xoma Corporation
XOMA,XOMA,2015-07-23,XOMA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Xoma Corporation
XOMA,XOMA,2015-07-22,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of XOMA Corporation.
XOMA,XOMA,2015-07-22,Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
XOMA,XOMA,2015-07-22,XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study
XOMA,XOMA,2015-07-17,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
XOMA,XOMA,2015-07-16,XOMA To Announce Second Quarter 2015 Financial Results And Host Webcast On August 6
XOMA,XOMA,2015-07-10,XOMA Stock Closed in the Green Following Upbeat Piper Note
XOMA,XOMA,2015-07-10,Stock To Watch: XOMA (XOMA) In Perilous Reversal
XOMA,XOMA,2015-07-09,Trade-Ideas: XOMA (XOMA) Is Today's "Dead Cat Bounce" Stock
XOMA,XOMA,2015-07-01,Trade-Ideas: XOMA (XOMA) Is Today's Weak On High Relative Volume Stock
XOMA,XOMA,2015-06-30,XOMA (XOMA) Showing Signs Of A Dead Cat Bounce Today
XOMA,XOMA,2015-06-23,Interesting XOMA Put And Call Options For August 21st
XOMA,XOMA,2015-06-23,XOMA (XOMA) Is Weak On High Volume Today
XOMA,XOMA,2015-06-22,XOMA (XOMA) Is Strong On High Volume Today
XOMA,XOMA,2015-06-16,XOMA Receives Orphan Drug Designation For XOMA 358 From U.S. FDA For Treatment Of Congenital Hyperinsulinism (HI)
XOMA,XOMA,2015-06-11,XOMA (XOMA) Is Today's Strong On High Volume Stock
XOMA,XOMA,2015-05-28,XOMA Stock Gains After Reaching Necessary Number of Events to Analyze Behcets Disease Drug Study
XOMA,XOMA,2015-05-28,XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event
XOMA,XOMA,2015-05-19,First Week Of July 17th Options Trading For XOMA
XOMA,XOMA,2015-05-07,XOMA Reports First Quarter 2015 Achievements And Financial Results
XOMA,XOMA,2015-05-04,XOMA To Present At Credit Suisse Antibody Day 2015
XOMA,XOMA,2015-04-30,XOMA To Announce First Quarter 2015 Financial Results And Host Conference Call On May 7
XOMA,XOMA,2015-04-21,First Week Of XOMA December 18th Options Trading
XOMA,XOMA,2015-03-25,First Week Of May 15th Options Trading For XOMA
XOMA,XOMA,2015-03-23,XOMA (XOMA): Today's Weak On High Volume Stock
XOMA,XOMA,2015-03-11,XOMA Highlights Recent Achievements And Reports Fourth Quarter And Full-Year 2014 Financial Results
XOMA,XOMA,2015-03-07,XOMA Presents Positive Phase 1 XOMA 358 Data At The ENDO Meeting
XOMA,XOMA,2015-03-05,XOMA Will Present XOMA 358 Phase 1 Data At ENDO 2015
XOMA,XOMA,2015-03-03,XOMA Announces Retirement Of Fred Kurland And Appointment Of Thomas Burns As Chief Financial Officer
XOMA,XOMA,2015-02-26,XOMA To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Webcast On March 11
XOMA,XOMA,2015-02-24,First Week Of April 17th Options Trading For XOMA
XOMA,XOMA,2015-02-18,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2015-01-23,First Week Of September 18th Options Trading For XOMA
XOMA,XOMA,2015-01-23,XOMA (XOMA) Weak On High Volume
XOMA,XOMA,2015-01-06,Stock To Watch: XOMA (XOMA) In Perilous Reversal
XOMA,XOMA,2014-12-24,XOMA (XOMA) Is Today's Dead Cat Bounce Stock
XOMA,XOMA,2014-12-09,Today's Perilous Reversal Stock: XOMA (XOMA)
XOMA,XOMA,2014-12-09,XOMA Announces Pricing Of $40.0 Million Registered Offering Of Common Stock And Warrants
XOMA,XOMA,2014-12-05,Strong On High Relative Volume: XOMA (XOMA)
XOMA,XOMA,2014-12-03,XOMA (XOMA) Stock: Weak On High Volume Today
XOMA,XOMA,2014-11-24,XOMA To Present At The Piper Jaffray Healthcare Conference
XOMA,XOMA,2014-11-20,Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock
XOMA,XOMA,2014-11-17,Interesting XOMA Call Options For January 2017
XOMA,XOMA,2014-11-10,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2014-11-07,XOMA (XOMA) Stock: Weak On High Volume Today
XOMA,XOMA,2014-11-06,XOMA Highlights Recent Achievements And Reports Financial Results For The Third Quarter Of 2014
XOMA,XOMA,2014-11-04,XOMA Initiates Pivotal Phase 3 Gevokizumab Study In Patients With Pyoderma Gangrenosum
XOMA,XOMA,2014-10-27,XOMA To Announce Third Quarter 2014 Financial Results And Host Webcast On November 6
XOMA,XOMA,2014-10-09,XOMA Launches XOMA 358 Clinical Development
XOMA,XOMA,2014-10-06,The Texas A&M University System And XOMA License Innovative Manufacturing Technology
XOMA,XOMA,2014-09-30,XOMA Initiates U.S. Clinical Trial Of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD(TM)-US
XOMA,XOMA,2014-08-19,First Week of October 18th Options Trading For XOMA
XOMA,XOMA,2014-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2014
XOMA,XOMA,2014-08-06,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2014-07-30,XOMA To Announce Second Quarter 2014 Financial Results And Host Webcast On August 7
XOMA,XOMA,2014-07-22,First Week of March 2015 Options Trading For XOMA
XOMA,XOMA,2014-07-11,XOMA Corp Stock Sees Short Interest Drop 27.6%
XOMA,XOMA,2014-06-30,XOMA Call Today At 4:30pm ET/1:30pm PT To Confirm Communication Plan For EYEGUARD(TM)-B Clinical Program
XOMA,XOMA,2014-06-24,Interesting XOMA Put And Call Options For August 16th
XOMA,XOMA,2014-05-28,XOMA To Present At The Jefferies Global Healthcare Conference
XOMA,XOMA,2014-05-16,Insider Trading Alert - ITMN, WAC And XOMA Traded By Insiders
XOMA,XOMA,2014-05-12,XOMA To Present At The Bank Of America Merrill Lynch Health Care Conference
XOMA,XOMA,2014-05-07,XOMA Reports First Quarter 2014 Operational Highlights And Financial Results
XOMA,XOMA,2014-04-30,XOMA To Announce First Quarter 2014 Financial Results And Host Webcast On May 7
XOMA,XOMA,2014-04-29,Why XOMA (XOMA) Stock Is Surging Today
XOMA,XOMA,2014-04-28,XOMA Finalizes Plans For Gevokizumab Phase 3 Clinical Program In Pyoderma Gangrenosum
XOMA,XOMA,2014-04-22,First Week of December 20th Options Trading For XOMA
XOMA,XOMA,2014-03-21,Insider Trading Alert - SFY, XOMA And SNI Traded By Insiders
XOMA,XOMA,2014-03-07,XOMA Corp Stock Downgraded (XOMA)
XOMA,XOMA,2014-03-06,July 19th Options Now Available For XOMA
XOMA,XOMA,2014-03-06,XOMA (XOMA) Marked As A Dead Cat Bounce Stock
XOMA,XOMA,2014-03-05,Why XOMA Corporation (XOMA) Is Plunging Today
XOMA,XOMA,2014-03-05,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
XOMA,XOMA,2014-03-04,XOMA Reports 2013 Operational Highlights And Fourth Quarter And Full-Year 2013 Financial Results
XOMA,XOMA,2014-03-04,XOMA Provides Update On Gevokizumab Proof-of-Concept Program
XOMA,XOMA,2014-02-25,First Week of XOMA April 19th Options Trading
XOMA,XOMA,2014-02-24,XOMA Receives Orphan Drug Designation From U.S. FDA For Pyoderma Gangrenosum
XOMA,XOMA,2014-02-20,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2014-01-22,Interesting XOMA Put And Call Options For September 20th
XOMA,XOMA,2013-12-26,Short Interest In XOMA Drops 19.7%
XOMA,XOMA,2013-12-18,XOMA Announces Closing Of The Offering And Exercise Of Option
XOMA,XOMA,2013-12-16,Today's Dead Cat Bounce Stock Is XOMA (XOMA)
XOMA,XOMA,2013-12-13,XOMA Announces Pricing Of Approximately $50.0 Million Offering Of Common Stock
XOMA,XOMA,2013-12-12,XOMA Announces Proposed Public Offering Of Common Stock
XOMA,XOMA,2013-11-26,XOMA To Present At The Piper Jaffray Healthcare Conference
XOMA,XOMA,2013-11-20,XOMA Awarded Key Flexible Manufacturing Patent
XOMA,XOMA,2013-11-19,First Week Of January 2014 Options Trading For XOMA
XOMA,XOMA,2013-11-11,XOMA January 2016 Options Begin Trading
XOMA,XOMA,2013-11-08,Interesting XOMA Put And Call Options For January 2015
XOMA,XOMA,2013-11-07,XOMA Highlights Recent Achievements And Reports Financial Results For Third Quarter 2013
XOMA,XOMA,2013-11-06,XOMA To Present At The Credit Suisse Healthcare Conference
XOMA,XOMA,2013-10-31,XOMA To Announce Third Quarter 2013 Financial Results And Host Webcast On November 7
XOMA,XOMA,2013-10-30,Results From Two Phase 2 Studies In XOMA's Gevokizumab Proof-of-Concept Program Are Very Encouraging And Compelling
XOMA,XOMA,2013-10-25,Short Interest In XOMA Falls 31.6%
XOMA,XOMA,2013-10-01,Interesting XOMA Call For November 16th
XOMA,XOMA,2013-09-05,XOMA To Present At The Morgan Stanley Healthcare Conference
XOMA,XOMA,2013-08-23,XOMA Announces Closing Of The Offering And Exercise Of Over-Allotment Option
XOMA,XOMA,2013-08-20,XOMA Announces Pricing Of $27.5 Million Offering Of Common Stock
XOMA,XOMA,2013-08-08,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2013-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2013
XOMA,XOMA,2013-07-25,XOMA To Announce Second Quarter 2013 Financial Results And Host Webcast On August 7
XOMA,XOMA,2013-07-22,XOMA Completes Enrollment In Phase 2 Proof-of-Concept Gevokizumab Trial In Patients With Erosive Osteoarthritis Of The Hand
XOMA,XOMA,2013-07-12,Short Interest Moves 10.7% Lower For XOMA
XOMA,XOMA,2013-07-03,XOMA Transfers Perindopril Franchise Rights To Symplmed
XOMA,XOMA,2013-07-02,XOMA To Present At The JMP Securities Healthcare Conference
XOMA,XOMA,2013-06-25,XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program For Gevokizumab
XOMA,XOMA,2017-03-23,XOMA Announces Four Presentations At The 2017 ENDO Meeting
XOMA,XOMA,2017-03-22,XOMA Announces Full Repayment Of Hercules Technology Growth Capital Debt Obligation
XOMA,XOMA,2017-03-16,XOMA Reports Fourth Quarter And Full Year 2016 Financial Results
XOMA,XOMA,2017-03-14,XOMA To Announce Fourth Quarter And Full Year 2016 Financial Results And Host Conference Call Focused On Its New Strategic Direction On March 16, 2017
XOMA,XOMA,2017-02-28,XOMA To Present New Strategic Initiatives At The Cowen And Company 37th Annual Health Care Conference
XOMA,XOMA,2017-02-16,XOMA Appoints Matthew Perry To Its Board Of Directors
XOMA,XOMA,2017-02-13,XOMA Announces Pricing Of $25 Million Registered Offering Of Common Stock And Convertible Preferred Stock
XOMA,XOMA,2017-01-31,XOMA Establishes Proof-of-Concept For 358 In Congenital Hyperinsulinism And Hypoglycemia Post-Bariatric Surgery
XOMA,XOMA,2016-12-21,XOMA Announces Up To $22 Million Generated From Sale Of Royalty Streams From Two License Agreements To HealthCare Royalty Partners And Provides Corporate Update
XOMA,XOMA,2016-11-09,XOMA Reports Third Quarter 2016 Achievements And Financial Results
XOMA,XOMA,2016-11-08,New XOMA Antibodies Unveiled At The Society For Immunotherapy Of Cancer 31st Annual Meeting
XOMA,XOMA,2016-10-19,XOMA Reaches Analyst Target Price
XOMA,XOMA,2016-10-19,XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study For XOMA 358 In Children With Congenital Hyperinsulinism
XOMA,XOMA,2016-10-14,XOMA Announces Reverse Stock Split
XOMA,XOMA,2016-09-15,XOMA Provides Update From Ongoing Phase 2 XOMA 358 Clinical Studies
XOMA,XOMA,2016-09-06,XOMA To Host XOMA 358 Clinical Update Webcast And Conference Call On September 15, 2016
XOMA,XOMA,2016-08-11,XOMA To Present At The 2016 Wedbush PacGrow Healthcare Conference
XOMA,XOMA,2016-08-03,XOMA Reports Second Quarter 2016 Achievements And Financial Results
XOMA,XOMA,2016-07-20,XOMA Receives Orphan Drug Designation In The European Union For XOMA 358 For Treatment Of Congenital Hyperinsulinism
XOMA,XOMA,2016-07-05,XOMA To Present At The Cantor Fitzgerald Healthcare Conference
XOMA,XOMA,2016-06-28,XOMA Initiates Phase 2 Proof-of-Concept Study Of XOMA 213
XOMA,XOMA,2016-06-02,XOMA To Present At The Jefferies Global Healthcare Conference
XOMA,XOMA,2016-05-04,XOMA Reports First Quarter 2016 Operational Achievements And Financial Results
XOMA,XOMA,2016-04-27,XOMA Initiates XOMA 358 Proof-of-Concept Study In Patients With Hypoglycemia Post Gastric Bypass Surgery
XOMA,XOMA,2016-04-04,XOMA Presented First Data From Novel Antibody Fragment To Address Severe Acute Hypoglycemia At The ENDO Meeting
XOMA,XOMA,2016-03-11,XOMA (XOMA) Weak On High Volume
XOMA,XOMA,2016-03-10,Xoma Stock Soaring on Q4 Earnings Beat
XOMA,XOMA,2016-03-09,Xoma Stock Surges in After-Hours Trading on Q4 Results
XOMA,XOMA,2016-03-09,XOMA Reports Fourth Quarter And Full-Year 2015 Financial Results
XOMA,XOMA,2016-03-02,XOMA To Present At The Cowen & Company Health Care Conference
XOMA,XOMA,2016-02-24,XOMA To Announce Fourth Quarter And Full Year 2015 Financial Results And Host Webcast On March 9
XOMA,XOMA,2015-12-11,Friday Small-Cap Focus: Xoma
XOMA,XOMA,2015-12-01,Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million
XOMA,XOMA,2015-12-01,XOMA Announces License Agreement With Novo Nordisk For XMetA Program In Diabetes
XOMA,XOMA,2015-11-12,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2015-11-09,Strong On High Volume: XOMA (XOMA)
XOMA,XOMA,2015-11-05,XOMA Announces The Sale Of Its Manufacturing Facilities To Agenus
XOMA,XOMA,2015-11-05,XOMA Provides Corporate Update And Reports Financial Results For Third Quarter 2015
XOMA,XOMA,2015-10-29,XOMA To Announce Third Quarter 2015 Financial Results And Host Webcast On November 5
XOMA,XOMA,2015-10-26,XOMA Initiates Proof-of-Concept Study For XOMA 358 In Patients With Congenital Hyperinsulinism
XOMA,XOMA,2015-10-01,XOMA Announces Development And Commercialization Agreement For First-in-Class Anti-TGF-beta Antibody Program In Immuno-Oncology
XOMA,XOMA,2015-09-08,Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action Against XOMA Corporation And Lead Plaintiff Deadline September 22, 2015
XOMA,XOMA,2015-08-18,TRADING ALERT: The Rosen Law Firm Reminds Xoma Corporation Investors Of Important Deadline In Class Action - XOMA
XOMA,XOMA,2015-08-07,XOMA To Present At The 2015 Wedbush PacGrow Healthcare Conference
XOMA,XOMA,2015-08-06,XOMA Reports Financial Results For Second Quarter 2015
XOMA,XOMA,2015-08-03,Robbins Arroyo LLP: XOMA Corporation (XOMA) Misled Shareholders According To A Recently Filed Class Action
XOMA,XOMA,2015-07-30,SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against XOMA Corporation
XOMA,XOMA,2015-07-30,EQUITY ALERT: The Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against Xoma Corporation
XOMA,XOMA,2015-07-23,XOMA SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Xoma Corporation
XOMA,XOMA,2015-07-22,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of XOMA Corporation.
XOMA,XOMA,2015-07-22,Xoma Is a Biotech Zombie in Need of a Kill Shot to the Head
XOMA,XOMA,2015-07-22,XOMA Announces Results From Phase 3 EYEGUARD(TM)-B Study
XOMA,XOMA,2015-07-17,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
XOMA,XOMA,2015-07-16,XOMA To Announce Second Quarter 2015 Financial Results And Host Webcast On August 6
XOMA,XOMA,2015-07-10,XOMA Stock Closed in the Green Following Upbeat Piper Note
XOMA,XOMA,2015-07-10,Stock To Watch: XOMA (XOMA) In Perilous Reversal
XOMA,XOMA,2015-07-09,Trade-Ideas: XOMA (XOMA) Is Today's "Dead Cat Bounce" Stock
XOMA,XOMA,2015-07-01,Trade-Ideas: XOMA (XOMA) Is Today's Weak On High Relative Volume Stock
XOMA,XOMA,2015-06-30,XOMA (XOMA) Showing Signs Of A Dead Cat Bounce Today
XOMA,XOMA,2015-06-23,Interesting XOMA Put And Call Options For August 21st
XOMA,XOMA,2015-06-23,XOMA (XOMA) Is Weak On High Volume Today
XOMA,XOMA,2015-06-22,XOMA (XOMA) Is Strong On High Volume Today
XOMA,XOMA,2015-06-16,XOMA Receives Orphan Drug Designation For XOMA 358 From U.S. FDA For Treatment Of Congenital Hyperinsulinism (HI)
XOMA,XOMA,2015-06-11,XOMA (XOMA) Is Today's Strong On High Volume Stock
XOMA,XOMA,2015-05-28,XOMA Stock Gains After Reaching Necessary Number of Events to Analyze Behcets Disease Drug Study
XOMA,XOMA,2015-05-28,XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event
XOMA,XOMA,2015-05-19,First Week Of July 17th Options Trading For XOMA
XOMA,XOMA,2015-05-07,XOMA Reports First Quarter 2015 Achievements And Financial Results
XOMA,XOMA,2015-05-04,XOMA To Present At Credit Suisse Antibody Day 2015
XOMA,XOMA,2015-04-30,XOMA To Announce First Quarter 2015 Financial Results And Host Conference Call On May 7
XOMA,XOMA,2015-04-21,First Week Of XOMA December 18th Options Trading
XOMA,XOMA,2015-03-25,First Week Of May 15th Options Trading For XOMA
XOMA,XOMA,2015-03-23,XOMA (XOMA): Today's Weak On High Volume Stock
XOMA,XOMA,2015-03-11,XOMA Highlights Recent Achievements And Reports Fourth Quarter And Full-Year 2014 Financial Results
XOMA,XOMA,2015-03-07,XOMA Presents Positive Phase 1 XOMA 358 Data At The ENDO Meeting
XOMA,XOMA,2015-03-05,XOMA Will Present XOMA 358 Phase 1 Data At ENDO 2015
XOMA,XOMA,2015-03-03,XOMA Announces Retirement Of Fred Kurland And Appointment Of Thomas Burns As Chief Financial Officer
XOMA,XOMA,2015-02-26,XOMA To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Webcast On March 11
XOMA,XOMA,2015-02-24,First Week Of April 17th Options Trading For XOMA
XOMA,XOMA,2015-02-18,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2015-01-23,First Week Of September 18th Options Trading For XOMA
XOMA,XOMA,2015-01-23,XOMA (XOMA) Weak On High Volume
XOMA,XOMA,2015-01-06,Stock To Watch: XOMA (XOMA) In Perilous Reversal
XOMA,XOMA,2014-12-24,XOMA (XOMA) Is Today's Dead Cat Bounce Stock
XOMA,XOMA,2014-12-09,Today's Perilous Reversal Stock: XOMA (XOMA)
XOMA,XOMA,2014-12-09,XOMA Announces Pricing Of $40.0 Million Registered Offering Of Common Stock And Warrants
XOMA,XOMA,2014-12-05,Strong On High Relative Volume: XOMA (XOMA)
XOMA,XOMA,2014-12-03,XOMA (XOMA) Stock: Weak On High Volume Today
XOMA,XOMA,2014-11-24,XOMA To Present At The Piper Jaffray Healthcare Conference
XOMA,XOMA,2014-11-20,Trade-Ideas: XOMA (XOMA) Is Today's Strong On High Relative Volume Stock
XOMA,XOMA,2014-11-17,Interesting XOMA Call Options For January 2017
XOMA,XOMA,2014-11-10,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2014-11-07,XOMA (XOMA) Stock: Weak On High Volume Today
XOMA,XOMA,2014-11-06,XOMA Highlights Recent Achievements And Reports Financial Results For The Third Quarter Of 2014
XOMA,XOMA,2014-11-04,XOMA Initiates Pivotal Phase 3 Gevokizumab Study In Patients With Pyoderma Gangrenosum
XOMA,XOMA,2014-10-27,XOMA To Announce Third Quarter 2014 Financial Results And Host Webcast On November 6
XOMA,XOMA,2014-10-09,XOMA Launches XOMA 358 Clinical Development
XOMA,XOMA,2014-10-06,The Texas A&M University System And XOMA License Innovative Manufacturing Technology
XOMA,XOMA,2014-09-30,XOMA Initiates U.S. Clinical Trial Of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD(TM)-US
XOMA,XOMA,2014-08-19,First Week of October 18th Options Trading For XOMA
XOMA,XOMA,2014-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2014
XOMA,XOMA,2014-08-06,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2014-07-30,XOMA To Announce Second Quarter 2014 Financial Results And Host Webcast On August 7
XOMA,XOMA,2014-07-22,First Week of March 2015 Options Trading For XOMA
XOMA,XOMA,2014-07-11,XOMA Corp Stock Sees Short Interest Drop 27.6%
XOMA,XOMA,2014-06-30,XOMA Call Today At 4:30pm ET/1:30pm PT To Confirm Communication Plan For EYEGUARD(TM)-B Clinical Program
XOMA,XOMA,2014-06-24,Interesting XOMA Put And Call Options For August 16th
XOMA,XOMA,2014-05-28,XOMA To Present At The Jefferies Global Healthcare Conference
XOMA,XOMA,2014-05-16,Insider Trading Alert - ITMN, WAC And XOMA Traded By Insiders
XOMA,XOMA,2014-05-12,XOMA To Present At The Bank Of America Merrill Lynch Health Care Conference
XOMA,XOMA,2014-05-07,XOMA Reports First Quarter 2014 Operational Highlights And Financial Results
XOMA,XOMA,2014-04-30,XOMA To Announce First Quarter 2014 Financial Results And Host Webcast On May 7
XOMA,XOMA,2014-04-29,Why XOMA (XOMA) Stock Is Surging Today
XOMA,XOMA,2014-04-28,XOMA Finalizes Plans For Gevokizumab Phase 3 Clinical Program In Pyoderma Gangrenosum
XOMA,XOMA,2014-04-22,First Week of December 20th Options Trading For XOMA
XOMA,XOMA,2014-03-21,Insider Trading Alert - SFY, XOMA And SNI Traded By Insiders
XOMA,XOMA,2014-03-07,XOMA Corp Stock Downgraded (XOMA)
XOMA,XOMA,2014-03-06,July 19th Options Now Available For XOMA
XOMA,XOMA,2014-03-06,XOMA (XOMA) Marked As A Dead Cat Bounce Stock
XOMA,XOMA,2014-03-05,Why XOMA Corporation (XOMA) Is Plunging Today
XOMA,XOMA,2014-03-05,XOMA (XOMA) Showing Signs Of Perilous Reversal Today
XOMA,XOMA,2014-03-04,XOMA Reports 2013 Operational Highlights And Fourth Quarter And Full-Year 2013 Financial Results
XOMA,XOMA,2014-03-04,XOMA Provides Update On Gevokizumab Proof-of-Concept Program
XOMA,XOMA,2014-02-25,First Week of XOMA April 19th Options Trading
XOMA,XOMA,2014-02-24,XOMA Receives Orphan Drug Designation From U.S. FDA For Pyoderma Gangrenosum
XOMA,XOMA,2014-02-20,XOMA To Present At Upcoming Investor Conferences
XOMA,XOMA,2014-01-22,Interesting XOMA Put And Call Options For September 20th
XOMA,XOMA,2013-12-26,Short Interest In XOMA Drops 19.7%
XOMA,XOMA,2013-12-18,XOMA Announces Closing Of The Offering And Exercise Of Option
XOMA,XOMA,2013-12-16,Today's Dead Cat Bounce Stock Is XOMA (XOMA)
XOMA,XOMA,2013-12-13,XOMA Announces Pricing Of Approximately $50.0 Million Offering Of Common Stock
XOMA,XOMA,2013-12-12,XOMA Announces Proposed Public Offering Of Common Stock
XOMA,XOMA,2013-11-26,XOMA To Present At The Piper Jaffray Healthcare Conference
XOMA,XOMA,2013-11-20,XOMA Awarded Key Flexible Manufacturing Patent
XOMA,XOMA,2013-11-19,First Week Of January 2014 Options Trading For XOMA
XOMA,XOMA,2013-11-11,XOMA January 2016 Options Begin Trading
XOMA,XOMA,2013-11-08,Interesting XOMA Put And Call Options For January 2015
XOMA,XOMA,2013-11-07,XOMA Highlights Recent Achievements And Reports Financial Results For Third Quarter 2013
XOMA,XOMA,2013-11-06,XOMA To Present At The Credit Suisse Healthcare Conference
XOMA,XOMA,2013-10-31,XOMA To Announce Third Quarter 2013 Financial Results And Host Webcast On November 7
XOMA,XOMA,2013-10-30,Results From Two Phase 2 Studies In XOMA's Gevokizumab Proof-of-Concept Program Are Very Encouraging And Compelling
XOMA,XOMA,2013-10-25,Short Interest In XOMA Falls 31.6%
XOMA,XOMA,2013-10-01,Interesting XOMA Call For November 16th
XOMA,XOMA,2013-09-05,XOMA To Present At The Morgan Stanley Healthcare Conference
XOMA,XOMA,2013-08-23,XOMA Announces Closing Of The Offering And Exercise Of Over-Allotment Option
XOMA,XOMA,2013-08-20,XOMA Announces Pricing Of $27.5 Million Offering Of Common Stock
XOMA,XOMA,2013-08-08,XOMA To Present At Two Upcoming Investor Conferences
XOMA,XOMA,2013-08-07,XOMA Highlights Recent Achievements And Reports Financial Results For Second Quarter 2013
XOMA,XOMA,2013-07-25,XOMA To Announce Second Quarter 2013 Financial Results And Host Webcast On August 7
XOMA,XOMA,2013-07-22,XOMA Completes Enrollment In Phase 2 Proof-of-Concept Gevokizumab Trial In Patients With Erosive Osteoarthritis Of The Hand
XOMA,XOMA,2013-07-12,Short Interest Moves 10.7% Lower For XOMA
XOMA,XOMA,2013-07-03,XOMA Transfers Perindopril Franchise Rights To Symplmed
XOMA,XOMA,2013-07-02,XOMA To Present At The JMP Securities Healthcare Conference
XOMA,XOMA,2013-06-25,XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program For Gevokizumab
VCEL,MACI,2017-02-01,Vericel Announces First MACI Implant In The United States For The Treatment Of Symptomatic Cartilage Defects Of The Knee
VCEL,MACI,2016-12-14,FDA Approves MACI For The Treatment Of Symptomatic Cartilage Defects Of The Knee In Adults
VCEL,MACI,2016-03-07,Vericel Announces FDA Acceptance For Filing Of BLA For MACI For The Treatment Of Symptomatic Cartilage Defects In The Knee
VCEL,MACI,2016-01-04,Vericel Submits Biologics License Application To The FDA For MACI For The Treatment Of Cartilage Defects In The Knee
VCEL,MACI,2015-06-10,Vericel Announces Plan To Submit Biologics License Application To FDA By Year-End 2015 For MACI For The Treatment Of Cartilage Defects In The Knee
VCEL,MACI,2015-03-25,Vericel Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study Of MACI(TM) Implant
TSRO,Rolapitant,2017-01-11,TESARO Receives Complete Response Letter For Rolapitant IV From U.S. FDA
TSRO,Rolapitant,2016-06-23,TESARO Announces Rolapitant Data Presentations At The 2016 MASCC/ISOO Annual Meeting On Supportive Care In Cancer
TSRO,Rolapitant,2016-03-23,TESARO Announces Validation Of Marketing Authorisation Application For Oral Rolapitant By The European Medicines Agency
TSRO,Rolapitant,2016-03-14,TESARO Submits New Drug Application For Intravenous Rolapitant To The U.S. Food And Drug Administration
TSRO,Rolapitant,2015-11-16,TESARO Announces The Launch Of VARUBI(TM) (Rolapitant) In The United States
TSRO,Rolapitant,2015-11-16,TESARO Announces The Launch Of VARUBI™ (rolapitant) In The United States
TSRO,Rolapitant,2015-09-24,TESARO Announces Inclusion Of VARUBI(TM) (rolapitant) In NCCN(R) Antiemesis Guidelines
TSRO,Rolapitant,2015-09-02,TESARO Announces U.S. FDA Approval Of VARUBI(TM) (rolapitant) For Nausea And Vomiting Associated With Cancer Chemotherapy
TSRO,Rolapitant,2015-07-30,Tesaro And Jiangsu Hengrui Medicine Announce Rolapitant License Agreement For China
TSRO,Rolapitant,2015-05-30,TESARO Announces Successful Completion Of Rolapitant Bioequivalence Study
TSRO,Rolapitant,2014-09-08,OPKO Licensee TESARO Submits New Drug Application For Rolapitant
TSRO,Rolapitant,2014-09-08,TESARO Announces Submission Of Rolapitant New Drug Application (NDA) To U.S. Food And Drug Administration
TSRO,Rolapitant,2014-06-27,TESARO Summarizes Rolapitant Data Presented At The 2014 MASCC/ISOO International Symposium On Supportive Care In Cancer
TSRO,Rolapitant,2014-06-01,Tesaro Summarizes Phase 3 Rolapitant Data Presented At The 2014 American Society Of Clinical Oncology (ASCO) Annual Meeting And Provides An Update On Niraparib Development Strategy
INCY,Baricitinib,2017-02-15,Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo
INCY,Baricitinib,2016-11-14,Baricitinib Demonstrates Early Response Compared To Placebo And Significant Improvement Compared To Adalimumab In Patient-Reported Outcomes
INCY,Baricitinib,2016-03-31,Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics
INCY,Baricitinib,2016-01-19,Lilly And Incyte Announce Submission Of New Drug Application To FDA For Oral Once-Daily Baricitinib For Treatment Of Moderate-to-Severe Rheumatoid Arthritis
INCY,Baricitinib,2015-11-07,Detailed Results Demonstrate Baricitinib Superiority To Adalimumab In Improving Signs And Symptoms Of Rheumatoid Arthritis
INCY,Baricitinib,2017-02-15,Additional Results From Pivotal RA-BEAM Study Published In New England Journal Of Medicine Show Baricitinib-treated Patients Demonstrated Sustained Improvement In Rheumatoid Arthritis Compared To Adalimumab And Placebo
INCY,Baricitinib,2016-11-14,Baricitinib Demonstrates Early Response Compared To Placebo And Significant Improvement Compared To Adalimumab In Patient-Reported Outcomes
INCY,Baricitinib,2016-03-31,Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics
INCY,Baricitinib,2016-01-19,Lilly And Incyte Announce Submission Of New Drug Application To FDA For Oral Once-Daily Baricitinib For Treatment Of Moderate-to-Severe Rheumatoid Arthritis
INCY,Baricitinib,2015-11-07,Detailed Results Demonstrate Baricitinib Superiority To Adalimumab In Improving Signs And Symptoms Of Rheumatoid Arthritis
BMRN,Cerliponase,2016-09-15,BioMarin Announces EMA Validation Of Brineura™ (Cerliponase Alfa) Marketing Authorization Application For Treatment Of CLN2 Disease, A Form Of Batten Disease
BMRN,Cerliponase,2016-09-06,BioMarin Announces Update To Brineura™ (Cerliponase Alfa) Program For Treatment Of CLN2 Disease, A Form Of Batten Disease
BMRN,Cerliponase,2016-07-27,FDA Accepts BLA For BioMarin's Cerliponase Alfa For CLN2 Disease, Form Of Batten Disease
BMRN,Cerliponase,2016-05-03,BioMarin Announces EMA Grants Accelerated Assessment For Cerliponase Alfa, Experimental Treatment For A Form Of Batten Disease
BMRN,Cerliponase,2016-03-02,BioMarin Announces Positive Data From Cerliponase Alfa Program For Treatment Of CLN2 Disease, A Form Of Batten Disease, At 12th Annual WORLDSymposium(TM) 2016
BMRN,Cerliponase,2016-09-15,BioMarin Announces EMA Validation Of Brineura™ (Cerliponase Alfa) Marketing Authorization Application For Treatment Of CLN2 Disease, A Form Of Batten Disease
BMRN,Cerliponase,2016-09-06,BioMarin Announces Update To Brineura™ (Cerliponase Alfa) Program For Treatment Of CLN2 Disease, A Form Of Batten Disease
BMRN,Cerliponase,2016-07-27,FDA Accepts BLA For BioMarin's Cerliponase Alfa For CLN2 Disease, Form Of Batten Disease
BMRN,Cerliponase,2016-05-03,BioMarin Announces EMA Grants Accelerated Assessment For Cerliponase Alfa, Experimental Treatment For A Form Of Batten Disease
BMRN,Cerliponase,2016-03-02,BioMarin Announces Positive Data From Cerliponase Alfa Program For Treatment Of CLN2 Disease, A Form Of Batten Disease, At 12th Annual WORLDSymposium(TM) 2016
SGYP,Plecanatide,2017-02-07,Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology
SGYP,Plecanatide,2017-01-19,Synergy Pharmaceuticals' TRULANCE™ (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation
SGYP,Plecanatide,2016-12-22,Synergy Pharmaceuticals Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
SGYP,Plecanatide,2016-12-09,Synergy Pharmaceuticals Announces Positive Results In First Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
SGYP,Plecanatide,2016-10-17,Synergy Pharmaceuticals Presents Long-Term Data For Plecanatide In Chronic Idiopathic Constipation At The American College Of Gastroenterology (ACG) Annual Scientific Meeting
SGYP,Plecanatide,2016-09-28,Synergy Pharmaceuticals Announces New Plecanatide Data Presentations At Upcoming Scientific Meeting And Provides Update On IBS-C Program
SGYP,Plecanatide,2016-07-15,Synergy Pharmaceuticals Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program
SGYP,Plecanatide,2016-05-24,Synergy Pharmaceuticals Presents New In Vitro Data Showing The PH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin
SGYP,Plecanatide,2016-05-22,Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data In Chronic Idiopathic Constipation At Digestive Disease Week
SGYP,Plecanatide,2016-05-21,Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week
SGYP,Plecanatide,2016-05-16,Synergy Pharmaceuticals To Present New Plecanatide Data At Digestive Disease Week 2016
SGYP,Plecanatide,2016-04-19,Synergy Pharmaceuticals Announces Acceptance Of New Drug Application For Plecanatide, A Novel Uroguanylin Analog, In Chronic Idiopathic Constipation
SGYP,Plecanatide,2016-01-29,Synergy Pharmaceuticals Files New Drug Application For Plecanatide In Chronic Idiopathic Constipation
SGYP,Plecanatide,2015-07-30,Synergy Pharmaceuticals Announces Positive Results In The Second Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
SGYP,Plecanatide,2015-06-23,Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2015-06-17,Synergy Pharmaceuticals Announces Positive Results In The First Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
SGYP,Plecanatide,2015-01-29,Synergy Pharmaceuticals Completes Patient Enrollment For The Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2015-01-08,Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2014-12-18,Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2014-10-21,Synergy Pharmaceuticals Presents Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2014-10-07,Synergy Pharmaceuticals To Present Additional Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation At ACG 2014 Annual Scientific Meeting
SGYP,Plecanatide,2014-09-18,Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2017-02-07,Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology
SGYP,Plecanatide,2017-01-19,Synergy Pharmaceuticals' TRULANCE™ (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation
SGYP,Plecanatide,2016-12-22,Synergy Pharmaceuticals Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
SGYP,Plecanatide,2016-12-09,Synergy Pharmaceuticals Announces Positive Results In First Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
SGYP,Plecanatide,2016-10-17,Synergy Pharmaceuticals Presents Long-Term Data For Plecanatide In Chronic Idiopathic Constipation At The American College Of Gastroenterology (ACG) Annual Scientific Meeting
SGYP,Plecanatide,2016-09-28,Synergy Pharmaceuticals Announces New Plecanatide Data Presentations At Upcoming Scientific Meeting And Provides Update On IBS-C Program
SGYP,Plecanatide,2016-07-15,Synergy Pharmaceuticals Provides Update On Ongoing FDA Review Of Plecanatide CIC NDA And IBS-C Clinical Development Program
SGYP,Plecanatide,2016-05-24,Synergy Pharmaceuticals Presents New In Vitro Data Showing The PH-Dependent Activity Of Plecanatide Replicates That Of Naturally Occurring GI Peptide Uroguanylin
SGYP,Plecanatide,2016-05-22,Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data In Chronic Idiopathic Constipation At Digestive Disease Week
SGYP,Plecanatide,2016-05-21,Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data In Chronic Idiopathic Constipation At Digestive Disease Week
SGYP,Plecanatide,2016-05-16,Synergy Pharmaceuticals To Present New Plecanatide Data At Digestive Disease Week 2016
SGYP,Plecanatide,2016-04-19,Synergy Pharmaceuticals Announces Acceptance Of New Drug Application For Plecanatide, A Novel Uroguanylin Analog, In Chronic Idiopathic Constipation
SGYP,Plecanatide,2016-01-29,Synergy Pharmaceuticals Files New Drug Application For Plecanatide In Chronic Idiopathic Constipation
SGYP,Plecanatide,2015-07-30,Synergy Pharmaceuticals Announces Positive Results In The Second Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
SGYP,Plecanatide,2015-06-23,Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2015-06-17,Synergy Pharmaceuticals Announces Positive Results In The First Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation (CIC)
SGYP,Plecanatide,2015-01-29,Synergy Pharmaceuticals Completes Patient Enrollment For The Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2015-01-08,Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
SGYP,Plecanatide,2014-12-18,Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2014-10-21,Synergy Pharmaceuticals Presents Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation
SGYP,Plecanatide,2014-10-07,Synergy Pharmaceuticals To Present Additional Positive Phase 2b Study Results For Plecanatide In Patients With Irritable Bowel Syndrome With Constipation At ACG 2014 Annual Scientific Meeting
SGYP,Plecanatide,2014-09-18,Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
BTX,AST-OPC1,2015-08-31,BioTime Subsidiary Asterias Therapeutics Concludes Recruitment Of Initial Safety Cohort Of The SCiStar Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury
BTX,AST-OPC1,2014-10-20,Asterias Biotherapeutics Announces Notice Of Grant Award With CIRM For Phase 1/2a Clinical Trial Of AST-OPC1 In Complete Cervical Spinal Cord Injury
BTX,AST-OPC1,2014-08-27,BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury
BTX,AST-OPC1,2014-08-27,Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury
SMMT,Ezutromid,2016-11-16,Summit Enrols Patients In The United States Into PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid In Patients With DMD
SMMT,Ezutromid,2016-09-27,Summit Receives Rare Pediatric Disease Designation From US FDA For Ezutromid In Treatment Of Duchenne Muscular Dystrophy
SMMT,Ezutromid,2016-09-26,Summit Receives Fast Track Designation From US FDA For Ezutromid In The Treatment Of Duchenne Muscular Dystrophy
SMMT,Ezutromid,2016-08-09,Summit Reports Positive Phase 1 New Formulation Data And Outlines Route To Market Strategy For DMD Candidate Ezutromid
SMMT,Ezutromid,2016-06-17,First Patient Enrolled In Summit's PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid In Boys With DMD
SMMT,Ezutromid,2016-04-26,Summit's IND Cleared By FDA Allowing Expansion Of PhaseOut DMD, A Phase 2 Clinical Trial Of Ezutromid (SMT C1100), Into The US
CLVS,Rucaparib,2017-03-12,Clovis Oncology Presents New Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer At 2017 SGO Annual Meeting On Women's Cancer
CLVS,Rucaparib,2017-02-01,Clovis Oncology And Strata Oncology Announce Collaboration To Accelerate Enrollment In Rucaparib Prostate Cancer Development Program
CLVS,Rucaparib,2016-12-19,Clovis Oncology Announces FDA Accelerated Approval Of RUBRACA™ (rucaparib) For The Monotherapy Treatment Of Advanced Ovarian Cancer In Women With Deleterious Germline Or Somatic BRCA Mutations Treated With Two Or More Chemotherapies
CLVS,Rucaparib,2016-10-07,Clovis Oncology Presents Efficacy And Safety Data From New Drug Application (NDA) Population For Rucaparib In The Treatment Of Advanced Mutant BRCA Ovarian Cancer At 2016 ESMO Congress
CLVS,Rucaparib,2016-09-28,Clovis Oncology Announces Rucaparib Data Presentations At ESMO 2016 Congress
CLVS,Rucaparib,2016-08-23,FDA Accepts Clovis Oncology's New Drug Application For Rucaparib For Priority Review For The Treatment Of Advanced Mutant BRCA Ovarian Cancer
CLVS,Rucaparib,2016-06-06,Clovis Oncology Presents Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer And Pancreatic Cancer At 2016 ASCO Annual Meeting
CLVS,Rucaparib,2015-05-30,Clovis Oncology's Phase 2 Studies Of Rucaparib In Ovarian Cancer Demonstrate Highly Compelling Clinical Activity, In Both BRCA-mutant And BRCA-like Patients, Together Comprising Approximately 60 Percent Of Patients
CLVS,Rucaparib,2015-04-06,Clovis Oncology Receives Breakthrough Therapy Designation For Rucaparib For Monotherapy Treatment Of Advanced Ovarian Cancer In Patients With BRCA-mutated Tumors (Inclusive Of Both Germline And Somatic BRCA Mutations)
CLVS,Rucaparib,2014-11-19,Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And BRCAness Patients
CLVS,Rucaparib,2014-09-28,Data From Ongoing Phase 2 Studies Of Rucaparib In Ovarian Cancer Demonstrate Safety And Clinical Activity, Validate Differentiated Strategy
RDUS,Abaloparatide-SC,2017-03-10,Radius Health Receives Notification Of PDUFA Extension For Abaloparatide-SC
RDUS,Abaloparatide-SC,2017-02-01,Mayo Clinic Proceedings Publishes Positive Results From The ACTIVExtend Clinical Trial Of Abaloparatide-SC In Postmenopausal Women With Osteoporosis
RDUS,Abaloparatide-SC,2016-09-18,Radius Announces Publication Of Additional Positive Results From The Phase 3 ACTIVE Trial Of Abaloparatide-SC In JBMR
RDUS,Abaloparatide-SC,2016-05-31,Radius Announces FDA Acceptance For Filing Of New Drug Application For Abaloparatide-SC For The Treatment Of Postmenopausal Women With Osteoporosis
RDUS,Abaloparatide-SC,2016-04-15,Radius Announces Three Oral Presentations For Abaloparatide-SC At World Congress On Osteoporosis, Osteoarthritis And Musculoskeletal Disease
RDUS,Abaloparatide-SC,2016-04-01,Radius Presents Analysis Results On Fracture Risk Reduction In Phase 3 ACTIVE Trial For Investigational Drug Abaloparatide-SC At The ENDO 2016 Annual Meeting
RDUS,Abaloparatide-SC,2016-03-30,Radius Health Submits New Drug Application To The U.S. Food And Drug Administration For Abaloparatide-SC For The Treatment Of Postmenopausal Women With Osteoporosis
RDUS,Abaloparatide-SC,2015-12-04,Radius Announces European Medicines Agency Validates Marketing Authorization Application For Abaloparatide-SC For The Treatment Of Osteoporosis In Postmenopausal Women
RDUS,Abaloparatide-SC,2015-11-17,Radius Health Has Submitted A Marketing Authorization Application For The Investigational Drug Abaloparatide-SC For The Treatment Of Postmenopausal Osteoporosis In Europe
RDUS,Abaloparatide-SC,2015-01-29,Radius Health Announces Oral Presentation Of The ACTIVE Phase 3 Clinical Trial Of Abaloparatide-SC For Postmenopausal Women With Osteoporosis At The International Society Of Endocrinology And The Endocrine Society (ICE/ENDO 2015)
RDUS,Abaloparatide-SC,2015-01-12,Radius Announces Follow-Up On The Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis
RDUS,Abaloparatide-SC,2014-12-21,Radius Announces Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis
ACOR,CVT-301,2017-02-09,Acorda Announces Positive Phase 3 Clinical Trial Results For CVT-301
ACOR,CVT-301,2016-10-13,Data From Clinical And Preclinical Trials Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Science Translational Medicine
ACOR,CVT-301,2016-04-20,Acorda Announces Results From Phase 2b Clinical Trial Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Movement Disorders
ACOR,CVT-301,2016-04-07,Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy Of Neurology (AAN) Annual Meeting
ACOR,CVT-301,2015-06-24,Acorda Data On Inhaled Levodopa Therapy CVT-301 Recognized In Blue Ribbon Highlights Session At International Congress Of Parkinson's Disease And Movement Disorders
ACOR,CVT-301,2015-06-16,Acorda Presents Data On Inhaled Levodopa Therapy CVT-301 At International Congress Of Parkinson's Disease And Movement Disorders
ACOR,CVT-301,2014-12-10,Acorda Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson's Disease
ACOR,CVT-301,2017-02-09,Acorda Announces Positive Phase 3 Clinical Trial Results For CVT-301
ACOR,CVT-301,2016-10-13,Data From Clinical And Preclinical Trials Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Science Translational Medicine
ACOR,CVT-301,2016-04-20,Acorda Announces Results From Phase 2b Clinical Trial Of CVT-301 For Treatment Of OFF Periods In Parkinson's Disease Published In Movement Disorders
ACOR,CVT-301,2016-04-07,Phase 2b Data On Inhaled Levodopa CVT-301 Featured In Invited Science Session At American Academy Of Neurology (AAN) Annual Meeting
ACOR,CVT-301,2015-06-24,Acorda Data On Inhaled Levodopa Therapy CVT-301 Recognized In Blue Ribbon Highlights Session At International Congress Of Parkinson's Disease And Movement Disorders
ACOR,CVT-301,2015-06-16,Acorda Presents Data On Inhaled Levodopa Therapy CVT-301 At International Congress Of Parkinson's Disease And Movement Disorders
ACOR,CVT-301,2014-12-10,Acorda Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson's Disease
ADHD,MDX,2017-01-17,Alcobra Reports Phase 3 Clinical Trial Of MDX In Adults With ADHD Missed Primary Endpoint
ADHD,MDX,2017-01-09,Alcobra Provides Update On Recent FDA Meeting And Path Forward For MDX Clinical Development Program
ADHD,MDX,2016-09-28,Alcobra Announces IND Clinical Hold Affecting The MDX Phase III MEASURE Study
ADHD,MDX,2015-09-21,FDA Grants Fast Track Designation To Alcobra's MDX For Fragile X Syndrome
ADHD,MDX,2015-06-24,Alcobra Announces Results From Phase 2 Clinical Trial Of MDX For Fragile X Syndrome
ADHD,MDX,2015-03-10,Alcobra's MDX Meets Primary Endpoint In Phase II Safety And Tolerability Clinical Trial In Adolescents With ADHD
ADHD,MDX,2014-10-06,Alcobra Announces Topline Results From Phase III Study Of MDX In Adult ADHD
ADHD,MDX,2014-09-19,Alcobra Announces Completion Of All Patient Visits In Phase III Clinical Trial Of MDX In Adult ADHD
ADHD,MDX,2014-09-02,Alcobra Announces Enrollment Of First Patient In Phase IIb Clinical Trial Of MDX In Adolescents With ADHD
ADHD,MDX,2014-08-19,Alcobra Announces Enrollment Of First Patient In Phase IIb Clinical Trial Of MDX In Fragile X Syndrome
ADHD,MDX,2014-08-08,Alcobra Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX
ADHD,MDX,2014-07-14,Alcobra Completes Patient Recruitment In Phase III Clinical Trial Of MDX In Adult ADHD
ADHD,MDX,2014-05-12,Alcobra Ltd. Presents Evidence Of Novel Mechanism Of Action For Metadoxine Extended Release (MDX) In Cognitive Disorders At The Society Of Biological Psychiatry Annual Meeting
ADHD,MDX,2014-05-08,Alcobra Announces FDA Clearance Of Protocol For Phase IIb Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome
ADHD,MDX,2014-05-05,Alcobra Ltd. Presents Positive Results From Phase IIb Study Of Metadoxine Extended Release (MDX) In Adults With Predominantly Inattentive ADHD At APA Annual Meeting
ADHD,MDX,2014-04-24,Alcobra Ltd. To Present New Data For Metadoxine Extended Release (MDX) At Upcoming Meetings
ADHD,MDX,2014-04-10,Alcobra Ltd. Submits Protocol To FDA For Phase IIb Clinical Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome
ADHD,MDX,2014-03-18,Alcobra Announces Enrollment Of First Patient In Phase 3 Clinical Trial For MDX In Adult ADHD
ADHD,MDX,2014-03-06,Alcobra Announces FDA Clearance Of IND For Metadoxine Extended Release (MDX)
AFMD,AFM13,2016-10-04,Affimed Presents Preclinical Data On Lead Candidate AFM13 At The Annual Meeting Of The Society For Natural Immunity
AFMD,AFM13,2016-04-21,Affimed Presents Data On AFM13-mediated Innate/Adaptive Immune Crosstalk At The AACR Annual Meeting 2016
AFMD,AFM13,2016-01-25,Affimed Enters Into Collaboration With Merck To Evaluate AFM13 In Combination With KEYTRUDA(R) (pembrolizumab) For Patients With Hodgkin Lymphoma
AFMD,AFM13,2015-12-06,Affimed Presents Additional Data On Combination Of AFM13 With Checkpoint Inhibitors At ASH
AFMD,AFM13,2014-12-08,Affimed Presents Final Data For AFM13 Phase 1 Trial At ASH
AKAO,Plazomicin,2017-02-22,Achaogen Announces Achievement Of A Key Milestone In Developing A Plazomicin Assay To Support Therapeutic Drug Management (TDM)
AKAO,Plazomicin,2016-12-12,Achaogen Announces Positive Results In Phase 3 CUTI And CRE Clinical Trials Of Plazomicin
AKAO,Plazomicin,2016-12-11,Achaogen To Host Conference Call And Webcast To Review Plazomicin Phase 3 Clinical Results
AKAO,Plazomicin,2016-11-07,Achaogen Reports Third Quarter 2016 Financial Results And Announces Acceleration Of Expected Timeline For Reporting Top-Line Results From Plazomicin Program
AKAO,Plazomicin,2016-10-24,Achaogen To Present First Plazomicin CARE Trial Data In Patients With Carbapenem-Resistant Enterobacteriaceae (CRE) Infections At IDWeek 2016
AKAO,Plazomicin,2016-09-01,Achaogen Completes Patient Enrollment In Phase 3 EPIC Clinical Trial Of Plazomicin
AKAO,Plazomicin,2016-06-20,Achaogen's Plazomicin Highlighted In Multiple Presentations At ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens
AKAO,Plazomicin,2016-06-09,Achaogen Announces Plazomicin Data Presentations At ASM Microbe 2016 Annual Meeting
AKAO,Plazomicin,2016-06-02,Achaogen Awarded $20 Million Contract Option By BARDA To Support Development Of Plazomicin For Multi-Drug Resistant Gram-Negative Infections
AKAO,Plazomicin,2016-06-02,Achaogen Reaches 50 Percent Patient Enrollment In Phase 3 EPIC Registration Trial Of Plazomicin
AKAO,Plazomicin,2016-04-05,Achaogen Announces Acceleration Of Expected Timeline For Reporting Top-Line Results From Phase 3 EPIC Registration Clinical Trial Of Plazomicin
AKAO,Plazomicin,2016-01-11,Achaogen Announces Enrollment Of First Patient In EPIC, A Phase 3 Clinical Trial For The Treatment Of Complicated Urinary Tract Infections (cUTI) With Plazomicin
AKAO,Plazomicin,2015-09-15,Achaogen To Present Data On Plazomicin At 55th Annual ICAAC Meeting
AKAO,Plazomicin,2015-03-30,Achaogen Announces Webcast Providing Update On Development Plan For Plazomicin
AKAO,Plazomicin,2015-01-08,Achaogen Announces Plazomicin Granted QIDP Designation By FDA
AKAO,Plazomicin,2014-09-17,Isis Pharmaceuticals Earns $4 Million From Achaogen For The Initiation Of A Phase 3 Study Of Plazomicin
AKAO,Plazomicin,2014-09-17,Achaogen Announces First Patient Enrollment In A Phase 3 Clinical Trial Of Plazomicin To Treat Infections Caused By Carbapenem-Resistant Enterobacteriaceae (CRE)
ARDX,Tenapanor,2017-02-15,Ardelyx Announces Successful Phase 3 Trial Of Tenapanor For Hyperphosphatemia In Patients With End-Stage Renal Disease
ARDX,Tenapanor,2016-10-19,Ardelyx Announces The Presentation Of Positive Global Endpoint Findings From Phase 2b Trial Of Tenapanor In Patients With IBS-C At ACG Annual Meeting
ARDX,Tenapanor,2015-10-08,Ardelyx To Present Phase 2 Data For Tenapanor In IBS-C Patients At The 2015 American College Of Gastroenterology Annual Meeting
ARDX,Tenapanor,2015-06-03,Ardelyx Regains Worldwide Development And Commercialization Rights For Its Late-Stage Development Candidate, Tenapanor, And Related Portfolio Of NHE3 Compounds
ARDX,Tenapanor,2015-05-05,Ardelyx Reports Results From Phase 2a Clinical Trial Evaluating Tenapanor In Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus And Albuminuria
ARDX,Tenapanor,2015-02-02,Ardelyx Reports Results From Phase 2b Clinical Trial Evaluating Tenapanor In Treating Hyperphosphatemia In Chronic Kidney Disease Patients On Hemodialysis
ARDX,Tenapanor,2014-11-17,Ardelyx's Tenapanor Reduces Phosphorus Absorption And Protects Against Vascular Calcification In Preclinical In Vivo Model Of Chronic Kidney Disease
ARDX,Tenapanor,2014-10-23,Ardelyx's Tenapanor Selected For Oral And Poster Presentations At The American Society Of Nephrology's Kidney Week 2014
ARDX,Tenapanor,2014-10-01,Ardelyx Reports Positive Results From Its Phase 2b Clinical Trial Evaluating Tenapanor In IBS-C Patients
ARQL,Tivantinib,2017-02-17,Daiichi Sankyo And ArQule Announce The Completion Of The METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Treatment Of MET-Overexpressing Hepatocellular Carcinoma
ARQL,Tivantinib,2016-03-22,Daiichi Sankyo And ArQule Announce Continuation Of METIV-HCC Phase 3 Study Of Tivantinib In Second-Line Hepatocellular Carcinoma
ARQL,Tivantinib,2016-01-25,ArQule Presents Clinical Biomarker Data From Phase 2 Study And Ongoing Phase 3 METIV-HCC Study Of Tivantinib In Second-Line Hepatocellular Carcinoma At The 2016 Gastrointestinal Cancers Symposium
ARQL,Tivantinib,2015-12-10,ArQule And Daiichi Sankyo Announce Completion Of Accrual In METIV-HCC Phase 3 Trial Of Tivantinib For Second-Line Hepatocellular Carcinoma
ARQL,Tivantinib,2015-11-09,UPDATE -- ArQule Presents Data On Tivantinib And Proprietary Pipeline At AACR-NCI-EORTC Conference
ARQL,Tivantinib,2015-11-09,ArQule Presents Data On Tivantinib And Propietary Pipeline At AACR-NCI-EORTC Conference
ARQL,Tivantinib,2015-10-27,ArQule To Present Data On Tivantinib, ARQ 087, ARQ 092, And ARQ 751 At AACR-NCI-EORTC Conference
ARQL,Tivantinib,2015-09-08,ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study Of Tivantinib In Hepatocellular Carcinoma At International Liver Cancer Association Conference
ARQL,Tivantinib,2015-07-06,ArQule Announces Interim Phase 2 Study Results For Tivantinib In Combination With Cetuximab In Patients With MET-High, KRAS Wild Type Colorectal Cancer Presented At ESMO World Congress On Gastrointestinal Cancer 2015
ARQL,Tivantinib,2015-05-29,ArQule Announces Data Presentations With Tivantinib And ARQ 087 To Be Featured At ASCO 2015
ARQL,Tivantinib,2014-11-10,ArQule Announces Positive Top-Line Results Of NIH-Sponsored Phase 2 Trial Of Tivantinib In Prostate Cancer
ARQL,Tivantinib,2014-05-30,ArQule Announces Data Presentations With Tivantinib To Be Featured At ASCO 2014
ARQL,Tivantinib,2014-02-04,ArQule Announces Commencement Of Phase 3 Clinical Trial With Tivantinib In Hepatocellular Carcinoma By Partner Kyowa Hakko Kirin In Japan
ARQL,Tivantinib,2014-01-16,ArQule Provides Updates On Clinical Trials In Hepatocellular Carcinoma And Non-Small Cell Lung Cancer With Tivantinib
ARQL,Tivantinib,2013-09-30,Data Presented At European Cancer Congress Suggest Clinical Benefit Of Tivantinib In Patients With MET High Non-Squamous Non-Small Cell Lung Cancer
ARQL,Tivantinib,2013-01-31,Daiichi Sankyo And ArQule Enroll First Hepatocellular Carcinoma Patient Into Global Phase 3 Trial For Tivantinib
ARQL,Tivantinib,2013-01-11,Daiichi Sankyo And ArQule Announce Top-Line Results Of Phase 2 Trial With Tivantinib In Colorectal Cancer
ARQL,Tivantinib,2012-10-16,ArQule And Daiichi Sankyo Reach Agreement With FDA On Special Protocol Assessment For Phase 3 Trial Of Tivantinib In Hepatocellular Carcinoma
ARQL,Tivantinib,2012-06-02,Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma To Be Presented At ASCO
ARQL,Tivantinib,2012-05-18,ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase 3 Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer
ARQL,Tivantinib,2012-05-17,Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma To Be Highlighted In Oral Presentation At 2012 Annual Meeting Of American Society Of Clinical Oncology
CAPR,CAP-1002,2016-02-22,Capricor Therapeutics Announces The First Patient With Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated With CAP-1002 In The HOPE-Duchenne Phase I/II Clinical Trial
CAPR,CAP-1002,2015-06-08,Capricor Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy
CAPR,CAP-1002,2016-02-22,Capricor Therapeutics Announces The First Patient With Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated With CAP-1002 In The HOPE-Duchenne Phase I/II Clinical Trial
CAPR,CAP-1002,2015-06-08,Capricor Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy
CAPR,CAP-1002,2016-02-22,Capricor Therapeutics Announces The First Patient With Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated With CAP-1002 In The HOPE-Duchenne Phase I/II Clinical Trial
CAPR,CAP-1002,2015-06-08,Capricor Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy
CAPR,CAP-1002,2016-02-22,Capricor Therapeutics Announces The First Patient With Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated With CAP-1002 In The HOPE-Duchenne Phase I/II Clinical Trial
CAPR,CAP-1002,2015-06-08,Capricor Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy
DERM,Cimzia,2017-03-04,New CIMZIA® (certolizumab Pegol) Data In Moderate-to-severe Plaque Psoriasis And Psoriatic Arthritis Presented At American Academy Of Dermatology 2017 Annual Meeting
DERM,Cimzia,2017-01-19,Final CIMZIA® (certolizumab Pegol) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Moderate-to-Severe Chronic Plaque Psoriasis
DERM,Cimzia,2016-12-08,Second CIMZIA® (certolizumab Pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints In Patients With Moderate-to-Severe Chronic Plaque Psoriasis
DERM,Cimzia,2016-10-03,CIMZIA® (certolizumab Pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints In Patients With Moderate-to-Severe Chronic Plaque Psoriasis
DERM,Cimzia,2016-01-08,Dermira Completes Patient Enrollment For Third CIMZIA® (certolizumab Pegol) Phase 3 Clinical Trial In Psoriasis Program And Updates Guidance For Release Of Topline Data
DERM,Cimzia,2015-11-19,Dermira Completes Patient Enrollment For Second CIMZIA(R) (certolizumab Pegol) Phase 3 Clinical Trial In Psoriasis Program
DERM,Cimzia,2015-10-12,Dermira Completes Patient Enrollment For First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial In Psoriasis Program
DERM,Cimzia,2015-01-08,Dermira And UCB Announce Start Of Phase 3 Program For CIMZIA(R) (certolizumab Pegol) In Psoriasis
EYEG,EGP-437,2017-01-09,EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals For EGP-437
EYEG,EGP-437,2016-12-05,EyeGate Reports Positive Data From Third Stage Of Phase 1b/2a Clinical Trial Of EGP-437 In Cataract Surgery Patients
EYEG,EGP-437,2016-09-12,EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals For EGP-437
EYEG,EGP-437,2016-08-01,EyeGate Announces Positive Top-line Data From Phase 1b/2a Clinical Trial Of EGP-437 For Treatment Of Post-Operative Inflammation And Pain In Cataract Surgery Patients
EYEG,EGP-437,2016-06-01,EyeGate Announces Encouraging Interim Data From Phase 1b/2a Clinical Trial Of EGP-437 For Treatment Of Ocular Inflammation And Pain Post Cataract Surgery
EYEG,EGP-437,2016-03-02,EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals For EGP-437
EYEG,EGP-437,2016-01-19,EyeGate Pharma Enrolls First Patient In Confirmatory Phase 3 Clinical Trial EGP-437-006 For Non-Infectious Anterior Uveitis
EYEG,EGP-437,2015-11-05,EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial Of Iontophoretic EGP-437 Ophthalmic Solution In Macular Edema Patients
EYEG,EGP-437,2015-07-14,EyeGate Pharma Treats First Patient In Phase 1b / 2a Trial Of EGP-437 In Macular Edema
EYEG,EGP-437,2015-07-10,EyeGate Signs Licensing Agreement With Valeant Pharmaceuticals For EGP-437 Combination Product In Uveitis
EYEG,EGP-437,2015-05-04,EyeGate Pharma Receives Positive Guidance From FDA On NDA Filing Requirements Of EGP-437 For The Treatment Of Anterior Uveitis
FGEN,FG-3019,2017-02-03,FibroGen Announces Publication Of Pamrevlumab (FG-3019) Clinical Data In Pancreatic Cancer Showing Safety And Improved Survival Outcomes In Combination With Chemotherapy
FGEN,FG-3019,2016-03-11,FibroGen Announces Publication Of Phase 2 Study Results Supporting The Potential Of FG-3019 To Treat Patients With Idiopathic Pulmonary Fibrosis
FGEN,FG-3019,2016-01-27,FibroGen Announces Early Phase 2 Data From A Clinical Study Of FG-3019 In Combination With Chemotherapy As Neoadjuvant In Locally Advanced, Unresectable Pancreatic Cancer
FGEN,FG-3019,2016-01-06,FibroGen Enrolls First Patients In Phase 2 Clinical Study Of Anti-Fibrotic Drug Candidate FG-3019 For The Treatment Of Duchenne Muscular Dystrophy
FGEN,FG-3019,2015-07-27,FibroGen Receives FDA Clearance To Proceed With Clinical Study Of FG-3019 In Duchenne Muscular Dystrophy
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
KPTI,Selinexor,2017-03-16,Karyopharm Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Selinexor Clinical Update
KPTI,Selinexor,2017-03-10,Karyopharm Announces Partial Clinical Hold To Pause Enrollment In Selinexor Trials
KPTI,Selinexor,2017-03-02,Karyopharm Announces Results From Interim Analysis Of Phase 2 SOPRA Study Evaluating Selinexor In Relapsed/Refractory Acute Myeloid Leukemia
KPTI,Selinexor,2016-09-29,Karyopharm Publishes Preclinical Data In Nature Demonstrating Selinexor's Potential In KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
KPTI,Selinexor,2016-09-28,Karyopharm Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication
KPTI,Selinexor,2016-09-06,Karyopharm Reports Positive Top-Line Phase 2b STORM Results And Reviews The Planned Development Path For Selinexor In Multiple Myeloma
KPTI,Selinexor,2016-07-27,Karyopharm Announces Phase 1b Selinexor Sarcoma Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-06-16,Karyopharm Outlines Key Selinexor Clinical Development Achievements
KPTI,Selinexor,2016-05-18,Karyopharm To Present Selinexor Clinical Data At The American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2016-03-04,Karyopharm's Selinexor First-in-Human Phase 1 Clinical Trial Data Published In Journal Of Clinical Oncology
KPTI,Selinexor,2016-01-14,Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced Liposarcoma
KPTI,Selinexor,2015-12-07,Karyopharm Therapeutics Presents Positive Clinical Data On The Activity Of Selinexor In Combination With Other Anticancer Agents Across Multiple Hematologic Malignancies At The 2015 American Society Of Hematology (ASH) Annual Meeting
KPTI,Selinexor,2015-11-30,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic Malignancies
KPTI,Selinexor,2015-10-19,Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple Myeloma
KPTI,Selinexor,2015-06-22,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma
KPTI,Selinexor,2015-06-15,Karyopharm Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-06-01,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-30,Karyopharm Presents Clinical Data For Selinexor (KPT-330) In Patients With Heavily Pretreated Gynecological Cancers And Asian Patients With Advanced Malignancies At 2015 ASCO Annual Meeting
KPTI,Selinexor,2015-05-28,Karyopharm Initiates STORM Clinical Trial Of Oral Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2015-05-27,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Solid Tumors
KPTI,Selinexor,2015-05-21,Karyopharm To Present Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting
KPTI,Selinexor,2015-05-13,Karyopharm To Present Solid Tumor Data On Lead Drug Candidate Selinexor At 2015 American Society Of Clinical Oncology Annual Meeting
KPTI,Selinexor,2015-04-13,Karyopharm Granted U.S. Composition-of-Matter Patent For Selinexor (KPT-330)
KPTI,Selinexor,2015-01-08,Karyopharm Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma
KPTI,Selinexor,2014-12-11,Karyopharm Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330)
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-08,Karyopharm Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At ASH 2014 Annual Meeting
KPTI,Selinexor,2014-12-01,Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Oncology
KPTI,Selinexor,2014-12-01,Karyopharm Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission
KPTI,Selinexor,2014-11-10,Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With Richter's Transformation
KPTI,Selinexor,2014-09-29,Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors
KPTI,Selinexor,2014-09-25,Karyopharm To Host Conference Call To Discuss Selinexor (KPT-330) Data Presented At ESMO 2014
LJPC,LJPC-501,2017-02-27,La Jolla Pharmaceutical Company Announces Positive Top-Line Results From ATHOS-3 Phase 3 Study Of LJPC-501
LJPC,LJPC-501,2015-11-30,La Jolla Pharmaceutical Company Announces Notice Of Allowance For U.S. Patent Covering LJPC-501
LJPC,LJPC-501,2015-03-24,La Jolla Pharmaceutical Company Announces Initiation Of Phase 3 Clinical Trial Of LJPC-501 In Catecholamine-Resistant Hypotension
LJPC,LJPC-501,2015-02-09,La Jolla Pharmaceutical Company Announces Special Protocol Assessment For Planned Phase 3 Trial Of LJPC-501 In Catecholamine-Resistant Hypotension
LJPC,LJPC-501,2014-08-25,La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome
LJPC,LJPC-501,2014-07-08,La Jolla Pharmaceutical Company Announces Planned Initiation Of Phase 3 Registration Program For LJPC-501 In Resistant Hypotension
LJPC,LJPC-501,2014-02-27,La Jolla Pharmaceutical Company And The George Washington University Enter Into Agreement For Technology Related To LJPC-501
MDCO,CARBAVANCE,2017-02-21,The Medicines Company Announces FDA Filing Acceptance Of New Drug Application For Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)
MDCO,CARBAVANCE,2016-06-27,The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®
MDCO,CARBAVANCE,2016-05-26,The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)
MDCO,CARBAVANCE,2016-04-11,FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)
MDCO,CARBAVANCE,2015-10-01,The Medicines Company Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE® (meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens
MDCO,CARBAVANCE,2014-11-05,The Medicines Company Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria
MDCO,CARBAVANCE,2017-02-21,The Medicines Company Announces FDA Filing Acceptance Of New Drug Application For Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)
MDCO,CARBAVANCE,2016-06-27,The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®
MDCO,CARBAVANCE,2016-05-26,The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)
MDCO,CARBAVANCE,2016-04-11,FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)
MDCO,CARBAVANCE,2015-10-01,The Medicines Company Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE® (meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens
MDCO,CARBAVANCE,2014-11-05,The Medicines Company Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria
MDCO,CARBAVANCE,2017-02-21,The Medicines Company Announces FDA Filing Acceptance Of New Drug Application For Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)
MDCO,CARBAVANCE,2016-06-27,The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®
MDCO,CARBAVANCE,2016-05-26,The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)
MDCO,CARBAVANCE,2016-04-11,FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)
MDCO,CARBAVANCE,2015-10-01,The Medicines Company Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE® (meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens
MDCO,CARBAVANCE,2014-11-05,The Medicines Company Announces First Patient Enrollment In Phase 3 Studies Of CARBAVANCE™ In Development For The Treatment Of Serious Bacterial Infections Due To Gram-Negative Bacteria
NKTR,NKTR-181,2017-03-20,NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain
NKTR,NKTR-181,2015-02-25,Nektar Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain
NKTR,NKTR-181,2013-09-26,Nektar Announces Preliminary Topline Results From Phase 2 Efficacy Study For NKTR-181 In Chronic Pain Patients With Osteoarthritis Of The Knee
NKTR,NKTR-181,2017-03-20,NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain
NKTR,NKTR-181,2015-02-25,Nektar Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain
NKTR,NKTR-181,2013-09-26,Nektar Announces Preliminary Topline Results From Phase 2 Efficacy Study For NKTR-181 In Chronic Pain Patients With Osteoarthritis Of The Knee
NKTR,NKTR-181,2017-03-20,NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain
NKTR,NKTR-181,2015-02-25,Nektar Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain
NKTR,NKTR-181,2013-09-26,Nektar Announces Preliminary Topline Results From Phase 2 Efficacy Study For NKTR-181 In Chronic Pain Patients With Osteoarthritis Of The Knee
NKTR,NKTR-181,2017-03-20,NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain
NKTR,NKTR-181,2015-02-25,Nektar Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain
NKTR,NKTR-181,2013-09-26,Nektar Announces Preliminary Topline Results From Phase 2 Efficacy Study For NKTR-181 In Chronic Pain Patients With Osteoarthritis Of The Knee
NKTR,Inhaled,2014-04-10,MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
NKTR,Inhaled,2013-04-16,Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia
NKTR,Inhaled,2014-04-10,MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
NKTR,Inhaled,2013-04-16,Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia
NKTR,Inhaled,2014-04-10,MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
NKTR,Inhaled,2013-04-16,Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia
NKTR,Inhaled,2014-04-10,MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
NKTR,Inhaled,2013-04-16,Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia
OCRX,OCR-002,2017-03-08,Ocera To Announce Additional Encouraging Results From Its Phase 2b STOP-HE Study Of IV OCR-002 In Patients With Hepatic Encephalopathy
OCRX,OCR-002,2017-01-05,Ocera Announces Successful Phase 1 Clinical Study Of Orally-Administered OCR-002 In Patients With Cirrhosis
OCRX,OCR-002,2016-12-07,Ocera Completes Enrollment Of STOP-HE, A Phase 2b Study Of OCR-002 In Hospitalized Patients With Hepatic Encephalopathy
OCRX,OCR-002,2016-09-21,Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study Of OCR-002 In The Treatment Of Patients With Acute Liver Failure
OCRX,OCR-002,2016-09-19,Ocera Initiates Phase 1 Clinical Study Of Orally Available OCR-002 In Patients With Cirrhosis For The Prevention Of Hepatic Encephalopathy
OCRX,OCR-002,2016-04-15,Ocera Therapeutics Announces Presentation Of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 At The International Liver Congress™ 2016 Of The European Association For The Study Of The Liver (EASL)
OCRX,OCR-002,2016-04-11,Ocera Therapeutics Announces Publication Of Promising Preclinical Data In Support Of Its Ammonia Scavenger OCR-002 In The Journal Of Hepatology
OCRX,OCR-002,2016-01-08,Ocera Announces Complete Plasma Data From Pilot Phase 1 Study For Orally-Available OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy
OCRX,OCR-002,2015-11-16,Ocera Announces Positive Phase 1 Results For Oral OCR-002 In Development For The Prevention Of Chronic Hepatic Encephalopathy
OCRX,OCR-002,2015-10-05,Ocera Therapeutics Highlights OCR-002 Data To Be Presented At The Annual Meeting Of The American Association For The Study Of Liver Diseases (AASLD)
OCRX,OCR-002,2015-09-16,Ocera Initiates Phase 1 Clinical Trial Of Oral Drug Candidate OCR-002 For Prevention Of Hepatic Encephalopathy
OCRX,OCR-002,2015-04-01,Ocera Completes Interim Analysis Of OCR-002 In Phase 2b STOP-HE Study For The Treatment Of Acute Hepatic Encephalopathy
OCRX,OCR-002,2015-02-18,Ocera Announces Preliminary Topline Results From Phase 2a Investigator-Sponsored Study Of OCR-002
OGXI,Apatorsen,2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
OGXI,Apatorsen,2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
OGXI,Apatorsen,2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
OGXI,Apatorsen,2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
OGXI,Apatorsen,2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
OGXI,Apatorsen,2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
OGXI,Apatorsen,2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
OGXI,Apatorsen,2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
OGXI,Apatorsen,2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
OGXI,Apatorsen,2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
OGXI,Apatorsen,2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
OGXI,Apatorsen,2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
OGXI,Apatorsen,2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2017-02-21,OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data For Two Clinical Trials Presented At The American Society Of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
OGXI,Apatorsen,2016-10-25,OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2™ Trial In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-12-09,OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion Of Futility Analysis
OGXI,Apatorsen,2015-09-30,OncoGenex Announces Completion Of Patient Enrollment In Borealis-2™ Clinical Trial Evaluating Apatorsen In Relapsed Or Refractory Metastatic Bladder Cancer
OGXI,Apatorsen,2015-06-01,OncoGenex Announces Data From Borealis-1™ Trial Showing Clinical Benefit With Apatorsen In Metastatic Bladder Cancer
OGXI,Apatorsen,2015-02-24,OncoGenex And Sarah Cannon Announce Completion Of Patient Enrollment In The Spruce™ Clinical Trial Evaluating Apatorsen In Combination With Carboplatin And Pemetrexed In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
OGXI,Apatorsen,2014-12-19,OncoGenex Announces Results From The Phase 2 Borealis-1™ Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer
OGXI,Apatorsen,2014-12-16,OncoGenex Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer
OGXI,Apatorsen,2014-07-01,OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-29,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OGXI,Apatorsen,2013-08-27,OncoGenex Announces That The Rainier™ Clinical Trial Evaluating Apatorsen (OGX-427) In Combination With ABRAXANE® Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer Is Now Open For Enrollment
OMED,Tarextumab,2016-08-30,OncoMed Pharmaceuticals Completes Enrollment Of Phase 2 PINNACLE Clinical Trial Of Tarextumab In Small Cell Lung Cancer
OMED,Tarextumab,2016-02-22,OncoMed Presents Updated Phase 1b Data For Tarextumab In Small Cell Lung Cancer
OMED,Tarextumab,2016-02-08,OncoMed Provides Update On Tarextumab Phase 2 Programs
OMED,Tarextumab,2016-01-25,OncoMed Provides Update On Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
OMED,Tarextumab,2015-09-09,OncoMed Pharmaceuticals Announces Presentation Of Tarextumab Small Cell Lung Cancer Data At The 16th World Conference On Lung Cancer
OMED,Tarextumab,2015-08-31,OncoMed Pharmaceuticals Completes Enrollment Of Phase 2 ALPINE Clinical Trial Of Tarextumab In Pancreatic Cancer
OMED,Tarextumab,2015-06-01,OncoMed Presents Phase 1b Clinical Trial Data For Tarextumab In Small Cell Lung Cancer At The 2015 ASCO Annual Meeting
OMED,Tarextumab,2015-05-28,OncoMed Pharmaceuticals To Review Key ASCO Data For Demcizumab And Tarextumab During Conference Call On Tuesday, June 2, 2015
OMED,Tarextumab,2015-05-01,OncoMed Publishes Data On Tarextumab's Anti-Cancer Stem Cell Activity In Clinical Cancer Research
OMED,Tarextumab,2015-01-29,FDA Grants Orphan Drug Designations To OncoMed's Tarextumab For The Treatment Of Pancreatic And Small Cell Lung Cancer
OMED,Tarextumab,2015-01-16,OncoMed Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium
OMED,Tarextumab,2015-01-13,OncoMed To Present Clinical Data And Biomarker Analysis For Tarextumab At The 2015 Gastrointestinal Cancer Symposium
OMED,Tarextumab,2014-12-01,OncoMed Begins Patient Dosing In Phase 2 Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) In Small Cell Lung Cancer
OMED,Tarextumab,2014-11-21,OncoMed Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The EORTC-NCI-AACR Symposium
OMED,Tarextumab,2014-09-29,OncoMed Presents Encouraging Data From Clinical Trials Of Tarextumab (Anti-Notch2/3) In Pancreatic Cancer And Small Cell Lung Cancer At The ESMO 2014 Congress
OMED,Tarextumab,2014-09-17,OncoMed To Present New And Emerging Data From Demcizumab (anti-DLL4, OMP-21M18) And Tarextumab (anti-Notch2/3, OMP-59R5) Clinical Studies At The European Society For Medical Oncology 2014 Congress
OMED,Tarextumab,2014-07-16,OncoMed Pharmaceuticals Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer
OPK,Factor,2016-02-23,OPKO Health Announces Dosing Of First Patient In Phase 2a Clinical Study Of A Long-Acting Factor VIIa For The Treatment Of Hemophilia
OPK,Factor,2016-02-23,OPKO Health Announces Dosing Of First Patient In Phase 2a Clinical Study Of A Long-Acting Factor VIIa For The Treatment Of Hemophilia
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PBYI,Neratinib,2017-03-01,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2017
PBYI,Neratinib,2016-12-06,Puma Biotechnology Initiates A Managed Access Program For PB272 (Neratinib) Outside The United States
PBYI,Neratinib,2016-09-20,Puma Biotechnology Announces U.S. FDA Acceptance Of New Drug Application For PB272 (Neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-08-22,Puma Biotechnology Announces European Medicines Agency Validation Of Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-07-21,Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
PBYI,Neratinib,2016-07-21,Puma Biotechnology Submits New Drug Application For PB272 (Neratinib) To U.S. FDA For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer
PBYI,Neratinib,2016-07-07,Puma Biotechnology Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal Of Medicine
PBYI,Neratinib,2016-06-27,Puma Biotechnology Submits Marketing Authorization Application For PB272 (Neratinib) As Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In Europe
PBYI,Neratinib,2016-05-18,Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2016 ASCO Annual Meeting
PBYI,Neratinib,2016-04-20,Puma Biotechnology's Neratinib Featured In Poster Presentations At The AACR Annual Meeting 2016
PBYI,Neratinib,2016-03-18,Puma Biotechnology Announces Publication Of Abstracts On Neratinib For The AACR Annual Meeting 2016
PBYI,Neratinib,2015-12-16,Puma Biotechnology To Host Conference Call To Discuss Loperamide Prophylaxis To Reduce Neratinib-Related Diarrhea
PBYI,Neratinib,2014-12-12,Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data At 2014 CTRC-AACR San Antonio Breast Cancer Symposium
PGNX,Azedra,2015-12-03,Progenics Pharmaceuticals Achieves Target Enrollment In Its Phase 2b Pivotal Trial Of Azedra™
PGNX,Azedra,2015-10-12,Phase 2 Dosimetry Data For Progenics' AZEDRA Presented At EANM Congress 2015
PGNX,Azedra,2015-07-28,Progenics Announces Breakthrough Therapy Designation For Azedra In Pheochromocytoma And Paraganglioma
PGNX,Azedra,2015-01-23,Progenics Pharmaceuticals Relaunches Pivotal Trial Of AZEDRA(TM) In Pheochromocytoma
PGNX,Azedra,2014-09-22,Progenics Pharmaceuticals Presents Long Term Follow-Up Of Pivotal Phase 2 Trial Of Azedra In Malignant Pheochromocytoma
PGNX,Azedra,2015-12-03,Progenics Pharmaceuticals Achieves Target Enrollment In Its Phase 2b Pivotal Trial Of Azedra™
PGNX,Azedra,2015-10-12,Phase 2 Dosimetry Data For Progenics' AZEDRA Presented At EANM Congress 2015
PGNX,Azedra,2015-07-28,Progenics Announces Breakthrough Therapy Designation For Azedra In Pheochromocytoma And Paraganglioma
PGNX,Azedra,2015-01-23,Progenics Pharmaceuticals Relaunches Pivotal Trial Of AZEDRA(TM) In Pheochromocytoma
PGNX,Azedra,2014-09-22,Progenics Pharmaceuticals Presents Long Term Follow-Up Of Pivotal Phase 2 Trial Of Azedra In Malignant Pheochromocytoma
PRTO,Vonapanitase,2016-12-13,Proteon Therapeutics Announces Top-Line Data From Phase 3 PATENCY-1 Clinical Trial Of Investigational Vonapanitase In Patients With CKD
PRTO,Vonapanitase,2016-11-10,Proteon Therapeutics Announces First Patient Dosed In Phase 1 Study Evaluating Vonapanitase For The Treatment Of Peripheral Artery Disease Below The Knee
PRTO,Vonapanitase,2016-10-25,Proteon Therapeutics Announces Overview Of Phase 1 Clinical Program Of Investigational Vonapanitase In Peripheral Artery Disease To Be Presented At The 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
PRTO,Vonapanitase,2016-04-13,Proteon Therapeutics Announces Publication In The Journal Of Cardiovascular Pharmacology Of Promising Nonclinical Results For Vonapanitase In Peripheral Artery Disease
PRTO,Vonapanitase,2015-11-02,Proteon Therapeutics Completes Enrollment In PATENCY-1, First Phase 3 Clinical Study Of Investigational Vonapanitase
PRTO,Vonapanitase,2015-10-12,Proteon Therapeutics Announces Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease Presented At TCT 2015
PRTO,Vonapanitase,2015-08-13,Proteon Therapeutics Announces Top-Line Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease
PRTO,Vonapanitase,2015-08-12,Proteon Therapeutics Initiates Second Phase 3 Clinical Study Of Investigational Drug Vonapanitase
PRTO,Vonapanitase,2015-03-26,Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis
PRTO,Vonapanitase,2016-12-13,Proteon Therapeutics Announces Top-Line Data From Phase 3 PATENCY-1 Clinical Trial Of Investigational Vonapanitase In Patients With CKD
PRTO,Vonapanitase,2016-11-10,Proteon Therapeutics Announces First Patient Dosed In Phase 1 Study Evaluating Vonapanitase For The Treatment Of Peripheral Artery Disease Below The Knee
PRTO,Vonapanitase,2016-10-25,Proteon Therapeutics Announces Overview Of Phase 1 Clinical Program Of Investigational Vonapanitase In Peripheral Artery Disease To Be Presented At The 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference
PRTO,Vonapanitase,2016-04-13,Proteon Therapeutics Announces Publication In The Journal Of Cardiovascular Pharmacology Of Promising Nonclinical Results For Vonapanitase In Peripheral Artery Disease
PRTO,Vonapanitase,2015-11-02,Proteon Therapeutics Completes Enrollment In PATENCY-1, First Phase 3 Clinical Study Of Investigational Vonapanitase
PRTO,Vonapanitase,2015-10-12,Proteon Therapeutics Announces Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease Presented At TCT 2015
PRTO,Vonapanitase,2015-08-13,Proteon Therapeutics Announces Top-Line Results From Phase 1 Study Of Investigational Drug Vonapanitase In Patients With Symptomatic Peripheral Artery Disease
PRTO,Vonapanitase,2015-08-12,Proteon Therapeutics Initiates Second Phase 3 Clinical Study Of Investigational Drug Vonapanitase
PRTO,Vonapanitase,2015-03-26,Proteon Therapeutics Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis
PTCT,Translarna,2017-03-06,PTC Therapeutics Announces FDA Acknowledgment Of New Drug Application Filing For Translarna™ For The Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy
PTCT,Translarna,2017-01-09,European Commission Ratifies Positive CHMP Opinion For The Renewal Of Translarna™ Marketing Authorization For The Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy
PTCT,Translarna,2017-01-09,PTC Therapeutics Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna™ And Advance Its Innovative Pipeline
PTCT,Translarna,2016-12-08,PTC Therapeutics Receives France's 2016 Prix Galien For Translarna™
PTCT,Translarna,2016-11-11,CHMP Recommends Renewal Of Translarna's™ Marketing Authorization For Nonsense Mutation Duchenne Muscular Dystrophy Based On Continued Positive Benefit-Risk Assessment
PTCT,Translarna,2016-10-17,PTC Therapeutics Provides Regulatory Update On Translarna™ (ataluren) For Nonsense Mutation Duchenne Muscular Dystrophy
PTCT,Translarna,2016-10-04,New Research Validates Translarna's™ (ataluren) Mechanism Of Action To Promote Readthrough Of Nonsense Mutations And Produce Full-length Functional Protein
PTCT,Translarna,2016-07-25,PTC Therapeutics Provides Regulatory Update On Translarna™ (ataluren)
PTCT,Translarna,2016-07-07,NHS England Enables Access To Translarna™ ¿ (ataluren) For Patients With Nonsense Mutation Duchenne Muscular Dystrophy
PTCT,Translarna,2016-06-10,New Analyses From Phase 3 Study 009 Of Translarna™ (ataluren) In Patients With Cystic Fibrosis Presented At 39th European Cystic Fibrosis Conference
PTCT,Translarna,2016-04-15,NICE Recommends Translarna™ (ataluren) For The Treatment Of Patients With Nonsense Mutation Duchenne Muscular Dystrophy In England
PTCT,Translarna,2016-03-14,PTC Therapeutics Provides Update On Health Canada Review Of Translarna™ (ataluren) For The Treatment Of Duchenne Muscular Dystrophy
PTCT,Translarna,2016-03-14,PTC Therapeutics Announces Presentation Of Results From Phase 3 ACT DMD Clinical Trial Of Translarna™ (ataluren) In Patients With Duchenne Muscular Dystrophy At 5th International Congress Of Myology
PTCT,Translarna,2016-02-26,PTC Therapeutics Provides Update On German Pricing And Reimbursement Process For Translarna™ (ataluren)
PTCT,Translarna,2016-02-23,PTC Receives Refuse To File Letter From FDA For Translarna™ (ataluren)
PTCT,Translarna,2016-01-11,PTC Therapeutics Outlines Business Priorities For The Development And Commercialization Of Translarna™ And Progress Of The Company Pipeline
PTCT,Translarna,2016-01-08,PTC Completes Rolling NDA Submission To FDA And Submits Phase 3 ACT DMD Clinical Trial Results To EMA For Translarna™ (ataluren) For Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy
PTCT,Translarna,2015-11-19,PTC Completes Enrollment Of Phase 3 Clinical Trial Of Translarna™ For Patients With Cystic Fibrosis
PTCT,Translarna,2015-10-15,PTC Announces Results From Phase 3 ACT DMD Clinical Trial Of Translarna™ (ataluren) In Patients With Duchenne Muscular Dystrophy
PTCT,Translarna,2015-09-30,PTC Therapeutics Submits European Application For Translarna™ For Cystic Fibrosis
PTCT,Translarna,2015-05-21,German Federal Joint Committee Issues Positive Medical Benefit Rating For Translarna™ In Patients With Nonsense Mutation Duchenne Muscular Dystrophy
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
QURE,AMT-060,2017-01-30,UniQure Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B
QURE,AMT-060,2016-12-03,UniQure Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B
QURE,AMT-060,2016-07-11,UniQure Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress
QURE,AMT-060,2016-05-19,UniQure Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
RIGL,Fostamatinib,2016-09-15,Rigel Restructures To Focus On Fostamatinib Commercialization
RIGL,Fostamatinib,2016-08-30,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
RIGL,Fostamatinib,2016-04-01,Rigel Completes Enrollment Of FIT Phase 3 Program For Fostamatinib In ITP
RIGL,Fostamatinib,2016-02-25,Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
RIGL,Fostamatinib,2016-01-28,Rigel Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT)
RIGL,Fostamatinib,2015-09-08,Rigel Granted Orphan Drug Designation For Fostamatinib In ITP
RIGL,Fostamatinib,2014-07-16,Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
RIGL,Fostamatinib,2012-12-13,AstraZeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
SUPN,SPN-812,2016-10-11,Supernus Announces Positive Results From Phase IIb Clinical Trial For SPN-812 In Children With ADHD
SUPN,SPN-812,2016-10-10,Supernus Schedules Conference Call To Present Results Of Phase IIb Clinical Trial Of SPN-812 In Children With ADHD
SUPN,SPN-812,2014-01-27,Supernus Announces Issuance Of First Use Patents Protecting SPN-812 As A Novel Non-Stimulant ADHD Product
SYN,SYN-004,2017-01-05,Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI)
SYN,SYN-004,2016-09-20,Synthetic Biologics Announces Completion Of Enrollment For Phase 2b Proof-of-Concept Clinical Trial For SYN-004 (ribaxamase) For The Prevention Of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea And The Emergence Of Antibiotic-Resistant Organisms
SYN,SYN-004,2016-07-07,Synthetic Biologics Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004
SYN,SYN-004,2016-05-16,Synthetic Biologics Announces Positive Topline Results From Second Phase 2a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea
SYN,SYN-004,2016-03-01,Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended For The Prevention Of C. Difficile Infection And Antibiotic-Associated Diarrhea
SYN,SYN-004,2015-12-01,Synthetic Biologics Announces Positive Topline Results From First Phase 2a Clinical Trial Of SYN-004, The Company's Candidate For The Prevention Of C. Difficile Infection
SYN,SYN-004,2015-09-28,Synthetic Biologics Initiates SYN-004 Phase 2b Proof-of-Concept Clinical Trial
SYN,SYN-004,2015-09-21,Synthetic Biologics Reports First Analysis Demonstrating SYN-004's Ability To Protect The Microbiome From Damage Caused By IV Antibiotics In A Humanized Pig Model
SYN,SYN-004,2015-05-19,Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted In Late-Breaking Poster At Digestive Disease Week® 2015
SYN,SYN-004,2015-04-01,Synthetic Biologics' SYN-004 Clinical Data For Protection Of Microbiome Selected For Poster Presentation At American Society Of Microbiology 2015
SYN,SYN-004,2015-03-30,Synthetic Biologics Initiates Phase 2a Clinical Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile
SYN,SYN-004,2015-03-19,Synthetic Biologics Announces Positive Pharmacokinetics Data From Phase 1a And 1b Trials Of SYN-004 To Protect The Microbiome And Prevent C. Difficile Infection
SYN,SYN-004,2015-02-10,Synthetic Biologics Announces Positive Topline Results From Phase 1b Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile Infection
SYN,SYN-004,2014-12-30,Synthetic Biologics Announces First Patient Dosed In Phase 1b Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection
SYN,SYN-004,2014-12-22,Synthetic Biologics Announces Positive Topline Results From Phase 1a Trial Of SYN-004 For The Prevention Of C. Difficile Infection
SYN,SYN-004,2014-12-02,Synthetic Biologics Announces First Patient Dosed In Phase 1a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection
SYN,SYN-004,2014-09-02,Synthetic Biologics To Initiate Clinical Trials Of SYN-004 In 4Q 2014 To Prevent Potentially Deadly C. Difficile Infections
SYN,SYN-004,2014-08-28,Synthetic Biologics And FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement In API Manufacturing Of SYN-004 For The Prevention Of C. Difficile
SYN,SYN-004,2014-08-26,Synthetic Biologics Announces Presentation Of Poster For SYN-004 C. Difficile Program At IDWeek 2014™
SYN,SYN-004,2014-08-05,Synthetic Biologics On Track To Initiate Clinical Program For SYN-004 To Protect Against C. Difficile
SYN,SYN-004,2013-11-14,Synthetic Biologics' SYN-004 For The Prevention Of C. Difficile Infections Named A "Top Project To Watch" By Elsevier Business Intelligence
SYN,SYN-004,2013-10-15,Synthetic Biologics Initiates Manufacturing Of SYN-004 For Use In Preclinical And Clinical Trials To Target The Prevention Of C. Difficile Infections
TRVN,Oliceridine,2017-02-21,Trevena Announces Positive Top-line Results From Two Phase 3 Pivotal Efficacy Studies Of Intravenous Oliceridine In Moderate-to-Severe Acute Pain
TRVN,Oliceridine,2017-01-04,Trevena Completes Enrollment Of Phase 3 APOLLO Pivotal Efficacy Trials Of Oliceridine For Moderate-to-Severe Acute Pain
TRVN,Oliceridine,2016-06-08,Trevena, Inc. Announces First Patients Enrolled In The APOLLO-1 And APOLLO-2 Phase 3 Pivotal Efficacy Studies Of Oliceridine In Acute Pain
TRVN,Oliceridine,2016-05-02,Trevena Announces Successful End-of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine
TRVN,Oliceridine,2016-02-22,Trevena, Inc. Receives FDA Breakthrough Therapy Designation For Oliceridine For The Management Of Moderate-to-Severe Acute Pain
TRVN,Oliceridine,2016-01-19,Trevena, Inc. Announces Initiation Of Oliceridine Phase 3 Clinical Program With Multi-Procedure Safety And Tolerability Study
TRVN,Oliceridine,2015-12-03,Trevena Announces FDA Grant Of Fast Track Designation To Oliceridine (TRV130) For The Management Of Moderate-to-Severe Acute Pain
WINT,Aerosurf,2016-11-28,Windtree Therapeutics' AEROSURF® (lucinactant For Inhalation) Phase 2a Data Presented At The 2016 International Congress Of Union Of European Neonatal And Perinatal Societies
WINT,Aerosurf,2016-09-19,Windtree Therapeutics Announces FDA Fast Track Designation For AEROSURF®
WINT,Aerosurf,2016-08-08,Windtree Receives $2.6 Million SBIR Grant To Support AEROSURF® Phase 2b Clinical Trial
WINT,Aerosurf,2016-11-28,Windtree Therapeutics' AEROSURF® (lucinactant For Inhalation) Phase 2a Data Presented At The 2016 International Congress Of Union Of European Neonatal And Perinatal Societies
WINT,Aerosurf,2016-09-19,Windtree Therapeutics Announces FDA Fast Track Designation For AEROSURF®
WINT,Aerosurf,2016-08-08,Windtree Receives $2.6 Million SBIR Grant To Support AEROSURF® Phase 2b Clinical Trial
XENE,XEN801,2017-03-24,Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints In Phase 2 Clinical Trial In Patients With Moderate To Severe Acne
XENE,XEN801,2016-02-10,Xenon Initiates Phase 2 Clinical Trial Of XEN801 To Treat Moderate To Severe Acne
XENE,XEN801,2015-09-24,Xenon Pharmaceuticals Announces Initiation Of XEN801 Phase 1 Clinical Trial
ZGNX,ZX008,2017-03-01,Zogenix Receives Orphan Drug Designation In The European Union For ZX008 In Lennox Gastaut Syndrome
ZGNX,ZX008,2017-02-13,Zogenix Announces Initiation Of Clinical Efficacy Portion Of Study 1504 For ZX008 In Dravet Syndrome
ZGNX,ZX008,2017-01-30,Zogenix Announces Issuance Of U.S. Patent For ZX008 In Dravet Syndrome
ZGNX,ZX008,2016-12-05,Zogenix Announces New Efficacy And Safety Data For ZX008 In Treatment Of Seizures In Lennox Gastaut Syndrome & Dravet Syndrome
ZGNX,ZX008,2016-11-22,New Data On Zogenix's ZX008 For Lennox Gastaut Syndrome & Dravet Syndrome To Be Presented At 70th Annual American Epilepsy Society Meeting
ZGNX,ZX008,2016-06-07,Zogenix Announces Initiation Of Multi-National Phase 3 Clinical Trial For ZX008 In Dravet Syndrome
ZGNX,ZX008,2016-05-05,Zogenix Announces New Efficacy And Safety Data On ZX008 For Treatment Of Seizures In Dravet Syndrome
ZGNX,ZX008,2016-04-21,New Data On Zogenix's ZX008 For Dravet Syndrome To Be Presented At 14th International Child Neurology Congress
ZGNX,ZX008,2016-01-19,Zogenix Receives Fast Track Designation From FDA For Development Of ZX008 In Dravet Syndrome
ZGNX,ZX008,2016-01-11,Zogenix Announces Initiation Of Phase 3 Program For ZX008 In Dravet Syndrome
ZGNX,ZX008,2015-12-14,Zogenix Announces FDA Acceptance Of Investigational New Drug Application For ZX008 Phase 3 Clinical Trial In Dravet Syndrome
ZGNX,ZX008,2015-12-07,Zogenix Announces New Efficacy And Safety Data On ZX008 For Treatment Of Seizures In Dravet Syndrome
ZGNX,ZX008,2015-11-25,New Data On Zogenix's ZX008 For Dravet Syndrome To Be Presented At 69th Annual American Epilepsy Society Meeting
ZGNX,ZX008,2015-10-19,Zogenix Provides Regulatory Update For ZX008
ZSAN,ZP-Triptan,2016-06-17,Zosano Pharma Enrolls First Subject In Pivotal Clinical Trial For ZP-Triptan Patch Program For Treatment Of Migraine
ZSAN,ZP-Triptan,2015-11-02,Zosano Pharma Announces Positive Phase 1 Results For Its ZP-Triptan Patch Program For Treatment Of Migraine
